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Abstract 
 
Amine Promoted Asymmetric Cascade Synthesis of 
Highly Functionalized Heterocycles 
 
ZHONG Cheng 
 
Enantioselective Intermolecular Crossed-Conjugate Additions between Nitroalkenes 
and α,β-Enals through a Dual 
Enantioselective intermolecular crossed-conjugated additions between 
nitroalkenes and enals were developed through Lewis base and iminium cation dual 
activation strategy. The optimal condition was suitable for a large group of nitroalkenes 
and enals with excellent yields and e.e.. Further derivatization led two diastereomers into 
single enantiomers of substituted pyrrolidine with excellent stereochemistry retention.  
 
One-pot cascade Michael-Michael-Aldol condensation for Diastereoselective 
Synthesis of Nitro-Substituted Cyclohexanes 
A one-pot Michael-Michael-Aldol cascade reaction of proline Lewis base 
activated nitroalkenes and enones was developed for the preparation of nitro-vinyl-
substituted cyclohexanes. Good yields and diastereoselectivity were observed. Further 
simple transformations easily lead to poly-N-heterocycles, which have great potential for 
the backbone synthesis of bioactive natural products.  
 
Concise Asymmetric Synthesis of Fully Substituted Isoxazoline-N-Oxide 
through Lewis Base Catalyzed Nitroalkene Activation 
A concise asymmetric synthesis of isoxazoline-N-oxides is reported through 
secondary amine Lewis base catalyzed nitroalkenes activation and sequential 
intermolecular condensation with aldehydes and ylides. Through the further application 
of camphor derived sulfur ylide, the enantiomeric enriched isoxazoline-N-oxides were 
prepared with excellent yields (up to 95%) and stereoselectivity (single trans isomers and 
up to 96% e.e.). The limitation of previous study had been successfully overcome. 
Further transformations of isoxazoline-N-oxide led to the gram-scale synthesis of a 
Clausenamide analogue, which has great potential for brain damage repair (Alzheimer’s 
disease). Notably, this strategy had provided the all-cis γ-lactam with four stereogenic 
centers in 4 steps, with excellent stereochemistry control. Asymmetric synthesis of other 
related analogues is underway. 
 
One-Step Synthesis of Substituted Di-Hydrofurans from Lewis Base 
Catalyzed Three-Component Condensation 
A one-pot synthesis of substituted di-hydrofuran was developed through Lewis 
base catalyzed three components cascade condensation between nitroalkene, aldehyde 
and 1,3-dicarbonyl compounds. The di-nucleophile moieties (1,3-dicarbonyl compounds) 
readily reacted with the nitro diene intermediate to provide the desired cyclization 
products with large substrate scope (> 20 examples) and excellent diastereoselectivity 
(only trans isomers) in good to excellent yields (up to 96%). Further application of the di-
hydrofuran towards useful synthetic building blocks is being studied with preliminary 
results. 
 
One-Pot Asymmetric Synthesis of Substituted Piperidines by Exocyclic 
Chirality Induction 
A highly efficient one-pot synthesis of substituted piperidines was developed 
through nitroalkene, amine, and enone condensation. The transformation was suitable for 
a large group of substrates, giving excellent yields and diastereoselectivity. Reactions 
using chiral amines revealed a chirality induction through the unusual exo-cyclic 
stereochemistry control, producing enantiomeric pure piperidines in simple steps. A six-
member ring chair transition state was proposed to account for the stereoselectivity. 
Reactions involving chiral amine for the similar transition state are being investigated to 
extend the exo-cyclic chirality transfer strategy.  
 
 
 
Anion Bridged Nanosheet from Self-Assembled G-Quadruplexes 
A novel, non-covalent polymeric nanosheet has been produced through 
functionalized Guanosine self-assembly via the cooperation of cations and corresponding 
anions. The nanosheet material was 3.0 nm in height 200 nm in average diameter. Its 
composition and structure have been characterized by solution NMR, solid-state NMR, 
powder XRD and AFM. Functionalized Guanosine had also been synthesized for further 
construction of nano scale supramolecular structures. 
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Part I 
Enantioselective Intermolecular Crossed-Conjugate 
Additions between Nitroalkenes and ! ,"-Enals through 
a Dual Activation Strategy 
1.1  Introduction 
1.1.1  Organocatalyzed cascade reaction in organic synthesis 
In modern organic syntheses, efficient construction of complex frameworks with 
multiple stereogenic centers continues to be of great importance and interests in both 
academic and industrial laboratories.1 As one of the most popular techniques to date, 
asymmetric multi-component organocatalytic cascade reaction (or domino reaction, 
tandem reaction) has been widely used to construct the backbones of natural products.2 
The high atom economy, great stereoselectivity and its biomimic pathway make it a 
prevalent strategy in organic syntheses yet with challenges.3 The iminium and enamine 
cascade reactions first reported by MacMillan and Jørgensen are perfect examples to 
functionalize enals with both nucleophiles and electrophiles in one pot (Scheme 1).4  
 
Scheme 1.  Iminium and enamine cascade catalysis 
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Moreover, the enamine chemistry has been successfully fused with different 
catalysis systems for the complex yet efficient cascade transformations. For example, the 
combination of enamine nucleophiles with transition-metal activated electrophiles had 
been well studied through the last decade (Scheme 2).5  
 
Scheme 2.  Combination of enamine catalysis with transition-metal catalysis 
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Another interesting and robust area is the bifunctional catalysis or dual catalysis 
of small organic molecules, which also falls into the cascade concept (Scheme 3).6 
Extensive studies had been well documented. In this case, one organocatalyst molecule 
can activate both of the substrate (as electrophile and nucleophile) and promote the new 
bond formation, also referred to as dual catalysis. For example, when a secondary amine 
is tethered to a thiourea functionality through a chiral scaffold, an aldol-Michael reaction 
will occur with excellent chemical yield, diastereoselectivity and enantioselectivity.7 
Proline is also widely considered as a bifunctional catalyst during the aldol reactions 
between aldehyde functional groups, inter- or intramolecularly.8  
 
Scheme 3.  Bifunctional or dual catalysis of organocatalyst  
 
N
H
R1
O
+
R
NO2
N
S
N R
2
-H2O
*
H H
NR1
R
N
N
S
N R
2
*
H H
O O
O O OHO
N
O
OH
O
L-proline
(A)
(B)
 
 3 
1.1.2  Amine Lewis base catalysis in organic synthesis 
Predominantly, chiral secondary amines were used for asymmetric enamine and 
iminium chemistry. Although there have been a few reports about the aza-Michael 
addition of aliphatic amine (primary and secondary) to electron deficient alkenes, few 
exploration of their nucleophilicity as Lewis basic catalyst had been reported. In the 
nitrogen containing Lewis base catalysis category, only two types of reactions have been 
well developed (Scheme 4). One is that the tertiary amines (Et3N or DABCO) are 
typically used for the activation of enones/enals for Baylis-Hillman reaction;9 the other is 
that the aromatic amines like DMAP or pyridine are used in the esterification and Aldol 
condensation.  
 
Scheme 4.  Amine Lewis base catalysis by organocatalysts 
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1.1.3  Previous study on L-proline Lewis base activation of nitro alkene 
In early 2007, a new reaction mode of L-proline was discovered in our research 
group. The concept started from Morita-Baylis-Hillman reaction,10 in which Lewis base 
activated electron deficient alkene to form a carbanion in situ, serving as the nucleophile 
and react with the aldehyde, followed by the elimination of Lewis base to yield the allylic 
alcohol product (Scheme 5A). We then wondered what would happen if we have another 
electron deficient alkene to substitute the aldehyde as electrophile, hoping for a cascade 
cross-conjugate addition (Scheme 5B). A simple model study was then set up between "-
nitro styrene and cyclohexanone, under the condition of proline (0.2 eq.) and NaN3 (1.0 
eq.) in DMSO at room temperature. The reaction finished in 3 hours with only 32% 
isolated yield of the desired product (only E isomer), which was quite difficult to isolate 
 4 
(Scheme 5C). The possible problem was that the cyclohexanone is a much weaker 
Michael receptor comparing to the " nitro styrene, which ended up with self-
polymerization rather than the cross addition, giving this messy reaction with low yield. 
To circumvent this problem, a methyl group was introduced to the ! position of the nitro 
alkene. Surprisingly, an allylic nitro functionality was obtained in high chemical yield, 
which indicated the proline Lewis base activation of the nitro alkene and the " 
elimination of the Lewis base to relocate the carbon double bond (Scheme 5D).11  
 
Scheme 5.  Evolution of the cross conjugate addition 
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In the brief condition optimization (Table 1), the reaction went smooth with only 
catalytic amount of proline (0.2 eq.) (entry 1). The rationale was that the reaction would 
have never happen with only the iminium activation of the enone but without the 
activation of nitro alkene. Thus, we proposed that proline would be the Lewis base to 
activate the nitro alkene. Even the combination of pyrrolidine and AcOH (both were 0.2 
equivalent in order to mimic proline) gave similar performance (entry 4). However, NaN3 
(1.0 eq.) by itself, which was supposed to serve as Lewis base, did not efficiently 
promote the reaction as expected (entry 2). In the presence of both proline (0.2 eq.) and 
 5 
NaN3 (1.0 eq.), the reaction went smooth and gave 87% isolated yield within 4 hours, 
which suggested NaN3 might provide a buffer media for the optimal performance of 
proline as Lewis base to activate nitroalkene and also the iminium electrophile formation 
(entry 3). Classic Lewis bases, such as Ph3P and DMAP were tested, presenting moderate 
yields yet confirming the nitro alkene Lewis base activation mechanism (entries 6, 7). 
Basic conditions were not suitable for the reaction (entries 8, 9), even in the presence of 
proline (entry 5). Other solvents were also tested indicating DMSO as the best. 
 
Table 1.  Brief reaction optimization of cross conjugate addition 
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1
2
3
4
5
6
7
8
9
10
11
12
sol. Lewis Base(0.2 eq.)
Additive
(1.0 eq.)
time
(h)
conv.b
(%)
yieldc
(%)
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
DMSO
MeOH
THF
MeNO2
proline
NaN3 (1.0)
proline
pyrrolidine
proline
Ph3P
DMAP
--
--
proline
proline
proline
--
--
NaN3
AcOH (0.2)
Et3N
--
--
t-BuONa
Et3N
NaN3
NaN3
NaN3
4
10
4
4
4
4
4
4
4
4
4
4
93
61
100
100
89
63
70
86
74
69
51
57
80 (78)
8
90 (87)
81(78)
41
48
38
<5
25
54
39
48
a Reactions were carried out at room temperature,ntiroalkene: enone = 1 : 1.2; b 
Conversion based on the consumption of nitroalkene. c NMR yields of both cis and
trans isomers, determined by 1,3,5-trimethoxybenzene as the internal standard, isolated 
yields in the parentheses.  
 
During the investigation, we found that in the presence of proline, nitro alkene a 
and its isomer b were in equilibrium under the reaction condition. Another concern was 
then raised, was it really the Lewis base activation of the nitroalkene a, or just simple 
deprotonation of allylic nitro compound b to conduct the nucleophilic addition to the 
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enone? For clarification, the comparison of molecule a exposed to proline and molecule b 
under basic condition was conducted, suggesting the validity of Lewis base activation 
pathway. On the other hand, the deprotonation pathway apparently disagreed with the 
pKa theory, since the allylic nitro carbanion was far more acidic than the carbonyl 
carbanion (pKa 11 v.s. pKa 20), which would drive the reaction go backwards to the 
starting materials, which was then later confirmed in later part of this document. 
Furthermore, computational studies also verified the viability of Lewis base activation 
nitro alkenes by proline (Scheme 5).  
 
Scheme 5.  Mechanistic rationale for proline catalysis as Lewis base 
 
Ph
Me
NO2 O
LB
Ph
Me
NO2
Ph
CH2
NO2
LB
a
b
Ph
CH2
NO2
base
a'
b'
reactant time (h) yield (%)
a
b
4 90
4 17
b 14 51
Ph
CH2
NO2
O
b'
Ph
CH2
NO2
pKa ~ 11 pKa ~ 20
O
 
 
Through almost three years of extensive study, several reactions between proline 
(or secondary amine) activated " alkyl nitro alkene and different electrophiles have been 
well developed. A more logical mechanism of secondary amine Lewis base activation of 
nitro alkenes was then proposed based on our studies (Scheme 6). Generally, after the 
nucleophilic addition of secondary amine to nitro alkene, a zwetterion species A is 
created, which is actually the resonance structure of the neutral nitronate B. Due to the 
stabilization of the secondary amine, nitronate B serves as a more general and milder 
nucleophile. In the presence of electrophile, a new covalent bond is formed, which is then 
followed by the " elimination to release the secondary amine and yield the allylic nitro 
product.  
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Scheme 6.  Proposed secondary amine activation of nitro alkene  
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1.2  Research Objective 
1.2.1  Lewis-base catalyzed enantioselective cross conjugate addition 
Based on our previous study, chiral cyclic secondary amines were then tested for 
the asymmetric cross conjugate addition between " alkyl nitro alkenes and enals. As 
proposed, the chiral secondary amine should activate both enals as iminium electrophiles 
and also the nitro alkene as stabilized nitronates (or nitro carbanions) to serve as mild 
nucleophiles. Good yields and enantioselectivity were expected.  
 
1.2.2  Synthesis of pyrrolidine derivatives and solution the d.r. problem  
The diastereoselective ratio might be low due to the low pKa of the allylic nitro 
functionality. To reach to a high diastereoselective radio, further transformations were 
desired to solve the d.r. problem. 
 
1.3  Results and Discussion 
1.3.1  Reaction optimization of the cross conjugate addition 
The reaction condition screening was summarized in Table 2. Conducting the 
reaction in DMSO gave the desired product 3a in modest yield (polymerization of 
starting material) with poor stereoselectivity (entry 1). Switching the solvent to MeOH 
when only L-proline (0.2 eq.) was used as catalyst, 78% yield and 11% e.e. of 3a was 
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observed (entry 2). This strongly supported the proposed dual activation mechanism, that 
is iminium cation carbonyl activation and nitroalkene Lewis base activation.  
 
Table 2.  Optimization of reaction conditions a 
 
Ph
O2N
Ph
O
H Ph
O
NO2
Ph
Ph
O
NO2
Ph
+ +
1a 2a anti-3a syn-3a
N
H
COOH N
H OH
PhPh
N
H OTBS
PhPh
N
H
N
O
Bn
cat-1 cat-2 cat-3 cat-5
N
H
H
N
S
H
N Ph-3,5-di-CF3
cat-4  
 
entry sol. cat.  co-cat.a temp (oC) 
time 
(h) 
convn 
(%)b 
yield 
(%)c 
e.e. 
(%)d 
1 DMSO cat-1 -- -- rt 3 95 58 0 
2 MeOH cat-1 -- -- rt 3 86 71 11 
3 MeOH cat-1 -- -- 0 12 69 64 23 
4 MeOH cat-1 (MeO)3P -- 0 8 83 78 28 
5 MeOH cat-2 -- -- rt 3 57 51 35 
6 MeOH cat-2 -- -- 0 12 54 47 79 
7 MeOH cat-2 -- -- -20 48 14 12 n.d. 
8 MeOH cat-2 (MeO)3P -- -20 48 69 64 90 
9 MeOH cat-2 (MeO)3P AcOH  -25 48 >95 90e 93 
10 other solventf cat-2 -- -- rt 8 <55 <50 <30 
11 MeOH cat-1 Other LBsg -- 0 24 <80 <74 <28 
12 MeOH cat-3 (MeO)3P AcOH 0 24 80 76 70 
13 MeOH cat-4 (MeO)3P AcOH 0 24 32 23 46 
14 MeOH cat-5 (MeO)3P AcOH 0 24 74 68 68 
a 1a:2a = 1:2, concentration of 1 is 0.2 M, catalyst was 20%, LB and AcOH co-catalysts were 
1 equiv.; b based on the consumption of 1 by NMR; c NMR yield with 1,3,5-
trimethoxybenzene as internal standard; d the two diastereomers were separated and e.e. were 
determined by chiral HPLC (anti isomer only).  The poor d.r. selectivity (less than 2:1) is all 
cases favoring the anti isomer; e isolated yields of both isomers; f includes DCM, EtOAc, 
Acetone, toluene, MeCN, THF. g includes Ph3P, DMAP, imidazole, NMI. 
 
When lower temperature (0 ºC) was applied, better enantioselectivity was 
received though longer reaction time was required to reach a reasonable yield (entry 3, 
63% yield, 23% e.e.). With the additional Lewis base (MeO3P, 1.0 eq.) added in the 
reaction system, better yield (78%) was observed with slightly improved e.e. (28%), 
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indicating the release of proline for the proposed Lewis base nitroalkene activation, 
which then helped the better formation of chiral iminium electrophile (entry 4, 78%, 28% 
e.e.). Application of cat-2 at lower temperature greatly improved the enantioselectivity 
up to 79% e.e. (entries 3 and 6).  But further lowering reaction temperature caused 
significant decrease of reaction rate (entry 7, -20 ºC, 12% yield in 48 hours), which might 
be caused by the slow release of amine catalyst from nitroalkene addition (resulting in the 
lack of iminium activation) at low temperature. To help the release of the amine, various 
Lewis bases were tested as the co-catalysts, including Ph3P, DMAP, imidazole, P(OMe)3 
and NMI, P(MeO)3 was identified as the best at -25 ºC. As expected, both reaction rate 
and enantioselectivity increased (entry 8, 64% yield, 90% e.e.). Further addition of AcOH 
promoted the iminium cation formation, gave 3a in excellent yield and slightly improved 
enantioselectivity (entry 9, 90% yield, 93% e.e.). Different solvents were also tested, 
including DCM, EtOAc, Acetone, toluene, MeCN, THF, all of which did not provide 
comparable performance of the reaction than in MeOH. Other typical chiral secondary 
catalysts were also tested under the same condition, but no better performance was 
observed.  
 
1.3.2  Reaction substrate scope 
With the optimized condition, this transformation is subjected to a wide range of 
substrates, with good yield and excellent enantioselectivity. Various "-substituted enals, 
including aryl, alkyl and heterocycles, were all suitable for this reaction. The aldehyde 
products 4 were all reduced into alcohol, which showed were more stable and easier for 
both isolation and the examination of enantioselectivity. Only two product aldehydes (4n 
and 4o) were not reduced due to their instability under reductive conditions.  
 
Moreover, both alkyl/aryl and di-alkyl substituted nitroalkenes could be promoted 
in this transformation. Mono-alkyl substituted nitroalkene, although possible for the "-
elimination, gave low yield due to significant polymerization. The substrate scope is 
summarized in Table 3. 
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Table 3.  Substrate scope of cross conjugate addition of nitro alkenes to enals a 
 
R1
O2N
R2
O
H R1
OH
NO2
R2
R1
OH
NO2
R2
+ +
1) cat-2 (0.2 eq.), (MeO)3P (1.0 eq.),
MeOH, -25ºC, 48~60h
1 2 4-anti4-syn
2) MeOH, NaBH4, r.t., 2h
 
 
Ph
OH
NO2
Ph
4a
91%, d.r. 1:1.2, 
e.e. 91%/93%
Ph
OH
NO2
n-Bu
Ph
OH
NO2
O
Ph OH
NO2
p-MeO-C6H4
Ph OH
NO2
p-NO2-C6H4
Ph OH
NO2
o-NO2-C6H4
Ph
OH
NO2
Me
p-Cl-C6H4
OH
NO2
Ph
p-Cl-C6H4
OH
NO2
O
p-Cl-C6H4 OH
NO2
p-MeO-C6H4 OH
NO2
Me
O p-Me-C6H4
OH
NO2
Ph
Napthyl OH
NO2
p-NO2-C6H4
p-CN-C6H4
O
NO2
Ph
p-NO2-C6H4
O
NO2
Ph OH
NO2
Ph
OH
NO2
p-MeO-C6H4
4b
83%, d.r. 1:1.1, 
e.e. 94%/86%
4c
76%, d.r. 1:1.1, 
e.e. 87%/87%
4d
80%, d.r. 1:1.2, 
e.e. 94%/95%
4e
89%, d.r. 1:1, 
e.e. 82%/83%
4f
85%, d.r. 1:1, 
e.e. 86%/86%
4g
92%, d.r. 1:1.2, 
e.e. 88%/88%
4h
89%, d.r. 1:1.2, 
e.e. 88%/90%
4i
78%, d.r. 1:1.1, 
e.e. 86%/86%
4j
74%, d.r. 1:1.2, 
e.e. 84%/88%
4k
64%, d.r. 1:1.1, 
e.e. 90%/88%
4l
82%, d.r. 1:1.1, 
e.e. 91%/92%
4m
82%, d.r. 1:1.3, 
e.e. 90%/88%
4nb
86%, d.r. 1:1, 
e.e. 80%/82%
4ob
79%, d.r. 1:1, 
e.e. 77%/81%
4q
71%, d.r. 1:2.5, 
e.e. 87%/87%
4p
75%, d.r. 1:2, 
e.e. 70%/75%
 
a 1:2= 1:3, concentration of 1 is 0.2 M; isolated yield of both isomers; d.r. values were determined 
by crude 1H-NMR; e.e. were determined by chiral HPLC; b yields of aldehydes, no further 
reduction.  
 
1.3.3  Diastereoselective disubstituted pyrrolidine synthesis  
Although the reported reaction had reached high yield and enantioselectivity, the 
diastereo ratio was always low due to the acidic proton (pKa~11) at the allylic nitro 
position. Further transformation was then required to convert both diastereomers into one 
to reach high atom efficiency. It had been known in our previous study that the nitro 
group (NO2) could be reduced into amine (NH2) via Zinc reduction under acidic 
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condition. Since intramolecular imine formation was predictable, a reductive cyclization 
would yield a disubstituted pyrrolidine derivative, which might improve the d.r..  
 
Scheme 7.  Enantioselective synthesis of disubstituted pyrrolidines 
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N
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93% retention
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72% from 3a
cat-2
1) Zn/HCl; 
2) NaCNBH3
1) Ac2O, Et3N; 
2) O3, -78 ºC;
3) K2CO3, MeOH
1) PhMgBr, 0 ºC; 
2) NH4Cl
1) Boc2O, Et3N, DMAP; 
2) O3, DCM, -78ºC;
K2CO3, MeOH
1) PhMgBr, 0 ºC; 
2) NH4Cl
 
 
As shown in Scheme 7, concise syntheses of disubstituted pyrrolidine derivatives 
had been developed towards nitrogen containing heterocycles. Reductive cyclization of 
syn/anti 3a gave pyrrolidines 5a, which were then further converted into carbamate or 
amide protected 6a and 6b through amine protection and ozonolysis. Mixtures of 
diastereomers were obtained for both 6a and 6b with d.r. < 2:1.  However, upon 
treatment of K2CO3 in MeOH, the cis isomer was successfully converted into trans 
isomers, with d.r. > 10:1 in 6a and only trans isomer observed in 6b. The trans 6b was 
then converted into 7b with excellent yield and stereochemistry retention. Interestingly, 
treating the cis carbamate 6a with PhMgBr gave the cis-cyclo-carbamate, which 
significantly extended the application of this transformation: with the different protecting 
groups, both cis and trans substituted pyrrolidine can be achieved with excellent 
stereochemistry retention. More interestingly, pyrrolidine 7b is fairly similar to the 
catalyst cat-2 with one more trans substitute group (Ph) at the C-3 position. Further 
application of 7b as organocatalyst is of great interest in our research group. 
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1.4  Conclusion 
A novel Lewis base catalysis mode of proline or secondary amines had been 
discovered and studied. The enantioselective crossed-conjugate addition of nitroalkene 
and enals was successfully developed. The wide substrate scope, excellent yields and 
enantioselectivity, and unique activation approach provided great potential of this new C-
C bond formation strategy. Simple derivatization had converted the diastereo mixtures 
into single enantiomers. Both cis and trans disubstituted pyrrolidine derivatives had been 
synthesized in great yields and stereochemistry retention.  
 
The allylic nitro functionality produced through our proline Lewis base catalysis 
has great potentials for further transformation, targeting interesting and useful building 
blocks. The nitrogen containing heterocycles can be easily synthesized which may 
possess great attractive chemical and biological activities. Also, studies of 7b as 
organocatalyst are currently underway in our group. 
 
 
This project was a collaborating work with Dr. Yunfeng Chen, Dr. Jeffrey 
Petersen and Dr. Novruz Akhmedov. Dr. Chen helped with the part of the derivatization 
of two diastereomers and the NMR spectra organization. Dr. Petersen helped with the X-
ray crystallography study to determine the relative stereochemistry and structures of 
target compounds. Dr. Akhmedov carried out the extensive NMR studies of the 
derivatization products 7a and 7b.  
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Part II 
One-pot cascade Michael–Michael–Aldol condensation 
for Diastereoselective Synthesis of Nitro-Substituted 
Cyclohexanes 
2.1  Introduction 
2.1.1  Lewis base catalyzed cascade reaction 
Compared to the Lewis acid, radical and transition metal promoted cascade 
reactions, the Lewis base mediated cascade transformations were much less documented 
in literature. However, with the unique reaction mechanism, successful Lewis base 
mediated cascade processes could provide feasible approaches to complex molecules 
construction that are difficult using other methods.12 Our interest in developing Lewis 
base mediated cascade reactions was initiated by the investigation of the Henry-Aldol 
condensation. With the presence of more acidic proton, the addition of nitro compounds 
to enone is thermodynamically unfavored (formation of stronger base), if no other 
reagents applied (Scheme 8). Thus, few successful Henry-Michael additions have been 
reported. However, novel 1, 4-nitro, ketone di-functionalities building blocks would be 
constructed that can be further converted to synthetic useful complex molecules.13  
 
Scheme 8.  Unfavored Henry-Michael addition 
Henry-Michael addition: challenging transformation with un-favored equilibrium
Base
RO2N RO2N
O
R
O
R
O2N
Un-favored equilibrium
weaker base stronger base
 
 
2.2  Research Objective 
2.2.1  Lewis-base catalyzed cascade synthesis of cyclohexanes 
Based on our previous study of the proline promoted cross conjugate addition of 
nitroalkene to enones and enals, we postulated a Michael-Michael-Aldol cascade 
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condensation of nitroalkenes and enones for the synthesis of functionality enriched 
cyclohexanes. 
 
Nitroalkene is one important synthetic building block for producing diverse 
functional groups through easy transformations. 14  In literature, nitroalkenes were 
commonly used as electrophiles or electron-deficient dienophiles.15 The Lewis base 
activation of nitroalkene provided a new interesting strategy, whereby the resulting nitro 
carbanion A could serves as nucleophile (Scheme 9). The challenge is the homo-
condensation of nitroalkenes, leading to the polymerization.16 Our recently reported 
alternative "-elimination approach had successfully solved the problem, producing the 
allylic nitro compound C. The key for the success of this new strategy is the introduction 
of one irreversible step in the overall equilibrium system.  
 
Scheme 9.  Proposed Lewis base catalyzed cascade synthesis of cyclohexanes  
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Encouraged by this result, we wondered whether this new cascade process could 
be further extended to a second Michael addition and sequential intramolecular aldol 
reaction, leading to nitro-substituted cyclohexane G in one-pot as shown in Scheme 9. 
We envisioned this proposed cascade condensation would result in nitro-substituted 
cyclohexanes that can be readily converted into functional group enriched N-heterocycles 
through simple steps. Moreover, the mechanism revealed would help us understanding 
the key factors that control this complex multi-component.  
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As indicated in the reaction path, the key for success Michael-Michael-Aldol 
condensation that converts simple nitroalkene into cyclohexane G is to switch the 
irreversible "-elimination step (B to C) into equilibrium and expect the intramolecular 
aldol reaction (formation of G) as the new irreversible step under proper reaction 
conditions. Since the !-proton of the allylic nitro compound C is acidic, deprotonation 
will be one simple approach in converting the B-C transformation as equilibrium. 
Experiments were then designed to test this hypothesis. 
 
2.2.2  Further mechanistic investigation and N-heterocycles synthesis 
We envisioned this proposed cascade condensation would result in nitro-
substituted cyclohexanes that can be readily converted into highly functionalized N-
heterocycles through simple steps. Moreover, the mechanism revealed through this 
process would certainly help us in understanding the key factors that control this complex 
multi-component condensation and lead to the discovery of other new cascade reactions. 
 
2.3  Results and Discussion 
2.3.1  Mechanistic study of the cross conjugate addition 
The reactions between allylic nitro compounds 8 and strong base tBuOK were 
then investigated. As shown in Scheme 10, treatment of nitroalkene with enone or !, "-
unsaturated ester gave the allylic nitroalkene 8 in excellent yields in the presence of L-
proline as Lewis base. No cyclohexane products were observed due to the irreversible "-
elimination. Reactions of 8 with tBuOK caused the decomposition of 8, returning both of 
the starting materials. However, no cyclization product was observed either and 
polymerization of nitroalkenes was detected when extending the reaction time. Since the 
base indeed led to the deprotonation of 8, converting the irreversible elimination to 
equilibrium, the fact that no cyclohexane was formed under this reaction may caused by 
either the equilibrium in the intramolecular aldol step (Scheme 9, F to G) or the 
unfavored equilibrium between A and B.  
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Scheme 10.  Decomposition of #-keto allylic nitro compounds towards base  
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2.3.2  Reaction condition optimization 
To evaluate these crucial factors that influence this transformation, reactions 
between 8 and carbonyl activated alkenes 9 were investigated. As indicated in Table 4, 
reactions between 8 and 9 would presumably form three different condensation products: 
the simple Michael addition product 10, the kinetic aldol condensation product 11 and the 
thermodynamic aldol condensation product 11´.17 The Henry-Michael addition did not 
occur between 8 and 9 in the absence of base, even for acroline 9a with the presence of 
proline catalyst in DMSO (entries 1-2). Enal polymerization occurred when 9a was 
treated with base in DMSO (entry 3). With the addition of the strong base (tBuOK), the 
allylic nitro compound 8 tended to decompose (entry 5) through the reaction path shown 
in Scheme 10. Application of mild base with 8b and ester 9c, the Henry-Michael addition 
product 10a was observed with low yield (entry 6). However, the desired intramolecular 
aldol condensation did not occur, which was likely due to the poor reactivity of the ester 
group under the reaction condition. This result suggested that the Henry-aldol addition is 
possible if proper basic condition was applied (deprotonation of the more acidic nitro 
carbon hydrogen other than the carbonyl !-proton).  
 
Encouraged by this result, we then investigated the reaction of ketone 8a with 
different Michael receptors 9 in the presence of various mild bases. To our please, 
reactions between 8a and 9a/9b gave the desired Michael-Aldol product 11a/11b in the 
presence of Et3N (entries 7 and 8), though with low reaction rates. The reaction rate for 
enal 9a were later improved with the addition of catalytic amount of proline (entry 9, 
carbonyl activation). Although NaN3 and K2CO3 could also promote this reaction, Et3N 
gave the best results, where nitro cyclohexane 11a was produced in excellent yield.  
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Table 4.  Michael-aldol condensation of allylic nitro compounds a 
 
Ph R1
O
NO2
O
R2+
8 9
R1=CH3, 8a;
R1=OCH3, 8b;
R2=H, 9a;
R2=CH3, 9b;
R2=OCH3, 9c;
NO2Ph
R2
O
R1
O
NO2Ph
R2
OHO R
1
NO2Ph
R1
O R
2 OH
10 11 11'
1
34
 
 
sub. conditions 
 8 2 cat.  (0.2 eq.) solv. 
base  
(1.0 eq.) 
time 
(h) 
conv. 
(%)b prod. d.r.
c yield (%)d 
1e 8a 9a proline DMSO - 48 0 - - - 
2e 8b 9a proline DMSO - 48 0 - - - 
3e 8a 9a proline DMSO Et3N 12 <5 n.d. n.d. n.d. 
4 8b 9c - DMSO - 48 0 - - - 
5 8b 9c - THF KOtBu 20 100 trace n.d. trace 
6 8b 9c - DMSO Et3N 20 10 10a - 8 
7 8a 9a - MeOH Et3N 20 75 11a 2.4:1 68 
8 8a 9b - MeOH Et3N 20 <5 11b n.d. <5 
9 8a 9a proline MeOH Et3N 5 100 11a 2.4:1 90 
10 8a 9b proline MeOH Et3N 20 <5 11b n.d. <5 
12 8a 9a proline MeOH NaOAc 5 100 11a - 0 
13 8a 9a proline MeOH NaN3 5 100 11a 2.4:1 86 
14 8a 9a proline MeOH K2CO3 5 100 11a 2.3:1 71 
15 8b 9a proline MeOH Et3N 5 100 11b - 90 
a 8 : 9 = 1:2, c = 0.2 M; b based on the consumption of 8 by NMR; c based on crude 
NMR analysis of two C-1 isomers; d isolated yields of all isomers; e polymerization 
of enal 9a. 
 
Notably, the thermodynamic product 11´ (ketone !-carbon addition to aldehyde) 
was not observed in all cases (even without proline activation, entry 7).18 This was also 
confirmed by the reaction between ester 8b and enal 9a, where Henry-Michael addition 
product 10b was received in excellent yield and no further cyclization product formed 
under the reaction condition (entry 15). Moreover, the Aldol product 11 was stable under 
even strong basic condition: treatment of 11a with tBuOK at 60 ºC, no decomposition 
occurred for 24 hours. All these results strongly suggested that the intramolecular aldol 
condensation was a rapid irreversible step in this cascade process, which drove the 
equilibrium into the desired cyclohexane product. 
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2.3.3  Cyclohexane synthesis through cascade condensation 
Meanwhile, although three stereogenic centers were generated in product 11, only 
two C-1 diastereomers were obtained. This is likely caused by the insignificant size 
difference between the nitro and the vinyl groups on the C-1 position in the six-member 
ring chair-like transition state. Various enals were applied to the reactions with allylic 
nitro compound 8 and the desired nitro-substituted cyclohexanes 11 were obtained with 
good yields and diastereoselectivity (Table 5). 
 
Table 5.  Cascade Michael-Aldol condensation of 8 and enals a 
R R1
O
NO2
O
H+
8 9
NO2R
CH2OH
HO R1
11-major
1R
R2
R3
R
R3
R2
2
5
NO2
R
CH2OH
HO R1
1
R
R3
R2
2
5
11-minor
1) NaN3 (1.0 eq.),
    Pro. (0.2 eq.), MeOH, r.t.
2) NaBH4, MeOH, r.t.
 
 
NO2Ph
CH2OH
H3C OH
11c
92%, d.r. 3.6:1
NO2Ph
CH2OH
C2H5 OH
11d
85%, d.r. 3.2:1
NO2Ph
CH2OH
Ph OH
11e
84%, d.r. 3.0:1
NO2Ph
CH2OH
H3C OH
11f
78%, d.r. 4.0:1
H3C
NO2
CH2OH
Ph OH
11g
82%, d.r. 2:2:1
11h
83%, d.r. 12:1
NO2Ph
CH2OH
H3C OH
CH3
 
a 1:2 = 1:2, c = 0.2 M; d.r. values are based on crude 1H NMR 
analysis;  isolated yields of all isomers. 
 
With this optimal condition for the intramolecular aldol reaction, we then 
investigated the direct condensation between nitroalkenes and enones. As expected the 
one-pot Michael-Michael-aldol condensation was successfully achieved with excellent 
yield and good diastereoselectivity. The substrate scope is summarized in Table 6. 
 
The proline catalyst could successfully promote the cascade Michael-Michael-
Aldol reaction with the addition of mild bases (Et3N or NaN3). Application of !, "-
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unsaturated ester gave good yield of Michael-Michael addition product 10a without 
further Dieckmann condensation. 19  Although enantioselective intramolecular Aldol 
condensation of 1,7-di-aldehyde has been reported in literature using proline as catalyst, 
the condensation reported by us gave rather low enantioselectivity (< 20% e.e. in all 
cases). We postulated the reason could be the difficult formation of H-bond between 
proline carboxylate group and carbonyl oxygen under basic condition.  
 
Table 6.  Cascade Michael-Michael-Aldol condensation a 
R1 NO2
O
R3+
1 9
O2N
R1
R4
O
OH
R3
R2
R2
R3
Et3N or NaN3 (1.0 eq.)
proline (0.2 eq.), MeOH, r.t.
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O2N
Ph
Me
O
OH
Me
12a
90%, d.r. 3.7:1
O2N
Ph
Et
O
OH
Et
12b
81%, d.r. 3.2:1
O2N
Ph
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O
OH
Ph
12c
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O2N
Me
O
OH
Me
12d
88%, d.r. 6.1:1
O2N
Et
O
OH
Et
12e
88%, d.r. 6.4:1
O2N
Ph
O
OH
Ph
12f
82%, d.r. 14:1
O2N
Me
Me
O
OH
Me
12g
80%, d.r. 4.5:1
O2N
Me
Et
O
OH
Et
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72%, d.r. 5.1:1
O2N
Me
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O
OH
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p-Me-C6H4
Me
O
OH
Me
12j
84%, d.r. 3.6:1
O2N
p-NO2-C6H4
Me
O
OH
Me
12k
87%, d.r. 3.8:1
O2N
p-Cl-C6H4
Me
O
OH
Me
12l
83%, d.r. 4.1:1
O2N
Me
O
OH
Me
12m
76%, d.r. 5.0:1
O2N
Me
O
OH
Me
12n
82%, d.r. 4.2:1
O2N
Me
O
OH
Me
12o
76%, d.r. 3.0:1
NO2Ph
OCH3
O
H3CO
O
10a
86%
O
 
a 1:2 = 1:4, c = 0.2 M, reaction generally finished in 10-20 hours; d.r. determined by crude 1H NMR 
analysis; isolated yields of all isomers. 
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2.3.4  Nitrogen containing heterocycles synthesis 
Simple reduction of nitro group into amine, two effective derivatizations were 
then carried out and summarized in Scheme 11, which further empathize the strength of 
the reported method as highly efficient new approach in complex molecule construction. 
 
Scheme 11.  Synthesis of complex N-heterocycles 
 
A) Transfermation 1,7-diester to N-hetero-bi-cycle
B) Efficient synthesis of poly-N-hetereocycle
NO2Ph
MeO2C
10a
Zn/HCl, MeOH
NH CO2Me
Ph
O
95% N
Ph
O O
OH
CH3
HNO2
Ph
OH
CH3H
N
Ph
OO
CH3
1) Zn/HCl, MeOH
2) ClCOCH2Cl, K2CO3, DCM
3) K2CO3, MeOH, 60 ºC
80% three steps12a
single diastereomer
13a
1) NaOH, MeOH
85% two steps
13b
2) Ac2O, 110 ºC
COCH3
13e
MeO2C
 
 
2.4  Conclusions 
In conclusion, a one-pot condensation of nitroalkenes and carbonyl-activated 
alkenes was developed. The optimal condition was developed with the application of 
both Lewis base and mild bases. Through this process functional group enriched 
cyclohexanes were prepared with excellent yields and good diastereoselectivity. The 
asymmetric transformation and application of this approach in natural product total 
synthesis are currently under investigation. 
 
 
 This project is a collaboration work with Dr. Yunfeng Chen. I helped with the 
substrate scope (Table 6) and the N containing heterocycle synthesis.  
 21 
Part III 
Concise Asymmetric Synthesis of Fully Substituted 
Isoxazoline-N-Oxide through Lewis Base Catalyzed 
Nitroalkene Activation 
 
3.1  Introduction 
3.1.1  Literature reported synthesis of Isoxazoline-N-Oxide  
 
Isoxazoline N-oxides and their derivatives are frequently used as intermediates in 
the synthesis of complex molecules in chemical20 and biological field21.  
 
Scheme 12.  Synthesis of complex isoxazoline-N-oxide via [3+2] cyclization 
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Back in the year 1964, nitronic esters were found to undergo 1,3-dipolar 
cycloaddition to alkenes to afford isoxazolidine. Representative works had been reported 
by Tartakovskii and co-workers22a (Scheme 12A). Later on, the same group also 
developed another similar strategy for the synthesis of isoxazoline N-oxides (Scheme 
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12B).22b Trinitromethane silver salt reacted with trimethylsilylchloride to form 
silylnitronate intermediate, which then went through a [3+2] cycloaddition with alkene to 
yield the isoxazolidine product. However, in this case, one molecule of silylnitronate was 
eliminated to give the final product. A more recent synthesis was done using the similar 
strategy targeting the isoxazoline-N-oxide molecules (Scheme 12C).23c Halides were 
used in this case to better the elimination process after the cycloaddition, which was 
nitronate previously. In the 1990’s, Denmark extended this [3+2] strategy into 
remarkable complex heterocycles synthesis and natural product synthesis.23  
 
Another important synthesis pathway of isoxazoline-N-oxide molecules is the O-
alkylation of NO2 containing molecule, pioneer works had been reported (Scheme 13).24 
The nucleophilicity of ! carbon was well studied to react with different electrophiles, 
such as aldehydes, epoxides and haloenones, which then followed by designed O-
alkylation to complete the cascade synthesis of isoxazoline-N-oxides. 
 
Scheme 13.  Synthesis of complex isoxazoline-N-oxide via O-alkylation 
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 The combination of ylide auxiliaries with nitroalkenes had also been well studied 
as one possible route. In 1976, Holy reported that dimethylsulfoxanium methylide could 
react with nitroalkene to afford isozaxoline-N-oxides in the presence of copper(I)25 
(Scheme 14 A). More recently, Tang and coworkers had successfully developed a more 
practical and simple method, using sulfur ylide through a much milder condition 
(Scheme 14 B).26a Later on, the same group reported the asymmetric synthesis of 
isoxazoline-N-oxide with good yields and excellent enantioselectivity (Scheme 14 C).26b  
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Scheme 14. Synthesis of complex isoxazoline-N-oxide through ylide auxiliary 
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3.1.2  Application of Isoxazoline-N-Oxide  
The stereoselective synthesis of isoxazoline N-oxide is an important task in the 
context of synthetic strategies toward the preparation of biological target molecules such 
as polyhydroxylated amino acids, aminopolyols and amino sugars 27 . Through 
chemoselective reductions, N-O bond could be easily cleaved, followed by hydrolytic 
workup to give !-hydroxyketone, which provides an alternate route to reach aldol 
product. The dehydrogenation of intermediate iminoalcohol arising from N-O bond 
cleavage affords !-hydroxy nitriles. Complete reduction of the isoxazoline ring delivers 
"-aminoalcohols. Base-mediated ring opening would provide #, !-unsaturated oximes. 
Chemoselective reduction could also yield #-hydroxyl, "-lactam functionality in one step. 
All the hydroxyl compounds can be easily dehydrated or the other functional group can 
be transformed further to obtain synthetically useful molecules (Scheme 15).  
 
Scheme 15.  Derivatization of isoxazoline-N-oxide through reduction 
 
N
O
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The dipolar character of these cyclic nitronates can be exploited for further 1,3-
dipolar cycloaddition with olefins to afford multi-cyclic structure moiety in total 
synthesis. The placement of the tether at the C3 position of the nitronate provides access 
to the spiro mode cycloadditions. This class has been evaluated for the preparation of 
five- and six-membered spiro ring systems28 (Scheme 16 A).  
 
Scheme 16.  Derivatization of isoxazoline-N-oxide through [3+2] cyclization 
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Rosini’s group reported the first example of a silicon-tethered intermolecular 1,3-
dipolar cycloaddition29 (Scheme 16 B). The tricyclic compound was converted to the 
corresponding bicyclic diol by an oxidative removal of the temporary silicon linker. The 
unstable diol was protected immediately as the diacetate. Reductive ring opening of the 
nitroso acetal moiety was performed with hygrogen and a catalytic amount of Raney Ni, 
to afford the polyhydroxylated aminolactone derivative. 
 
3.1.3  Previous study in our group  
In 2008, an alternate synthesis pathway was discovered in our group based on the 
Lewis base activation of nitroalkenes, using "-alkyl nitroalkene and vinyl ester as the 
simple starting materials.30 A [3+2] cyclization between proline activated nitroalkene and 
vinyl ester was proposed, yet to be confirmed, followed by a series of transformation to 
reach the diene intermediate A. Sequential conjugate addition by the second nitro 
carbanion led to the di-nitro intermediate B and intramolecular cyclization gave the 
substituted isoxazoline-N-oxide as single trans isomer in moderate to good yields 
(Scheme 17). 
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Scheme 17.  Isoxazoline-N-oxide synthesis in previous study and its mechanism 
O2N
R1
N
H
R1
N
R2
NO OH
R1
O2N
R2 A
R1
N
R2
H
NO2
B
N O
O
R3
R1
R1
R2
R2
1
3 4
5 Nu-LG-NO2-
R1
NO2
+ L-proline (0.2 eq.), NaOAc (1.0 eq.)
DMSO, r.t., 10 h
OAc N O
R1 R1
O
R3
R2 R2
R3
R2
 single trans isomers
55 - 88% yields
R3
OAc
R2
R3
R1
NR2
R3 NO2
R1 R2
O
O
 
 
This cascade approach was attractive since it revealed a new strategy in producing 
active diene intermediate A in-situ, which allowed the preparation of isoxazoline N-oxide 
without going through the challenging nitronate intermediate synthesis in literature 
reported studies. Moreover, the reaction condition tended to be milder and two vinyl 
groups were set up at the C3 and C5 positions for further easy derivatizations. 
 
However, despite the high efficiency, this cascade reaction did suffer from three 
obvious problems:  
 
a) The C-4 substitution was limited to only aliphatic groups, since vinyl 
esters were used as starting materials. 
b) Two identical vinyl groups on both C-3 and C-5 positions, which 
lowers the synthetic value of the molecules. 
c) Poor enantioselectivity when chiral secondary amines were applied as 
catalysts. (< 15% e.e. was observed in all cases). 
 
Owing to the unique mechanism and high efficiency, it is expected that successful 
strategies in overcoming the above-mentioned limitations will lead to the discovery of 
concise synthesis of the isoxazoline-N-oxide motifs. 
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3.2  Research Objectives 
3.2.1  Asymmetric three-component synthesis of isoxazoline-N-oxide 
As described in the last section, three limitations need to be extended. First, more 
various functionalities are supposed to be suitable for C4 position, instead of only 
aliphatic groups. Second, in order to differentiate the functional groups at C3 and C5 
positions, further modifications are needed. Or, a third component needs to be introduced 
into the reaction system. Third, asymmetric synthesis needs to be investigated to reach 
optical active molecules for further natural product derivatives syntheses.  
 
3.2.2  Further application towards the synthesis of natural products 
With the asymmetric three-component synthesis of the isoxazoline-N-oxide 
motifs, a wide range of natural molecules or their backbones are expected to be readily   
realized, due to the well set-up of the multi-functionality at the very beginning.  
 
3.3  Results and Discussion 
3.3.1  Diversity of C-4 position in isoxazoline-N-oxides 
Since we had known that the key step for the isoxazoline-N-oxide synthesis was 
the formation of diene intermediate A. Besides the [3+2] cycloaddition approach 
(Scheme 17), we postulated that the intermediate could be accessible through the Lewis 
based mediated Henry aldol condensation between nitroalkene 1 and aldehyde 14a. Thus, 
the desired homo-isoxazoline-N-oxide 15a would be prepared through a more general 
process with broader substrate scopes on the C-4 position.  
 
Scheme 18. Proposed isoxazoline-N-oxide synthesis through proline promoted 
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3.3.1.1 Reaction optimization 
The reactions between 1a and benzyl aldehyde 14a were investigated. As 
expected, isoxazoline-N-oxide 15a was obtained as single trans diastereomer. The 
reaction condition optimization is summarized in Table 7. 
 
Table. 7 One-pot synthesis of homo-isoxazoline-N-oxide by Lewis base 
activated nitroalkene-aldehyde condensation a 
Ph
Me
NO2 Ph H
O N O
O
Ph
Ph
Ph
+ proline (LB)
1a 14a
Ph
NO2Ph
Active diene intermediate
A
single diasteromer
15a  
 
entry sol. LB(0.2 eq.) additive t(h) conv.(%)b yield(%)c 
1 DMSO proline -- 12 46 11 
2 DMSO -- NaOAc (1.0 eq) 12 79 <5 
3 DMSO proline NaOAc (1.0 eq) 3 >95 87d 
4 DMSO proline K2CO3 (0.5eq) 3 >95 92d 
5 DMSO proline NaOtBu (1.0eq) 3 84 70d 
6 DMSO proline Et3N (1.0 eq) 12 89 65d 
7 DMSO otherse K2CO3 (0.5eq) 3 >95 <50 
8 THF proline K2CO3 (0.5eq) 12 23 19 
9 THF proline BF3-THF(1.0 eq) 12 35 trace 
10 othersf proline K2CO3 (0.5eq) 3~12 45~90 13~49 
11 MeOH proline K2CO3 (0.5eq) 12 >95 43 
12 DMSO pyrrolidine K2CO3 (0.5eq) 3 >95 88 
a general reaction condition: 1a (2.1 eq.), 14a (1.0 eq., 0.1 M) and catalysts were 
mixed in solvents. The reactions were monitored by TLC; b based on the 
consumption of 14a; c NMR yield with 1,3,5-trimethoxybenzene as internal 
standard; d isolated yield; e other Lewis bases include DMAP, DABCO, NMI, 
Ph3P.  f other solvents include EtOAc, DCM, Toluene, MeCN, iPrOH. 
 
Similar to the previous reported cases, the reaction did not precede well when 
only proline was present since base was required for neutralization of the HNO2 
generated in the reaction (entry 1); nor only weak base NaOAc was applied without 
Lewis base activation of nitroalkene (entry 2). The major side reaction was the 
polymerization of 1a. However, the desired isoxazoline-N-oxide 14a was obtained in 
good yield when both proline (0.2 eq.) and NaOAc (1.0 eq.) were used and the reaction 
finished within 3 hours (entry 3), much faster than the previous vinyl ester version of 
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synthesis, which required at least 7 hours. Strong base, such as tBuONa, caused 
significant polymerization of 1a (entries 5, 6) and 0.5 equivalent of K2CO3 was identified 
as the optimal choice with minimum polymerization of nitroalkene and the maximum 
yield (entry 4). Other common nucleophilic base catalysts, such as DMAP, DABCO, 
NMI etc. have also been tested, giving only moderate yields (entry 7), yet confirming the 
Lewis base catalysis mechanism. These results highlighted the unique reaction nature of 
proline nucleophilic addition to nitroalkenes: the problematic nitroalkene polymerization 
associated with the Lewis base catalyzed mechanism was successfully avoided by 
forming a rather stable H-bond intermediate (Part I, 1.3, Scheme 6). Pyrrolidine 
(secondary amine) was also tested to be effective LB catalyst for this transformation 
(entry 12, 88% yield) and proline was selected in this study because of its practical nature 
(low cost and easy to handle). Other solvents were also tested, including EtOAc, DCM, 
toluene, MeCN, iPrOH, giving lower yields compared to DMSO (entry 10). 
 
Scheme 19. Experimental confirmation of Lewis base catalysis mechanism  
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Furthermore, to confirm the Lewis base addition mechanism in this 
transformation, the allylic nitro compound (1a´) was prepared and. As expected, a much 
slower reaction was observed with low yield (32% yield while 95% starting material was 
consumed in 12 hours). This significant difference between 1a and 1a´ as the starting 
materials provided strong evidence for the proposed Lewis base addition mechanism 
other than the alternative base deprotonation path. 
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3.3.1.2 Substrate scope 
With the optimal reaction conditions in hand, various isoxazoline-N-oxides were 
prepared with different substitution on C-4 position from corresponding aldehydes as 
shown in Table 8. 
 
Table 8. Substrate scope of “homo” isoxazoline-N-oxide  
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Ph
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O
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O
N O
O
O
O
N O
O
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Me
Me
N O
O
Me
Me O
NO2
15u, 46% 15v, 74% 15w, 71%
 
 
Among all these substrates, excellent diastereoselectivity were achieved and only 
trans isomers were obtained. This reaction was not only subjected to the simple aromatic 
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aldehydes with excellent yields, but also the heterocyclic aromatic aldehydes with good 
yields. For aliphatic aldehydes, the reaction also worked though lower yields. This might 
be caused by the side reactions resulting from the formation of enamines in the presence 
of proline. In these cases, the previously reported [3+2] cyclization strategy could be an 
alternative route for the synthesis of desired products. Therefore, combining these two 
strategies, large variety of functional groups could be readily introduced into the C-4 
position with high efficiency. 
 
3.3.2  Differentiation of C-3 and C-5 position in isoxazoline-N-oxides 
3.3.2.1 Characterization of diene intermediate and cross cyclization 
As discussed earlier, the nitro-diene A was the key intermediate that accounted 
for the formation of the desired product. Interestingly, previous experiment of deuterium 
exchange suggested that the C-4 stereogenic center was not epimerizable (Scheme 20). 
Therefore, the absolute stereochemistry of the products would be determined by the 
second nucleophilic addition to the diene. Efforts were then made in obtaining the diene 
intermediate. 
 
Scheme 20. Deuterium exchange experiment  
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As show in Scheme 21, diene A´ was successfully isolated even though as a 
mixture of isomers (Z/E = 1:1.5, conformations were determined by 2D NMR, see 
experimental section). The formation of Z/E isomer mixture raised concern for the 
potential asymmetric synthesis, since it was hard to achieve good enantioselectivity with 
two diastereomeric intermediates (Z/E isomers) present in such a similar ratio. To 
investigate the diene’s reactivity, a cross-condensation between diene A´ and nitroalkene 
1c was then performed. Interestingly, mixtures of all the four possible isoxazoline-N-
oxides were obtained in the crude NMR (Scheme 21), which indicated the equilibrium 
between nitroalkene A´ and starting materials (nitroalkene 1b and aldehyde 14b).  
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Scheme 21. Cross condensation with nitro-diene  
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Another important information from these two experiments is that the 
enantioselective synthesis of the desired isoxazoline-N-oxides relied on the different 
reactivity of the two isomers, under the assumption that these two isomers could inter-
convert into each other (dynamic kinetic resolution). Then, it is feasible to control the C-4 
stereogenic center with proper nucleophile with dynamic kinetic resolution (vide infra). 
 
3.3.2.2  Chemical difference of vinyl groups on C-3 and C-5 
Scheme 22. Chemoselective differentiation of vinyl groups on C-3 and C-5 
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Although there are two exactly same vinyl groups on the C-3 and C-5 positions of 
the “homo” isoxazoline-N-oxide molecules, they are different by electronic effects. One 
tends to accept electrons (C-3 position), while the other tends to give electrons (C-5 
position). Thus, chemoselective oxidation would be possible to differentiate these two 
vinyl groups. When treated with m-CPBA, C-3 vinyl group of 15a was readily converted 
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into epoxide 16a with 1:2 d.r.. When OsO4/NaIO4 condition was applied, C-5 vinyl group 
was oxidized into ketone 18a in good yield. Other chemoselective operations could be 
applied for the differentiation of C-3 and C-5 vinyl groups, however, multi-steps are 
required which makes the described strategy less practical. Thus, the desire to develop a 
three-component cascade synthesis of isoxazoline-N-oxide drove us ahead.  
 
3.3.3  Three-component cascade synthesis of isoxazoline-N-oxide 
3.3.3.1 Probing for the appropriate third component  
As demonstrated by our previous work, the diene A was the key intermediate for 
this synthesis. We postulated an alternative path that involved the third component with 
the featured functionality as Nu-LG moiety (nucleophile tethered leaving group) as 
shown in Scheme 23. Based on this hypothesis, compounds with Nu-LG functionality 
were applied to react with nitroalkene 1a and aldehyde 14a. The results are summarized 
in Table 9. 
 
Scheme 23. Proposed three-component reaction involving a Nu-LG moiety 
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As shown in Table 9, application of 17a and 17b, under the previous developed 
optimal condition, produced only the homo-isoxazoline-N-oxide 15a as the major 
product, which was probably due to the low reactivity of the sulfonate nucleophiles 
(entries 1 and 2). The phosphine ylide 17c and amine ylide 17d did generate the desired 
product 18, although in low yields.  Also, the reaction suffered from significant 
competition of homo-condensation (entries 3 and 4). To our delight, application of 
sulphur ylides 17e and 17f gave compound 18 as the dominant product in excellent yields 
(entries 5 and 6) with only trace amount of 15a observed. 
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Table 9. Substrates screening for the third component (Nu-LG)  
1a
+
14a
+ Nu LG
17
DMSO, r.t., 3~5h
proline(0.1 eq.), K2CO3 (0.5 eq.)
ON
O
Ph
Ph
Ph
Homo product 15a 18
Nu
ON
O
PhPh
H3C Ts H2N Ts
O
Ph PPh3
Br-
O
Ph NEt3
Br-
O
Ph SMe2
Br-
O
MeO SMe2
Br-
17a 17b 17c 17d 17e 17f
Ph
Me
NO2 Ph H
O
 
 
product product entry Nu-LG 15a (%) 18 (%) entry Nu-LG 15a (%) 18 (%) 
1 17a 76b <5 4 17d 74b 18b 
2 17b 85b <5 5 17e <5b 93c 
3 18c 58b 35b 6 17f <5b 91c 
a reaction condition: 1a (1.0 eq.), 14a (1.0 eq., 0.15 M) and catalysts were mixed in 
solvents.  The reactions were monitored by TLC; b NMR yields with 1,3,5-
trimethoxybenzene as internal standard; c isolated yield. 
 
Notably, as demonstrated in Scheme 24, it is well known that reaction between 
aldehyde 14a and sulfur ylide 17e could produce the corresponding epoxide 15´ in great 
yield under basic conditions. Without the involvement of the sulfur ylide, the dominant 
product would be 15a, as the “homo” isoxazoline-N-oxide product. However, under 
current reaction conditions, no significant amount of epoxide or the homo product was 
observed. This information further highlighted the superior chemoselectivity among the 
three designated components. The significance of the reported cascade process had also 
been emphasized: in the presence of alternative reaction paths (formation of homo-
condensation product 15a or epoxide 15´), well-designed cascade process could direct the 
reaction pathway to products that would not be achieved from the step-wise approach. 
 
Scheme 24. Perfect chemoselectivity among the three components  
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3.3.3.2  Substrate scope of the designed cascade reaction 
Table 10. Representative isoxazoline-N-oxides syntheses via the designed three-
component strategy a 
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DMSO, r.t., 2-4 h
proline(0.1 eq.), K2CO3 (0.5 eq.)
ON
O
R1Ph
MePh
NO2
+
O
HR1
+ S R2
Br- R2
18
ON
O
Ph
Ph
O
18a, 91%
ON
O
Ph
Ph
O
18b, 92%
ON
O
Ph
Ph
O
18c, 73%
ON
O
Ph
Ph
O
18d, 68%
O
Me
ON
O
Ph
Ph
O
18e, 52%
ON
O
Ph
Ph
O
18f, 92%
ON
O
Ph
CO2Et
18g, 88%
ON
O
Ph
CO2Et
18h, 92%
ON
O
Ph
O
18l, 92%
ON
O
Ph
O
18k, 92%
ON
O
Ph
O
18j, 73%
ON
O
Ph
O
18i, 91%
NO2
N
Br
Me NO2
Br
OMe
Br Br
NO2
 
a reaction condition: 1a (1.1 eq.), 14 (1.0 eq., 0.15 M) and ylide 17 (1.1 eq.) were 
mixed with proline (0.1 eq.) and K2CO3 (0.5 eq.) in DMSO; isolated yields. 
 
Up to this stage, the isoxazoline-N-oxide synthesis had been successfully 
developed into a real three-component cascade reaction. The summarized substrate scope 
investigation is shown in Table 10. Various aldehydes were tested, including simple 
aromatic aldehydes and heterocyclic aromatic aldehydes (18c, 18l), good to excellent 
yields were received. The aliphatic aldehydes, linear and branched (18d, 18e), were also 
subjected to the designed cascade reaction system. Different sulfur ylides were also 
investigated, giving the desirable performance.  
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3.3.4  Asymmetric cascade synthesis of isoxazoline-N-oxides 
3.3.4.1 Attempts of chiral Lewis base catalysis  
Table 11. Summarized chiral Lewis base catalysis for the asymmetric synthesis a 
 
N
H
COOH N
H
N
H NH
N
N
H
Ph
OH
Ph
Ph
Ph
OTMS
H
N
H
N
S
Ph-3,5, diCF3
O
Bn
N
H
N
O
OH
N
H
N
O
NH
N
H
N
OH
N
H
N
O
NH
HN
S
Ph-3,5, diCF3Me
yield 90%, e.e. 5%
-25 ºC, MeOH, 36h
yield 84%, e.e. 8%
-10 ºC, MeOH, 48h
yield 63%, e.e. 12%
0 ºC, MeOH, 48h
yield 46%, e.e. -5%
-15 ºC, MeCN, 36h
yield 74%, e.e. 10%
0 ºC, MeOH, 36h
yield 76%, e.e. -6%
-25 ºC, MeNO2, 36h
yield 87%, e.e. -11%
-10 ºC, MeOH, 36h
yield 70%, e.e. -5%
-25 ºC, MeNO2, 36h
yield 61%, e.e. -13%
0 ºC, MeCN, 36h
cat-1 cat-2 cat-3 cat-4 cat-5
cat-5 cat-6 cat-7 cat-8
 
a reaction condition: 1a (1.1 eq.), 14a (1.0 eq., 0.15 M) and ylide 17b (1.1 eq.) were mixed with catalyst 
(0.2 eq.) and K2CO3 (0.5 eq.) in solvents; NMR yields of 18h; data presented were the best combinations of 
yield and e.e. under the listed conditions. 
 
Enantioselective synthesis of isoxazoline derivatives is considered as one 
challenging task and few asymmetric syntheses of this compound have been reported.31,32 
Discussed in previous sections, although the Lewis base catalyzed cascade approach gave 
excellent trans diastereoselectivity. However, during the screening of chiral Lewis bases 
as catalysts, no encouraging enantioselectivity was observed (Table 11, <15% e.e. in all 
cases), which might be due to the poor involvement of the catalysts in the 
stereochemistry-determining step (formation of the C-4 stereogenic center).  
 
3.3.4.2 Attempts of chiral auxiliary and condition optimization 
Based on previous discussion (2.3.2.1, Part II), one valid approach for 
asymmetric synthesis of fully substituted isoxazoline-N-oxides is to develop 
stereoselective nucleophilic addition of ylides to the diene intermediates (A in Table 7), 
through dynamic kinetic resolution. Thus, it is possible to deliver the chirality from the 
chiral auxiliary type of ylides. Several literature reported chiral ylides were then 
synthesized and applied (Table 12).  
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Table 12. Condition optimization of different auxiliaries asymmetric synthesis a  
+
1a 14a aux
+
19
MePh
NO2 O
HPh
R
SR R'
O
Br-
N O
Ph
O
Ph
O
R'
N
EtO2C
OMe
N
OMe
Br-
aux-a
S
O R2
R1
Br-
aux-b: R1=Me, R2=H, R3=Ph;
aux-c: R1=Bn, R2=H,  R3=OEt;
aux-d: R1=Me, R2=H,  R3=OEt;
aux-e: R1=Bn, R2=Me, R3=OEt;
aux-f:  R1=Me, R2=Me, R3=OEt;
R3
O
 
 
entry sol. LB (0.2 eq.) base (1.0 eq.) aux temp (oC) time (h) yield%b (e.e.%)c 
1 DMSO L-proline K2CO3 aux-a r.t. 12 <5 (n.d.)d 
2 DMSO L-proline K2CO3 aux-b r.t. 12 <5 (n.d.)d 
3 DMSO L-proline K2CO3 aux-c r.t. 6 19 (n.d.) 
4 Acetone L-proline K2CO3 aux-c r.t. 6 16 (n.d.) 
5 THF L-proline K2CO3 aux-c r.t. 24 13 (n.d.) 
6 MeOH L-proline K2CO3 aux-c r.t. 6 60e (36) 
7 MeOH L-proline K2CO3 aux-d r.t. 6 81e (75) 
8 MeOH L-proline K2CO3 aux-e r.t. 6 23 (40) 
9 MeOH L-proline K2CO3 aux-f r.t. 6 43 (59) 
10 MeOH L-proline Cs2CO3 aux-d r.t. 6 54 (76) 
11 MeOH L-proline Cs2CO3 aux-d -25 48 87e (82) 
12 MeOH L-proline Cs2CO3 aux-d -40 60 62e (82) 
13 MeOH D-proline Cs2CO3 aux-d -25 48 90e (86) 
14 MeOH pyrrolidine Cs2CO3 aux-d -25 48 86e (91) 
15 MeOH N-Me-Gly Cs2CO3 aux-d -25 48 51e (89) 
a general reaction condition: 1a (1.2 eq.), 14a (1.0 eq., 0.15 M) and aux (1.1 eq.) . Fast ester 
exchange happened in MeOH, only methyl ester was detected. b NMR yields with 1,3,5-
trimethoxybenzene as internal standard; c determined by chiral HPLC; d major products were 
homo-isoxazoline 15a and the epoxide 15´; e isolated yield. 
 
As shown in Table 12, the quinine derived chiral tertiary amine ylide aux-a, well 
developed by Tang et. al.,31a did not promote the hetero coupling reaction (entry 1), 
giving the homo coupling product 15a (>85% yield). This was also suggested by our 
previous study (Table 9). Then we switch to camphor derived thio ether ylides, since 
sulfur ylides gave excellent yields for the three-component synthesis of isoxazoline-N-
oxides. However, similar result was observed with ketone ylide aux-b (entry 2), which 
was likely caused by the reduced nucleophilicity associated with more hindered chiral 
ylide (comparing with the simple ketone ylide 17e, which gave the desired hetero 
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coupling product in excellent yields). The ester modified ylide aux-c did give the hetero-
coupling product 19 though with poor yield (entry 3). Solvent screening indicated that 
MeOH was the optimal solvent (entries 4-6). Further modification on the ylides revealed 
aux-d (R1 = Me and R2 =H) as the optimal auxiliary (entry 7) and Cs2CO3 as preferred 
choice of base (entry 10), producing the desired product 19 in excellent yield. In addition, 
to our great please, good enantioselectivity was also received (75% e.e.). Considering that 
diene intermediate would likely give low Z/E selectivity, the success in obtaining good 
enantioselectivity supported the hypothesis that chiral ylide nucleophile reacted with the 
diene intermediate with good stereochemistry control and the asymmetric synthesis 
achieved through dynamic kinetic resolution (DKR).  
 
Interestingly, the secondary amine Lewis base catalyst also indicated influence on 
the stereochemistry of the product.  With either L-proline or D-proline, the absolute 
stereochemistry of the product 19 was identical (entries 11 and 13), which indicated that 
the ylide auxiliary dominated the stereochemistry control in the diene nucleophilic 
addition. However, to our surprise, slightly improved stereoselectivity was observed 
when D-proline was applied as catalyst (entry 13). Further investigation revealed that 
achiral secondary amine Lewis base, such as pyrrolidine, gave the best stereoselectivity. 
The desired product 19 was also received in excellent yield (entry 14).  Application of N-
methyl-glycine gave similar good enantioselectivity, though with lower yield (entry 15). 
Notably, >50% of the camphor auxiliary was recovered during the purification.  
 
Scheme 25. X-ray structure of related camphor-derived ylide aux-g 
S
O
Br-
S-O = 2.747 Å
H
O
Br
aux-g
 
 
Moreover, one related camphor-derived auxiliary aux-g presented us an 
interesting finding (Scheme 25). An intramolecular hydrogen bonding between the 
alcohol and sulfonium was proposed in the X-ray crystallography analysis (S–O bond 
distance 2.747 å), which might account for the optimal yield and stereoselectivity. 
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3.3.4.3 Substrate scope of asymmetric three-component cascade 
synthesis of isoxazoline-N-oxides 
Table 13. Substrate scope of asymmetric three-component synthesis  
+
1a 14a
+
19
R
NO2 O
HR2
N O
R1
O
CO2Me
R2
R
S
OH
OEt
O
Br-
aux-d
pyrrolidine (0.2 eq.)
Cs2CO3 (1.0 eq.)
MeOH, -25 ºC
 
N O
O
CO2Me
Ph
19a
86%, 91% e.e.
N O
O
CO2Me
Ph
19b
82%, 94% e.e.
N O
O
CO2Me
Ph
19c
89%, 91% e.e.
N O
O
CO2Me
Ph N
19d
90%, 80% e.e.
N O
O
CO2Me
Ph
19e
71%, 90% e.e.
OMe Me
O
N O
O
CO2Me
Ph
19f
86%, 96% e.e.
N O
O
CO2Me
Ph
19g
63%, 88% e.e.
N O
O
CO2Me
Ph
19h
92%, 81% e.e.
N O
O
CO2Me
Ph
19i
82%, 70% e.e.
N O
O
CO2Me
Ph
19j
84%, 88% e.e.
NO2
NO2 OMe
N O
O
CO2Me
Ph
19k
79%, 92% e.e.
Me
N O
O
CO2Me
p-Cl-C6H4
19l
81%, 76% e.e.
N O
O
CO2Me
Me
19p
75%, 81% e.e.
OMe
Me
N O
O
CO2Me
p-Cl-C6H4
19m
88%, 81% e.e.
N O
O
CO2Me
p-Cl-C6H4
19n
81%, 92% e.e.
O
OMe
OMe
N O
O
CO2Me
p-Cl-C6H4
19o
91%, 93% e.e.
N O
O
CO2Me
Me
19q
70%, 93% e.e.
N O
O
CO2Me
Me
19r
80%, 85% e.e.
N O
O
CO2Me
19s
80%, 90% e.e.
N O
O
CO2Me
19t
56%, 91% e.e.
N O
O
CO2Me
19u
93%, 65% e.e.
Me NO2
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As shown in Table 13, the reaction tolerates various nitroalkenes, including aryl, 
alkyl and cyclic structures. Moreover, various aldehydes, including aromatic, aliphatic 
and heteroaromatic substrates, were also suitable for this transformation. Compared to the 
nitroalkenes, the aldehyde substrates indicated stronger influence to the overall yield and 
stereoselectivity. With electron deficient aldehyde (i.e. 19h), excellent yield was 
obtained. However, the enantioselectivity was slightly decreased. This could be caused 
by the higher reactivity of the diene intermediate, which led to the lower efficiency in the 
DKR step. Sterically hindered aldehydes (i.e. 19f), on the other hand, promoted the 
stereoselectivity by providing better spatial control (larger difference of the reaction rates 
for the two Z/E isomers). As a result, excellent enantioselectivity were obtained. With the 
same reason, good enantioselectivity was also received for aliphatic aldehyde (19g), 
though in moderate yield. Similar steric-electronic effect of the aldehyde was observed 
for all the other substrates tested. 
 
3.3.5  Further application of isoxazoline-N-oxide product in total 
synthesis of (-) Clausenamide derivatives 
3.3.5.1 Asymmetric synthesis of substituted #-lactam 
This new enantioselective isoxazoline-N-oxides synthesis not only provided a 
general, highly efficient approach in preparing isoxazolines, but also gave opportunity to 
reach complex molecules in simple steps. One particularly interesting class of molecules 
is the #-lactams due to their significance in biological and pharmatheutical research.  
 
As shown in Scheme 25A, during our previous study, the reductive opening of 
isoxazoline ring could be highly diastereoselective, while treating homo isoxazoline 
derivative with LiAlH4 gave the ring opening product "-amino alcohol as a single 
diastereomers.30 This stereoselective reduction was probably achieved through a 
diastereoselective reduction of imine intermediate with possible metal chelated six-
member-ring transition state. Encouraged by this result, we envisioned that compounds 
19 could be applied as common precursors for the stereoselective construction of #-
lactams 20 through one simple reduction step (Scheme 26B). The key concern for this 
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transformation is the diastereoselectivity, especially on the C-5 position, which will be 
determined by the imine reduction. 
 
Scheme 26. Diastereoselective ring opening to reach #-lactam 
1) LAH, THF
2) Ac2O, Et3N, DCM
AcHN OH
85% yield,
single diastereomer
N O
N O
R1
R2
19
CO2Me
O
red.
R1
N
R2
O
CO2Me
Mn+H H
R1
NH2
R2
OH
CO2Me N
H
R1
R2 OH
O1 2
34
5
20
N
H
Ph OH
O
HPh
HO
21
Clausenamide 
derivatives
(A)
(B)
 
 
Furthermore, we expected simple transformations from 20 would lead to the 
Clausenamide derivatives 21,33 which are a class of natural products with #-lactam 
moieties and concise but complicated stereochemistry. As a model study, different 
reduction methods were applied to 19a targeting the #-lactam 20 and the Clausenamide 
derivatives 21. The proposed synthetic pathway was described in Scheme 27. 
 
Scheme 27. Retrosynthetic design of Clausenamide derivatives 20 
N O
OHPh
Ph
HO
Me
H N O
OTBSPh
Ph
TBSO
H NH
O
OHPh
Ph
HO
H
H2N
HO
Ph
HO
Ph
CO2Me N
OO
Ph
HO
Ph
CO2Me 19a
21 25
Me
24 23
25'
 
 
A few simple steps were expected to reach the target molecule. The final product 
21 could be obtained from the TBAF deprotection of di-TBS silyl ether 25´, which was 
methylated after TBS protection from 25. The #-lactam 25 could be chemoselectively 
reduced from the hydroxyl isoxazoline-N-oxide 23 to open the heterocycle and generate 
the amino alcohol 24 followed by the expected intramolecular amino-ester exchange. 
Ozonolysis or OsO4/NaIO4 oxidation could readily convert the terminal double bond into 
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ketone, after which diastereoselective reduction would be applied to reach to 23 from 
isoxazoline-N-oxide 19a. 
 
3.3.5.2 Asymmetric synthesis Clausenamide analogue 
Scheme 28. First attempt based on the proposed synthetic pathway 
N O
O
Ph Ph
CO2Me
OsO4/ NaIO4
THF/H2O, 0 ºC
N O
O
Ph
O
Ph
CO2Me NaBH4, MeOH
N O
O
Ph
HO
Ph
CO2Me
NiCl2•6H2O/NaBH4
MeOH, -40 ºC~r.t. H2N
HO
Ph
HO
Ph
CO2Me
N
H
O
OHPh
Ph
HO TBSOTf/Et3N;
MeI, K2CO3;
then TBAF
N O
OHPh
Ph
HO
Me
HH
91% -40 ºC, 3h
d.r. >10:1
overnight
19a 22 23
24 25 21
(A)
 
 
Efforts were then put in to the designed synthesis pathway. (Scheme 28A) As 
expected, 19a was oxidized to reach ketone 22 in 91% yield. Simple NaBH4 reduction 
was applied under low temperature (-40 ºC) to reach alcohol 23. The reaction revealed a 
high diastereo ratio (>10:1), based on both TLC detection and in situ NMR study. 
However, this hydroxyl isoxazoline-N-oxide was quite unstable toward room temperature 
and acidic conditions. Thus, one more reductive operation was followed up in one pot. 
NiCl2•6H2O/NaBH4 was reported as one of the typical choices to chemoselectively 
reduce isoxazoline type of heterocycles. But the performance of this reduction failed to 
yield the desired di-ol #-lactam, whose hydroxyl groups were supposed to be protected by 
TBSOTf. The problem could be, also confirmed in later studies, the sensitivity of the !-
oxy ester moiety to NaBH4. So, alternative routes were then planned and carried out 
(Scheme29).  
 
Since the alcohol 23 in previous attempt was quite fragile, we thought it might be 
due to the high valence of the nitrogen in the isoxazoline-N-oxide heterocycle (Scheme 
29B). Thus, 19a was reduced to isoxazoline using (MeO)3P as solvent under 115 ºC 
reflux, after which OsO4/NaIO4 oxidation was then applied to give ketone 26 in 72% 
yield for 2 steps. NaBH4 reduction under low temperature, alcohol 27 was obtained in 
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86% yield with d.r. 8:1. Notably, the !-oxy ester moiety was very sensitive to NaBH4 
environment. Any reductant in excess tended to reduce the ester into alcohol (see 
experimental section). Three different reductive conditions were tested for the ring-
opening step to reach the amino alcohol 28, but no product was observed. 
NiCl2•6H2O/NaBH4 reduction presented the previous problem, while Pd/C H2 reduction 
stopped at the diol oxime. During the treatment of Zn/H+, 27 did disappear on TLC, but 
no desired product was successfully isolated. The desired product 25 is a diol lactam that 
is extremely polar and the Zn dust was used in great excess (20 eq.), both of which 
increased the difficulty for isolation process. 
 
Scheme 29. Another two alternative routes 
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Another attempt started from Pd/C, H2 reduction of ketone isoxazoline-N-oxide 
22. Hydroxyl oxime 29 was prepared in excellent yield from 19a. NaBH4 reduction 
followed by TBSOTf was then applied for the protection of alcohols, yielding the tri-TBS 
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silyl ether in great yield. However, further reduction of the oxime silyl ether moiety failed 
to generate the amine group (Scheme 29C).  
Scheme 30. Zn/H+ reduction of vinyl isoxazoline-N-oxide 19a  
N O
O
Ph Ph
CO2Me Zn/HCl
N
H
O
OHPh
Ph
Me
O HO
Ph Ph
CO2MeMe
67%, Z/E  5:1 20%
N
H
O
OHPh
Ph
7%, d.r. 3:1
+ +
19a 31 31' 31''
MeOH, r.t.
 
 
Although it requires only a few oxidation and reduction steps to reach the target 
molecule, the myth of this five-membered heterocycle certainly has a secret but specific 
map, which had to be probed by different combination of available operation techniques. 
Not long after, when attempt was put in for the reduction of 19a by Zn/H+, two #-lactams 
were tested after the full conversion of the starting material (Scheme 30). One is the vinyl 
#-lactam 31´ which was the major product (67% yield, Z/E 5:1), the other is the allylic #-
lactam 31. Although only 7% yield (d.r. 3:1), this finding certainly lit up our hope 
towards the target molecule 21.  
 
Scheme 31. Synthesis of 3-ent-6-ent-Clausenamide 33 
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After careful condition optimization, the yield of the desired molecule 31 raised 
up to 57% yield. As shown in Scheme 31, the Clausenamide derivatives 33 was prepared 
within 5 steps from nitroalkene 1a with 38% overall yield, in gram scale. The synthesis 
involved neither exotic reagents nor protecting groups, which gave the high atomic 
efficiency. Moreover, excellent stereochemistry retention was achieved in this 
transformation, where 33 was prepared in 85% e.e.. One recrystallization operation easily 
improved the purity to >99% e.e. (determined by chiral HPLC, experimental section).  
The reduction of 32 was highly diastereoselective and the relative stereochemistry of 33 
was undoubtedly confirmed by X-ray crystallography, as an all-cis-#-lactam.  
 
Notably, the Clausenamide derivative 33 is one of the most challenging isomers 
in the Clausenamide family due to its all-cis-substitution on the #-lactam ring. With the 
reported synthetic route, preparation of different Clausenamide derivatives, including 
different substitute groups on C-4 and C-5 position and different stereoisomers at all four 
stereogenic centers, is accessible with simple modifications. Construction of compound 
library based on the Clausenamide core skeleton is currently undergoing in our group. 
 
3.4  Conclusion 
Although a facile proline Lewis base catalyzed isoxazoline-N-oxide synthesis was 
previously discovered in our group, three limitations needed to be extended in order to 
make the overall protocol more general and accessible towards the asymmetric synthesis 
of complex building blocks or even natural products. 
 
The overall methodology was based on Lewis base catalyzed multi-component 
condensation of nitroalkene, aldehyde and sulfur ylide. This had allowed easy 
derivatization to achieve various substitutions at selected positions. Excellent yields and 
enantioselectivity were obtained when camphor derived sulfur ylide was applied. With 
the high efficiency and excellent chemo and enantioselectivity, this reported method had 
provided a new strategy for the preparation of isoxazoline derivatives, which could be 
applied either for the new drug candidate discovery or for the construction of complex 
building blocks.  Successful transformation of isoxazoline-N-oxide 19a into the all-cis #-
lactam in a highly stereoselective fashion and gram-scale synthesis of Clausenamide 
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analogue 9e further highlighted the advantage of the reported method as a powerful 
approach in complex molecules preparation with high atom efficiency and good 
stereoselectivity. 
 
 
This project is collaborated with Lekh Nath S. Gautam, Dr. Jeffrey Petersen and 
Dr. Novruz Akhmedov. Lekh Nath helped with part of the substrates synthesis and 
supporting information preparation. Dr. Petersen helped with the X-ray crystallography 
study to determine the relative stereochemistry and structures of target compounds. Dr. 
Akhmedov carried out the extensive NMR studies of the derivatization products. 
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Part IV 
One-Step Synthesis of Substituted Di-Hydrofurans from 
Lewis Base Catalyzed Three-Component Condensation 
4.1  Introduction 
4.1.1  Literature reported furan and di-hydrofuran synthesis 
Furans and their derivatives are an important class of compounds in chemical and 
biological research.34 The first documented approaches for the synthesis of substituted 
furan was the Feist-Bénary reaction, which was developed in the early 20th century. 1,3-
di-carbonyl compounds were used to react with a-halo-ketones under basic conditions 
(Scheme 32).35 Some modified conditions have also been reported (often referred as 
“interrupted” Feist-Bénary reaction) to avoid the water elimination, giving the hydroxyl 
substituted hydrofurans. In 2005, Calter et. al. successfully developed a asymmetric 
pathway of the “interrupted” Feist-Bénary furan synthesis. 36 
 
Scheme 32. First examples of furan derivatives synthesis known in literature 
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Meanwhile, oxidative coupling strategies had also been well studied. Two 
representative examples are Ce (IV) or Mn (III) oxidative coupling of 1,3 diketo 
functionalities and alkenes 37  (Scheme 33A) and the palladium (II) catalysis via 
propargyl-allenyl isomerization and Alder-Ene transformation38 (Scheme 33B).  
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Scheme 33. Oxidative coupling and Pd (II) catalysis in di-hydrofuran syntheses 
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In 1967, during the investigation of cyclopropanation of !,"-enones and sulfur 
ylides, Payne discovered a di-hydrofuran byproduct through a formal [4+1] annulation 
pathway.39 This finding had been well studied in recent years by Ma,40a Liang40b and 
Piras40c (Scheme 34A). However, these strategies suffered either low diastereoselectivity 
problems or the competitive cyclopropanation side reaction. More recently, Tang and co-
workers41 had reported an enantioselective synthesis of optical active di-hydrofurans via 
camphor derived ylide auxiliary. Excellent yields and enantioselectivity were received, 
although the substrate scope was limited (Scheme 34B). Moreover, these methods 
usually involved rather specific !-ylidene-"-diketones and ylide auxiliaries, most of 
which were not readily available and lowered the atomic efficiency of the overall 
methods.  
 
Scheme 34. Formal [4+1] annulation strategy for the synthesis of di-hydrofurans 
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Thus, there is a strong desire for new method that overcomes all the previous 
problems and allows the easy preparation of dihydrofurans (DHF) with high atom 
efficiency and, more importantly, feasibility to assemble various substitution patterns. 
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4.1.2  Proposal for DHF synthesis inspired by our previous studies 
In our previous studies, several amine catalyzed new multi-component 
condensations had led to the formation of various heterocycles with good to excellent 
yields and stereoselectivity, represented by the isoxazoline-N-oxide synthesis 
(Scheme35A) and the 4,5-disubstituted 1,2,3-NH triazole synthesis (Scheme 35B).  
 
Scheme 35. Nitro group as leaving group in previous studies 
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Both reactions required the formation of the nitro-diene intermediate A via the 
Henry-Aldol condensation of Lewis base (proline) activated nitroalkene and aldehyde.  
This highly reactive intermediate could then react with proper nucleophiles and precede 
the cascade processes. Mechanistically, one important message was that the allylic nitro 
groups were knocked away by O or N nucleophiles through intramolecular SN2 
substitutions, under relatively mild conditions. As a leaving group, the elimination of 
NO2– usually requires harsher conditions (such as high temperature)42, transition-metal 
assistance43 or strong Lewis acids activation44 (Scheme 36).  
 
Scheme 36. Reported removal of (allylic) nitro group by nucleophilic substitution 
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Thus, the effective substitution of allylic nitro group under mild conditions in our 
previous studies provided an appealing approach to further extend the cascade strategy 
for the stereoselective synthesis of complex building blocks.  
 
Combining these mechanistic discoveries, we postulated that the treatment of 
reactants with “di-nucleophile” moieties to the nitro-diene intermediate A could lead to 
the facile synthesis of complex functionalized cyclic molecules in a “one-pot” fashion 
(Scheme 37A). When the 1,3-diketo functionality was applied, we envisioned that an O 
substitution of allylic nitro group would present the di-hydrofuran moieties under mild 
basic conditions. (Scheme 37B)  
 
Scheme 37. Proposed di-hydrofuran synthesis 
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4.2  Research Objectives 
As proposed in last section, the Lewis base catalyzed three-component cascade 
synthesis of di-hydrofuran will be examined. The validity of 1,3-diketo molecules as di-
nucleophiles will be tested. The proposed elimination of nitro group will be studied 
during the condition screening. Different nitroalkenes, aldehydes and di-nucleophiles will 
be applied as the substrate scope exploration. More importantly, the Lewis base catalysis 
mechanism should be tested to confirm the secondary amines are effective catalysts. 
 
4.3  Results and Discussion 
4.3.1  Reaction condition screening  
To testify our hypothesis, reactions between nitroalkene 1a, aldehyde 2a and 
cyclohexane-1,3-dione 3a were investigated (Table 14). The competing side reactions for 
this three-component condensation included the formation of isoxazoline 15f and 
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nitroalkene polymerization. To our please, the desired DHF 35a was formed when 
treating the three starting materials with proline, though with low yield (30%, entry 1).  
Significant nitroalkene polymerization was observed in this case.  Since one equivalent of 
HNO2 would be generated in this process, various bases were added to balance the 
acidity of the overall reaction.  With the application of 1.0 equivalent of K2CO3, the yield 
of DHF was significantly improved (71%, entry 2). 
 
Table 14. Reaction condition optimization a 
Ph N
O
Ph
O
Ph Me
NO2
+
O
O
1a 14f 34a
O
Ph
O
35a 15f
conditions
Me
O
Me Me
+ +
 
yield (%)c entry cat. (eq.) base (eq.) sol time (h) convb (%) 
4a 5a 
1 proline (0.2 eq.) -- DMSO 2 77 30 11 
2 proline (0.2 eq.) K2CO3 (1.0) DMSO 2 100 71d 8 
3 -- K2CO3 (1.0) DMSO 2 90 22 <5 
4 proline (0.2 eq.) K2CO3 (0.5) DMSO 2 100 80d <5 
5 proline (0.1 eq.) K2CO3 (0.5) DMSO 3 100 87d <5 
6 proline (0.05 eq.) K2CO3 (0.5) DMSO 4 100 87d <5 
7 proline (0.02 eq.) K2CO3 (0.5) DMSO 8 100 74d <5 
8 proline (0.05 eq.) K2CO3 (0.5) DMSO 4 100 91e <5 
9 proline (0.05 eq.) other basesf DMSO 4 100 <85e <5 
10 proline (0.05 eq.) K2CO3 (0.5) solventsg 4 100 <72e <5 
11 PPh3 (0.2 eq.) K2CO3 (0.5) DMSO 3 100 26 18 
12 Et3N (0.2 eq) K2CO3 (0.5) DMSO 8 100 37 <5 
13 DMAP (0.2 eq.) K2CO3 (0.5) DMSO 8 100 30 21 
14 glycine (0.2 eq.) K2CO3 (0.5) DMSO 4 100 69e <5 
a 1a:14f:34a = 1:1:1, concentration of 14f is 0.15 M; b based on the consumption of 
nitroalkene 1a. c NMR yield with 1,3,5-trimethoxybenzene as internal standard. d 
isolated yields. e isolated yield based on aldehyde, with the loading of 1a:14f:34a = 
1.2:1.0:1.1, concentration of 14f is 0.15 M. f other bases include Cs2CO3, NaOAc, 
tBuONa, Et3N and DIPEA. g solvents include DCM, EtOAc, acetone, toluene and THF.  
 
Notably, a much significantly lower yield was received when only K2CO3 was 
applied (22%, entry 3). These results were consistent with our previously reported 
proline-nitroalkene activation mechanism. Considering that strong basic conditions 
usually favored the undesired nitroalkene polymerization, the amount of K2CO3 was 
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reduced to 0.5 equivalent. Higher yield of 35a was received as expected (80%, entry 4). 
Interestingly, decreasing the loading of proline resulted in better performance with only a 
slight increase in reaction time (entries 5-7).  This could be explained by the relatively 
slower nitroalkene polymerization associated with the lower Lewis base loading.  With 
this optimal condition, excellent yield of DHF 35a was received as the single trans 
isomer, when slightly excess amount (1.2 equiv.) of nitroalkene was applied (91%, entry 
8). Different bases (such as DIPEA, Et3N and Cs2CO3) and various solvents have also 
been investigated and K2CO3 (0.5 eq.) in DMSO was confirmed as the optimal choice.  
Different Lewis base catalysts, such as PPh3 and DMAP, have also been applied to 
catalyze this reaction. However, much lower yields were obtained (entries 11, 12) along 
with the formation of significant amounts of 15f.  
 
In addition, no cis diastereo isomers or cyclopropanation products were detected 
in all cases. The competing side reaction, homo-isoxazoline-N-oxide formation, was also 
successfully diminished. These results highlighted the unique reaction nature of proline 
catalyzed nitroalkene activation in cascade syntheses. 
 
4.3.2  Substrate scope 
Various nitroalkenes, aldehydes and 1,3-diketones/"-keto-esters were then 
applied to investigate the reaction substrate scope (Table 15). This new method worked 
great for a big variety of substrates, giving the desired trans DHF in good to excellent 
yields. Both aromatic nitroalkene and aliphatic nitroalkene were suitable for this 
transformation, giving good diversity on the C-5 position. Meanwhile, the allylic ether 
functionality was introduced, providing a new “synthetic handle” to the product. A large 
group of different aldehydes, including aromatic (with either electron donating groups or 
electron withdrawing groups), aliphatic and heterocyclic structures, were all suitable for 
this reaction, which provided an efficient strategy to introduce different carbon-substitute 
groups on the C-4 position. The efficient assembly of readily available diverse groups on 
the C-4 and C-5 position made the reported method highly efficient for the preparation of 
functional substituted DHF that would be challenging to reach via other methods.  
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Table 15. Substrate scope a 
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O
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O
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O
O
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Me
O
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O
CO2Me
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Ph
O
CO2Et
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Ph
Ph Me
O
CO2Me
35n, 95%
p-Cl-C6H4
O2N
O
CO2Me
35r, 80%
Me
N
O
O
35p, 90%
Me
O
O
O
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MeO
O
O
O
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Me
O2N
O
CO2Me
35s, 85%
Me
O
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Me
O
CO2Et
Ph
35u, 75%
O
35v, 92%
Me
O O O
 
a 1a:14a:34a = 1.2:1.0:1.1, concentration of 14a is 0.15 M; yields are isolated yields; only trans 
isomers were observed. 
 
The application of different 1,3-di-ketone and "-keto-esters further extended this 
method for easy introduction of various functional groups on C-2 and C-3 positions. In 
the case of "-keto-esters, good chemoselectivity was achieved, giving only the ketone 
cyclization products. This result gave advantage to selectively introduce different groups 
on either C-2 or C-3 positions through the reaction with corresponding di-nucleophiles 
(i.e. 4u). Notably, excellent diastereoselectivity was achieved in all cases, while only 
trans isomers were observed. Thus, with the great diversity, high efficiency and excellent 
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diastereoselectivity, this reported method could be applied as a new general protocol for 
the synthesis of various functional di-hydrofuran building blocks. 
 
4.3.3  Mechanistic study of the proposed mechanism 
Although the proposed mechanism in Scheme 36 looked valid, another possibility 
was that the 1,3-diketones 34b would go through condensation with aldehyde 14f to give 
the di-carbonyl activated alkenes B as the intermediate. Nucleophilic addition of Lewis 
base activated nitroalkenes to B followed by the intramolecular SN2 substitution would 
then reach the product 35e (Scheme 38B). Simple experiment was then carried out to test 
the possible formal [4+1] annulation pathway.  
 
Scheme 38. Possible [4+1] formal annulation pathway of the synthesis of DHF 
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When the enone B (prepared from 34b and 14f) was treated with nitroalkene 1a 
under the optimal condition, only 13% NMR yield was detected after 4 hours and 21% 
yield after 10 hours, with large amount of B was left and 1a polymerized.  
 
4.3.4  Attempts to enantioselective synthesis and further transformation 
4.3.4.1 Enantioselective synthesis study 
Efforts had been also put into the enantioselective synthesis of the highly 
functionalized di-hydrofurans. The catalysts tested are listed below in Scheme 38, 
however, no obvious enantiomeric excess was received. Similar to the previous 
asymmetric catalysis in the isoxazoline-N-oxide synthesis, the chiral secondary amines 
 54 
(cat-1, 2, 3, 5, 6) did catalyze the reaction and give moderate to good yields. The poor 
enantioselectivity (>10% e.e.) might be due to the poor involvement of the chiral amines 
as Lewis base with the diene intermediate A.  
 
Scheme 39. Attempts towards asymmetric catalysis 
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For the thio urea catalysts (cat-4 and cat-8), however, the reaction was 
dramatically shut down, only trace amount of product could be observed in the crude 
NMR. This could be reasoned that with the strong coordination of thiourea and nitro 
group, the NO2 containing moieties were either locked up (Scheme 39 a) and changed 
into a ineffective leaving group, or activated by the similar interaction to be a perfect 
electrophile (Scheme 39 b). Further attempts of other effective catalysts are underway. 
 
4.3.4.2 Further transformations 
With the highly functionalized di-hydrofurans, facile transformations could easily 
lead to natural product backbones and useful building blocks (Scheme 39). the allylic 
ether moieties could be readily applied to palladium chemistry to form the Pd $-allyl 
complex a. the b-ether enone could be transformed into Danishefsky’s diene b for inter- 
(or intra-) molecular Diels-Alder reactions. Also, the integrated allylic vinyl ether 
moieties could be used to reach the Claisen rearrangement products c. On the other hand, 
functionalities on the aldehydes could also be utilized to reach the tricyclic (or 
tetracyclic) structures d (via intramolecular Heck coupling) or lectam moieties e (via 
amino ester exchange). Moreover, 2-keto-furan derivatives f could be easily prepared, 
 55 
which would be starting materials for the de novo synthesis of functionalized 
carbohydrates.  
 
Scheme 40. Possible Transformation and Pd(0) catalyzed dihydropyran synthesis 
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Up to date, the only one derivatization of the three-component di-hydrofurans is 
the palladium catalysis, which had presented unexpected results. When 35 was treated 
with Pd(PPh3)4 (0.1 eq.) under acidic condition (TsOH ,1.0 eq.) in toluene reflux for 5 
hours, a dihydropyran 36a was obtained in good yield (76%) with partial 35a transformed 
into its cis isomer 35a´. The reaction did not proceed without acid, nor only acid but no 
palladium catalyst. Detailed mechanistic study is underway to investigate this unexpected 
1,4-hydride shift observation. 
 
4.4  Conclusion 
In conclusion, a highly efficient cascade synthesis of di-hydrofuran was 
developed through proline catalyzed one-pot three-component condensation of nitro 
alkene, aldehyde and 1,3-di-ketones/"-keto-esters. This reaction used readily available 
starting materials under mild conditions and gave the desired products in excellent yields, 
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excellent chemoselectivity and diastereoselectivity. Substituted groups on all the four 
positions of furan could be readily controlled with the applications of corresponding 
starting materials. With the great atomic efficiency and functional group tolerability, the 
reported methods would be of great interests for chemical and pharmaceutical researchers 
by providing a readily available compound library. In addition, the success of this method 
provided another strong support for the proposed secondary amine nucleophilic addition 
to nitroalkene. Further extension of this strategy with other plausible di-nucleophiles for 
new transformations is being examined. Enantioselective version of DHF synthesis and 
application in natural product synthesis are also under investigation in our group. 
 
 
This project is a collaborated work with Tao Liao and Odbadrakh Tuguldur. They 
helped with some of the substrates preparation and the spectra organization. 
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Part V 
One-Pot Asymmetric Synthesis of Substituted 
Piperidines by Exocyclic Chirality Induction 
5.1  Introduction 
5.1.1  Piperidines syntheses in literature and their bioactivity values 
Functionalized piperidines are one very important group of heterocycles in 
chemistry and biological research due to their unique chemical properties and important 
biological activity.45 Many biologically active natural compounds share the piperidines 
moieties in their skeletons, such like anopterine, scopolamine, himbacine and 
morphine45d (Scheme 41).  
 
Scheme 41. Biologically active piperidine moieties containing natural molecules  
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As a consequence, considerable interest is centered on the synthesis of this 
heterocycle with the focus on high efficiency and good stereoselectivity.46 This need is 
particularly emphasized by the fast growing call for enantiomeric pure, diverse 
piperidines in alkaloids47 and aza-sugar48 researches. Three examples are listed below, 
representing the recent efforts put in synthesizing piperidines, including the 
enantioselective total syntheses of natural product. (+)-nankakurines A and B had been 
successfully synthesized by Overman’s group in 200849a (Scheme 42A). The key step 
was the intramolecular azomethine imine [3+2] cycloaddition to reach the tetracyclic 
pyrazolidine, which then went thorough several steps to get the final product. Another 
elegant natural product synthesis via the piperidine intermediates was reported by 
Denmark’s group in 200649b (Scheme 42B). A tandem double intramolecular [4+2]/[3+2] 
cyclization of nitroalkene was developed with great diastereoselectivity. Catalyzed by 
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AlMe3, at -78 ºC in toluene, nitroalkene which contained a diene as the dienophile served 
well in the tandem cyclization to yield the nitroso acetal product in good yield. 
Subsequent functional group manipulations allowed for high yield synthesis of 
diphnilactone B. Also, an interesting [4+2] hetero-cycloaddition strategy was well 
developed by Nelson’s group, targeting the diastereoselective synthesis of piperidines49c 
(Scheme 42C). Through the Lewis acid catalysis, the N-alkenyl iminium was easily 
formed. In the presence of electron rich alkenes, a facile [4+2] cyclization was observed 
to yield the iminium product, which could be readily transformed into fully substituted 
piperidine in the presence of appropriate nucleophiles.  
 
Scheme 42. Literature reported piperidines syntheses  
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5.1.2  Rationale of piperidine synthesis based on our previous studies 
Our group has recently focused on the secondary amine Lewis base activation of 
nitroalkenes. Related studies had been discussed in previous parts. Generally, secondary 
amine served as Lewis base to activate the "-alkyl nitroalkene and provided a stabilized 
!-nitro carbanion (or nitronate) to react with electrophiles. After the "-elimination to 
release the Lewis base, a new covalent bond was formed with an allylic-nitro 
functionality (Scheme 43A) 
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Scheme 43. Proposed piperidine synthesis 
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Revealed by our previous experimental and computational studies, the addition of 
amine to nitroalkene is a fast equilibrium. We then postulated that the amine-nitroalkene 
adduct a might be suitable for sequential Michael addition and ring closure, providing the 
substituted piperidines through a one-pot cascade process (Scheme 43B). From the aza-
Michael adduct a, tow ring-closing pathways were proposed, one was the Henry-Aldol 
reaction after the aza-Michael reaction between a and MVK (Path A); the other was the 
Henry-Michael reaction after the iminium formation from a and MVK (Path B).  
 
5.2  Research Objectives 
The three-component reaction between primary amine, nitroalkene and enones 
would be investigated. The two pathways proposed in Scheme 43B would be examined, 
or there might be other unpredicted reactions between these three components. The 
mechanism of the reaction should be explained with further understanding, which might 
be useful in our further research.   
 
5.3  Results and Discussion 
To test our hypothesis, reactions between nitroalkene 37a, benzyl amine 38a and 
enone 9b were set up. Surprisingly, the condensation between thess three components 
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dominantly favored Path A, giving piperidine 39a in 65% yield with d.r. 5:1 in MeOH 
after 14 hours, upon the first try. Notably, 30% 37a was recovered.  
 
5.3.1 Reaction condition optimizationa 
Table 16. Reaction condition screening 
NO2
Ph
BnNH2
O
r.t. N
O2N
HO
Ph
Bn
N
O2N
HO
Ph
Bn
+ + +THF
37a 38a 9b 39a-major 39a-minor  
 
entry solvent base time (h) yield (%)b d.r.c 
1 MeOH -- 14 66 5:1 
2 MeOH K2CO3 14 5 -- 
3 MeOH DMAP 14 65 5:1 
4 MeOH Et3N 14 60 4:1 
5 MeOH -- 36 70 5:1 
6 MeCN -- 14 6 -- 
7 DMSO -- 14 19 4:1 
8 CH2Cl2 -- 14 40 10:1 
9 THF -- 14 82d 7:1 
10 THF Et3N 14 80d 6:1 
11 THF DMAP 14 78d 7:1 
12 THF -- 36 97d 7:1 
a nitroalkene 37a:38a:9b=1.0:1.5:2.0, (0.2 M for 37a). Bases were 0.2 eq.; b yields of 
both isomers were determined by 1H NMR with 1,3,5-trimethoxybenzene as internal 
standard; c d.r. determined by 1H NMR integration. d isolated yields. 
 
During the condition optimization (Table 16), we found that additional base 
(K2CO3, 0.2 eq.) dramatically shut down the reaction (entry 2). However, when organic 
base like DMAP (0.2 eq.) or Et3N (0.2 eq.) were applied, no great differences were 
observed in term of yield and d.r.. (entries 3, 4) Extending the reaction time from 14 
hours to 36 hours, slightly improved yield (70%) was received. (entry 5) MeCN, DMSO 
and DCM were also tested as solvent, with much lower yields although the d.r. jumped 
up to 10:1 in DCM. (entries 6-8) When we switch to THF as solvent, 82% isolated yield 
and 7:1 d.r. were observed. (entry 9) Notably, the reaction performed in THF was much 
cleaner than other solvents, after which the product 39a-major could be even purified by 
simple crystallization. Additional DMAP and Et3N did not improve the yields (entries 10, 
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11). However, extending the reaction time to 36 hours in THF at room temperature, 
almost quantitative yield was received (97%) with similar d.r. (7:1). (entry 12)  
 
5.3.2 Substrate scope 
Table 17. Representative substratesa 
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a General reaction conditions: compounds 37 (1.0 eq.), 38 (1.5 eq.), and 9 (2.0 eq.) were 
mixed in THF (0.2 M of 1). The reactions were monitored by TLC till 37 was totally 
consumed. b Isolated yields of both isomers. c d.r. determined by NMR of crude reaction 
mixtures. d Structure and relative stereochemistry determined by X-ray crystallography. 
 
As summarized in Table 17, a large group of substrates were suitable for this 
transformation, including alkyl and aryl nitroalkenes, primary amine even ammonia, and 
!/" substituted enones. Good to excellent diastereoselectivity was observed in all cases 
with only C-4 isomers obtained. The diastereo-selectivity can be improved by different 
amines, where cyclohexyl amine and NH3 gave excellent d.r. (>20:1).  The wide scope of 
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substrates, excellent yields and diastereo-selectivity made this method promising new 
protocol for the synthesis of substituted piperidines. 
 
5.3.3 Rationale for the high diastereoselectivity  
In all the substrates, although at least three stereogenic centers were set up at the 
same time, only C-4 isomers were detected, which was confirmed by the X-ray crystal 
structures (Scheme 43).  
 
Scheme 44. Account for the high diastereoselectivity: the equilibrium of aza-
Michael addition of amine to nitroalkene and enone 
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As we expected, cis isomer between C-4 hydroxyl and C-3 nitro was the major 
product due to the intramolecular H-bonding. All the stereochemistry was driven by the 
six-member ring transition state, in which the big substitute groups (phenyl and nitro) 
located at equatorial positions. This result was consistent with our proposal, the final 
Henry-Aldol reaction was the rate determining irreversible step, before which both the 
aza-Michael addition to nitroalkene and enone were in equilibrium. This was also 
confirmed by the NMR study of the first step, amine addition to nitroalkene. The adduct 
a could be isolated from the reaction, but not stable at all. Recharging it back into 
solvents, the nitroalkene 37a and amine 38a were released. 
 
5.3.4 Enantiomeric piperidine synthesis 
5.3.4.1 Chiral amine chiral induction and the NMR evidence 
 
With this efficient new method available, the enantioselective transformation 
became highly desirable. Since the rate determining chair transition state led to the 
excellent diastereoselectivity, we therefore wondered whether chiral amines could be 
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applied in this transformation to deliver the chirality into the piperidine ring via the 
spatial arrangement in the six-member ring transition state.  
 
To investigate the chirality induction by chiral amines, arylethanamines 40a-c 
were applied (Table 18). As expected, piperidines 41a-c were obtained in good yields. 
With the formation of two possible C-4 isomers, introduction of new stereogenic center 
on C-7 position could result in the formation of four diastereomers. Excellent 
diastereoselectivity on C-4 position was obtained in 41a and 41b (comparing P1 to P3 
and P2 to P4), giving d.r. >10:1. For amine 40c, MeOH was required for optimal 
performance, due to the slow reaction rate in THF, which caused a slight decrease of d.r. 
on C-4 selectivity. However, to evaluate the chirality transfer by chiral amine, the relative 
stereochemistry of the exocyclic C-7 and the piperidine ring is the key (comparing the C-
7 isomers: P1 to P2 or P3 to P4). If the exocyclic N-C bond is free rotation of the, one 
may not expect any stereochemistry control. To our surprise, modest chirality induction 
was obtained in all three cases, giving C-7 isomers around 4:1 d.r.. 
 
Table 18. Piperidine synthesis with chiral amines and NMR study a 
+
r.t.
N
H3C
OH
Ph
O2N
H
CH3N
H3C
CH3
Ar
H
41-P241-P1
Ph
O2NHO
37a 9b
1
2
4
71
2
4 7
H2N Ar
Me
(-)-40
40a: Ar=C6H5; 
40b: Ar=p-MeO-C6H4; 
40c: Ar=p-NO2-C6H4
8
8
N
HO
CH3
Ph
O2N
Ar
H
CH3N
HO
CH3
Ar
H
41-P441-P3
Ph
O2NH3C
1
2
4
71
2
4 7
8
8
9
R
Ph
NO2
Me
O
C4 isomers
C7 isomers
product
d.r. (%)
P1:P2:P3:P4
13C chemical shift of C-8
41a
41b
41c
82:18:0:0
78:15:7:0
73:16:11:0
P1 P2 P3 P4
8.6 18.8 -- --
8.7 19.1 8.3 --
8.8 18.4 8.6 --
13C chemical shift of C-9
P1 P2 P3 P4
143.3 137.9 -- --
135.3 130.0 135.0 --
151.1 145.8 150.8 --  
a General reaction condition as described in Table 17. b Combined 
isolated yields of all isomers. Structures of all reported isomers 
were determined by either X-ray crystallography or comprehensive 
1D and 2D NMR experiments. c d.r. determined by NMR of crude 
reaction mixtures. 
 
Based on the X-ray crystallography and NMR spectroscopy, structures of all 
obtained isomers were identified. Interestingly, as shown in all crystal structures, the 
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exocyclic C-7 adopted a perfect staggered conformation with the piperidine ring. 
Moreover, the chemical shifts of the C-8 and C-9 carbons were significantly shifted 
upfield when they were at the antiparallel positions relative to the nitrogen lone pair 
electrons (C-8 in P1/P3 and C-9 in P2, Table 18). Therefore, it strongly suggested that 
the N1-C7 $-bond rotation was restricted. Considering all these results, a Henry-aldol 
cyclization chair transition state with the exo-cyclic chiral amine induction was proposed 
in Scheme 45.  
 
Scheme 45. Proposed exo-cyclic chirality induction 
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As part of the six-membered ring, the N-1 nitrogen lone pair electrons adopted the 
axial position. Thus, with the preferred staggered N1-C7 conformation, three syn-pentane 
interactions would be generated in the transition state: [C-2-R to C-7-H] and [C-2/C-6-H 
to C-7-R2]. This proposed transition-state model was consistent with the experimental 
observation in the synthesis of piperidine 41a-c, where in the major stereoisomers the less 
bulky methyl group (relative to the aryl groups) was placed on the R1 position to generate 
the energetically favored transition state by minimizing the syn-pentane steric repulsion. 
However, besides the steric interaction, the stability of the chair transition state could also 
be influenced by the p-$* electronic interaction between nitrogen lone pair electrons and 
exocyclic axial R2 group. Compared to the methyl group, the more bulky phenyl group 
could form stronger p-$* interactions if it were placed on the R1 position.  
 
5.3.4.2 Enhanced exo-cyclic stereochemistry control by amino esters 
Therefore, we wondered whether this chirality induction could be further 
enhanced by application of the chiral amine with a less bulky group that would produce 
stronger p-$* interaction (Scheme 46).  
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Scheme 46. Enhanced chirality transfer by amino esters and enantiomeric pure 
piperidine synthesis 
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The readily available amino acid derivatives become ideal chiral amines for this 
application with the smaller CO2Me group that provides stronger p-$* interaction, giving 
energetically a more favored transition state than other different alternatives (Scheme 
45A). As expected, reactions among 37a, 9b and amino esters 40d and 40e generated the 
desired enantiomeric pure piperidine 41d and 41e with only C-4 isomers observed: 100% 
chirality induction was achieved through the chirality control by exocyclic asymmetry. 
Based on the reaction crude NMR, the C-4 isomers were the only piperidine products 
observed. Under the reaction conditions, 25% of unreacted 37a was recovered in both 
cases, making the theoretical isolated yields of 41d and 41e to 83% and 87%. No 
epimerization occurred under the reaction conditions and compounds 41d and 41e were 
indeed prepared with 100% enantiomeric purity. Through some simple transformations, 
the two C-4 isomers were converted into single enantiomers 42a and 42b (Scheme 45B 
and C).  
 
5.3.5 Extension of the exo-cyclic chirality transfer concept 
In the history of organic synthesis, a lot of classic and elegant reactions are based 
on the six-member ring chair transition state (Zimmerman-Traxler transition state). It had 
explained the excellent diastereo involved in Aldo reactions and all the Claisen type of 
rearrangement reactions (Scheme 47).  
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Scheme 47. Six-member ring transition-state and Claisen rearrangement 
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Scheme 48. Proposed exo-cylcic chirality transfer in aza-Claisen rearrangement 
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Inspired by our three-component syntheses of piperidines with chiral amines, 
which also shared the same transition state, the extension of the exo-cylcic chirality 
transfer certainly had caught our strong attention. Further exploration was then carried 
out. What we had hoped is to reach the allylic vinyl amine from the condensation of allyl 
bromide, chiral amine and ketone, which then might go through a six-member ring aza-
Claisen type of transition state to give the rearrangement product with the chirality 
transferred from the amine (Scheme 48A). Also, we wished the reaction required only 
catalytic amount of chiral amine. A racemic model reaction was then set up between 
cinnamyl bromide 43a, benzyl amine 38a and ketone 44a (Scheme 48B). However, only 
the allyl amine 45a was observed under basic condition. We reasoned it that the basic 
condition did not help the formation of enamine to reach the allylic vinyl amine 
intermediate. Therefore, 45a was treated with ketone 44a under various conditions, 
including acidic and high temperature to reach the proposed intermediate and overcome 
the kinetic barriers of the rearrangement process (Scheme 48C). No desired product was 
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observed, with either large amount of 45a left intact or decomposition under high 
temperature.  
However, it is our belief that the exo-cyclic chirality transfer will fruit in organic 
synthesis in the future, rather than just a concept. 
 
5.4  Conclusion 
In conclusion, applying the one-pot cascade strategy, substituted piperidines were 
prepared with excellent yields and great stereoselectivity. The transformation was 
suitable for a large group of substrates and selective functionalization on each position of 
the piperidine ring have been achieved. Moreover, based on an exocyclic stereochemistry 
control, 100% chirality induction was achieved with amino esters, giving enantiomeric 
pure substituted piperidines in less than three steps. This new stereochemistry control 
strategy will be further applied into similar systems for the synthesis of other chemical 
and biological important heterocycles. 
 
 
This project is a collaboration work with Dr. Yunfeng Chen. I helped with the substrate 
scope (Table 17) and the exo-cyclic chirality transfer expriments.  
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Part VI 
Anion Bridged Nanosheet from Self-Assembled G-
Quadruplexes 
6.1 Introduction 
6.1.1  Self-assembly study involving Guanosine  
Bottom-up nanotechnology, or so-called ‘‘molecular manufacturing’’ or 
‘‘molecular nanotechnology’’, has attracted explosive attention in recent years. The 
bottom-up approach has been demonstrated to create larger scale architectures through 
the precisely controlled assembly of specific atoms or molecules. Self-assembly has been 
recognized as one of the enabling strategies to prepare the functionalized molecular 
architectures50, which has been applied in many areas of nanotechnology, including 
nanoparticle synthesis51, surface modification52 and device development53. However, self-
assembly involving organic molecules did not receive enough attention in 
nanotechnology researches. 
 
Scheme 49. Guanosine self-assembly and its nano size 
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Guanosine, well known as self-assembly precursor, has been found for a long 
time in nature as the guanosine quartet (G-quartet), a motif formed through self-
complementary hydrogen bonding of the purine base54 (Scheme 49). In the presence of 
proper cations (Ba2+, K+, Na+ etc.) and counter anions (like picrate), four of the tetramer 
Guanosine complexes, which are flat structures, would be easily piled up as a bigger 
hexadecamer called G-quadruplex. This type of complex usually contains at least two 
sandwich subunits with the metal cations in the middle of the layers, binding with the 
four carbonyl groups in each layer; while the counter anions were bonding with the N-H 
between the two middle layers. The size of the cylinder shape of complex is 3.0 nm in 
height and 3.4 nm long as the diameter.  
 
Substantial work had been done in recent years; influence of different cations and 
different anions had been studied in detail. Amazingly, the lipophilic Guanosine G-1 (46) 
form self-assembled hexadecamer in solid state, solution and even gas phase,55 through 
alkali and alkali earth metal cation templation, whose structure, composition and 
properties could be easily characterized by NMR or even X-ray crystallography. It was 
important to notice that picrate anions bound at the side of the quadruplex through H-
bonds. Extensive studies have been made for this unique anion binding properties and 
various anions, including 2,6-DNP, SCN-, p-OMe-2,6-DNP etc, were found promoting 
the formation of same hexadecamer structures with different kinetic and thermodynamic 
properties. 
 
Intrigued by this unique anion binding property, we wondered whether the anion-
binding site could serve as a new synthetic handle to extend the supramolecular 
architecture of the G-quadruplex. In the crystal structure of the G-hexadecamer, picrate 
anions coordinate with the exocyclic amino group of the central two G- quartets through 
the anion’s phenolate oxygen and the two nitro groups at the ortho position. The para 
position, which is solvent-exposed from the G-quadruplex, provides an ideal synthetic 
handle for the extension of the supermolecule without disturbing the G-quartet’s key non-
covalent interactions. Thus, we proposed that with the 2,6,2',6'- tetranitrobiphenolate 
(TNBP) dianion, which might serve as the bridging anion, could be used to tether 
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individual G-hexadecamers in a two dimensional pattern. In this case, a nano size sheet 
structure would be possibly prepared wit a height of 3.0 nm (Scheme 50).  
 
Scheme 50. Proposed nano sheet through Guanosine self-assembly 
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6.2  Research Objectives 
The proposed Guanosine self-assembly nano sheet structure would be prepared 
for characterization. The composition and the structure of the complex would be studied. 
Different cations would be applied and tested. Further application of this non-covalent 
nano size supramolecular complex would be performed.  
 
6.3  Results and Discussion 
6.3.1  Preparation of complex and the composition study 
Both G-1 (46) and Na2TNBP (47) were prepared using literature procedures.56 
The preparation of the polymeric G-quadruplexes was performed in two methods: 1) 
direct treatment of G-1 (46) with Na2TNBP (47), and 2) anion exchange of preformed G-
hexadecamer (G-1)16•Na4•SCN4 with (Bu4N)2•TNBP (48). In the first approach, the G-1 
was dissolved in CH2Cl2, and the Na2TNBP was dissolved in water. Notably, the 
Na2TNBP salt is not soluble in CH2Cl2 while G-1 has little solubility in water. Mixing 
two clear solutions yielded a red solid at the interface of the two solutions (Scheme 51).  
 
Scheme 51. Formation of nano size Guanosine complex 
 
   
G-1 (46) in DCM Na2TNBP in H2O
+ 5 minutes, r.t.
Red precipitate
at the interface  
 71 
The same polymeric complexes were also obtained through the anion exchange 
between preformed G-hexadecamer, (G-1)16•Na4•SCN4, and TNBP anions.  It has been 
demonstrated previously that sodium thiocyanate promotes the formation of G-
hexadecamer by directing self-assembly of G-1.  Because it is a relatively poor H-bond 
receptor, the SCN- anion binding with the G-quartets in (G-1)16•Na4•SCN4 is highly 
dynamic. Compared to SCN-, the 2,6-DNP anion forms stronger H-bonds with the G-
quartets, resulting in the formation of kinetically and thermodynamically more stable 
guanosine complexes.11a  The (Bu4N)2•TNBP salt was prepared to perform this anion 
exchange study due to its solubility in CH2Cl2 and the weak binding between the Bu4N+ 
cation and the G-quartet.  Upon mixing of (G-1)16•Na4•SCN4 with (Bu4N)2•TNBP 
solutions in CH2Cl2, a red precipitate was again observed within 5 minutes. 
 
Scheme 52. Solution NMR study of the composition of the complex 
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The precipitate was easily filtered and obtained as red floppy solid. DMSO could 
break the non-covalent H-bonds, which held up the molecules as one piece. As revealed 
by the 1H NMR in DMSO in Scheme 52, the signals for the H8 proton of G-1 (46) and 
for the Na2TNBP (47) protons gave a 2:1 ratio, indicating a 16:4 ratio between G-1 (46) 
and TNBP anions. This result was consistent with the proposed nano-sheet structure. The 
13C NMR comparison of these three compounds was also performed   Both 1H NMR and 
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13C NMR confirm that the nano-sheets are formed from G-1 (46) and Na2TNBP (47) 
through non-covalent interactions. 
 
6.3.2  Atomic force microscope (AFM) study, solid phase NMR study 
and powder X-ray characterization 
Furthermore, the size and shape of the G-quadruplex polymer formed upon cross-
linking by TNBP were also measured by atomic force microscope (AFM). The resulting 
nanoparticles were about 90-200 nm in lateral size with the height of 3.0 ± 0.05 nm, 
which is consistent with the size of guanosine hexadecamers. This result confirmed that 
the TNBP anion bridges link the non-covalent G-quadruplexes together and produce even 
bigger, highly ordered supramolecular architectures (Scheme 53).  
 
Scheme 52. AFM images of the prepared Guanosine nano-sheet 
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(A) 2D topography AFM image of (G-1)16%Na+4•TNBP2-2 complex; (B) 3D 
topography AFM image of the same sampling area as B; (C) cross sectional 
profile of (G-1)16Na+4•TNBP2-2 complex over the line indicated in B. 
 
Since we used Na2TNBP (47) to prepare the nano-sheet, it is important to 
characterize the Na+ cation within the non-covalent nano-sheet structure.  Recently, solid 
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state NMR techniques have been successfully developed for the determination of cation 
coordination within the G-quartet. Wu’s group has studied the solid-state 23Na, 39K, and 
87Rb NMR of guanosine complexes and clearly demonstrated the cation-G-quartet 
binding in the solid state. 57  Several 23Na solid-state NMR experiments were then 
performed on the polymeric nanosheet (Scheme 53). 
 
Scheme 54. 23Na solid phase NMR comparison 
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The Na2(2,6-DNP) salt was examined to simulate the ion’s chemical environment 
within the nano-sheet complexes.  The G- hexadecamer formed from G-1 and Na(2,6-
DNP) has been previously characterized by X-ray and solution NMR studies. Solid state 
23Na NMR spectra yielded different chemical shifts for “free” Na+ and G-quartet bound 
Na+ (Scheme 54A and B). Through the direct comparison of these standard samples, 
more than 90% of the Na+ cations are bound to the G-quartets in the nano-sheet 
complexes (Scheme 54D).  
 
Moreover, the powder X-ray diffraction of the nano-sheet materials has been 
performed. The powder X‑ray pattern reveals two low angle peaks observed at 
d‑spacing 47.5 Å and 23.75 Å, which indicating the presence of large unit cell. As 
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reported previously, the typical guanosine hexadecamer crystal has the unit cell around 
47 Å (for example, (G-1)16•Ba2•(P-OME-2,6-DNP)4 has a unit cell as a=46.662 Å, 
b=24.259 Å, c=45.111 Å). Therefore, the large unit cell revealed by the powder X-ray is 
consistent with Guanosine hexadecamer and support the formation proposed nano-sheet 
structure. 
 
6.4  Conclusion 
In conclusion, the covalent linked dianion, TNBP2-, promotes the formation of a 
non-covalent polymer by cross-linking lipophilic G-quadruplexes. The AFM images, the 
solution NMR data, the solid state 23Na NMR analysis and powder X-ray measurement, 
all strongly support the formation of novel non-covalent network as proposed.  This novel 
supramolecular architecture exhibits a highly ordered structure.  Notably, this novel 
nano-scale non-covalent complex is produced simply through the self-assembly of small 
molecules (G-1 and Na2TNBP) in one step.  Since the complex construction is based on 
non-covalent interactions, the molecular architecture is dynamic and potentially 
reversible, and may provide unique properties as novel nanomaterial.  Meanwhile, the 
hydrophobic stacking of G-quartet and cation transport properties of G-quadruplexes 
makes this complex potentially interesting in the studies of electron and ion transfer and 
nano-device development.  Screening studies of various anions and spacer linkers and 
deposition of the nano-sheet on metal surfaces for device development are currently 
under investigation in our group. 
 
 
This project was collaborated with Dr. Jin Wang, Dr. Nianqiang Wu, Dr. Gang Wu and 
Dr. Peter Y. Zavalij. Dr. Wang and Dr. Nianquang Wu helped with the AFM image 
characterization. Dr. Gang Wu helped with solid-state NMR experiments of 23Na of the 
complex. Dr. Zavalij helped with the powder X-ray analysis of the complex. 
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Part VII 
Experimental Section 
 
Section A: General Methods and Materials 
 
Unless otherwise noted, all commercial reagents and solvents were obtained from the 
commercial provider and used without further purification. Air and/or moisture-sensitive 
reactions were carried out under an atmosphere of nitrogen using oven/flame-dried 
glassware and standard syringe/septa techniques. 1H-NMR and 13C-NMR spectra were 
recorded on Joel 270 and Varian 600 MHz spectrometers. Chemical shifts were reported 
relative to internal tetramethylsilane (! 0.00 ppm) or CDCl3 (! 7.26 ppm) for 1H and 
CDCl3 (! 77.0 ppm) or DMSO (! 39.5 ppm) for 13C. Flash column chromatography was 
performed on 230-430 mesh silica gel. Analytical thin layer chromatography was 
performed with precoated glass baked plates (250µ) and visualized by fluorescence and 
by charring after treatment with potassium permanganate or ninhydrin stain. Rf values 
were obtained by elution in the stated solvent ratios. Optical rotations were measured 
with a Jasco DIP- 370 digital polarimeter in the solvent specified. High Pressure Liquid 
chromatography (HPLC) was performed on a SHIMADZU SPD-M20A (LC-20AB) 
chromatographs using a chiral column (50 cm) and guard column (5 cm) as noted for 
each compound. Mass spectra were obtained from the Micro-Mass/Analytical Facility 
operated by the Department of Chemistry, West Virginia University. Atomic force 
microscope (AFM) measurement was carried out on Molecular Imaging (PICOPLUS) in 
Department of Mechanical & Aerospace Engineering. Solid-state NMR spectra were 
recorded at 11.75 T on a Bruker Avance-500 spectrometer. XRD measurement was 
performed on Bruker D8 Advance diffractometer using CuKa radiation (scan rate 0.1 
deg/min, scan step 0.02 deg). 
 
The nitroalkene starting materials 1a-1e were prepared according to reported procedures:  
Ohta, H.; Kobayashi, N.; Ozaki, K. J. Org. Chem. 1989, 54, 1802-1804.  
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Matin, N. J. A.; Ozores, L.; List, B. J. Am. Chem. Soc. 2007, 129, 8976-8977.  
Nitroalkene 1f-1h were prepared according to reported procedure: Jang, Y. J.; Lin, W. 
W.; Shih, Y. K.; Liu, J. T.; Hwang, M. H.; Yao, C. F. Tetrahedron, 2003, 59, 4979–4992. 
Allylic nitro compounds 1a-1e were synthesized according to the literature: X. Sun, S. 
Sengupta, J. L. Petersen, H. Wang, J. P. Lewis, X. Shi, Org. Lett. 2007, 9, 4495-4498. 
 
The catalysts (cat-1 to cat-8) were either purchased directly from Aldrich or prepared 
based on the reported literature.  
 
The corresponding quinine tertiary amine ylide (aux-a) and camphor derived sulfur 
ylides (aux-b-f) were prepared according to related literature.  
Zheng, J.; Zhu, C.; Sun, L.; Tang, Y.; Dai, L. J. Org. Chem. 2008, 73, 6909-6912. 
Zhu, C.; Deng, X.; Sun, X.; Zheng, J.; Tang, Y. Chem. Commun. 2008, 738-740. 
 
Nitroalkenes 37 was synthesis according to the literature as below: 
Bowman, R. K.; Johnson, J. S. J. Org. Chem. 2004, 69, 8537-8540.   
Trost, B. M.; Mueller, C. J. Am. Chem. Soc. 2008, 130, 2438-2439. 
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Section B: General Experimental Procedures  
 
General procedure of crossed conjugate addition of nitroalkene to enal:  
 
Ph
O2N
Ph
O
H Ph
O
NO2
Ph
Ph
O
NO2
Ph
+ +
1a 2a anti-3a syn-3a  
 
1) Racemic sample preparation:  
 
The nitroalkene 1a (1.0 mmol, 1.0 eq.) was added to a solution of ",#-unsaturated 
aldehyde 2a (1.5 mmol, 1.5 eq.), L-Proline (0.2mmol, 20 mol%), AcOH (0.2 mmol, 0.2 
eq) and NaN3 (1.0 eq.) in MeOH, with a concentration of 0.1M for 1a. The resulting 
reaction mixture was stirred at room temperature for 5~8 hours followed by the dilution 
with dichloromethane. The organic layer was washed with NaHCO3 sat. solution and 
brine and then dried over anhydrous sodium sulfate. The solvent was removed under 
reduced pressure with flash silica gel chromatography to give the pure product. The two 
diastereomers were difficult to separate. NaBH4 (1.0 eq.) was then applied to reduce 
aldehydes quantitatively into alcohols, which were then separated and examined for e.e. 
 
2) Optical sample preparation:  
 
The ",#-unsaturated aldehyde 2a (3.0 mmol, 3.0 eq.) was added to (S)-(-)-2-
(Diphenylhydroxymethyl)pyrrolidine (0.2 mmol, 20 mol%), AcOH (1.0 mmol, 1.0 eq.) 
and (MeO)3P (1.0 mmol, 1.0 eq.) in 5 mL MeOH. Stir at room temperature for 30 
minutes, cool down to -25 ºC, stir for another 15 minutes, nitroalkene 1a (1.0 mmol, 1.0 
eq., 0.2 M) was added in and keep stirring for 48~60 hours. The resulting reaction 
mixture was diluted with dichloromethane. The organic layer was washed with sat. 
NaHCO3 solution and brine and then dried over anhydrous sodium sulfate. The solvent 
was removed under reduced pressure with flash silica gel chromatography to give the 
pure product. NaBH4 (1.0 eq.) was then applied to reduce aldehydes quantitatively into 
alcohols, which were then separated and examined for e.e. 
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Synthesis of compound 6b 
 
Ph
NO2
Ph
O
1. Zn/HCl, 0 ºC~r.t.
2. NaCNBH3
3. Ac2O, Et3N, DMAP
4. O3, CH2Cl2, -78 ºC, 
then DMS
N
Ac
Ph
O
PhHN
Ph
Ph 5. K2CO3, MeOH
3a syn/anti 5a 6b  
 
To a solution of aldehydes (anti-3a & syn-3a) (500 mg, 1.69 mmol) in 2-propanol (50 
ml), 1N HCl (25 ml, 25 mmol) and activated Zn powder (2.17 g, 33.9 mmol) were added 
at 0 ºC. And the mixture was stirring for another 3hours at room temperature. To the 
mixture, NaCl sat. solution (50ml) was added, followed by the extraction by CH2Cl2 
(35ml x 3). The combined organic layer was washed with NaHCO3 (aq.) and brine, then 
dried over with Na2SO4. After filtration and evaporation, the residue was dissolved in 
CH2Cl2 (25 ml). To the solution, Et3N (341 mg, 3.38mmol) and Ac2O (260 mg, 2.54 
mmol) and DMAP (10.3 mg, 0.08 mmol) were added at 0oC. The mixture was stirred at 
room temperature and monitored by TLC till the reaction was done in 3 hours. After 
removal of the solvent, the residue was diluted in 50ml ether and washed with 50ml 
water. The aqueous phase was then extracted with 50ml ether again. The combined 
organic solution was then washed with Brine and dried over Na2SO4. After filtration and 
evaporation, the residue was dissolved in CH2Cl2 (25ml) in a 50ml two-neck flask 
equipped with a gas dispersing tube. A stream of ozone was bubbled through the solution 
at -78 ºC. Ozone treatment was terminated when the starting material was gone. To the 
solution added Me2S after which the solvent was removed under reduced pressure. 
K2CO3 MeOH solution was then applied and followed by flash silica gel chromatography 
to gave 356mg amide 6b. The yield over these four steps is 72%.  Only one trans was 
obtained since. 
 
Synthesis of compound 7b 
 
HN
Ph
HO
Ph
Ph
7b
N
Ac
Ph
O
Ph
6b
1) PhMgBr, 0 ºC; 
2) NH4Cl
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To a solution of amide 6b (150 mg, 0.51 mmol) in dry THF under N2 atmosphere at 0 ºC, 
was added PhMgBr (0.18 mL, 2.8M in THF) dropwise. The mixture was stirred at room 
temperature and monitored by TLC till starting materials all gone. NH4Cl (aq.) (5mL) 
was added to quench the reaction, the mixture was extracted with ether (25ml x 3), 
washed with brine and dried over with Na2SO4. After removal of the solvent, the residue 
was purified by flash silica gel chromatography to give 136mg as an oil, yield 81%.  
 
Synthesis of compound 6a 
 
Ph
NO2
Ph
O
1. Zn/HCl, 0 ºC~r.t.
2. NaCNBH3
3. (Boc)2O, Et3N, DMAP
4. O3, CH2Cl2, -78 ºC
N
Ph
O
PhHN
Ph
Ph
Boc
3a syn/anti 5a 6a
6a d.r.=1.8 (trans):1(cis)
6a d.r.>10 (trans):1(cis)K2CO3, MeOH  
 
To a solution of aldehydes (anti-3a & syn-3a) (500 mg, 1.69 mmol) in 2-propanol (50 
ml), 1N HCl (25 ml, 25 mmol) and activated Zn powder (2.17 g, 33.9 mmol) were added 
at 0oC. And the mixture was stirring for another 3hr at room temperature. To the mixture, 
NaCl sat. solution (50ml) was added, followed by the extraction by CH2Cl2 (35ml x 3). 
The combined organic layer was washed with NaHCO3(aq) and brine, then dried over 
with  Na2SO4. After filtration and evaporation, the residue was dissolved in CH2Cl2 (25 
ml). To the solution, Et3N (341 mg, 3.38mmol) and (Boc)2O (553 mg, 2.54 mmol) and 
DMAP (10.3 mg, 0.08 mmol) were added at 0oC. The mixture was stirred at room 
temperature and monitored by TLC till the reaction was done in 3 hours. After removal of 
the solvent, the residue was diluted in 50ml ether and washed with 50ml water. The 
aqueous phase was then extracted with 50ml ether again. The combined organic solution 
was then washed with Brine and dried over Na2SO4.  After filtration and evaporation, the 
residue was dissolved in CH2Cl2 (25ml) in a 50ml two-neck flask equipped with a gas 
dispersing tube. A stream of ozone was bubbled through the solution at -78oC. Ozone 
treatment was terminated when the starting material was gone. To the solution added 
Me2S after which the solvent was removed under reduced pressure and followed by flash 
silica gel chromatography to gave carbamide 6a 462 mg as white solid. A diastereo ratio 
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of 1.8:1 (trans: cis) was detected. Treatment of K2CO3 (1.0 eq.) in MeOH (0.2 M) for 5 
hours at room temperature improved d.r. to 10:1 (trans: cis), without loss of yield. 
 
Synthesis of compound 7a 
 
Ph
O Ph
N
Boc
Ph
NO
Ph Ph
O
cis 6a 7a
1) PhMgBr, 0 ºC; 
2) NH4Cl
 
 
To a solution of carbamide cis-6a (100 mg, 0.28 mmol)in dry THF under N2 atmosphere 
at 0oC, was added PhMgBr (0.1ml, 2.8M in THF) dropwise. The mixture was stirred at 
room temperature and monitored by TLC. NH4Cl (aq.) (5 mL) was added to quench the 
reaction, the mixture was extracted with ether (25 x 2ml), washed with brine and dried 
over with Na2SO4. After removal of the solvent, the residue was purified by flash silica 
gel chromatography (EtOAc/Hexane, V/V = 1:5) gave 87mg as a white solid, yield 87%.  
 
Procedure for synthesis of cyclohexane derivatives 11  
 
Ph Me
O
NO2
O
H+
8a 9a
1. L-proline, Et3N, MeOH, r.t.
Ph
NO2
OH
CH2OH O2N
OH
CH2OH
Ph
+
2. NaBH4, MeOH, 0 ºC
11c-major 11c-minor
H H
 
 
The allylic nitro compound 8a (233 mg, 1 mmol) and L-proline (23 mg, 0.2 mmol) was 
dissolved in MeOH (5 mL, 0.2 M). To this solution was added the Et3N (101 mg, 1 
mmol) and acrolein 9a (117 mg, 90%, 1.5 mmol) at room temperature. The resulting 
mixture was then stirred and checked by TLC. After the reaction had completed, the 
mixture was diluted with MeOH (10 mL), the solution was passed through a short silica 
gel column and then treated with NaBH4 (152 mg, 4 mmol) at 0 ºC. 15 minuntes later, the 
solution was quenched with water, neutralized by dilute HCl (1M) solution and extracted 
with EtOAc (40 mL x 3). The combined organic layer was washed with brine and dried 
over with anhydrous Na2SO4. The solvent was removed under reduced pressure to give a 
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residue, the residue was the purified by flash silica gel chromatography to obtain two 
diasteroisomers 11c as colorless oil, yield: 92%. 
 
Procedure for synthesis of cyclohexane derivatives 12  
 
Ph
NO2 O
+
L-rroline, Et3N
MeOH, r.t. Ph
NO2
OH
COCH3 O2N
OH
COCH3
Ph
+
1a 9b 12a-major 12a-minor
H H
 
 
The nitroalkene 1a (163 mg, 1 mmol, 1.0 eq.) and L-proline (23 mg, 0.2 mmol, 0.2 eq.) 
was dissolved in MeOH (5 mL, 0.2 M). To this solution was added Et3N (101 mg, 1 
mmol) and MVK 9b (280 mg, 4 mmol, 4.0 eq.) at room temperature. The resulting 
mixture was then stirred at room temperature and checked by TLC. When the reaction 
had completed, the solvent was removed under reduced pressure to give a residue, the 
residue was then purified by flash silica gel chromatography to obtain two 
diasteroisomers (3.7:1) 12a as white solids, yield: 90%. 
 
Procedure for synthesis of 10a  
 
Ph
NO2 O
O+
L-proline, Et3N
MeOH, r.t.
1a 9c 10a
Ph
NO2
CO2Me
CO2Me
 
 
The nitroalkene 1a (163 mg, 1 mmol) and L-proline (23 mg, 0.2 mmol) was dissolved in 
MeOH (5 mL, 0.2 M). To this solution was added the Et3N (101 mg, 1 mmol) and methyl 
acrylate 9c (344 mg, 4 mmol) at room temperature. The resulting mixture was then stirred 
and checked by TLC. After the reaction had completed, the solvent was removed under 
reduced pressure to give a residue, the residue was the purified by flash silica gel 
chromatography to obtain 10a (298 mg, 0.89 mmol) as white solid, yield: 89%.   
 
Procedure for synthesis of 13a  
 
Zn/HCl
MeOH, 0 ºC~r.t.
10a
Ph
NO2
CO2Me
CO2Me
13a
Ph
HN
CO2Me
O
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To a solution of 10a (200 mg, 0.6 mmol) in MeOH (40 mL), 1N HCl (6 mL, 6 mmol) and 
activated Zn powder (585 mg, 9 mmol) were added at 0 ºC. And the mixture was stirred 
at room temperature for 8 hours. To the mixture, was added NaHCO3 (aq.) until pH > 10, 
followed by the extraction with CH2Cl2 (30 mL x 5). The combined organic layer was 
washed with brine and then dried over with anhydrous Na2SO4. After filtration and 
evaporation, the residue was purified by flash silica gel chromatography with 
EtOAc/Hexane (1:2, v/v) to get 13a (140 mg, 0.51 mmol) as a white solid, yield: 85%. 
 
Procedure for synthesis of 13b  
 
13a
Ph
HN
CO2Me
O
1. NaOH/MeOH, r.t.
2. Ac2O, 110 ºC
N
Ph
O O
13b  
 
To a solution of 13a (100 mg, 0.37 mmol) in MeOH (5 mL) was added the NaOH (22 
mg, 0.56 mmol) at room temperature. The mixture was stirred for an hour. To this 
mixture was added 2N HCl (0.5 mL) and then extract with EtOAc (20 mL x 3), the 
combined organic layer was washed with brine, dried over with anhydrous Na2SO4. The 
solvent was removed under reduced pressure to get a colorless solid. To this solid was 
added Ac2O (5 mL), the solution was stirred for 3 hr at 110 ?. After returned to room 
temperature, the solution was poured into water (20 mL) and stirred for half an hour. 
Then neutralized by NaHCO3 (aq.), followed by extraction with EtOAc (20 mL x 3), the 
combined organic layer was washed with brine, dried with anhydrous Na2SO4. The 
solvent was removed under reduced pressure to get a residue. The residue can purified by 
recrystallization (EtOAc/Hexane, 1:5, v/v) or flash silica gel chromatography with 
EtOAc/Hexane (1:3, v/v) to give 13b (70 mg, 0.29 mmol) as colorless crystal, yield: 
79%. 
 
Procedure for synthesis of 13c  
Zn/HCl
MeOH, 0 ºC~r.t.
13c
Ph
NO2
OH
COCH3
12a-major
H
Ph
NH2
OH
COCH3
H
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To a solution of 12a-major (303 mg, 1 mmol) in MeOH (25 mL), 1N HCl (10 mL, 10 
mmol) and Zn powder (975 mg, 15 mmol) were added at 0 ?. And the mixture was 
stirred at room temperature for 4 hr. To the mixture was added NaHCO3 (aq) until pH > 
10, followed by the extraction with CH2Cl2 (20 mL x 5). The combined organic layer was 
washed with brine and dried over with anhydrous Na2SO4. After filtration and 
evaporation, the residue was purified by flash silica gel chromatography with 
EtOAc/hexane (1:1, v/v) to give 13c (240 mg, 0.88 mmol) as colorless oil, yield: 88%.   
 
Procedure for synthesis of 13d  
 
ClCH2COCl, Et3N
DMAP,CH2Cl2, r.t.
13d13c
Ph
NH2
OH
COCH3
H
Ph
HN
OH
COCH3
H
O Cl
 
 
To a solution of 13c (273 mg, 1 mmol) DMAP (6 mg, 0.05 mmol) and Et3N (150 mg, 1.5 
mmol) in CH2Cl2 (10 mL), 2-chloroacetyl chloride (136 mg, 1.2 mmol) was added by 
dropwise.  The mixture solution was stirred at room temperature and monitored by TLC. 
The solution was diluted with EtOAc (20 mL), and poured into NaHCO3 (aq), then 
extracted with EtOAc (20 mL x 3). The combined organic layer was washed with brine, 
dried over with anhydrous Na2SO4. After filtration and evaporation, the residue was 
purified by flash silica gel chromatography with EtOAc/Hexane (1:5, v/v) to give 13d 
(318 mg, 0.91 mmol) as white solid, yield: 91%. 
 
Procedure for synthesis of 13e  
 
K2CO3
MeOH, 50 ºC
Ph
N
OH
OO
13e13d
Ph
HN
OH
COCH3
H
O Cl
 
 
To a solution of 13d (50 mg, 0.14 mmol) in MeOH (2 mL) was added the K2CO3 (29 mg, 
0.21 mmol), the mixture solution was stirred at 50 ºC and checked by TLC. The solvent 
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was removed under reduced pressure and the residue was purified by flash silica gel 
chromatography with EtOAc/Hexane (1:2, v/v) to obtain 13e (36 mg, 0.12 mmol) as 
colorless oil, yield: 83%.  
 
General Procedure for preparation of homo-isoxazoline-N-oxide (15):  
 
N O
O
Ph
Ph
Ph
O2N
Ph
+
O
PhH
L-proline (20%), K2CO3 (50%)
1a 14a 15a
DMSO, 25 oC, 3h
 
 
The nitroalkene 1a (1.1 mmol, 1.1 eq.) was added to a DMSO solution of aldehyde 14a 
(0.5 mmol, 0.5 eq.), L-proline (25 mg, 0.22 mmol, 0.2 eq.), and K2CO3 (35 mg, 0.25 
mmol, 0.5 eq.), with a concentration of 0.1 M for aldehyde. The resulting reaction 
mixture was stirred at room temperature for 2~5 hours monitored by TLC. Upon the 
aldehyde was all consumed, the mixture was diluted with EtOAc (100 mL). The organic 
phase was washed by HCl solution (1.0 M), saturated NaHCO3 (aq.) and brine and then 
dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give a 
residue. Flash silica gel chromatography was then applied to give the product. 
 
Procedure for the synthesis of diene intermediate A´: 
 
NO2 O
CHO DMSO/DCM, r.t., 5 h
proline(10%), K2CO3 (50%) NO2
O
65% yield
Z/E = 1/1.5
1b 14b A'
+
 
 
The nitroalkene 1b (1.0 mmol, 0.1 M, 1.0 eq.) DMSO solution was added to a DCM 
solution of aldehyde 14b (1.5 mmol, 0.15 M. 1.5 eq.), L-Proline (11 mg, 0.1 mmol, 0.1 
eq.), and K2CO3 (35 mg, 0.25 mmol, 0.5 eq.). Upon the DCM solution was mixed well, 
the nitroalkene was added dropwise through 5 min. The resulting reaction mixture was 
stirred at room temperature for 2 hours monitored by TLC. Upon the nitroalkene was all 
consumed, the mixture was diluted with EtOAc (100 mL). The organic phase was washed 
by brine and then dried over anhydrous Na2SO4. The solvent was removed under reduced 
pressure to give a residue. Flash silica gel chromatography was then applied to give the 
 91 
Z/E isomers A$ as a mixture, Z/E = 1/1.5, 143 mg, 65% yield based on the nitroalkene. 
Detailed NMR study of A$ is shown as below. 
 
1H NMR 
 
13C NMR 
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Assignment of 1H NMR signals 
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Procedure for the cross condensation through diene intermediate A' and 1a: 
 
NO2
O
NO2
ON
O
O
A'
1a
15p, 26%+
DMSO, r.t.
Proline(10%)
K2CO3 (50%)
ON
O
O
15p', 24%
ON
O
O
15b, 18% 15b', 6%
ON
O
O
 
 
The diene A' (0.6 mmol, 1.0 equiv.) was then mixed with nitroalkene 1a (0.65 mmol, 1.1 
equiv.) in DMSO, with A' as 0.1 M. Proline (14 mg, 0.12 mmol, 0.2 equiv.) and K2CO3 
(41 mg, 0.30 mmol, 0.5 equiv.) were added in the solution. Keep stirring and monitored 
by TLC. Two hrs later, when all the nitroalkene was consumed, the mixture was diluted 
with EtOAc (100 mL). The organic phase was washed by saturated NaHCO3 (aq.) and 
brine and then dried over anhydrous Na2SO4. The solvent was removed under reduced 
pressure to give a residue. Flash silica gel chromatography was then applied to give the 
crude product 3b (18%), 3b' (6%), 3s (26%), 3s' (24%). These four compounds could not 
be separated by chromatography.  
 95 
 
 
 
General Procedure for preparation of three-component isoxazoline-N-oxide (18):  
 
1) Racemic sample preparation: 
 
1a 14 17
DMSO, r.t.
Proline(10%), K2CO3 (50%)
ON
O
R1Ph
MePh
NO2
+
O
HR1
+ S R2
Br- R2
18  
 
The nitroalkene 1a (0.6 mmol, 1.2 eq.) was added to a solution of the corresponding 
sulfur ylide (0.55 mmol, 1.1 eq.) DMSO (0.2 M for nitroalkene) solution, till the ylide is 
all dissolved. Proline (12 mg, 0.1 mmol, 0.2 eq.) and K2CO3 (35 mg, 0.25 mmol, 0.5 eq.) 
were then added in and stir for 5 minutes. The aldehyde (0.5 mmol, 1.0 eq.) DMSO 
solution (0.2 M) was added drop wise through 5 minutes. The resulting reaction mixture 
was stirred at room temperature for 1~5 hrs monitored by TLC. Upon the aldehyde was 
all consumed, the mixture was diluted with EtOAc (100 mL). The organic phase was 
washed by HCl solution (1.0 M), saturated NaHCO3 (aq.) and brine and then dried over 
anhydrous Na2SO4. The solvent was removed under reduced pressure to give a residue. 
Flash silica gel chromatography was then applied to give the product. 
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2) Optical sample preparation:  
 
+
1 2
+
19
R
NO2 O
HR2
N O
R1
O
R2
O
OMeR
S
OH
Me
OEt
O
Br-
aux-d
20% pyrrolidine
Cs2CO3 1 equiv;
MeOH, -25 oC
 
 
 
The nitroalkene 1 (0.7 mmol, 1.4 eq.) was added to a solution of the sulfur ylide (0.6 
mmol, 1.2 eq.) MeOH solution (0.4 M for nitroalkene), till the ylide is all dissolved. The 
mixture was cooled down to -25 oC. pyrrolidine (7 mg, 0.1 mmol, 0.2 eq.) and K2CO3 (35 
mg, 0.25 mmol, 0.5 eq.) were then added in and stir for 30 minutes. The aldehyde (0.5 
mmol, 1.0 eq.) MeOH solution (0.4 M) was added drop wise through 10 minutes. The 
resulting reaction mixture was stirred at -25 oC for 48~60 hours, monitored by TLC. The 
mixture was then diluted with EtOAc (20 mL) and the water phase was extracted with 
EtOAc (20 mL x 3). The organic phase was washed by HCl solution (1.0 M), saturated 
NaHCO3 (aq.) and brine and then dried over anhydrous Na2SO4. The solvent was 
removed under reduced pressure to give a residue. Flash silica gel chromatography was 
then applied to give the product, which were then examined for e.e values. 
 
Procedure for preparation of ketone 22 
 
N O
O
Ph Ph
CO2Me
OsO4/ NaIO4
THF/H2O, 0 ºC
N O
O
Ph
O
Ph
CO2Me
91%
19a 22  
 
The isozaxoline-N-oxide 19a (323 mg, 1.0 mmol, 1.0 equiv.) was dissolved in THF/H2O 
(1:1) (10 ml) at 0 oC and keep stirring for 10minutes. OsO4 (13 mg, 0.05 mmol, 0.05 
equiv.) was added in the solution followed by the addition of NaIO4 (1065 mg, 5.0 mmol, 
5.0 equiv.). The reaction was stirred for 5 hours until the starting material 19a was all 
gone. Na2S2O8 saturated solution (20 ml) was then added in to quench the reaction. 
EtOAc was used for extraction (20 ml x 3). The combined organic solution was then 
dried over anhydrous Na2SO4 and evaporated by rotavapor after a simple filtration of 
celite column. The residue was then purified by column. 294 mg of ketone 22 was 
obtained as solid.  
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Procedure for preparation of ketone 26 
 
N O
O
Ph Ph
CO2Me i) (MeO)3P, reflux;
N O
Ph
O
Ph
CO2Me
19a 26
ii) OsO4/ NaIO4
72% for 2 steps
 
 
The isozaxoline-N-oxide 19a (323 mg, 1.0 mmol, 1.0 equiv.) was dissolved in (MeO)3P 
(20 ml) and degassed by argon, the reaction was heated up to 120 ºC for 8 hours until the 
starting material was all gone. The reaction was then cooled down to 0 ºC and HCl (5N) 
was added in to quench the reaction. EtOAc (20 ml) was added in for extraction. 
NaHCO3 (aq.) (30 ml) was then applied another 20 ml of EtOAc was added. The organic 
layer was then dried over Na2SO4 and condensed down on rotapavor for next step. The 
crude product was dissolved in THF/H2O (1:1) (10 ml) at 0 oC and keep stirring for 
10minutes. OsO4 (13 mg, 0.05 mmol, 0.05 equiv.) was added in the solution followed by 
the addition of NaIO4 (1065 mg, 5.0 mmol, 5.0 equiv.). The reaction was stirred for 5 
hours until the starting material was all gone. Na2S2O8 saturated solution (20 ml) was 
then added in to quench the reaction. EtOAc was used for extraction (20 ml x 3). The 
combined organic solution was then dried over anhydrous Na2SO4 and evaporated by 
rotavapor after a simple filtration of celite column. The residue was then purified by 
column. 226 mg of ketone 26 was obtained as oil.  
 
Procedure for preparation of alcohol 27 
 
N O
Ph
O
Ph
CO2Me
N O
Ph
HO
Ph
CO2Me
86%, d.r. 8:1
26 27
NaBH4, MeOH, 
-40 ºC, 3h
 
 
The ketone 26 (226 mg, 0.72 mmol, 1.0 equiv.) was dissolved into MeOH (10 ml) at -40 
ºC and NaBH4 (28 mg, 0.72 mmol, 1.0 equiv.) was applied. 3 hours later, once all the 
ketone was consumed, the reaction was quenched by HCl (1N) at low temperature. 
NaHCO3 (aq.) was added in to remove the HCl in excess. EtOAc (20ml x 2) was used for 
extraction and the organic layer was dried over Na2SO4 and evaporated to have the 
residue. Crude NMR gave an 8:1 diastereo ratio. Column was then applied to purify the 
product alcohol 27 (183 mg) as solid.  
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Procedure for preparation of %-oxime alcohol 29 
N O
O
Ph
O
Ph
CO2Me Pd/C, H+, H2
NHO
HO
Ph
O
Ph
CO2Me
r.t., quant.
22 29  
 
The ketone 26 (226 mg, 0.72 mmol) was dissolved into MeOH (10 ml) at room 
temperature. Pd/C (10%) was added in, followed by the H2 gas applied to the reaction. 
The reaction went smooth and yielded the product 29 in quantitative yield (226 mg). The 
reaction was quenched and filtered through celite. No further purification required.  
 
Procedure for preparation of tri-TBS-silyl ether 30 
 
NHO
HO
Ph
O
Ph
CO2Me TBSOTf, DCM, Et3N
NTBSO
Ph
TBSO
Ph
CO2Me
81% over two steps
d.r.12:1
29 30
TBSO
NaBH4, MeOH
-40 ºC
NHO
HO
Ph
HO
Ph
CO2Me
29'  
 
Ketone 29 (226 mg, 0.72 mmol, 1.0 equiv.) was treated with NaBH4 (28 mg, 0.72 mmol, 
1.0 equiv.) in MeOH under -40 ºC. 3 hours later, once all the ketone was consumed, the 
reaction was quenched by HCl (1N) at low temperature. NaHCO3 (aq.) was added in to 
remove the HCl in excess. EtOAc (20ml x 2) was used for extraction and the organic 
layer was dried over Na2SO4 and evaporated to have the residue. Crude NMR gave a 12:1 
diastereo ratio. Without further purification, TBSOTf (792 mg, 3.0 mmol, 4 equiv.) was 
added in the DCM (20 ml) solution of crude product at room temperature. 4 hours later, 
when the oxime diol 29´ was all consumed, 30 ml DCM was added and wash the reaction 
with HCl (1N), NaHCO3 (aq.) and brine. The organic layer was dried over Na2SO4 and 
evaporated to have the residue. Purification by column give the product 30 550 mg as 
colorless oil. 
 
Procedure for preparation of %-lactam 31 
 
19a
N O
O
Ph
O
OMe
Ph
N
H
Ph OH
Ph
O
Zn/HCl, MeOH
-15 oC, 6 h
then Et3N, rt, 5 h
31
N
H
Ph OH
Ph
O
31'
+ Me
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The isozaxoline-N-oxide 19a (323 mg, 1.0 mmol, 1.0 equiv.) was dissolved in MeOH (20 
ml) at -15 oC and keep stirring for 10minutes. Zn dust (975 mg, 15 mmol, 15 equiv., 
activated) was added in the solution slowly. Five molar HCl and MeOH (5 ml, 25 mmol, 
25 equiv.) solution was added in drop wise through 10 minutes. Keep cold and stir for 6 
hours. Et3N (2500 mg, 25 mmol, 25 equiv.) was then added in to form white precipitate. 
Warm up to room temperature and keep stirring for another 5 hours. The reaction mixture 
was put under the vacuum to remove most of the solvent. The mixture was then diluted 
with EtOAc (50 mL) and the water phase was extracted with EtOAc (20 mL x 3). The 
organic phase was washed by HCl solution (1.0 M), saturated NaHCO3 (aq.) and brine 
and then dried over anhydrous Na2SO4. The solvent was removed under reduced pressure 
to give a residue. Flash silica gel chromatography was then applied to give the product %-
lactam 31 as white solid 160 mg, in 57% yield. The byproduct 31´ was isolated in 37% 
yield. A 11:1 diastereo ratio was observed.  
 
Procedure for preparation of %-lactam ketone 32 
 
N
H
Ph OH
Ph
O
31
1. MeI, tBuONa, Acetone, 0oC
2. OsO4/NaIO4, THF/H2O.
N
Ph OH
O
Ph
O
Me
32  
 
The %-lactam 31 (160 mg, 0.57 mmol, 1.0 equiv.) was then dissolved into 10 ml acetone 
at 0oC. tBuONa (55 mg, 0.57 mmol, 1.0 equiv.) was added in the solution and stir for 20 
minutes. MeI (81 mg, 0.58 mmol, 1.0 equiv.) acetone (5 ml) solution was added in the 
reaction drop wise, through 5 minutes. The reaction was monitored by TLC and 
quenched by adding H2O after 5 hours. Carefully vacuumed out most of the acetone and 
dilute the mixture with EtOAc 20 ml for extraction. The water phase was extracted with 
EtOAc (20 mL x 3). The organic phase was washed by HCl solution (1.0 M), saturated 
NaHCO3 (aq.) and brine and then dried over anhydrous Na2SO4. After vacuum, the crude 
product was then dissolved in THF and H2O (1:1) solution (10 ml in total). At room 
temperature, NaIO4 (487 mg, 2.28 mmol, 4.0 equiv.) was added in the solution and keep 
stirring till all dissolved. OsO4 (8 mg, 0.029 mmol, 0.05 equiv.) was added in the reaction 
mixture. Monitored by TLC, the reaction was quenched by Na2S2O3 saturated solution 
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after 4 hours. 50 ml of EtOAc and 20 ml of brine were then added in the reaction mixture 
for extraction. The water phase was extracted with EtOAc (20 mL x 3). The organic 
phase was washed brine and then dried over anhydrous Na2SO4. The solvent was 
removed under reduced pressure to give a residue. Flash silica gel chromatography was 
then applied to give 79% (132 mg) of the product 32 as white solid. 
 
Procedure for preparation of target molecule 33 
 
N
Ph OH
O
Ph
O
Me
NaBH4, 0 oC, DCM/MeOH
32
> 98% yield, 
single diastereomer
N
Ph OH
HO
Ph
O
MeH
33  
 
The ketone 32 (132 mg, 0.45 mmol, 1.0 equiv.) was dissolved in 5 ml of MeOH/DCM 
(1:1) solution and cooled down to 0oC. NaBH4 (20 mg, 0.52 mmol, 1.1 equiv.) was added 
in the solution portion wise through 5 minutes. 2 hours later, TLC indicated the ketone 9d 
all consumed, warm up the reaction and dilute in EtOAc (50 ml), 50 ml of brine was 
added in for extraction. The water phase was extracted with EtOAc (20 mL x 2). The 
organic phase was washed by HCl solution (1.0 M), saturated NaHCO3 (aq.) and brine 
and then dried over anhydrous Na2SO4. The solvent was removed under reduced pressure 
to give a residue. Flash silica gel chromatography was then applied to give 33 (132 mg, 
>98% yield) as white crystals.  
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1H NMR of 33 
 
 
 
 
13C NMR of 33 
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COSY,  
  
 104 
 
 
 
 
 
 105 
General Procedure for preparation of dihydrofuran (35a):  
 
Ph Me
NO2
+
O
O
1a 14f 34a
O
Ph
O
35a
Me
O
Me
+ proline, (5%)
K2CO3, (0.5 eq.)
DMSO, r.t.
 
 
The nitroalkene 1a (202 mg, 1.2 mmol, 1.2 equiv.) was added to a DMSO 
solution of aldehyde 14f (1.0 mmol, 1.0 equiv.), cyclohexane-1, 3-dione 34a (1.1 mmol, 
1.1 equiv.) and L-proline (6 mg, 0.05 mmol, 0.05 equiv.), with a concentration of 0.15 M 
for aldehyde. The reaction mixture was stirred for 5~10 minutes to have the clear 
solution; K2CO3 (69 mg, 0.5 mmol, 0.5 equiv.) was then added. The resulting reaction 
mixture was stirred at room temperature for 4 hours monitored by TLC. Upon the 
aldehyde was all consumed, the mixture was diluted with EtOAc (100 mL). The organic 
phase was washed by HCl solution (1.0 M), saturated NaHCO3 (aq.) and brine and then 
dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give a 
residue. Flash silica gel chromatography was then applied to give the product 35a. 
 
General Procedure for Palladium catalyzed rearrangement (36a):  
 
O
O
35a
Ph
Me
toluene, reflux, 5h
Pd(PPh3)4 (0.1 eq.), TsOH (1.0 eq.)
O
O
Ph
Me
35a', 12%
O
O
Me
Ph
Me 36a, 76%
+
 
 
330 mg of 35a (1.0 mmol, 1.0 equiv.) was dissolved in distilled toluene 20 ml, followed 
by the addition of Pd(PPh3)4 (115 mg, 0.1 equiv.) and TsOH (172 mg, 1.0 mmol, 1.0 
equiv.). The reaction was then degassed by argon for 10 minutes and heated in oil bath to 
reflux. After 5 hours, the reaction was cooled down to room temperature and NaHCO3 
(aq.) was applied to remove the acid. Routine extraction was applied after which the 
organic phase was dried over anhydrous Na2SO4. The solvent was removed under 
reduced pressure to give a residue. Flash silica gel chromatography was then applied to 
give the product 36a (250 mg, 0.76 mmol) in 76% yield and 35a´ (40 mg, 0.12 mmol) in 
12% yield. 
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Representative Procedure for Synthesis of Piperidine (39a) 
 
NO2
Ph
BnNH2
O
r.t. N
O2N
HO
Ph
Bn
N
O2N
HO
Ph
Bn
+ + +THF
37a 38a 9b 39a-major 39a-minor  
 
To a solution of nitroalkene 37a (149 mg, 1 mmol, 1 eq.) in dry THF (5 mL), was added 
successively phenylmethanamine 38a (158 mg, 1.5 mmol, 1.5 eq.) and MVK 9b (140 
mg, 2.0 mmol, 2.0 eq.) under N2 atmosphere. The mixture was stirred at room 
temperature and monitored by TLC. After removing the solvent, the residue was purified 
by flash silica gel chromatography (Hexane-EtOAc v/v 10:1) gave two diastereomers 
piperidines 39a-major (275 mg, 0.85 mmol, yiled: 85%) and 39a-minor (38 mg, 0.12 
mmol, yiled: 12%) as white solids. 
 
Representative Procedure for Synthesis of Piperidine (39m)  
 
O2N Ph NH3
O
Ph r.t. N
H
O2N
HO Ph
Ph
+ +
THF
37a
Ph
Ph
9d 39m  
 
Nitroalkene 37a (149 mg, 1 mmol, 1 eq) was dissolved in dry THF (10 mL) in a 25 mL 
two-neck flask equipped with a gas dispersing tube. A stream of NH3 gas was bubbled 
into the solution at room temperature. After the color of solution turned colorless, the 
NH3 gas was stopped and then chalcone 9d (312 mg, 1.5 mmol, 1.5 eq) was added. The 
mixture was stirred at room temperature and monitored by TLC, NH3 gas was refilled 12 
hr later. After removing the solvent, the residue was purified by flash silica gel 
chromatography (Hexane-EtOAc v/v 10:1) gave piperidines 39m (310 mg, 0.83 mmol, 
yield: 83%) as white solid. 
 
Representative Procedure for Synthesis of Piperidine (41d)  
 
O2N Ph
O
+ +
H2N COOMe
MeOH
rt
N
COOMe
Ph
Me
HO
O2N
N
COOMe
Ph
HO
Me
O2N
+
41d-major 41d-minor40d 9b37a  
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To a solution of nitroalkene 37a (149 mg, 1 mmol, 1 eq) in MeOH (10 mL), was added 
successively L-Valine methyl ester 40d (196 mg, 1.5 mmol, 1.5 eq) and MVK 9b (140 
mg, 2.0 mmol, 2.0 eq) under N2 atmosphere. The mixture was stirred at room temperature 
for 36h. After removing the solvent, the residue was purified by flash silica gel 
chromatography (Hexane-EtOAc v/v 5:1) gave two diastereomers piperidines 41d-major 
(168 mg, 0.48 mmol, yield: 48%) and 41d-minor (49 mg, 0.14 mmol, yield: 14%) as 
white solids. 
 
Synthesis of Compound 42a 
 
N
COOMe
Ph
Me
HO
O2N
Ph
N
COOMe
Ph
HO
Me
O2N
Ph
+
41e-major 41e-minor
1. Zn/HCl, MeOH 0 oC - rt
2. Ac2O, Et3N, DMAP, CH2Cl2
3. SOCl2, CH2Cl2, 0 oC
N
COOMe
PhAcHN
Ph
Me
42a  
 
To a solution of 41e (major & minor) (200 mg, 0.5 mmol, 1eq) in MeOH (25 mL), 1N 
HCl (5 mL, 5 mmol, 10 eq) and Zn powder (488 mg, 7.5 mmol, 15 eq) were added at 0?
. The mixture was then stirred at room temperature and monitored by TLC. To the 
mixture, NaHCO3 (aq) was added until pH > 10, followed by the extraction with CH2Cl2 
(30 mL x 5). The combined organic layer was washed with brine and then dried over 
anhydrous Na2SO4. After filtration and evaporation, the residue was dissolved in CH2Cl2 
(25 mL). To the solution, Et3N (101 mg, 1 mmol, 2 eq) and Ac2O (78 mg, 0.75 mmol, 
1.5 eq) and DMAP (3 mg, 0.025 mmol, 0.05 eq) were added at 0?. The mixture was 
stirred at room temperature and monitored by TLC. After removal of the solvent, the 
residue was diluted with EtOAc (20 mL) and washed with water. The aqueous phase was 
then extracted with EtOAc (20 mL x 3). The combined organic solution was then washed 
with brine and dried over anhydrous Na2SO4. After filtration and evaporation, the 
residue was dissolved in CH2Cl2 (10 mL) at 0 ?. To this solution was added thionyl 
chloride (298 mg, 2.5 mmol, 5 equiv) by dropwise. The mixture was stirred at 0? and 
monitored by TLC. To this solution was added NaHCO3 (aq.) to quench the reaction and 
then extract with EtOAc (30 mL x 3). The combined organic solution was then washed 
with brine and dried over anhydrous Na2SO4. After filtration and evaporation, the 
residue was purified by flash silica gel chromatography (Hexane-EtOAc v/v 3:1) gave 
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42a (156 mg, 0.40 mmol, yield: 80%) as white solid. 
 
Synthesis of compound 7b 
 
N
COOMe
Ph
Me
HO
O2N
Ph
N
COOMe
Ph
HO
Me
O2N
Ph
+
41e-major 41e-minor
SOCl2, pyridine, CH2Cl2, 0 oC N
COOMe
Ph
Ph
42b
O2N
 
 
To a solution of 41 (100 mg, 0.25 mmol, 1 eq) in dry pyridine (1 mL) and dry CH2Cl2 (3 
mL) at 0 ?, thionyl chloride (119 mg, 1 mmol, 5 eq) was added dropwise. The mixture 
was stirred at 0 ? and monitored by TLC. To this solution was added NaHCO3 (aq) to 
quench the reaction and then extract with EtOAc (30 mL x 3). The combined organic 
solution was then washed with brine and dried over anhydrous Na2SO4. After filtration 
and evaporation, the residue was purified by flash silica gel chromatography (Hexane-
EtOAc v/v 10:1) gave 42b (62 mg, 0.16 mmol, yield: 65%) as a colorless oil. 
 
Synthesis of compound 41´ 
N
COOMe
Ph
Me
HO
O2N
41d-major
Zn/HCl N
COOMe
PhNH
41'
N
COOMe
Ph
Me
HO
H2N
COOHPh
CF3MeO
DCC, CH2Cl2
HO
Me
O
Ph
F3C
MeO
 
 
To a solution of 41d-major (70 mg, 0.2 mmol, 1eq) in MeOH (25 mL), 1N HCl (2 mL, 2 
mmol, 10 eq) and Zn powder (195 mg, 3 mmol, 15 eq) were added at 0?. And the 
mixture was stirred at room temperature and monitored by TLC. To the mixture, was 
added NaHCO3 (aq.) until pH > 10, followed by the extraction with CH2Cl2 (20 mL x 5). 
The combined organic layer was washed with brine and then dried over with anhydrous 
Na2SO4. After filtration and evaporation, the residue was dissolved in dry CH2Cl2 (10 
mL). To this solution was added Acid (56 mg, 0.24 mmol, 1.2eq) and DCC (50 mg, 0.24 
mmol, 1.2 equiv.) at 0?. The mixture was stirred at room temperature for 5hr. After 
removal the solvent, the residue was diluted with EtOAc (30 mL), the mixture was got 
through a short column to remove most of insoluble solid and get a clear solution. After 
removal of the solvent, the residue was purified by flash silica gel chromatography 
(Hexane-EtOAc v/v 2:1) gave 41´ (87 mg, 0.16 mmol, yiled: 81%) as a colorless oil. 
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General procedures for nano-sheet preparation:  
 
Guanosine G-1 (46) and Na2TNBP were prepared following published methods. 
Approach I: The guanosine monomer G-1 (200 mg, 428 umol) was dissolved in CH2Cl2 
(5 mL) forming a colorless, clear solution. The bridging salt Na2TNBP (51 mg, 125 umol) 
was dissolved in distilled water (5 mL) as a transparent, dark red solution. The two 
resulting solutions were mixed together at room temperature and a red precipitate was 
observed at the interface of two the solutions after 10 minutes. The heterogeneous 
reaction mixture was left overnight and the solid was filtered followed by the washing 
with CH2Cl2 (20 ml???2) and distilled water (20 ml ??2) respectively. The remaining red 
solid (233 mg, 93%) was dried under vacuum and used for the AFM measurement and 
NMR studies. 
 
Approach II: The guanosine monomer G-1 (200 mg, 428 umol) was dissolved in CH2Cl2 
(5 mL) forming a clear solution, followed by the addition of NaSCN aqueous solution 
(5ml, 25.2 mmol/L). The mixture was stirred for 5 hrs. The organic layer was separated 
and washed by distilled water (10 ml?2). The organic solution was treated by flowing 
through a pipette column filled with Na2SO4 to remove the trace amount of water. The 
solution of (G-1)16•Na4•SCN4 complex was then prepared. Dissolving the (Bu4N)2•TNBP 
(106 mg, 125 umol) in CH2Cl2 (5 mL) giving the dark-red TBA-TNBP solution. The two 
solutions of (G-1)16•Na4•SCN4 and (Bu4N)2•TNBP were mixed together. Within 1 min, 
the clear solution turned turbid. The red precipitate suspension was formed in 5 hours. 
After vacuum filtration, the red precipitate was washed by CH2Cl2 (20ml ??4) to 
remove the remaining free (Bu4N)2•SCN and (G-1)16•Na4•SCN4. The red solid was dried 
under vacuum (198 mg, 88%) and used for the AFM measurement and NMR studies. 
 
AFM measurement 
 
The nano-sheets were observed with an atomic force microscope (AFM) (Molecular 
Imaging, PICOPUS). The suspensions of nano-sheet particles were prepared in various 
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solvents, including CH2Cl2, CH3CN, MeOH and deionized H2O. The AFM images 
shown below were prepared in the deionized water, which produced best quality of 
pictures of nano-sheet without severe aggregation. The nano-sheet was first suspended  
in deionized water and stirred for 3hrs. The suspension was then filtered through a tissue-
packed pipette. This process removed the large aggregated nano-particles and the non-
aggregated/less-aggregated nano-particle can go through to form a nano-particle “solution” 
(suspension). The resulting clear “solution” was transferred to the surface of mica 
substrate (SPI, V4 grade). The mica with sample was then dried in the desiccator prior to 
AFM measurement. AFM measurement was performed on the nano-sheet sample under 
tapping mode with the Si tip (Applied Nanostructure, Model ACT) with a resonance 
frequency of ~300 kHz and spring constant of 40 N/m. During scanning, the tip was kept 
at a distance from the sample at which the oscillation amplitude was dampened by the 
intermolecular repulsive force with sample to 90% of its free amplitude. The scanning 
speed was 2um/s. 
 
100nm 
 
   AFM 2D image     AFM 3D image 
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Cross section profile over the line indicated (green line) 
 
Powder X-ray determination 
 
The powder X-ray diffraction was measured using Bruker D8 Discover equipped with 
HiStar 2D detector and Göbel mirror. Two 2D frames were measured using CuKa 
radiation for 10 min each and integrated resulting XRD pattern shown below. The powder 
X‑ray pattern reveals two low angles peaks observed at d‑spacing 47.5 Å and 23.75 Å, 
which suggest 1st and 2nd orders (e.g. 100 and 200). This result indicates the presenting 
of large unit cell. The other smaller peaks cannot be interpreted from this pattern due to 
broadening and overlapping of the peaks. In the supporting information of reference 3, 
the unit cells of guanosine hexadecamer have been determined, which is 47 Å. For 
example, the unit cell for (G-1)16•Ba2•(P-OME-2,6-DNP)4 hexadecamer is: 
a=46.662 Å ! = 90o 
b=24.259 Å " = 93.139o 
c=45.111 Å # = 90o 
In the crystal structure, the dihedral angle between a G-quartet plane and the edge of unit 
cell is about 45o. The diameter of the G-quartet formed by G1 is around 33 Å. Therefore, 
the correlation is 33 X 1.414 = 47 Å, determining the size of the unit cell. 
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Section C: Compound characterization 
 
Part I 
4a was purified by flash chromatography (Hexane-EtOAc, v/v 7/1) as white oil with 
overall isolated yield: 91% for both isomers. 
Ph
NO2
Ph
OH
 
4a-syn 
(3S,4R)-4-nitro-3,5-diphenylhex-5-en-1-ol (4a-syn) 1H NMR (270 MHz, CDCl3) $ 
(ppm) 1.29 (br s, 1H), 1.90-2.00 (m, 2H), 3.31-3.40 (m, 1H), 3.48-3.56 (m, 1H), 3.70-
3.80 (m, 1H), 5.42 (s, 1H), 5.67 (d, J = 11.4 Hz, 1H), 5.75 (s, 1H), 6.97-7.02 (m, 4H), 
7.14-7.22 (m, 6H); 13C NMR (67.5 MHz, CDCl3) $ (ppm) 36.1, 46.5, 60.0, 94.5, 119.7, 
126.7.9, 127.6, 128.1, 128.4, 128.8, 129.0, 137.4, 140.3, 143.0. HRMS Calculated for 
[C18H19NO3Na]+: 320.1263, Found: 320.1257. [!]D26 = –67.8º (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 0.5 mL/min; tminor = 9.184 min, tmajor 
= 31.704 min; ee% = 91%.  
 
Ph
NO2
Ph
OH
  
 4a-anti 
(3S,4S)-4-nitro-3,5-diphenylhex-5-en-1-ol (4a-anti) 1H NMR (270 MHz, CDCl3) $ 
(ppm) 1.22 (br s, 1H), 1.53-1.66 (m, 1H), 1.94-2.07 (m, 1H), 3.22-3.31 (m, 1H), 3.40-
3.47 (m, 1H), 3.76 (dt, J =11.7, 3.0 Hz, 1H), 5.69 (d, J = 11.6 Hz, 1H), 5.74 (s, 1H), 5.97 
(s, 1H), 7.25-7.53 (m, 10H); 13C NMR (67.5 MHz, CDCl3) $ (ppm) 34.3, 46.8, 59.8, 94.7, 
119.5, 125.9, 126.8, 128.0, 128.2, 128.7, 129.0, 138.6, 140.1, 142.7. HRMS Calculated 
for [C18H19NO3Na]+: 320.1263, Found: 320.1257. [!]D26 = 76.0° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 50/50; Flow rate: 1.0 mL/min; tminor = 4.584 min, tmajor 
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= 12.044 min; ee% = 92%.  
 
4b was purified by flash chromatography (Hexane-EtOAc, v/v 10/1) as white oil with 
overall isolated yield 83% for both isomers. 
Ph
NO2
OH
 
 4b-syn 
(S)-3-((R)-1-nitro-2-phenylallyl)octan-1-ol (4b-syn): 1H NMR (270 MHz, CDCl3) $ 
(ppm) 0.78 (t, J = 6.9 Hz, 3H), 1.04-1.80 (m, 11H), 2.40-2.51 (m, 1H), 3.62-3.73 (m, 
2H), 5.49 (d, J = 9.9 Hz, 1H), 5.63 (s, 1H), 5.71 (s, 1H), 7.35-7.44 (m, 5H); 13C NMR 
(67.5 MHz, CDCl3) $ (ppm) 14.0, 22.9, 28.1, 28.7, 32.7, 38.7, 60.3, 93.6, 118.6, 126.7, 
128.6, 128.9, 140.0, 143.1. HRMS Calculated for [C17H25NO3Na]+: 314.1732, Found: 
314.1725. [!]D26 = –69.5° (c = 1.0 CHCl3). Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 95/5; 
Flow rate: 1.0 mL/min; tminor = 16.780 min, tmajor = 18.372 min; ee% = 94%. 
 
Ph
NO2
OH
 
 4b-anti 
(S)-3-((S)-1-nitro-2-phenylallyl)octan-1-ol (4b-anti): 1H NMR (270 MHz, CDCl3) $ 
(ppm) 0.88 (t, J = 6.7 Hz, 3H), 1.10 (br s, 1H), 1.22-1.72 (m, 10H), 2.45-2.57 (m, 1H), 
3.56-3.67 (m, 2H), 5.49 (d, J = 10.4 Hz, 1H), 5.66 (s, 1H), 5.75 (s, 1H), 7.33-7.50 (m, 
5H); 13C NMR (67.5 MHz, CDCl3) $ (ppm) 14.1, 23.0, 28.0, 31.4, 38.8, 60.2, 93.4, 119.0, 
126.7, 128.6, 129.0, 140.1, 143.0. HRMS Calculated for [C17H25NO3Na]+: 314.1732, 
Found: 314.1725. [!]D26 = 62.4° (c = 1.0 CHCl3). Enantiomeric excess was determined 
by HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 
85/15; Flow rate: 1.0 mL/min; tminor = 4.728 min, tmajor = 13.240 min; ee% = 87%. 
 
4c was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as light yellow oil 
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with overall isolated yield 76% for both isomers. 
 
Ph
NO2
OH
O
 
 4c-syn 
(3S,4R)-3-(furan-2-yl)-4-nitro-5-phenylhex-5-en-1-ol  (4c-syn): 1H NMR (270 MHz, 
CDCl3) $ (ppm) 1.30 (br s, 1H), 1.83-2.07 (m, 2H), 3.38-3.47 (m, 1H), 3.57-3.65 (m, 
1H), 3.91 (dt, J = 10.8, 3.7 Hz, 1H), 5.49 (s, 1H), 5.70 (s, 1H), 5.74 (s, 1H), 6.07 (d, J = 
3.0 Hz, 1H), 6.18-6.21 (m, 1H), 7.13-7.30 (m, 6H); 13C NMR (67.5 MHz, CDCl3) $ 
(ppm) 34.0, 40.1, 60.0, 92.3, 109.3, 110.4, 119.2, 126.7, 128.2, 128.5, 139.4, 142.2, 
142.8, 150.6. HRMS Calculated for [C16H17NO4Na]+: 310.1055, Found: 310.1049. [!]D26 
= -68.6° (c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel 
AS-H column; &= 254 nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; 
tminor = 11.164 min, tmajor = 7.232 min; ee% = 87%. 
 
Ph
NO2
OH
O
 
 4c-anti 
(3S,4S)-3-(furan-2-yl)-4-nitro-5-phenylhex-5-en-1-ol (4c-anti): 1H NMR (270 MHz, 
CDCl3) $ (ppm) 1.20 (br s, 1H), 1.68-1.81 (m, 1H), 1.87-1.99 (m, 1H), 3.30-3.41 (m, 
1H), 3.50-3.58 (m, 1H), 3.96 (dt, J = 11.4, 3.5 Hz, 1H), 5.72-5.76 (m, 2H), 5.89 (s, 1H), 
6.24 (d, J = 3.0 Hz, 1H), 6.29-6.30 (m, 1H), 7.35-7.50 (m, 6H); 13C NMR (67.5 MHz, 
CDCl3) $ (ppm) 32.4, 40.3, 60.0, 92.4, 109.9, 110.6, 119.7, 126.8, 128.8, 129.0, 139.7, 
142.3, 142.6, 151.7. HRMS Calculated for [C16H17NO4Na]+: 310.1055, Found: 310.1049. 
[!]D26 = 63.7° (c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a 
Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 
mL/min; tminor = 5.676 min, tmajor = 16.436 min; ee% = 87%. 
 
 116 
4d was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as light yellow oil 
with overall isolated yield 80% for both isomers. 
 
Ph
NO2
OH
O
 
 4d-syn 
(3S,4R)-3-(4-methoxyphenyl)-4-nitro-5-phenylhex-5-en-1-ol (4d-syn): 1H NMR (270 
MHz, CDCl3) $ (ppm) 1.20 (br s, 1H), 1.82-2.04 (m, 2H), 3.32-3.41 (m, 1H), 3.47-3.57 
(m, 1H), 3.64-3.74 (m, 4H), 5.42 (s, 1H), 5.62 (d, J = 11.1 Hz, 1H), 5.73 (s, 1H), 6.67-
6.73 (m, 2H), 6.89-6.94 (m, 2H), 6.99-7.04 (m, 2H), 7.18-7.23 (m, 3H); 13C NMR (67.5 
MHz, CDCl3) $ (ppm) 34.4, 46.3, 55.4, 60.0, 95.0, 114.4, 119.5, 126.8, 128.7, 129.0, 
129.2, 130.4, 140.2, 142.8, 159.2. HRMS Calculated for [C19H21NO4Na]+: 350.1368, 
Found: 350.1362. [!]D26 = -91.2° (c = 1.1 CHCl3). Enantiomeric excess was determined 
by HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 
80/20; Flow rate: 1.0 mL/min; tminor = 8.516 min, tmajor = 22.676 min; ee% = 94%. 
 
Ph
NO2
OH
O
 
4d-anti 
(3S,4S)-3-(4-methoxyphenyl)-4-nitro-5-phenylhex-5-en-1-ol (4d-anti): 1H NMR (270 
MHz, CDCl3) $ (ppm) 1.21 (br s, 1H), 1.53-1.64 (m, 1H), 1.94-2.05 (m, 1H), 3.25-3.34 
(m, 1H), 3.42-3.51 (m, 1H), 3.66-3.80 (m, 4H), 5.63 (d, J = 11.6 Hz, 1H), 5.74 (s, 1H), 
5.96 (s, 1H), 6.82-6.88 (m, 2H), 7.16-7.22 (m, 2H), 7.40-7.52 (m, 5H) ; 13C NMR (67.5 
MHz, CDCl3) $ (ppm) 34.2, 46.0, 55.2, 59.8, 94.8, 114.2, 119.3, 126.6, 128.5, 128.8, 
129.0, 130.2, 140.0, 142.6, 159.0. HRMS Calculated for [C19H21NO4Na]+: 350.1368, 
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Found: 350.1362. [!]D26 = 124.1° (c = 0.75 CHCl3). Enantiomeric excess was determined 
by HPLC with a Chiralcel AS-H column; &= 254 nm; eluent: Hexane/Isopropanol = 
60/40; Flow rate: 1.0 mL/min; tminor = 15.528 min, tmajor = 11.180 min; ee% = 95%. 
 
4e was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as light yellow solid 
with overall isolated yield: 89% for both isomers. 
Ph
NO2
OH
NO2
      
 4e-syn 
(3S,4R)-4-nitro-3-(4-nitrophenyl)-5-phenylhex-5-en-1-ol (4e-syn): 1H NMR (270 
MHz, CDCl3) $ (ppm) 1.24 (br s, 1H), 1.84-2.10 (m, 2H), 3.23-3.34 (m, 1H), 3.50-3.59 
(m, 1H), 3.96 (dt, J = 10.8, 3.5 Hz, 1H), 5.44 (s, 1H), 5.68-5.73 (m, 2H), 6.96-6.99 (m, 
2H), 7.14-7.24 (m, 5H), 7.97-8.01 (m, 2H) ; 13C NMR (67.5 MHz, CDCl3) $ (ppm) 34.1, 
46.4, 59.2, 94.0, 120.0, 124.2, 126.8, 129.0, 129.2, 129.3, 139.7, 142.4, 146.6, 147.6. 
HRMS Calculated for [C18H18N2O5Na]+: 365.1113, Found: 365.1107. [!]D26 = -81.1° (c = 
1.5 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column; &= 254 nm; eluent: Hexane/Isopropanol = 60/40; Flow rate: 1.0 mL/min; tminor = 
5.548 min, tmajor = 13.250 min; ee% = 82%. 
 
Ph
NO2
OH
NO2
    
 4e-anti 
(3S,4S)-4-nitro-3-(4-nitrophenyl)-5-phenylhex-5-en-1-ol (4e-anti): 1H NMR (270 
MHz, CDCl3) $ (ppm) 1.25 (br s, 1H), 1.58-1.69 (m, 1H), 2.01-2.13 (m, 1H), 3.16-3.27 
(m, 1H), 3.45-3.54 (m, 1H), 3.98 (dt, J = 11.6, 3.2 Hz, 1H), 5.71 (d, J = 11.6 Hz, 1H), 
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5.78 (s, 1H), 5.96 (s, 1H), 7.41-7.53 (m, 7H), 8.19-8.22 (m, 2H) ; 13C NMR (67.5 MHz, 
CDCl3) $ (ppm) 35.9, 46.3, 59.3, 93.5, 119.9, 123.8, 126.5, 128.5, 128.7, 129.9, 139.6, 
142.7, 145.3, 147.2. HRMS Calculated for [C18H18N2O5Na]+: 365.1113, Found: 
365.1107. [!]D26 = -81.1° (c = 1.5 CHCl3). Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 85/15; 
Flow rate: 1.0 mL/min; tminor = 15.916 min, tmajor = 14.444 min; ee% = 83%. 
 
4f was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as yellowish oil with 
overall isolated yield: 85% for both isomers. 
 
Ph
NO2
OH
NO2
       
 4f-syn 
(3S,4R)-4-nitro-3-(2-nitrophenyl)-5-phenylhex-5-en-1-ol (4f-syn): 1H NMR (270 
MHz, CDCl3) $ (ppm) 1.25 (br s, 1H), 1.66-1.78 (m, 1H), 2.02-2.18 (m, 1H), 3.44-3.55 
(m, 2H), 4.51-4.58 (m, 1H), 5.70 (d, J = 11.6 Hz, 1H), 5.75 (s, 1H), 5.88 (s, 1H), 7.38-
7.64 (m, 8H), 7.79-7.83 (m, 1H); 13C NMR (67.5 MHz, CDCl3) $ (ppm) 35.9, 46.3, 59.3, 
93.5, 119.9, 125.3, 126.8, 127.9, 128.9, 129.2, 133.4, 139.7, 142.5, 151.8. HRMS 
Calculated for [C18H18N2O5Na]+: 365.1113, Found: 365.1108. [!]D26 = -90.4° (c = 1.3 
CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel AS-H column; 
&= 254 nm; eluent: Hexane/Isopropanol = 60/40; Flow rate: 1.0 mL/min; tminor = 11.448 
min, tmajor = 6.708 min; ee% = 86%. 
 
Ph
NO2
OH
NO2
                
 4f-anti 
(3S,4S)-4-nitro-3-(2-nitrophenyl)-5-phenylhex-5-en-1-ol (4f-anti): 1H NMR (270 
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MHz, CDCl3) $ (ppm) 0.96 (d, J = 6.7 Hz, 3H), 1.25 (br s, 1H), 1.42-1.54 (m, 1H), 1.64-
1.78 (m, 1H), 2.55-2.72 (m, 1H), 3.63-3.81 (m, 2H), 5.27 (d, J = 10.4 Hz, 1H), 5.64 (s, 
1H), 5.73 (s, 1H), 7.32-7.44 (m, 5H) ; 13C NMR (67.5 MHz, CDCl3) $ (ppm) 34.8, 40.6, 
59.6, 94.4, 119.8, 125.5, 126.1, 127.4, 128.3, 129.7, 133.5, 139.9, 142.1, 151.3. HRMS 
Calculated for [C18H18N2O5Na]+: 365.1113, Found: 365.1108. [!]D26 = -90.4° (c = 1.3 
CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel AS-H column; 
&= 254 nm; eluent: Hexane/Isopropanol = 60/40; Flow rate: 1.0 mL/min; tminor = 11.448 
min, tmajor = 6.708 min; ee% = 86%. 
 
4g was purified by flash chromatography (Hexane-EtOAc, v/v 7/1) as white oil with 
overall isolated yield: 93% for both isomers. 
 
Ph
NO2
OH
 
 4g-syn 
(3S,4R)-3-methyl-4-nitro-5-phenylhex-5-en-1-ol (4g-syn): 1H NMR (270 MHz, CDCl3) 
$ (ppm) 0.96 (d, J = 6.7 Hz, 3H), 1.25 (br s, 1H), 1.42-1.54 (m, 1H), 1.64-1.78 (m, 1H), 
2.55-2.72 (m, 1H), 3.63-3.81 (m, 2H), 5.27 (d, J = 10.4 Hz, 1H), 5.64 (s, 1H), 5.73 (s, 
1H), 7.32-7.44 (m, 5H) ; 13C NMR (67.5 MHz, CDCl3) $ (ppm) 15.5, 34.4, 36.1, 60.1, 
95.4, 118.9, 126.8, 128.5, 128.9, 140.1, 143.1. HRMS Calculated for [C13H17NO3Na]+: 
258.1106, Found: 258.1106. [!]D26 = -81.4° (c = 1.2 CHCl3). Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: 
Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor = 8.232 min, tmajor = 7.052 
min; ee% = 88%. 
 
Ph
NO2
OH
 
 4g-anti 
(3S,4S)-3-methyl-4-nitro-5-phenylhex-5-en-1-ol (4g-anti): 1H NMR (270 MHz, CDCl3) 
$ (ppm) 1.07 (d, J = 5.8 Hz, 3H), 1.22-1.35 (m, 2H), 1.69-1.81 (m, 1H), 2.54-2.70 (m, 
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1H), 3.59-3.75 (m, 2H), 5.29 (d, J = 9.9 Hz, 1H), 5.67 (s, 1H), 5.76 (s, 1H), 7.33-7.45 (m, 
5H) ; 13C NMR (67.5 MHz, CDCl3) $ (ppm) 16.4, 34.2, 34.8, 60.1, 95.5, 119.1, 126.7, 
128.6, 128.9, 140.0, 142.7. HRMS Calculated for [C18H18N2O5Na]+: 365.1113, Found: 
365.1106. [!]D26 = 72.6° (c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC 
with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 60/40; Flow 
rate: 1.0 mL/min; tminor = 4.928 min, tmajor = 10.824 min; ee% = 88%. 
 
4h was purified by flash chromatography (Hexane-EtOAc, v/v 10/1) as white oil with 
overall isolated yield: 89% for both isomers. 
 
NO2
OH
Cl
Ph
 
 4h-syn 
(3S,4R)-5-(4-chlorophenyl)-4-nitro-3-phenylhex-5-en-1-ol (4h-syn): 1H NMR (600 
MHz, CDCl3) $ (ppm) 1.26 (br s, 1H), 1.89-1.99 (m, 2H), 3.34-3.38 (m, 1H), 3.50-3.54 
(m, 1H), 3.73 (dt, J = 11.4, 3.6 Hz, 1H), 5.39 (s, 1H), 5.59 (d, J = 11.4 Hz, 1H), 5.76 (s, 
1H), 6.88-6.90 (m, 2H), 6.97-6.99 (m, 2H), 7.14-7.17 (m, 5H); 13C NMR (150 MHz, 
CDCl3) $ (ppm) 35.9, 46.4, 59.7, 94.2, 120.1, 127.5,  127.9, 128.4, 128.6, 128.7, 134.0, 
137.1, 138.5, 142.1. HRMS Calculated for [C18H18ClNO3Na]+: 354.0872, Found: 
354.0867. [!]D26 = -74.3° (c = 0.9 CHCl3). Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 95/5; 
Flow rate: 1.0 mL/min; tminor = 23.852 min, tmajor = 25.560 min; ee% = 89%. 
 
NO2
OH
Cl
Ph
 
 4h-anti 
(3S,4S)-5-(4-chlorophenyl)-4-nitro-3-phenylhex-5-en-1-ol (4h-anti): 1H NMR (600 
MHz, CDCl3) $ (ppm) 1.18 (br s, 1H), 1.58-1.64 (m, 1H), 1.95-2.00 (m, 1H), 3.26-3.30 
(m, 1H), 3.43-3.47 (m, 1H), 3.75 (dt, J = 11.4, 3.0 Hz, 1H), 5.63 (d, J = 12.0 Hz, 1H), 
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5.74 (s, 1H), 5.98 (s, 1H), 7.25-7.27 (m, 3H), 7.31-7.33 (m, 2H), 7.37-7.40 (m, 2H), 7.43-
7.45 (m, 2H); 13C NMR (150 MHz, CDCl3) $ (ppm) 36.2, 46.6, 59.9, 94.4, 120.3, 127.7,  
128.1, 128.7, 128.9, 129.0, 134.2,  137.3, 138.8, 142.3. HRMS Calculated for 
[C18H18ClNO3Na]+: 354.0872, Found: 354.0867. [!]D26 = 84.1° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 95/5; Flow rate: 1.0 mL/min; tminor = 7.240 min, tmajor = 
10.480 min; ee% = 90%. 
 
4i was purified by flash chromatography (Hexane-EtOAc, v/v 10/1) as light yellowish oil 
with overall isolated yield: 78% for both isomers. 
 
NO2
OH
Cl
O
 
4i-syn 
(3S,4R)-5-(4-chlorophenyl)-3-(furan-2-yl)-4-nitrohex-5-en-1-ol (4i-syn): 1H NMR 
(600 MHz, CDCl3) $ (ppm) 1.32 (br s, 1H), 1.86-1.91 (m, 1H), 1.95-2.01 (m, 1H), 3.39-
3.45 (m, 1H), 3.60-3.62 (m, 1H), 3.90 (dt, J = 10.8, 3.6 Hz, 1H), 5.46 (s, 1H), 5.65 (d, J = 
10.8 Hz, 1H), 5.71 (s, 1H), 6.05 (d, J = 3.0Hz, 1H), 6.20-6.21 (m, 1H), 7.06-7.08 (m, 
2H), 7.15-7.16 (m, 1H), 7.23-7.25 (m, 2H); 13C NMR (150 MHz, CDCl3) $ (ppm) 33.9, 
40.1, 59.8, 92.1, 109.3, 110.3, 119.6, 128.0, 128.5, 134.2, 137.8, 141.9, 142.1, 150.4. 
HRMS Calculated for [C16H16ClNO4Na]+: 344.0665, Found: 344.0660. [!]D26 = -78.2° (c 
= 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel AS-H 
column; &= 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor = 
11.084 min, tmajor = 7.168 min; ee% = 87%. 
 
NO2
OH
Cl
O
 
 4i-anti 
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(3S,4R)-5-(4-chlorophenyl)-3-(furan-2-yl)-4-nitrohex-5-en-1-ol (4i-anti): 1H NMR 
(600 MHz, CDCl3) $ (ppm) 1.23 (br s, 1H), 1.72-1.78 (m, 1H), 1.87-1.92 (m, 1H), 3.34-
3.39 (m, 1H), 3.52-3.56 (m, 1H), 3.94 (dt, J = 11.4, 3.6 Hz, 1H), 5.68 (d, J = 11.4 Hz, 
1H), 5.73 (s, 1H), 5.89 (s, 1H), 6.23 (d, J = 3.0Hz, 1H), 6.29-6.30 (m, 1H), 7.35-7.38 (m, 
3H), 7.40-7.42 (m, 2H); 13C NMR (150 MHz, CDCl3) $ (ppm) 32.2, 39.9, 59.7, 92.2, 
108.9, 110.4, 120.3, 128.1, 129.0, 134.7, 137.8, 141.1, 142.4, 151.3. HRMS Calculated 
for [C16H16ClNO4Na]+: 344.0665, Found: 344.0660. [!]D26 = 74.1° (c = 0.9 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel AS-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor = 5.832 min, tmajor 
= 17.144 min; ee% = 86%. 
 
4j was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as light yellowish oil 
with overall isolated yield: 74% for both isomers. 
 
NO2
OH
Cl
O
 
 4j-syn 
(3S,4R)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4-nitrohex-5-en-1-ol (4j-syn): 1H 
NMR (600 MHz, CDCl3) $ (ppm) 1.24 (br s, 1H), 1.84-1.90 (m, 1H), 1.91-1.97 (m, 1H), 
3.34-3.38 (m, 1H), 3.50-3.54 (m, 1H), 3.67 (dt, J = 11.1, 3.0 Hz, 1H), 3.74 (s, 3 H), 5.40 
(s, 1H), 5.55 (d, J = 11.4 Hz, 1H), 5.74 (s, 1H), 6.70-6.71 (m, 2H), 6.89-6.93 (m, 4H), 
7.16-7.17 (m, 2H); 13C NMR (150 MHz, CDCl3) $ (ppm) 35.9, 45.6, 55.2, 59.8, 94.4, 
114.1, 119.9, 128.0, 128.4, 128.9, 129.7, 134.0, 138.5, 142.1, 158.8. HRMS Calculated 
for [C19H20ClNO4Na]+: 384.0979, Found: 384.0974. [!]D26 = -138.3° (c = 0.62 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel AS-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor = 17.876 min, 
tmajor = 8.460 min; ee% = 89%. 
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NO2
OH
Cl
O
 
 4j-anti 
(3S,4S)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4-nitrohex-5-en-1-ol (4j-anti): 1H 
NMR (600 MHz, CDCl3) $ (ppm) 1.12 (br s, 1H), 1.55-1.60 (m, 1H), 1.93-1.98 (m, 1H), 
3.29-3.33 (m, 1H), 3.44-3.47 (m, 1H), 3.70 (dt, J = 11.4, 3.0 Hz, 1H), 3.78 (s, 3 H), 5.56 
(d, J = 11.4 Hz, 1H), 5.73 (s, 1H), 5.97 (s, 1H), 6.84-6.86 (m, 2H), 7.16-7.19 (m, 2H), 
7.37-7.40 (m, 2H), 7.42-7.44 (m, 2H); 13C NMR (150 MHz, CDCl3) $ (ppm) 34.2, 45.8, 
55.2, 59.8, 94.8, 114.4, 120.1, 128.1, 129.0, 129.1, 130.0, 134.6, 138.4, 141.7, 159.1. 
HRMS Calculated for [C19H20ClNO4Na]+: 384.0979, Found: 384.0974. [!]D26 = 68.3° (c 
= 1.1 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column; &= 254 nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor = 
7.640 min, tmajor = 8.936 min; ee% = 85%. 
 
4k was purified by flash chromatography (Hexane-EtOAc, v/v 7/1) as yellow oil with 
overall isolated yield: 64% for both isomers. 
 
NO2
OH
O
Me
 
4k-syn 
(3S,4R)-5-(furan-2-yl)-3-methyl-4-nitrohex-5-en-1-ol (4k-syn): 1H NMR (600 MHz, 
CDCl3) $ (ppm) 1.11 (d, J = 6.6 Hz, 3H), 1.20 (t, J = 4.8 Hz, 1H), 1.32-1.38 (m, 1H), 
1.70-1.75 (m, 1H), 2.69-2.74 (m, 1H), 3.65-3.70 (m, 1H), 3.73-3.77 (m, 1H), 5.18 (d, J = 
10.8 Hz, 1H), 5.64 (s, 1H), 5.96 (s, 1H), 6.41 (dd, J = 3.6, 1.8 Hz, 1H), 6.53 (d, J = 3.6 
Hz, 1H), 7.40 (d, J = 1.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) $ (ppm) 16.4, 33.0, 34.7, 
59.9, 93.2, 107.8, 111.6, 115.2, 131.3, 143.1, 151.7. HRMS Calculated for 
[C11H15NO4Na]+: 248.0899, Found: 248.0894. [!]D26 = -138.3° (c = 0.56 CHCl3). 
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Enantiomeric excess was determined by HPLC with a Chiralcel AS-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor = 8.208 min, tmajor 
= 7.052 min; ee% = 89%. 
 
NO2
OH
O
Me
 
 4k-anti 
(3S,4S)-5-(furan-2-yl)-3-methyl-4-nitrohex-5-en-1-ol (4k-anti): 1H NMR (600 MHz, 
CDCl3) $ (ppm) 1.13 (d, J = 6.6 Hz, 3H), 1.24 (t, J = 4.8 Hz, 1H), 1.30-1.40 (m, 1H), 
1.71-1.75 (m, 1H), 2.73-2.79 (m, 1H), 3.60-3.67 (m, 1H), 3.71-3.76 (m, 1H), 5.19 (d, J = 
10.8 Hz, 1H), 5.70 (s, 1H), 5.95 (s, 1H), 6.43 (dd, J = 3.6, 1.8 Hz, 1H), 6.56 (d, J = 3.6 
Hz, 1H), 7.41 (d, J = 1.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) $ (ppm) 16.3, 33.4, 34.2, 
59.9, 93.7, 106.4, 112.1, 115.9, 132.3, 144.5, 152.1. HRMS Calculated for 
[C11H15NO4Na]+: 248.0899, Found: 248.0894. [!]D26 = 70.3° (c = 0.95 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 65/35; Flow rate: 1.0 mL/min; tminor = 4.908 min, tmajor 
= 10.864 min; ee% = 88%. 
 
4l was purified by flash chromatography (Hexane-EtOAc, v/v 10/1) as white oil with 
overall isolated yield: 82% for both isomers. 
 
NO2
OH
Me
Ph
 
 4l-syn 
(3S,4R)-4-nitro-3-phenyl-5-p-tolylhex-5-en-1-ol (4l-syn): 1H NMR (600 MHz, CDCl3) 
$ (ppm) 1.18 (br s, 1H), 1.91-2.00 (m, 2H), 2.29 (s, 3H), 3.35-3.39 (m, 1H), 3.50-3.54 (m, 
1H), 3.74 (dt, J = 11.1, 4.2 Hz, 1H), 5.39 (s, 1H), 5.66 (d, J = 11.4 Hz, 1H), 5.69 (s, 1H), 
6.89-6.90 (m, 2H), 6.99-7.02 (m, 4H), 7.15-7.19 (m, 3H); 13C NMR (150 MHz, CDCl3) $ 
(ppm) 21.1, 35.9, 46.2, 59.9, 94.4, 119.0, 126.4, 127.4, 128.6, 128.7, 129.0, 137.2, 137.5, 
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137.8, 142.6. HRMS Calculated for [C19H21NO3Na]+: 334.1419, Found: 334.1415. [!]D26 
= -86.5° (c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel 
OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; 
tminor = 10.352 min, tmajor = 12.964 min; ee% = 90%. 
 
NO2
OH
Me
Ph
 
 4l-anti 
(3S,4S)-4-nitro-3-phenyl-5-p-tolylhex-5-en-1-ol (4l-anti): 1H NMR (600 MHz, CDCl3) 
$ (ppm) 1.58-1.63 (m, 1H), 1.98-2.18 (m, 1H), 2.38 (s, 3H), 3.26-3.30 (m, 1H), 3.42-3.46 
(m, 1H), 3.75 (dt, J = 12.0, 3.0 Hz, 1H), 5.68 (d, J = 11.4 Hz, 1H), 5.71 (s, 1H), 5.91 (s, 
1H), 7.21-7.22 (m, 2H), 7.25-7.28 (m, 3H), 7.31-7.33 (m, 2H), 7.40-7.41 (m, 2H); 13C 
NMR (150 MHz, CDCl3) $ (ppm) 21.1, 34.3, 46.7, 59.8, 94.6, 118.5, 126.6, 127.8, 128.0, 
128.9, 129.5, 137.1, 138.5, 138.7, 142.6. HRMS Calculated for [C19H21NO3Na]+: 
334.1419, Found: 334.1415. [!]D26 = 84.3° (c = 1.0 CHCl3). Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: 
Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor = 8.524 min, tmajor = 14.888 
min; ee% = 92%.  
 
4m was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as yellow oil with 
overall isolated yield: 82% for both isomers. 
NO2
OH
NO2
 
 4m-syn 
(3S,4R)-5-(naphthalen-2-yl)-4-nitro-3-(4-nitrophenyl)hex-5-en-1-ol (4m-syn): 1H 
NMR (600 MHz, CDCl3) $ (ppm) 1.28 (t, J = 4.2 Hz, 1H), 1.92-1.98 (m, 1H), 2.05-2.11  
(m, 1H), 3.29-3.33 (m, 1H), 3.54-3.58 (m, 1H), 4.03 (dt, J = 10.8, 3.0 Hz, 1H), 5.57 (s, 
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1H), 5.83-5.85 (m, 2H), 6.96-6.99 (m, 2H), 7.08-7.10 (m, 1H), 7.16-7.18 (m, 2H), 7.46-
7.49 (m, 3H), 7.67-7.73 (m, 2H), 7.76-7.78 (m, 1H), 7.95-7.97 (m, 2H) ; 13C NMR (150 
MHz, CDCl3) $ (ppm) 35.8, 46.3, 59.2, 93.4, 120.1, 123.6, 124.1, 125.6, 126.6, 126.7, 
127.6, 128.1, 128.4, 129.8, 132.8, 132.9, 136.8, 142.6, 145.2, 147.1. HRMS Calculated 
for [C22H20N2O5Na]+: 415.1270, Found: 415.1265. [!]D26 = -147.5° (c = 0.45 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.5 mL/min; tminor = 28.316 min, 
tmajor = 20.900 min; ee% = 77%. 
 
NO2
OH
NO2
 
 4m-anti 
(3S,4S)-5-(naphthalen-2-yl)-4-nitro-3-(4-nitrophenyl)hex-5-en-1-ol (4m-anti): 1H 
NMR (600 MHz, CDCl3) $ (ppm) 1.16 (t, J = 4.2 Hz, 1H), 1.62-1.67 (m, 1H), 2.10-2.15  
(m, 1H), 3.20-3.25 (m, 1H), 3.48-3.51 (m, 1H), 4.03 (dt, J = 11.4, 3.0 Hz, 1H), 5.86 (d, J 
= 11.4 Hz, 1H), 5.91 (s, 1H), 6.05 (s, 1H), 7.50-7.57 (m, 4H), 7.61-7.63 (m, 1H), 7.86-
7.91 (m, 3H), 7.96-7.97 (m, 1H), 8.20-8.22 (m, 2H); 13C NMR (150 MHz, CDCl3) $ 
(ppm) 34.0, 46.4, 59.1, 93.9, 120.0, 124.1, 124.4, 125.8, 126.8, 126.9, 127.7, 128.3, 
128.9, 129.1, 133.1, 133.2, 136.8, 142.3, 146.4, 147.5. HRMS Calculated for 
[C22H20N2O5Na]+: 415.1270, Found: 415.1265. [!]D26 = 139.2° (c = 0.50 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 75/25; Flow rate: 1.0 mL/min; tminor = 11.436 min, 
tmajor = 8.944 min; ee% = 74%. 
 
4n was purified by flash chromatography (Hexane-EtOAc, v/v 5/1) as white oil with 
overall isolated yield: 86% for both isomers. 
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NO2
O
NC
Ph
 
 4n-syn 
(3S,4R)-4-nitro-5-(4-cyano)-3-phenylhex-5-enal (4n-syn): 1H NMR (600 MHz, CDCl3) 
$ (ppm) 1.58 (br s, 1H), 2.81-2.84 (m, 1H), 2.99-3.04 (m, 1H), 4.11-4.15 (dt, J = 10.2, 3.0 
Hz, 1H), 5.53 (s, 1H), 5.64 (d, J = 11.4 Hz, 1H), 5.90 (s, 1H), 7.00-7.01 (m, 2H), 7.05-
7.06 (m, 2H), 7.16-7.17 (m, 3H), 7.48-7.49 (m, 2H), 9.58-9.59 (m, 1H); 13C NMR (150 
MHz, CDCl3) $ (ppm) 43.9, 46.8, 92.6, 112.0, 118.3, 121.8, 127.2, 128.0, 128.7, 128.9, 
132.2, 136.4, 141.6, 144.1, 198.1. HRMS Calculated for [C19H16N2O3Na]+: 320.1161, 
Found: 320.1157. [!]D26 = -76.4° (c = 0.60 CHCl3). Enantiomeric excess was determined 
by HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 
91/10; Flow rate: 1.0 mL/min; tminor = 10.192 min, tmajor = 8.804 min; ee% = 82%. 
 
NO2
O
NC
Ph
 
 4n-anti 
(3S,4S)-4-nitro-5-(4-cyano)-3-phenylhex-5-enal (4n-anti): 1H NMR (600 MHz, CDCl3) 
$(ppm) 1.58 (br s, 1H), 2.68-2.80 (m, 2H), 4.18-4.22 (m, 1H), 5.73 (d, J = 11.4 Hz, 1H), 
5.86 (s, 1H), 6.11 (s, 1H), 7.27-7.34 (m, 5H), 7.59-7.60 (m, 2H), 7.72-7.74 (m, 2H), 9.51-
9.52 (m, 1H); 13C NMR (150 MHz, CDCl3) $ (ppm) 43.7, 45.7, 92.8, 112.8, 118.2, 122.7, 
127.4, 127.9, 128.4, 129.2, 132.9, 137.6, 140.8, 143.7, 198.1. HRMS Calculated for 
[C19H16N2O3Na]+: 320.1161, Found: 320.1157. [!]D26 = 84.6° (c = 0.55 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor = 14.124 min, 
tmajor = 11.992 min; ee% = 80%. 
 
4o was purified by flash chromatography (Hexane-EtOAc, v/v 7/1) as yellowish oil with 
overall isolated yield: 79% for both isomers. 
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NO2
O
O2N
Ph
 
 4o-syn 
(3S,4R)-4-nitro-5-(4-nitrophenyl)-3-phenylhex-5-enal (4o-syn): 1H NMR (600 MHz, 
CDCl3) $ (ppm) 2.82-2.85 (m, 1H), 3.00-3.05 (m, 1H), 4.12-4.16 (m, 1H),  5.58 (s, 1H), 
5.66 (d, J = 11.4 Hz, 1H), 5.95 (s, 1H), 7.01-7.03 (m, 2H), 7.11-7.12 (m, 2H), 7.16-7.17 
(m, 3H), 8.04-8.06 (m, 2H), 9.59 (t, J = 1.2 Hz, 1H) [!]D26 = -76.4° (c = 0.60 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; &= 254 
nm; eluent: Hexane/Isopropanol = 95/5; Flow rate: 1.5 mL/min; tminor = 18.736 min, 
tmajor = 17.144 min; ee% = 77%. 
 
NO2
O
O2N
Ph
 
 4o-anti 
(3S,4S)-4-nitro-5-(4-nitrophenyl)-3-phenylhex-5-enal (4o-anti): 1H NMR (600 MHz, 
CDCl3) $ (ppm) 2.70-2.74 (m, 1H), 2.78-2.83 (m, 1H), 4.20-4.24 (m, 1H), 5.77 (d, J = 
11.4 Hz, 1H), 5.91 (s, 1H), 6.14 (s, 1H), 7.25-7.28 (m, 2H), 7.30-7.34 (m, 3H), 7.64-7.66 
(m, 2H), 8.26-8.28 (m, 2H), 9.51 (t, J = 1.2Hz, 1H); 13C NMR (150 MHz, CDCl3) $ 
(ppm) 43.6, 45.6, 92.8, 123.2, 124.2, 127.6, 127.9, 128.3, 129.1, 137.5, 140.5, 145.4, 
147.9, 198.1. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column; &= 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor = 
5.168 min, tmajor = 5.860 min; ee% = 81%. 
 
4p was purified by flash chromatography (Hexane-EtOAc, v/v 15/1) as white oil with 
overall isolated yield: 75% for both isomers. 
NO2
Ph
OH
 
 4p-syn 
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(3S,4S)-4-cyclohexenyl-4-nitro-3-phenylbutan-1-ol (4p-syn): 1H NMR (600 MHz, 
CDCl3) $ (ppm) 1.21-1.45 (m, 5H), 1.73-1.78 (m, 1H), 1.85-1.95 (m, 5H), 3.34-3.38 (m, 
1H), 3.49-3.53 (m, 1H), 3.66-3.71 (m, 1H), 5.10 (d, J = 11.4 Hz, 1H), 6.75-6.77 (m, 1H), 
7.13-7.14 (m, 2H), 7.22-7.31 (m, 3H); 13C NMR (150 MHz, CDCl3) $ (ppm) 21.5, 22.1, 
24.3, 25.2, 36.1, 43.4, 60.0, 98.7, 127.3, 128.4, 128.6, 130.9, 132.9, 138.1. HRMS 
Calculated for [C16H21NO3Na]+: 298.1419, Found: 298.1415. [!]D26 = -63.7° (c = 0.75 
CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; 
&= 254 nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor = 7.536 
min, tmajor = 12.184 min; ee% = 70%.  
 
NO2
Ph
OH
 
 4p-anti 
(3S,4R)-4-cyclohexenyl-4-nitro-3-phenylbutan-1-ol (4p-anti): 1H NMR (600 MHz, 
CDCl3) $ (ppm) 1.23 (br s, 1H), 1.58-1.74 (m, 5H), 1.82-1.88 (m, 1H), 2.12-2.25 (m, 
4H), 3.32-3.36 (m, 1H), 3.47-3.51 (m, 1H), 3.63 (dt, J = 11.7, 3 Hz, 1H), 5.12 (d, J = 11.4 
Hz, 1H), 6.12-6.13 (m, 1H), 7.22-7.31 (m, 4H); 13C NMR (150 MHz, CDCl3) $ (ppm) 
21.8, 22.3, 23.5, 25.6, 34.4, 42.4, 59.9, 99.5, 127.6, 128.0, 128.8, 131.0, 133.7, 138.8. 
HRMS Calculated for [C16H21NO3Na]+: 298.1419, Found: 298.1415. [!]D26 = 85.4° (c = 
0.70 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column; &= 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor = 
6.628 min, tmajor = 10.056 min; ee% = 75%.  
 
4q was purified by flash chromatography (Hexane-EtOAc, v/v 10/1) as white oil with 
overall isolated yield: 79% for both isomers. 
 
NO2
OH
O  
 4q-syn 
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(3S,4S)-4-cyclohexenyl-3-(4-methoxyphenyl)-4-nitrobutan-1-ol (4q-syn): 1H NMR 
(600 MHz, CDCl3) $ (ppm) 1.14 (br s, 1H), 1.25-1.46 (m, 4H), 1.76-1.93 (m, 6H), 3.35-
3.39 (m, 1H), 3.49-3.53 (m, 1H), 3.63 (dt, J = 11.4, 4.2 Hz, 1H), 3.79 (s, 3H), 5.04 (d, J = 
12 Hz, 1H), 5.75-5.77 (m, 1H), 6.82-6.84 (m, 2H), 7.04-7.06 (m, 2H); 13C NMR (150 
MHz, CDCl3) $ (ppm) 21.5, 22.1, 24.3, 25.3, 36.2, 42.7, 55.2, 60.1, 98.9, 114.1, 129.4, 
129.9, 131.1, 132.8, 158.7. HRMS Calculated for [C17H23NO4Na]+: 238.1525, Found: 
238.1520. [!]D26 = -72.0° (c = 0.75 CHCl3). Enantiomeric excess was determined by 
HPLC with a Chiralcel AS-H column; &= 254 nm; eluent: Hexane/Isopropanol = 80/20; 
Flow rate: 1.0 mL/min; tminor =11.700 min, tmajor = 8.452 min; ee% = 87%.  
 
NO2
OH
O  
 4q-anti 
(3S,4R)-4-cyclohexenyl-3-(4-methoxyphenyl)-4-nitrobutan-1-ol (4q-anti): 1H NMR 
(600 MHz, CDCl3) $ (ppm) 1.23 (br s, 1H), 1.56-1.72 (m, 5H), 1.80-1.85 (m, 1H), 2.12-
2.25 (m, 4H), 3.33-3.37 (m, 1H), 3.48-3.52 (m, 1H), 3.58 (dt, J = 12, 3.0 Hz, 1H), 3.77 (s, 
3 H), 5.06 (d, J = 12 Hz, 1H), 6.10-6.11 (m, 1H), 6.82-6.84 (m, 2H), 7.13-7.16 (m, 2H); 
13C NMR (150 MHz, CDCl3) $ (ppm) 21.8, 22.3, 23.5, 25.6, 34.4, 41.7, 55.2, 60.0, 99.8, 
114.3, 129.0, 130.6, 131.1, 133.6, 158.9. HRMS Calculated for [C17H23NO4Na]+: 
238.1525, Found: 238.1520. [!]D26 = 61.4° (c = 0.68 CHCl3). Enantiomeric excess was 
determined by HPLC with a Chiralcel AS-H column; &= 254 nm; eluent: 
Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor = 14.828 min, tmajor = 10.184 
min; ee% = 87%. 
 
4z was purified by flash chromatography (Hexane-EtOAc, v/v 10/1) as white oil with 
overall isolated yield: 90% for both isomers. 
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Ph
NO2
OH
 
 4z-syn 
(2S,4R)-2-methyl-4-nitro-5-phenylhex-5-en-1-ol (4z-syn):1H NMR (270 MHz, CDCl3) 
$ (ppm) 0.92 (d, J = 6.7 Hz, 3H), 1.25 (br s, 1H), 1.67-1.77 (m, 1H), 2.05-2.25 (m, 2H), 
3.44-3.50 (m, 1H), 3.58-3.63 (m, 1H), 5.58 (s, 1H), 5.59(s, 1H), 5.69-5.75 (m, 1H), 7.33-
7.40 (m, 5H) ; 13C NMR (67.5 MHz, CDCl3) $ (ppm) 16.8, 32.7, 37.1, 67.4, 88.5, 117.9, 
126.6, 128.4, 128.7, 138.6, 143.7. HRMS Calculated for [C13H17NO3Na]+: 258.1106, 
Found: 258.1104. [!]D26 = -19.4° (c = 1.5 CHCl3). Enantiomeric excess was determined 
by HPLC with a Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 
90/10; Flow rate: 1.0 mL/min; tminor =7.432 min, tmajor = 13.276 min; ee% = 15%. 
 
Ph
NO2
OH
 
4z-anti 
(2S,4S)-2-methyl-4-nitro-5-phenylhex-5-en-1-ol (4z-anti): 1H NMR (270 MHz, CDCl3) 
$ (ppm) 0.99 (d, J = 6.7 Hz, 3H), 1.25 (br s, 1H), 1.63-1.79 (m, 1H), 2.46-2.56 (m, 2H), 
3.43-3.55 (m, 2H),  5.58 (s, 2H), 5.62-5.67 (m, 1H), 7.34-7.40 (m, 5H) ; 13C NMR (67.5 
MHz, CDCl3) $ (ppm) 16.0, 32.9, 36.8, 67.7, 88.1, 117.9, 126.6, 128.5, 128.7, 138.7, 
143.8. HRMS Calculated for [C13H17NO3Na]+: 258.1106, Found: 258.1104. [!]D26 = 
18.0° (c = 1.5 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel 
OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; 
tminor = 7.276 min, tmajor = 9.880 min; ee% = 19%. 
 
Ph
O Ph
N
Boc  
 6a 
N-Boc protected phenyl((2R,3S)-3-phenylpyrrolidin-2-yl)methanone, 6a was purified 
by flash chromatography (Hexane-EtOAc, v/v 10/1) as white solid with overall isolated 
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yield: 76%. 2 sets of signals ratio (1:1.6), HRMS Calculated for [C22H25NO3Na]+: 
374.1732, Found: 374.1728. 
 
Set 1:1H NMR (600 MHz, CDCl3) $ (ppm) 1.47 (s, 9H), 2.10-2.15 (m, 1H), 2.63-2.75 
(m, 1H), 3.52-3.58 (m, 1H), 3.73-3.82 (m, 1H), 3.93 (dt, J = 10.2, 1.0 Hz, 1H), 5.64 (d, J 
= 8.4 Hz, 1H), 6.94-7.51 (m, 10H);  13C NMR (150 MHz, CDCl3) $ (ppm) 28.2, 28.5, 
46.0, 49.0, 64.0, 80.0, 127.2, 127.8, 128.0, 128.1, 128.3, 132.2, 136.1, 137.4, 153.6, 
200.6.  
Set 2:1H NMR (600 MHz, CDCl3) $ (ppm) 1.24 (s, 9H), 2.10-2.15 (m, 1H), 2.63-2.75 
(m, 1H), 3.52-3.58 (m, 1H), 3.73-3.82 (m, 1H), 4.03 (dt, J = 10.2, 1.2 Hz, 1H), 5.55 (d, J 
= 8.4 Hz, 1H), 6.94-7.51 (m, 10H);  13C NMR (150 MHz, CDCl3) $ (ppm) 27.6, 28.4, 
46.2, 48.0, 64.0, 79.8, 127.1, 127.7, 127.8, 128.1, 128.3, 132.1, 136.2, 137.6, 154.4, 
201.1. 
 
Ph
N
O
Ph Ph
O  
7a 
(7R,7aS)-tetrahydro-1,1,7-triphenylpyrrolo[1,2-c]oxazol-3(1H)-one, 7a was purified 
by flash chromatography (Hexane-EtOAc, v/v 8/1) as white oil with overall isolated 
yield: 87%. Only trans isomer.  
 
1H NMR (600 MHz, CDCl3) $ (ppm) 2.14-2.18 (m, 1H), 2.46-2.53 (m, 1H), 3.29 (t, J = 
6.6 Hz, 1H), 3.46-3.50 (m, 1H), 4.06-4.11 (m, 1H), 4.88-4.90 (m, 1H), 6.43 (d, J = 7.8 
Hz, 2H), 6.86-7.05 (m, 8H), 7.22-7.31 (m, 3H), 7.50-7.52 (m, 2H); 13C NMR (150 MHz, 
CDCl3) $ (ppm) 34.5, 44.8, 46.2, 72.4, 84.8, 124.5, 125.2, 125.7, 126.7, 127.6, 127.9, 
128.1, 128.5, 139.5, 140.1, 144.9, 159.8. HRMS Calculated for [C24H21NO2Na]+: 
378.1470, Found: 378.1466. Enantiomeric excess was determined by HPLC with a 
Chiralcel OD-H column; &= 254 nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 
mL/min; tminor = 10.124 min, tmajor = 6.196 min; ee% = 84%. 
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Ph
O Ph
N
Ac  
 6b 
N-acetate phenyl((2R,3S)-3-phenylpyrrolidin-2-yl)methanone, 6b was purified by 
flash chromatography (Hexane-EtOAc, v/v 5/1) as white oil with overall isolated yield: 
72%. Only trans isomer. 2 sets of signals ratio (1:4), HRMS Calculated for 
[C19H19NO2Na]+: 316.1313, Found: 316.1309. 
 
Set 1:1H NMR (600 MHz, CDCl3) $ (ppm) 2.18 (s, 3H), 2.11-2.16 (m, 1H), 2.46-2.51 
(m, 1H), 3.43 (dt, J = 6.0, 6.0 Hz, 1H), 3.75-3.79 (m, 1H), 3.85-3.89 (m, 1H), 5.61 (d, J = 
4.8 Hz, 1H), 7.20-7.79 (m, 10H); 13C NMR (150 MHz, CDCl3) $ (ppm) 22.2, 33.4, 47.3, 
47.8, 67.0, 126.7, 126.9, 127.4, 128.4, 128.5, 129.0, 129.2, 133.2, 135.3, 141.4, 169.0, 
197.6. 
 
Set 2:1H NMR (600 MHz, CDCl3) $ (ppm) 1.91 (s, 3H), 2.11-2.16 (m, 1H), 2.28-2.36 
(m, 1H), 3.52 (dt, J = 4.8, 4.8 Hz, 1H), 3.85-3.89 (m, 1H), 3.90-3.94 (m, 1H), 5.37 (d, J = 
3.6 Hz, 1H), 7.26-7.83 (m, 10H); 13C NMR (150 MHz, CDCl3) $ (ppm) 22.5, 36.4, 48.3, 
47.1, 66.0, 126.7, 126.8, 127.3, 128.2, 128.4, 129.1, 129.3, 133.2, 135.4, 141.8, 169.0, 
197.9. 
 
Ph
HNHO
Ph Ph
 
 7b 
diphenyl((2S,3R)-3-phenylpyrrolidin-2-yl)methanol, 7b was purified by flash 
chromatography (Hexane-EtOAc, v/v 10/1) as white oil with overall isolated yield: 81%. 
 
1H NMR (600 MHz, CDCl3) $ (ppm) 1.22 (br s, 1H), 1.80-1.85 (m, 1H), 2.22-2.29 (m, 
1H), 3.16-3.20 (m, 2H), 3.30-3.34 (m, 1H), 4.12-4.13 (m, 1H), 6.68-6.70 (m, 2H), 7.00-
7.07 (m, 5H), 7.15-7.17 (m, 1H), 7.25-7.29 (m, 5H), 7.57-7.58 (m, 2H); 13C NMR (150 
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MHz, CDCl3) $(ppm) 36.4, 44.8, 47.0, 72.4, 77.8, 125.4, 125.8, 125.9, 126.2, 126.5, 
127.4, 127.6, 128.0, 128.3, 143.9, 146.8, 148.1. HRMS Calculated for [C23H23NONa]+: 
352.1677, Found: 352.1673. 
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Pat II 
Ph
O
NO2
8a  
5-nitro-6-phenylhept-6-en-2-one (8a) was purified by flash silica gel chromatography 
(Hexane-EtOAc, v/v, 5/1) as colorless oil, yield: 87%. 1H NMR (270 MHz, CDCl3): $ 
7.33-7.38(m, 5H), 5.59(s, 1H), 5.48-5.57(m, 2H), 2.21-2.58(m, 4H), 2.11(s, 3H). 13C 
NMR (67.5 MHz, CDCl3): $ 206.6, 143.4, 138.4, 128.8, 128.7, 126.7, 118.1, 88.9, 39.2, 
30.1, 26.7. HRMS Calculated for C13H15NO3Na [M+Na]+ : 256.09441, Found: 
256.09446. 
 
Ph O
O
NO2
8b  
Methyl 4-nitro-5-phenylhex-5-enoate (8b) was purified by flash silica gel 
chromatography (Hexane-EtOAc, v/v, 5/1) as colorless oil, yield: 82%. 1H NMR (270 
MHz, CDCl3): 7.30-7.35(m, 5H), 5.50-5.67(m, 3H), 3.65(s, 3H), 2.01-2.62(m, 4H). 13C 
NMR (67.5 MHz, CDCl3): $ 172.4, 143.3, 138.3, 128.8, 128.7, 126.7, 118.3, 88.9, 52.0, 
30.1, 27.9. HRMS Calculated for C13H15NO4Na [M+Na]+ : 272.08933, Found: 
272.08918. 
 
Ph
O
NO2
8c  
 
6-nitro-7-phenyloct-7-en-3-one (8c) was purified by flash silica gel chromatography 
(Hexane-EtOAc, v/v, 5/1) as colorless oil, yield: 86% (combined all isomers). 1H NMR 
(600 MHz, CDCl3): $ 7.27-7.39(m, 5H), 5.59(s, 1H), 5.51-5.59(m, 2H), 2.41-2.51(m, 
3H), 2.27-2.40(m, 3H), 1.02(t, J = 7.4 Hz, 3H). 13C NMR (150 MHz, CDCl3): $ 209.2, 
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143.3, 138.3, 128.7, 128.5, 126.8, 117.8, 88.8, 37.7, 36.0, 26.6, 7.6. HRMS Calculated 
for C14H18NO3 [M+H]+: 248.12812, Found: 248.12815. 
 
Ph Ph
O
NO2
8d  
 
4-nitro-1,5-diphenylhex-5-en-1-one and isomer (8d) was purified by flash silica gel 
chromatography (Hexane-EtOAc, v/v, 5/1) as colorless oil, yield: 83% (combined all 
isomers). 1H NMR (600 MHz, CDCl3): $ 7.97-7.99(m, 0.26H), 7.90-7.92(m, 2H), 7.55-
7.61(m, 1.13H), 7.28-7.50(m, 7.65H), 7.15-7.17(m, 0.26H), 5.67(q, J = 4.8 Hz, 1H), 
5.63(s, 1H), 5.61(s, 1H), 3.28-3.31(m, 0.26H), 3.03-3.15(m, 2.26H), 2.62-2.70(m, 1H), 
2.48-2.54(m, 1H), 2.20(s, 0.39H). 13C NMR (150 MHz, CDCl3): $ 197.9, 143.5, 138.3, 
136.3, 133.4, 128.72, 128.66, 128.5, 127.9, 126.6, 118.1, 89.2, (35.9), 34.4, (31.6), 27.1, 
(24.6). HRMS Calculated for C18H18NO3 [M+H]+: 294.12812, Found: 294.12813. 
 
NO2
Ph
O
8e  
 
4-cyclohexenyl-4-nitro-1-phenylbutan-1-one (8e) was purified by flash silica gel 
chromatography (Hexane-EtOAc, v/v, 10/1) as white solid, yield: 85%. 1H NMR (270 
MHz, CDCl3): $ 7.90-8.01(m, 2H), 7.51-7.63(m, 1H), 7.41-7.50(m, 2H), 5.96(s, 1H), 
5.00(dd, J = 9.0 Hz, J = 6.0 Hz, 1H), 2.90-3.11(m, 2H), 2.50-2.62(m, 1H), 2.26-2.42(m, 
1H), 1.93-2.18(m, 4H), 1.46-1.76(m, 4H). 13C NMR (67.5 MHz, CDCl3): $ 198.0, 136.4, 
131.9, 131.1, 128.7, 127.9, 92.8, 34.4, 25.3, 25.0, 24.1, 22.2, 21.7. HRMS Calculated for 
C16H19NO3Na [M+Na]+ : 296.12626, Found: 296.12555. 
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Ph
NO2
O
O
O
O
10a  
 
Dimethyl 4-nitro-4-(1-phenylvinyl)heptanedioate (10a) was purified by flash silica gel 
chromatography (Hexane-EtOAc, v/v, 5/1) as white solid, m. p: 85.5-86.6 ?, yield: 89%. 
1H NMR (600 MHz, CDCl3): $ 7.26-7.30(m, 3H), 7.05-7.07(m, 2H), 5.59(s, 1H), 5.45(s, 
1H), 3.65(s, 6H), 2.51-2.57(m, 2H), 2.31-2.40(m, 4H), 2.18-2.26(m, 2H). 13C NMR (150 
MHz, CDCl3): $ 172.1, 146.1, 138.2, 128.3, 128.2, 128.1, 120.8, 95.3, 51.8, 28.8, 28.6. 
HRMS Calculated for C17H21NO6Na [M+Na]+ : 358.12411, Found: 358.12422. 
 
Ph
NO2
O
O OH
10b  
 
Methyl 7-hydroxy-4-nitro-4-(1-phenylvinyl)heptanoate (10b) was purified by flash 
silica gel chromatography (Hexane-EtOAc, v/v, 2/1) as colorless oil, yield: 90%. 1H 
NMR (600 MHz, CDCl3):  7.28-7.50(m, 3H), 7.07-7.09(m, 2H), 5.63(s, 1H), 5.45(s, 1H), 
3.68(s, 3H), 3.60-3.69(m, 2H), 2.57-2.63(m, 1H), 2.21-2.47(m, 4H), 2.04-2.09(m, 1H), 
1.51-1.64(m, 2H), 1.35-1.43(m, 1H). 13C NMR (150 MHz, CDCl3): $ 172.6, 146.7, 138.7, 
128.4, 128.22, 128.15, 120.7, 95.9, 62.0, 52.0, 30.2, 29.0, 28.4, 27.0. HRMS Calculated 
for C16H21NO5Na [M+Na]+ : 330.13119, Found: 330.13128. 
 
Ph
NO2
OH
CHO
H
11a-major  
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(1S,2R,5R)-2-hydroxy-2-methyl-5-nitro-5-(1-phenylvinyl)cyclohexanecarbaldehyde 
(11a-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
then was recrystallized from CH2Cl2/Hexane (1:5) to get a colorless crystal, m.p: 103.1-
104.3 ?. 1H NMR (600 MHz, CDCl3): $ 9.80(s, 1H), 7.29-7.35(m, 3H), 7.07-7.10(m, 
2H), 5.66(s, 1H), 5.30(s, 1H), 2.75(dt, J = 14.4 Hz, J = 3.6 Hz, 1H), 2.52-2.60(m, 2H), 
2.30(s, 1H), 2.21(td, J = 14.4 Hz, J = 4.2 Hz, 1H), 2.06(dd, J = 14.4 Hz, J = 13.2 Hz, 
1H), 1.69(dt, J = 15.0 Hz, J = 3.6 Hz, 1H), 1.37-1.44(m, 1H), 1.36(s, 3H). 13C NMR (150 
MHz, CDCl3): $ 203.8, 148.7, 138.4, 128.6, 128.2, 128.1, 118.8, 92.8, 68.6, 53.3, 35.9, 
29.6, 29.0, 28.5. HRMS Calculated for C16H20NO4 [M+H]+ : 290.13869, Found: 
290.13879.  
11a-major and 11a-minor are unstable. At the same time, 11a-minor is hard to be 
separated to obtain pure product, so in situ reduction the mixture of 11a by treatment with 
NaBH4 give stable 11c. 
 
11c-major
Ph
NO2
OH
CH2OH
H
 
 
(1R,2R,4R)-2-(hydroxymethyl)-1-methyl-4-nitro-4-(1-phenylvinyl)cyclohexanol 
(11c-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1-
1/1) as colorless oil, yield: 92% (combined two isomers). 1H NMR (600 MHz, CDCl3): $ 
7.29-7.32(m, 3H), 7.08-7.11(m, 2H), 5.66(s, 1H), 5.26(s, 1H), 4.21(dd, J = 12.0 Hz, J = 
3.0 Hz, 1H), 3.61(dd, J = 10.8 Hz, J = 1.8 Hz, 1H), 2.39-2.58(m, 5H), 2.20(dt, J = 13.8 
Hz, J = 3.6 Hz, 1H), 1.61-1.65(m, 1H), 1.40-1.47(m, 2H), 1.31(s, 3H). 13C NMR (150 
MHz, CDCl3): $ 149.4, 138.6, 128.7, 128.0, 127.8, 118.3, 94.6, 70.9, 64.1, 41.5, 36.6, 
32.9, 29.3, 28.3. HRMS Calculated for C16H22NO4 [M+H]+: 292.15434, Found: 
292.15444.  
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O2N
OH
CH2OH
Ph
11c-minor
H
 
 
(1R,2R,4S)-2-(hydroxymethyl)-1-methyl-4-nitro-4-(1-phenylvinyl)cyclohexanol (11c-
minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1-1/1) as 
colorless oil, 1H NMR (600 MHz, CDCl3): $ 7.28-7.32(m, 3H), 7.08-7.11(m, 2H), 5.84(s, 
1H), 5.63(s, 1H), 4.11(dd, J = 11.4 Hz, J = 3.6 Hz, 1H), 3.48(dd, J = 10.8 Hz, J = 2.4 Hz, 
1H), 2.69(t, J = 13.2 Hz, 1H), 2.38-2.50(m, 2H), 2.33(dt, J = 7.8 Hz, J = 3.0 Hz, 1H), 
2.01(br, 2H), 1.61(dt, J = 6.6 Hz, J = 3.6 Hz, 1H), 1.40-1.50(m, 2H), 1.32(s, 3H). 13C 
NMR (150 MHz, CDCl3): $ 144.8, 139.2, 128.3, 128.1, 128.0, 123.5, 92.4, 70.9, 64.1, 
42.5, 37.1, 32.4, 29.0, 28.3. HRMS Calculated for C16H21NO4Na [M+Na]+ : 314.13628, 
Found: 314.13635.  
 
Ph
NO2
OH
Et
CH2OH
H
11d-major  
 
(1R,2R,4R)-1-ethyl-2-(hydroxymethyl)-4-nitro-4-(1-phenylvinyl)cyclohexanol (11d-
major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1-1/1) as 
colorless oil, yield: 85% (combined two isomers). 1H NMR (600 MHz, CDCl3): $ 7.28-
7.33(m, 3H), 7.09-7.12(m, 2H), 5.66(s, 1H), 5.26(s, 1H), 4.19(dd, J = 10.8 Hz; J = 2.4 
Hz, 1H), 3.59(dd, J = 10.8 Hz, J = 2.4 Hz, 1H), 2.47-2.60(m, 1H), 2.43-2.46(m, 2H), 
2.20(dt, J = 13.8 Hz, J = 4.2 Hz, 1H), 2.12 (br, 2H), 1.68-1.75(m, 1H), 1.57-1.64(m, 2H), 
1.50-1.55(m, 1H), 1.40(dt, J = 13.8 Hz, J = 4.2 Hz, 1H), 0.86(t, J = 7.8 Hz, 3H). 13C 
NMR (150 MHz, CDCl3): $ 149.5, 138.9, 128.7, 128.0, 127.8, 118.3, 94.5, 73.1, 63.9, 
39.3, 33.2, 33.0, 32.1, 29.1, 7.9. HRMS Calculated for C17H23NO4Na [M+Na]+ : 
328.15193, Found: 328.15215. 
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CH2OH
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11d-minor  
 
(1R,2R,4S)-2-(hydroxymethyl)-4-nitro-1-phenyl-4-(1-phenylvinyl)cyclohexanol (11d-
minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1-1/1) as 
colorless oil, hard to get purified product, NMR shows some major isomer included. 1H 
NMR (600 MHz, CDCl3): $ 7.30-7.32(m, 3H), 7.09-7.12(m, 2H), 5.85(s, 1H), 5.63(s, 
1H), 4.07(dd, J = 10.8 Hz, J = 3.0 Hz, 1H), 3.43(dd, J = 11.4 Hz, J = 3.0 Hz, 1H), 2.74(t, 
J = 13.2 Hz, 1H), 2.32-2.50(m, 3H), 1.37-1.75(m, 7H), 0.88(t, J = 7.2 Hz, 3H). 13C NMR 
(150 MHz, CDCl3): $ 145.0, (139.3, 128.7, 128.3, 128.1, 128.03, 127.99, 127.8, 123.4, 
118.3), 92.2, 73.1, (63.93), 63.89, 40.1, (39.4), (33.2), (33.0), 32.7, 32.4, (32.2), (29.2), 
28.9, 8.0. HRMS Calculated for C21H23NO4Na [M+Na]+ : 376.15193, Found: 376.15185. 
 
O2N
OH
Ph
CH2OH
Ph H
Ph
NO2
OH
Ph
CH2OH
H
11e-major 11e-minor  
 
2-(hydroxymethyl)-4-nitro-1-phenyl-4-(1-phenylvinyl)cyclohexanol) (11e) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1-1/1) as colorless oil, 
yield: 84% (combined two isomers). Two disastereomers are hard to separated, NMR 
give d.r. = 3:1 isomers. 1H NMR (600 MHz, CDCl3): $ 7.12-7.38(m, 13H), 5.95(s, 
0.33H), 5.74(s, 0.33H), 5.70(s, 1H), 5.30(s, 1H), 3.57(dd, J = 10.2 Hz, J = 3.0 Hz, 1H), 
3.45-3.48(m, 1.33H), 3.26(dd, J = 13.2 Hz, J = 3.0 Hz, 0.33H), 2.87(t, J = 13.2 Hz, 
0.33H), 2.34-2.65(m, 5.32H), 1.66-2.00(m, 3.99H). 13C NMR (150 MHz, CDCl3): $ 
149.5, 146.6, 146.4, 145.1, 139.3, 138.9, 128.7, 128.44, 128.42, 128.1, 127.9, 127.0, 
126.9, 124.6, 124.5, 123.7, 118.4, 94.5, (92.2), (75.7), 75.6, 64.4, (42.6), 41.7, (37.5), 
36.9, 32.8, (32.3), 29.6, (29.4). HRMS Calculated for C21H23NO4Na [M+Na]+ : 
376.15193, Found: 376.15212. 
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Ph
NO2
OH
CH2OH
H
11f-major  
 
(1R,2R,4R,6S)-2-(hydroxymethyl)-1,6-dimethyl-4-nitro-4-(1-phenylvinyl)cyclo- 
hexanol (11f-major) was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v, 5/1-2/1) as colorless oil, yield: 78% (combined two isomers).  1H NMR (600 MHz, 
CDCl3): $ 7.28-7.32(m, 3H), 7.07-7.10(m, 2H), 5.65(s, 1H), 5.24(s, 1H), 4.24(dd, J = 
11.4 Hz, J = 3.0 Hz, 1H), 3.61(J = 11.4 Hz, J = 3.0 Hz, 1H), 2.59(s, 2H), 2.50(dt, J = 
14.4 Hz, J = 3.0 Hz, 1H), 2.40-2.46(m, 2H), 1.96(dd, J = 12.0 Hz, J = 14.4 Hz, 1H), 1.41-
1.51(m, 2H), 1.29(s, 3H), 0.95(d, J = 6.6 Hz, 3H). 13C NMR (150 MHz, CDCl3): $ 149.4, 
138.8, 128.7, 128.0, 127.8, 118.3, 94.4, 72.8, 64.3, 42.4, 37.6, 37.4, 33.0, 24.4, 14.3. 
HRMS Calculated for C17H23NO4Na [M+Na]+ : 328.15193, Found: 328.15201.  
 
O2N
OH
CH2OH
Ph H
11f-minor  
 
(1R,2R,4S,6S)-2-(hydroxymethyl)-1,6-dimethyl-4-nitro-4-(1-phenylvinyl)cyclo-
hexanol (11f-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v, 5/1-2/1) as colorless oil. 1H NMR (600 MHz, CDCl3): $ 7.27-7.32(m, 3H), 7.06-
7.10(m, 2H), 5.83(s, 1H), 5.61(s, 1H), 4.15(dd, J = 10.8 Hz, J = 3.0 Hz, 1H), 3.48(dd, J = 
10.8 Hz, J = 3.0 Hz, 1H), 2.68(t, J = 13.2 Hz, 1H), 2.26-2.35(m, 2H), 2.35(t, J = 13.2 Hz, 
1H), 2.06(s, 3H), 0.92(d, J = 5.4 Hz, 3H). 13C NMR (150 MHz, CDCl3): $ 145.2, 139.2, 
(128.7), 128.3, 128.1, 128.02, 127.96, 127.8, 123.2, (118.3), (94.4), 92.0, 72.8, 64.4, 
(64.3), 43.4, (42.4), 38.4, (37.6), (37.4), 37.1, (33.0), 32.4, 24.6, (22.4), 14.3. HRMS 
Calculated for C17H24NO4 [M+H]+ : 306.16999, Found: 306.17019. 
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Ph
NO2
OH
CH3
CH2OH
CH3
11g-isomer one 11g-isomer two
Ph
NO2
OH
CH3
CH3
CH2OH
 
 
2-(hydroxymethyl)-1,2-dimethyl-4-nitro-4-(1-phenylvinyl)cyclohexanol (11g) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1-1/1) as colorless oil. 
NMR shows 1:1 ratio isomers (NMR show 2:2:1 ratio for three isomers), yield: 66% 
(combined two isomers). 1H NMR (600 MHz, CDCl3): $ 7.28-7.32(m, 5.7H), 7.06-
7.10(m, 3.8H), 5.70(s, 1H), 5.68(s, 0.9H), 5.26(s, 0.9H), 5.23(s, 1H), 3.91(d, J = 11.4 Hz, 
1H), 3.25(d, J = 11.4 Hz, 1H), 3.22(s, 1.8H), 2.89(d, J = 13.2 Hz, 1H), 2.69(dd, J = 15.6 
Hz, J = 2.4 Hz, 1H), 1.82-2.62(m, 10.3H), 1.60-1.93(m, 1.9H), 1.57(dt, J = 14.4 Hz, J = 
2.4 Hz, 1H), 1.23(s, 3H), 1.18(s, 2.7H), 1.12(s, 3H), 0.64(s, 2.7H). 13C NMR (150 MHz, 
CDCl3): $ 150.3, (149.6), 138.9, (138.7), 128.8, 128.7, 128.2, 128.00, 127.96, 127.9, 
127.8, (118.8), 118.3, (92.9), 92.1, 75.1, 71.0, 69.8, 65.4, 43.1, 40.2, 37.0, 36.0, 33.9, 
32.9, (29.0), 28.8, 25.0, (24.8), 19.7, (19.3). HRMS Calculated for C17H23NO4Na 
[M+Na]+ : 328.15193, Found: 328.15190.  
 
O2N
OH
CH3
CH2OH
Ph CH3
11g-isomer three  
 
(1R,2R,4R)-2-(hydroxymethyl)-1,2-dimethyl-4-nitro-4-(1-phenylvinyl)cyclohexa-nol 
(11g-isomer three) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 
5/1-1/1) as colorless oil, yield: 16%. 1H NMR (600 MHz, CDCl3): $ 7.28-7.33(m, 3H), 
7.04-7.07(m, 2H), 5.76(s, 1H), 5.22(s, 1H), 3.65(d, J = 10.2 Hz, 1H), 3.12(d, J = 10.2 Hz, 
1H), 2.73(dq, J = 15.0 Hz, J = 3.0 Hz, 1H), 2.54(dd, J = 3.0 Hz, J = 15.0 Hz, 1H), 
2.40(br, 2H), 2.02(td, J = 13.2 Hz, J = 3.6 Hz, 1H), 1.64-1.71(m, 2H), 1.45(dt, J = 13.8 
Hz, J = 3.6 Hz, 1H), 1.28(s, 3H), 1.03(s, 3H). 13C NMR (150 MHz, CDCl3): $ 145.0, 
138.7, 128.6, 128.1, 128.0, 118.4, 90.5, 73.9, 70.9, 41.0, 93.3, 33.4, 31.2, 23.1, 16.8. 
HRMS Calculated for C17H23NO4Na [M+Na]+ : 328.15193, Found: 328.15215. 
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NO2
OH
Ph
CH2OH
11h-major
H
 
 
(1R,2R,4R)-4-cyclohexenyl-2-(hydroxymethyl)-4-nitro-1-phenylcyclohexanol (11h-
major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1) as 
colorless oil, yield: 83%. 1H NMR (600 MHz, CDCl3): $ 7.37-7.41(m, 2H), 7.30-7.36(m, 
2H), 7.23-7.26(m, 1H), 6.02-6.04(m, 1H), 3.62(dd, J = 10.8 Hz, J = 3.0 Hz, 1H), 3.52(dd, 
J = 10.8 Hz, J = 3.0 Hz, 1H), 2.64-2.68(m, 1H), 2.53(t, J = 14.4 Hz, 1H), 2.31(td, J = 
13.2 Hz, J = 4.2 Hz, 1H), 2.10-2.14(m, 2H), 2.03-2.09(m, 2H), 1.98(dq, J = 12.6 Hz, J = 
3.0 Hz, 1H), 1.82(td, J = 12.6 Hz, J = 4.2 Hz, 1H), 1.74(dq, J = 14.4 Hz, J = 2.4 Hz, 1H), 
1.62-1.67(m, 2H), 1.54-1.60(m, 2H). 13C NMR (150 MHz, CDCl3): $ 146.7, 136.5, 128.4, 
126.9, 125.9, 124.6, 95.6, 75.9, 64.7, 41.8, 37.1, 31.8, 28.4, 25.4, 23.8, 22.7, 21.7. HRMS 
Calculated for C19H25NO4Na [M+Na]+ : 354.16758, Found: 354.16756. 
 
Ph
NO2
OH
COCH3
12a-major
H
 
 
1-((1S,2R,5R)-2-hydroxy-2-methyl-5-nitro-5-(1-phenylvinyl)cyclohexyl)ethanone 
(12a-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as white solid, m.p: 98.2-98.9 ?, yield: 66%. 1H NMR (270 MHz, CDCl3): $ 7.22-
7.36(m, 3H), 6.98-7.09(m, 2H), 5.60(s, 1H), 5.24(s, 1H), 3.40-3.90 (br, 1H), 2.47-2.67(m, 
3H), 2.17-2.32(m, 4H), 2.08(t, J = 13.6 Hz, 1H), 1.69(dq, J = 14.6 Hz, J = 1.5 Hz, 1H), 
1.19-1.33(m, 1H), 1.14(s, 3H). 13C NMR (67.5 MHz, CDCl3): $ 214.5, 148.5, 138.3, 
128.6, 128.1, 128.0, 118.7, 93.1, 68.3, 52.3, 34.8, 32.1, 31.5, 29.0, 28.2. HRMS 
Calculated for C17H21NO4Na [M+Na]+ : 326.13683, Found: 326.13606. 
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O2N
OH
COCH3
Ph
12a-minor
H
 
 
1-((1S,2R,5S)-2-hydroxy-2-methyl-5-nitro-5-(1-phenylvinyl)cyclohexyl)ethanone 
(12a-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as white solid, m.p: 75.6-77.1 ?, yield: 24%. 1H NMR (270 MHz, CDCl3): $ 7.32-
7.43(m, 3H), 7.16-7.25(m, 2H), 5.92(s, 1H), 5.73(s, 1H), 3.88(d, J = 2.5 Hz, 1H), 2.24-
2.62(m, 5H), 1.69-1.81(m, 4H), 1.37-1.53(m, 1H), 1.17(s, 1H). 13C NMR (67.5 MHz, 
CDCl3): $ 213.0, 144.0, 138.9, 128.5, 128.3, 128.1, 124.0, 90.7, 68.5, 52.7, 35.8, 31.0, 
30.0, 29.6, 28.0. HRMS Calculated for C17H21NO4Na [M+Na]+ : 326.13683, Found: 
326.13608. 
 
Ph
NO2
OH
Et
COEt
H
12b-major  
 
1-((1S,2R,5R)-2-ethyl-2-hydroxy-5-nitro-5-(1-phenylvinyl)cyclohexyl)propan-1-one 
(12b-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as white solid, m.p: 78.7-80.3 ?, yield: 61%. 1H NMR (270 MHz, CDCl3): $ 7.18-
7.42(m, 3H), 6.96-7.14(m, 2H), 5.61(s, 1H), 5.25(s, 1H), 3.79(d, J = 2.5 Hz, 1H), 2.06-
2.76(m, 8H), 1.75(dt, J = 14.6 Hz, J = 3.7 Hz, 1H), 1.10-1.54(m, 3H), 1.05(t, J = 7.2 Hz, 
3H), 0.74(t, J = 7.4 Hz, 3H). 13C NMR (67.5 MHz, CDCl3): $ 217.5, 148.7, 138.3, 128.6, 
128.1, 127.9, 118.6, 93.2, 70.9, 50.7, 37.8, 33.6, 32.5, 30.6, 28.8, 7.7, 7.2. HRMS 
Calculated for C19H25NO4Na [M+Na]+ : 354.16813, Found: 354.16738. 
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O2N
OH
Et
COEt
Ph H
12b-minor  
 
1-((1S,2R,5S)-2-ethyl-2-hydroxy-5-nitro-5-(1-phenylvinyl)cyclohexyl)propan-1-one 
(12b-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as colorless oil, yield: 20%. 1H NMR (270 MHz, CDCl3): $ 7.30-7.44(m, 3H), 7.15-
7.25(m, 2H), 5.92(s, 1H), 5.71(s, 1H), 3.89(d, J = 2.7 Hz, 1H), 2.28-2.65(m, 5H), 1.88-
2.07(m, 2H), 1.75(dt, J = 14.1 Hz, J = 3.7 Hz, 1H), 1.23-1.55(m, 3H), 0.78-0.92(m, 6H). 
13C NMR (67.5 MHz, CDCl3): $ 216.1, 144.2, 139.0, 128.5, 128.24, 128.15, 124.0, 90.7, 
71.1, 50.3, 36.4, 33.4, 31.7, 31.4, 29.5, 29.4, 7.9, 7.1. HRMS Calculated for 
C19H25NO4Na [M+Na]+ : 354.16813, Found: 354.16739. 
 
Ph
NO2
OH
Ph
COPh
H
11c-major  
 
1-((1S,2R,5R)-2-hydroxy-5-nitro-2-phenyl-5-(1-phenylvinyl)cyclohexyl)(phenyl) 
methanone (11c-major) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v, 10/1) as white solid, m.p: 163.2-164.8 ?, yield: 72%. 1H NMR (600 MHz, 
CDCl3): $ 7.91-7.93(m, 2H), 7.55-7.59(m, 1H), 7.43-7.46(m, 2H), 7.30-7.36(m, 5H), 
7.17-7.21(m, 2H), 7.09-7.13(m, 3H), 5.66(s, 1H), 5.30(s, 1H), 5.12(d, J = 3.0 Hz, 1H), 
4.21(dd, J = 12.6 Hz, J = 3.0 Hz, 1H), 2.93(dt, J = 14.4 Hz, J = 3.0 Hz, 1H), 2.71(dq, J = 
14.4 Hz, J = 3.0 Hz, 1H), 2.47-2.58(m, 2H), 1.90(dq, J = 14.4 Hz, J = 3.0 Hz, 1H), 1.67-
1.75(m, 1H).  13C NMR (150 MHz, CDCl3): $ 204.6, 148.8, 146.3, 138.4, 135.5, 134.2, 
129.0, 128.7, 128.4, 128.3, 128.2, 128.1, 127.0, 124.4, 118.8, 93.8, 73.2, 46.5, 36.9, 33.8, 
29.9. HRMS Calculated for C27H25NO4Na [M+Na]+ : 450.16813, Found: 450.16712. 
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O2N
OH
Ph
COPh
Ph H
11c-minor  
 
1-((1S,2R,5S)-2-hydroxy-5-nitro-2-phenyl-5-(1-phenylvinyl)cyclohexyl)(phenyl) 
methanone (11c-minor) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v, 10/1-3/1) as colorless oil, yield: 10%. 1H NMR (600 MHz, CDCl3): $ 7.41-
7.48(m, 6H), 7.33-7.35(m, 2H), 7.09-7.23(m, 7H), 6.08(s, 1H), 5.88(s, 1H), 5.40(s, 1H), 
3.85(dd, J = 12.0 Hz, J = 4.2 Hz, 1H), 2.73-2.84(m, 4H), 1.88-1.92(m, 2H). 13C NMR 
(150 MHz, CDCl3): $ 204.4, 146.2, 144.6, 139.4, 135.4, 133.8, 129.0, 128.7, 128.6, 
128.41, 128.35, 127.9, 127.0, 124.9, 124.4, 90.7, 73.4, 46.4, 37.8, 32.4, 30.6.  HRMS 
Calculated for C27H25NO4Na [M+Na]+ : 450.16813, Found: 450.16723. 
 
12d-major
NO2
OH
CH3
H
COCH3
 
 
1-((1S*,2R*,5R*)-5-cyclohexenyl-2-hydroxy-2-methyl-5-nitrocyclohexyl)ethanone 
(12d-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as white solid, m.p: 129.5-130.8 ?, yield: 74%. 1H NMR (270 MHz, CDCl3): $ 5.84(m, 
1H), 3.81(d, J = 2.4Hz, 1H), 2.50-2.64(m, 2H), 2.43(dq, J = 14.4 Hz, J = 3.0 Hz, 1H), 
2.20(s, 3H), 1.83-2.18(m, 6H), 1.37-1.35(m, 5H), 1.03-1.26(m, 1H), 1.09(s, 3H). 13C 
NMR (67.5 MHz, CDCl3): $ 214.4, 135.5, 125.9, 94.0, 68.3, 52.6, 31.2, 31.1, 27.6, 25.1, 
23.5, 22.4, 21.3. HRMS Calculated for C15H23NO4Na [M+Na]+ : 304.15248, Found: 
304.15180.  
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12d-minor
O2N
OH
CH3COCH3
H
 
 
1-((1S,2R,5S)-5-cyclohexenyl-2-hydroxy-2-methyl-5-nitrocyclohexyl)ethanone (12d-
minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) as 
white solid, m.p: 54.2-55.1 ?, yield: 14%. 1H NMR (270 MHz, CDCl3): $ 6.17(m, 1H), 
3.85(d, J = 2.4 Hz, 1H), 2.15-2.60(m, 7H), 2.25(s, 3H), 1.94-2.05(m, 1H), 1.52-1.77(m, 
5H), 1.22-1.38(m, 1H), 1.17(s, 3H). 13C NMR (67.5 MHz, CDCl3): $ 213.2, 131.3, 130.6, 
92.2, 68.6, 53.5, 36.0, 30.9, 29.8, 27.4, 25.8, 24.1, 222.6, 21.4. HRMS Calculated for 
C15H23NO4Na [M+Na]+ : 304.15248, Found: 304.15177.  
 
NO2
OH
Et
H
COEt
12e-major  
 
1-((1S,2R,5R)-5-cyclohexenyl-2-ethyl-2-hydroxy-5-nitrocyclohexyl)propan-1-one 
(12e-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as white solid, m.p: 91.8-92.9 ?, yield: 71%. 1H NMR (270 MHz, CDCl3): $ 5.80(m, 
1H), 3.70(d, J = 2.5 Hz, 1H), 2.29-2.67(m, 5H), 1.80-2.13(m, 6H), 1.61(dt, J = 13.6 Hz, J 
= 3.7 Hz, 1H), 1.14-1.54(m, 6H), 1.07(dt, J = 13.6 Hz, J = 3.5 Hz, 1H), 0.95(t, J = 7.2 
Hz, 3H), 0.72(t, J = 8.6 Hz, 3H). 13C NMR (67.5 MHz, CDCl3): $ 217.2, 135.5, 125.7, 
93.9, 70.8, 50.5, 37.4, 33.4, 31.4, 30.5, 27.4, 25.1, 23.4, 22.3, 21.3, 7.5, 6.9. HRMS 
Calculated for C17H27NO4Na [M+Na]+ : 332.18378, Found: 332.18303. 
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O2N
OH
Et
COEt
H
12e-minor  
 
1-((1S,2R,5S)-5-cyclohexenyl-2-ethyl-2-hydroxy-5-nitrocyclohexyl)propan-1-one 
(12e-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 6/1) 
as colorless oil, yield: 13%. 1H NMR (270 MHz, CDCl3): $ 6.14(t, J = 1.0 Hz, 1H), 
3.82(d, J = 2.5 Hz, 1H), 2.10-2.69(m, 9H), 1.88-2.02(m, 2H), 1.08-1.78(m, 8H), 1.02(t, J 
= 7.2 Hz, 3H), 0.81(t, J = 7.4 Hz, 3H). 13C NMR (67.5 MHz, CDCl3): $ 216.3, 131.2, 
130.6, 92.1, 71.0, 51.5, 37.2, 33.3, 31.7, 30.2, 27.1, 25.8, 24.0, 22.5, 21.4, 7.6, 7.1. 
HRMS Calculated for C17H27NO4Na [M+Na]+ : 332.18378, Found: 332.18305. 
 
NO2
OH
Ph
H
COPh
12f-major  
 
1-((1S,2R,5R)-5-cyclohexenyl-2-hydroxy-5-nitro-2-phenylcyclohexyl)(phenyl)me-
thanone (12f-major) was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v, 6/1) as white solid, m.p: 133.1-134.6 ?, yield: 82%. 1H NMR (600 MHz, CDCl3): $ 
7.96-7.98(m, 2H), 7.56-7.60(m, 1H), 7.45-7.48(m, 2H), 7.35-7.38(m, 2H), 7.19-7.22(m, 
2H), 7.09-7.13(m, 1H), 5.98(m, 1H), 5.17(d, J = 1.8 Hz, 1H), 4.20(dd, J = 12.6 Hz, J = 
3.0 Hz, 1H), 2.96(dt, J = 14.4 Hz, J = 3.0 Hz, 1H), 2.70(dq, J = 14.4 Hz, J = 3.0 Hz, 1H), 
2.48(td, J = 13.2 Hz, J = 4.2 Hz, 1H), 2.39(dd, J = 13.2 Hz, J = 12.6 Hz, 1H), 1.96-
2.12(m, 4H), 1.89(dq, J = 13.0 Hz, J = 3.0 Hz, 1H), 1.51-1.71(m, 5H). 13C NMR (150 
MHz, CDCl3): $ 204.8, 146.5, 135.7, 135.5, 134.2, 129.0, 128.5, 128.3, 126.9, 126.5, 
124.4, 94.7, 73.5, 46.6, 37.0, 32.9, 28.5, 25.4, 23.8, 22.6, 21.5. HRMS Calculated for 
C25H27NO4Na [M+Na]+ : 428.18378, Found: 428.18291. 
 
 149 
12g-major
NO2
OH
COCH3
H
 
 
1-((1S,2R,5R)-2-hydroxy-2-methyl-5-nitro-5-(prop-1-en-2-yl)cyclohexyl)ethan-one 
(12g-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 10/1) 
as white solid, m.p: 62.6-62.9 ?, yield: 65%. 1H NMR (270 MHz, CDCl3): $ 5.11(s, 1H), 
5.06(q, J = 1.2 Hz, 1H), 3.85(d, J = 2.7 Hz, 1H), 2.56-2.69(m, 2H), 2.51(dq, J = 14.6 Hz, 
J = 3.0 Hz, 1H), 2.26(s, 3H), 1.99-2.24(m, 2H), 1.64-1.78(m, 4H), 1.17-32(m, 1H), 
1.15(s, 3H). 13C NMR (67.5 MHz, CDCl3): $ 214.2, 142.5, 114.7, 93.7, 68.2, 52.5, 34.8, 
31.2, 31.1, 28.1, 28.0, 27.9. HRMS Calculated for C12H19NO4Na [M+Na]+ : 264.12118, 
Found: 264.12043. 
 
O2N
OH
COCH3
H
12g-minor  
 
1-((1S,2R,5S)-2-hydroxy-2-methyl-5-nitro-5-(prop-1-en-2-yl)cyclohexyl)ethanone 
(12g-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 10/1) 
as colorless oil, yield: 15%. 1H NMR (270 MHz, CDCl3): $ 5.18(s, 1H), 5.12(q, J = 1.5 
Hz, 1H), 2.69-2.86(m, 3H), 2.46(s, 1H), 2.32(s, 3H), 1.53-2.00(m, 8H), 1.18(s, 3H). 13C 
NMR (67.5 MHz, CDCl3): $ 210.6, 142.5, 115.2, 93.5, 71.1, 55.3, 38.4, 32.4, 32.2, 30.4, 
21.5, 21.4, 18.7. HRMS Calculated for C12H19NO4Na [M+Na]+ : 264.12118, Found: 
264.12051. 
 
12h-major
NO2
OH
Et
COEt
H
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1-((1S,2R,5R)-2-ethyl-2-hydroxy-5-nitro-5-(prop-1-en-2-yl)cyclohexyl)propan-1-one 
(12h-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 10/1) 
as white solid, m.p: 112.3-113.9 ?, yield: 60%. 1H NMR (600 MHz, CDCl3): $ 5.16(s, 
1H), 5.10(q, J = 1.2 Hz, 1H), 2.70-2.82(m, 4H), 2.44-2.53(m, 1H), 2.17(br, 1H), 2.02(dd, 
J = 13.2 Hz, J = 15.0 Hz, 1H), 1.96(td, J = 3.6 Hz, J = 13.8 Hz, 1H), 1.77(d, J = 0.6 Hz, 
3H), 1.66(dt, J = 4.2 Hz, J = 15.0 Hz, 1H), 1.55-1.63(m, 1H), 1.28-1.40(m, 2H), 1.03(t, J 
= 7.2 Hz, 3H), 0.87(t, J = 7.2 Hz, 3H).  13C NMR (150 MHz, CDCl3): $ 212.9, 142.6, 
115.2, 93.6, 72.8, 55.5, 37.8, 32.5, 32.3, 29.9, 24.4, 18.7, 7.4, 6.8. HRMS Calculated for 
C14H24NO4 [M+H]+ : 270.16999, Found: 270.17004.  
 
O2N
OH
Et
COEt
H
12h-minor  
 
1-((1S,2R,5S)-2-ethyl-2-hydroxy-5-nitro-5-(prop-1-en-2-yl)cyclohexyl)propan-1-one 
(12h-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 10/1) 
as white solid, m.p: 77.6-78.9 ?, yield: 12%. 1H NMR (600 MHz, CDCl3): $ 5.34(s, 1H), 
5.32(s, 1H), 2.68-2.74(m, 2H), 2.35-2.62(m, 4H), 2.05-2.23(m, 3H), 1.81(d, J = 0.6 Hz, 
3H), 1.64-1.71(m, 1H), 1.42-1.52(m, 2H), 1.04(t, J = 7.2 Hz, 3H), 0.87(t, J = 7.2 Hz, 3H). 
13C NMR (150 MHz, CDCl3): $ 212.1, 140.1, 118.5, 91.8, 72.8, 54.4, 36.4, 31.8, 31.0, 
28.8, 27.1, 18.9, 7.5, 6.7. HRMS Calculated for C14H23NO4Na [M+Na]+ : 292.15193, 
Found: 292.15205. 
 
12i-major
NO2
OH
Ph
COPh
H
 
 
1-((1S,2R,5R)-2-hydroxy-5-nitro-2-phenyl-5-(prop-1-en-2-yl)cyclohexyl)phenyl-
methanone (12i-major) was purified by flash silica gel chromatography (Hexane-
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EtOAc, v/v, 10/1) as white solid, m.p: 141.8-142.7 ?, yield: 77%. 1H NMR (600 MHz, 
CDCl3): $ 7.95-7.97(m, 2H), 7.58-7.61(m, 1H), 7.45-7.49(m, 2H), 7.35-7.38(m, 2H), 
7.19-7.23(m, 2H), 7.10-7.14(m, 1H), 5.21(s, 1H), 5.17(d, J = 3.0 Hz, 1H), 5.13(q, J = 1.2 
Hz, 1H), 2.95(dt, J = 14.4 Hz, J = 2.4 Hz, 1H), 2.72(dq, J = 14.4 Hz, J = 3.0 Hz, 1H), 
2.54(td, J = 14.4 Hz, J = 4.2 Hz, 1H), 2.45(dd, J = 14.4 Hz, J = 13.2 Hz, 1H), 1.92(dq, J 
= 14.4 Hz, J = 3.0 Hz, 1H), 1.83(s, 3H), 1.67-1.74(m, 1H). 13C NMR (150 MHz, CDCl3): 
$ 204.7, 146.4, 142.6, 135.4, 134.2, 129.0, 128.5, 128.4, 127.0, 124.4, 115.2, 94.4, 73.4, 
46.4, 37.0, 32.9, 28.8, 18.7. HRMS Calculated for C22H23NO4Na [M+Na]+ : 388.15193, 
Found: 388.15213. 
 
12j-major
NO2
OH
COCH3
H
 
 
1-((1S*,2R*,5R*)-2-hydroxy-2-methyl-5-nitro-5-(1-p-tolylvinyl)cyclohexyl)ethanone 
(12j-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) as 
colorless oil, yield: 63%. 1H NMR (270 MHz, CDCl3): $ 7.11(d, J = 8.0 Hz, 2H), 6.95(d, 
J = 8.0 Hz, 2H), 5.59(s, 1H), 5.24(s, 1H), 3.86(d, J = 2.7 Hz, 1H), 2.49-2.69(m, 3H), 
2.04-2.36(m, 8H), 1.66-1.76(m, 1H), 1.20-1.35(m, 1H), 1.16(s, 3H). 13C NMR (67.5 
MHz, CDCl3): $ 214.5, 148.5, 137.7, 135.4, 128.7, 128.4, 118.4, 93.3, 68.3, 52.6, 34.9, 
32.1, 31.5, 29.0, 28.2, 21.1. HRMS Calculated for C18H23NO4Na [M+Na]+ : 340.15248, 
Found: 340.15170. 
 
12j-minor
O2N
OH
COCH3
H
 
 
1-((1S,2R,5S)-2-hydroxy-2-methyl-5-nitro-5-(1-p-tolylvinyl)cyclohexyl)ethanone 
(12j-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) as 
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colorless oil, yield: 21%. 1H NMR (270 MHz, CDCl3): $ 7.17(d, J = 8.2 Hz, 2H), 7.07(d, 
J = 8.2 Hz, 2H), 5.88(s, 1H), 5.69(s, 1H), 3.88(d, J = 2.5 Hz, 1H), 2.33-2.60(m, 8H), 
1.81(s, 3H), 1.74(dt, J = 14.4 Hz, J = 3.8 Hz, 1H), 1.36-1.52(m, 1H), 1.17(s, 3H). 13C 
NMR (67.5 MHz, CDCl3): $ 213.1, 143.9, 138.2, 136.0, 129.1, 128.0, 123.6, 90.9, 68.5, 
52.8, 35.9, 31.0, 30.2, 29.5, 28.1, 21.1. HRMS Calculated for C18H23NO4Na [M+Na]+ : 
340.15248, Found: 40.15169. 
 
12k-major
NO2
OH
COCH3
O2N
H
 
 
1-((1S,2R,5R)-2-hydroxy-2-methyl-5-nitro-5-(1-(4-nitrophenyl)vinyl)cyclohexyl) 
ethanone (12k-major) was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v, 8/1) as white solid, m.p: 106.9-108.1 ?, yield: 62%. 1H NMR (600 MHz, CDCl3): $ 
8.16(d, J = 9.0 Hz, 2H), 7.24(d, J = 9.0 Hz, 2H), 5.74(s, 1H), 5.33(s, 1H), 3.69(br, 1H), 
2.64(dd, J = 12.6 Hz, J = 3.0 Hz, 1H), 2.59(dt, J = 14.4 Hz, J = 3.0 Hz, 1H), 2.52(dq, J = 
14.4 Hz, J = 3.0 Hz, 1H), 2.22-2.28(m, 4H), 2.11(t, J = 13.2 Hz, 1H), 1.71(dt, J = 14.4 
Hz, J = 3.0 Hz, 1H), 1.28(td, J = 14.4 Hz, J = 3.6 Hz, 1H), 1.16(s, 3H). 13C NMR (150 
MHz, CDCl3): $ 214.0, 147.7, 146.9, 145.0, 129.7, 123.4, 120.4, 92.6, 68.2, 52.5, 34.8, 
32.1, 31.6, 29.1, 28.1. HRMS Calculated for C17H21N2O6 [M+H]+ : 349.13941, Found: 
349.13966. 
 
12k-minor
O2N
OH
COCH3
O2N
H
 
 
1-((1S,2R,5R)-2-hydroxy-2-methyl-5-nitro-5-(1-(4-nitrophenyl)vinyl)cyclohexyl) 
ethanone (12k-minor) was purified by flash silica gel chromatography (CH2Cl2/MeOH, 
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v/v, 50/1) as colorless oil, yield: 25%. 1H NMR (600 MHz, CDCl3): $ 8.24(d, J = 9.0 Hz, 
2H), 7.40(d, J = 9.0 Hz, 2H), 6.03(s, 1H), 5.79(s, 1H), 3.79(br, 1H), 2.49-2.56(m, 2H), 
2.44(dq, J = 13.8 Hz, J = 3.0 Hz, 1H), 2.33-2.40(m, 2H), 1.75(dt, J = 14.4 Hz, J = 3.6 Hz, 
1H), 1.34(td, J = 12.6 Hz, J = 3.6 Hz, 1H), 1.19(s, 3H). 13C NMR (150 MHz, CDCl3): $ 
212.1, 147.7, 145.5, 142.8, 129.3, 125.9, 123.8, 90.5, 68.4, 53.1, 35.8, 31.1, 30.5, 29.1, 
28.1. HRMS Calculated for C17H21N2O6Na [M+Na]+ : 371.12136, Found: 371.12125. 
 
12l-major
NO2
OH
COCH3
Cl
H
 
 
1-((1S,2R,5R)-5-(1-(4-chlorophenyl)vinyl)-2-hydroxy-2-methyl-5-nitrocyclohex-
yl)ethanone (12l-major) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v, 5/1) as white solid, m.p: 78.6-79.9 ?, yield: 65%. 1H NMR (270 MHz, 
CDCl3): $ 7.29(d, J = 8.4 Hz, 2H), 7.00(d, J = 8.4 Hz, 2H), 5.65(s, 1H), 5.28(s, 1H), 
3.85(d, J = 2.5 Hz, 1H), 2.48-2.71(m, 3H), 2.26(s, 3H), 2.00-2.34(m, 2H), 1.67-1.78(m, 
1H), 1.20-1.35(m, 1H), 1.17(s, 3H). 13C NMR (67.5 MHz, CDCl3): $ 214.3, 147.5, 136.6, 
134.1, 129.9, 128.3, 119.4, 92.9, 68.2, 52.6, 34.8, 32.0, 31.6, 29.0, 28.2. HRMS 
Calculated for C17H20ClNO4Na [M+Na]+ : 360.09786, Found: 360.09710.  
 
12l-minor
O2N
OH
COCH3
Cl
H
 
 
1-((1S,2R,5S)-5-(1-(4-chlorophenyl)vinyl)-2-hydroxy-2-methyl-5-nitrocyclohexyl) 
ethanone (12l-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v, 5/1) as colorless oil, yield: 18%. 1H NMR (270 MHz, CDCl3): $ 7.36(d, J = 8.4 Hz, 
2H), 7.14(d, J = 8.4 Hz, 2H), 5.93(s, 1H), 5.72(s, 1H), 3.86(d, J = 2.5 Hz, 1H), 2.30-
2.55(m, 5H), 1.88(s, 3H), 1.75(dt, J = 14.3 Hz, J = 3.5 Hz, 1H), 1.31-46(m, 1H), 1.18(s, 
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3H). 13C NMR (67.5 MHz, CDCl3): $ 212.7, 143.1, 137.3, 134.4, 129.5, 128.7, 124.6, 
90.7, 68.5, 52.8, 35.8, 31.0, 30.3, 29.3, 28.0. HRMS Calculated for C17H20ClNO4Na 
[M+Na]+ : 360.09786, Found: 360.09715.  
 
 
12m-major
NO2
OH
COCH3
H
 
 
1-((1S,2R,5R)-5-cyclopentenyl-2-hydroxy-2-methyl-5-nitrocyclohexyl)ethanone 
(12m-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as colorless oil, yield: 61%. 1H NMR (270 MHz, CDCl3): $ 5.73-5.79(m, 1H), 3.82(d, J = 
2.7 Hz, 1H), 2.44-2.72(m, 3H), 1.95-2.36(m, 9H), 1.72-1.87(m, 2H), 1.62(dq, J = 14.6 
Hz, J = 2.7 Hz, 1H), 1.09-1.25(m, 1H), 1.10(s, 3H). 13C NMR (67.5 MHz, CDCl3): $ 
214.2, 142.1, 129.6, 91.1, 68.4, 52.5, 34.7, 32.3, 31.4, 31.2, 31.0, 28.2, 28.1, 22.7. HRMS 
Calculated for C14H21NO4Na [M+Na]+ : 290.13683, Found: 290.13612. 
 
12m-minor
O2N
OH
COCH3
H
 
 
1-((1S,2R,5S)-5-cyclopentenyl-2-hydroxy-2-methyl-5-nitrocyclohexyl)ethanone 
(12m-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 5/1) 
as colorless oil, yield: 15%. 1H NMR (270 MHz, CDCl3): $ 5.77-5.85(m, 1H), 2.57-
2.89(m, 3H), 1.95-2.35(m, H), 1.71-1.89(m, 2H), 1.61(dq, J = 14.4 Hz, J = 3.0 Hz, 1H), 
1.01-1.27(m, 1H), 1.12(s, 3H). 13C NMR (67.5 MHz, CDCl3): $ 210.7, 142.1, 130.1, 
90.9, 71.2, 55.3, 38.3, 32.6, 32.5, 32.2, 31.2, 30.7, 22.8, 21.4. HRMS Calculated for 
C14H21NO4Na [M+Na]+ : 290.13683, Found: 290.13616. 
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12n-major
NO2
OH
COCH3
H
 
 
1-((1S,2R,5R)-2-hydroxy-2-methyl-5-(1-(naphthalen-2-yl)vinyl)-5-nitrocyclohex-yl) 
ethanone (12n-major) was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v, 10/1) as white solid, m.p: 133.9-134.8 ?, yield: 64%. 1H NMR (600 MHz, CDCl3): 
$ 7.77-7.85(m, 3H), 7.48-7.56(m, 3H), 7.21(d, J = 8.4 Hz, 1H), 5.72(s, 1H), 5.37(s, 1H), 
3.81(br, 1H), 2.60-2.71(m, 3H), 2.36(td, J = 13.8 Hz, J = 4.2 Hz, 1H), 2.23(s, 3H), 2.19(t, 
J = 13.8 Hz, 1H), 1.73(dt, J = 14.4 Hz, J = 3.6 Hz, 1H), 1.31(td, J = 13.8 Hz, J = 3.6 Hz, 
1H), 1.17(s, 3H). 13C NMR (150 MHz, CDCl3): $ 214.3, 148.7, 135.9, 132.8, 132.7, 
128.0, 127.73, 127.65, 127.5, 126.43, 126.38, 126.3, 119.1, 93.2, 68.3, 52.7, 34.9, 32.3, 
31.5, 29.2, 28.2. HRMS Calculated for C21H23NO4Na [M+Na]+ : 376.15193, Found: 
376.15208.  
 
12n-minor
O2N
OH
COCH3
H
 
 
1-((1S,2R,5S)-2-hydroxy-2-methyl-5-(1-(naphthalen-2-yl)vinyl)-5-nitrocyclohex-
yl)ethanone (12n-minor) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v, 10/1) as colorless oil, yield: 18%. 1H NMR (600 MHz, CDCl3): $ 7.81-
7.86(m, 3H), 7.67(s, 1H), 7.50-7.54(m, 2H), 7.30(dd, J = 6.4 Hz, J = 1.8 Hz, 1H), 6.00(s, 
1H), 5.82(s, 1H), 3.82(br, 1H), 2.40-2.61(m, 5H), 1.76(dt, J = 14.4 Hz, J = 3.6 Hz, 1H), 
1.69(s, 3H), 1.49(td, J = 13.8 Hz, J = 4.2 Hz, 1H), 1.19(s, 3H). 13C NMR (150 MHz, 
CDCl3): $ 212.9, 144.2, 136.4, 133.0, 132.8, 128.2, 127.9, 127.6, 127.3, 126.8, 126.6, 
125.9, 124.4, 91.0, 68.5, 52.9, 35.9, 31.2, 30.1, 29.6, 28.1. HRMS Calculated for 
C21H23NO4Na [M+Na]+ : 376.15193, Found: 376.15207.  
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12o-major
NO2
OH
COCH3
O H
 
 
1-((1S,2R,5R)-5-(1-(furan-2-yl)vinyl)-2-hydroxy-2-methyl-5-nitrocyclohexyl)eth-
anone (12o-major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 
8/1) as light-yellow solid, m. p: > 70 ? decomp, yield: 56%. 1H NMR (270 MHz, 
CDCl3): $ 7.29-7.38(m, 1H), 6.29-6.43(m, 2H), 5.77(s, 1H), 5.43(s, 1H), 3.91(d, J = 2.5 
Hz, 1H), 2.81-2.91(m, 1H), 2.73(td, J = 2.7 Hz, J = 14.4 Hz, 1H), 2.41-2.58(m, 2H), 
2.19-2.31(m 4H), 1.73(td, J = 3.8 Hz, J = 14.4 Hz, 1H), 1.34-1.68(m, 1H), 1.98(s, 3H). 
13C NMR (67.5 MHz, CDCl3): $ 214.5, 150.3, 142.65, 142.56, 138.0, 115.6, 111.3, 108.7, 
92.3, 68.7, 52.7, 34.8, 32.4, 31.7, 29.2, 28.5. HRMS Calculated for C15H19NO5Na 
[M+Na]+ : 316.11609, Found: 316.11538. 
 
12o-minor
O2N
OH
COCH3
O
H
 
 
1-((1S,2R,5S)-5-(1-(furan-2-yl)vinyl)-2-hydroxy-2-methyl-5-nitrocyclohexyl)eth-
anone (12o-minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 
8/1) as light-yellow oil, yield: 20%. 1H NMR (270 MHz, CDCl3): $ 7.41(s, 1H), 6.40(d, J 
= 9.7 Hz, 2H), 6.11(s, 1H), 5.8(s, 1H), 3.88(d, J = 2.2 Hz, 1H), 2.40-2.76(m, 5H), 2.03(s, 
3H), 1.80(td, J = 14.1 Hz, J = 3.5 Hz, 1H), 1.41-1.56(m, 1H), 1.19(s, 3H). 13C NMR 
(67.5 MHz, CDCl3): $ 213.0, 150.8, 142.6, 142.5, 133.6, 121.8, 111.1, 109.0, 90.6, 68.7, 
53.2, 36.1, 30.9, 30.5, 29.3, 28.0. HRMS Calculated for C15H19NO5Na [M+Na]+: 
316.11609, Found: 316.11537. 
 
 157 
NH
Ph
O
O
O
13a  
 
Methyl 3-(5-oxo-2-(1-phenylvinyl)pyrrolidin-2-yl)propanoate (13a) was purified by 
flash silica gel chromatography (Hexane-EtOAc, v/v, 3/1) as white solid, yield: 91%. 1H 
NMR (600 MHz, CDCl3): $ 7.46(s, 1H), 7.29-7.34(m, 3H), 7.21-7.23(m, 2H), 5.38(s, 
1H), 5.16(m, 1H), 3.63(s, 3H), 2.31-2.44(m, 5H), 2.07-2.14(m, 2H), 1.93-1.99(m, 1H). 
13C NMR (150 MHz, CDCl3): $ 177.6, 173.5, 152.1, 140.2, 128.2, 128.1, 127.6, 1115.4, 
65.4, 51.7, 34.1, 33.2, 30.0, 29.1. HRMS Calculated for C16H20NO3 [M+H]+ : 274.14377, 
Found: 274.14383. 
 
N
Ph
O O
13b  
 
Tetrahydro-7a-(1-phenylvinyl)-6H-pyrrolizine-3,5-dione (13b) was purified by flash 
silica gel chromatography (Hexane-EtOAc, v/v, 2/1) as white solid, m.p: 141.2-143.0 ?, 
yield: 83%. 1H NMR (600 MHz, CDCl3): $ 7.35-7.39(m, 5H), 5.52(s, 1H), 5.40(s, 1H), 
2.68-2.76(m, 2H), 2.55-2.61(m, 4H), 2.13-2.18(m, 2H). 13C NMR (150 MHz, CDCl3): $ 
171.4, 148.0, 138.2, 128.6, 128.2, 127.6, 115.4, 72.0, 34.5, 31.1. HRMS Calculated for 
C15H15NO2Na [M+Na]+ : 264.09950, Found: 264.09953. 
 
13c
Ph
NH2
OH
COCH3
H
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1-((1S,2R,5R)-5-amino-2-hydroxy-2-methyl-5-(1-phenylvinyl)cyclohexyl)ethan-one 
(13c) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 2/1) as 
colorless oil, yiled: 88%. 1H NMR (600 MHz, CDCl3): $ 7.22-7.29(m, 3H), 7.11-7.14(m, 
2H), 5.28(s, 1H), 4.84(s, 1H), 3.86(br, 1H), 3.09(dd, J = 13.2 Hz, J = 3.6 Hz, 1H), 2.15(s, 
3H), 2.09(td, J = 13.2 Hz, J = 4.2 Hz, 1H), 1.98(t, J = 13.2 Hz, 1H), 1.67(td, J = 10.2 Hz, 
J = 4.2 Hz, 1H), 1.44-1.50(m, 2H), 1.28-1.33(m, 1H), 1.17(s, 3H). 13C NMR (150 MHz, 
CDCl3): $ 216.4, 159.2, 141.4, 129.0, 127.6, 126.7, 111.9, 69.1, 53.7, 52.3, 35.0, 34.0, 
31.4, 31.1, 28.6. HRMS Calculated for C17H24NO2 [M+H]+ : 274.18016, Found: 
274.18012. 
 
13d
Ph
HN
OH
COCH3
H
O Cl
  
 
13d was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 1/1) as white 
solid, m.p: 154.2-155.9 ?, yield: 91%. 1H NMR (600 MHz, CDCl3): $ 7.24-7.28(m, 3H), 
7.08-7.11(m, 2H), 6.24(s, 1H), 5.36(s, 1H), 5.04(s, 1H), 3.95(d, J = 2.4 Hz, 1H), 3.94(d, J 
= 15.0 Hz, 1H), 3.87(d, J = 15.0 Hz, 1H), 2.90(dt, J = 13.2 Hz, J = 3.0 Hz, 1H), 2.56(dd, 
J = 13.2 Hz, J = 3.0 Hz, 1H), 2.18(s, 3H), 2.09(td, J = 13.8 Hz, J = 4.2 Hz, 1H), 1.98(t, J 
= 13.8Hz, 1H), 1.71(dq, J = 13.8 Hz, J = 3.0 Hz, 1H), 1.60(dq, J = 14.4 Hz, J = 3.0 Hz, 
1H), 1.37(tt, J = 13.8 Hz, J = 3.0 Hz, 1H), 1.18(s, 3H). 13C NMR (150 MHz, CDCl3): $ 
215.2, 165.3, 152.5, 140.6, 128.7, 127.7, 127.1, 114.9, 68.4, 58.9, 52.8, 42.9, 34.4, 32.2, 
30.8, 29.8, 28.5. HRMS Calculated for C19H25ClNO3 [M+H]+ : 350.15175, Found: 
350.15174. 
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Ph
N
OH
OO
13e  
 
13e was purified by flash silica gel chromatography (Hexane-EtOAc, v/v, 2/1) as 
colorless oil, yield: 83%. 1H NMR (600 MHz, CDCl3): $ 7.27-7.32(m, 3H), 7.17-7.23(m, 
2H), 5.44(s, 1H), 5.10(s, 1H), 4.65(d, J = 14.4 Hz, 1H), 4.98(d, J = 14.4 Hz, 1H), 4.04(s, 
1H), 2.53-2.58(m, 1H), 2.28(ddd, J = 13.2 Hz, J = 4.8 Hz, J = 3.6 Hz, 1H), 1.98(d, J = 
4.8 Hz, 1H), 1.86-1.94(m, 2H), 1.74-1.81(m, 1H), 1.57-1.64(m, 1H), 1.28(s, 3H), 1.25(s, 
3H). 13C NMR (150 MHz, CDCl3): $ 172.2, 150.2, 140.2, 129.1, 127.7, 127.3, 115.1, 
106.7, 71.9, 71.4, 67.2, 51.4, 42.8, 35.8, 29.3, 27.3, 25.5. HRMS Calculated for 
C19H24NO3Na [M+H]+ : 314.17507, Found: 314.17518. 
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Part III 
 
N O
O
Ph
Ph
Ph
15a  
4-Phenyl-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15a).  
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) ! = 7.37-7.34 (m, 5H), 7.22-7.17 (m, 4H), 7.15-7.12 (m, 2H), 6.85-
6.81 (m, 4H), 6.17 (s, 1H), 5.67 (s, 1H), 5.53 (d, J = 7.8 Hz, 2H), 5.31 (d, J = 4.2 Hz, 
1H), 4.15 (d, J = 5.4 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 144.8, 138.7, 138.0, 
137.1, 135.9, 128.9, 128.7, 128.4, 128.0, 127.9, 127.8, 127.5, 127.1, 127.0, 121.8, 116.2, 
115.0, 82.9, 56.7; HRMS Calculated for [C25H21NO2+H]+: 368.16450, Found: 368.16474. 
 
N O
O
Ph
Ph O
 
            15b 
4-Furyl-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15b) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 85%); 1H NMR 
(600 MHz, CDCl3) $ = 7.41-7.33 (m, 5H), 7.30-7.29 (s, 1H), 7.23-7.17 (m, 3H), 6.93-
6.91 (m, 2H), 6.19 (s, 1H), 6.16 (s, 1H), 5.82 (d, J = 3.0 Hz, 1H), 5.67 (s, 1H), 5.60 (s, 
1H), 5.57 (s, 1H), 5.57-5.47 (m, 1H), 4.35 (d, J = 4.2 Hz, 1H); 13C NMR (150 MHz, 
CDCl3): $ = 149.9, 144.2, 142.7, 137.9, 136.9, 135.8, 128.7, 128.4, 128.1, 127.9, 127.3, 
127.0, 121.6, 115.7, 113.6, 110.5, 108.0, 80.2, 50.3; HRMS Calculated for 
[C23H19NO3+H]+: 358.14377, Found: 358.14397. 
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O
Ph
Ph
N  
            15c 
4-Pyridine-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15c) 
Purified by flash chromatography (hexane-EtOAc) as yellowish solid (yield: 91%); 1H 
NMR (600 MHz, CDCl3) $ = 8.42-8.41 (dd, J = 4.8 Hz, J = 3.6 Hz, 2H), 7.39-7.36 (m, 
3H), 7.33-7.32 (m, 2H), 7.21-7.18 (m, 1H), 7.15-7.12 (m, 2H), 6.80-6.78 (dd, J = 7.2 Hz, 
J = 1.8 Hz, 2H), 6.73-6.72 (dd, J = 4.2 Hz, J = 3.0 Hz, 2H), 6.30 (s, 1H), 5.68 (s, 1H), 
5.58 (s, 1H), 5.56 (s, 1H), 5.27-5.26 (d, J = 4.2Hz, 1H), 4.13-4.12 (d, J = 3.6 Hz, 1H); 13C 
NMR (150 MHz, CDCl3): $ = 150.31, 147.42, 144.28, 137.8, 136.8, 135.4, 128.8, 128.6, 
128.1, 128.0, 127.6, 127.0, 122.0, 115.5, 115.0, 82.0, 55.93; HRMS Calculated for 
[C24H20N2O2+Na]+: 391.14170, Found: 391.14190. 
 
N O
O
pNO2-C6H4
Ph
Ph  
            15d 
4-p-Nitro-phenyl-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15d) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 95%); 1H NMR 
(600 MHz, CDCl3) $ = 8.03-8.01 (d, J = 9.0 Hz, 2H), 7.38-7.37 (m, 3H), 7.32-7.31 (m, 
2H), 7.21-7.18 (t, J = 7.8 Hz, 1H), 7.14-7.11 (t, J = 7.8 Hz, 2H), 6.93-6.92 (d, J = 8.4 Hz, 
2H), 6.78-6.76 (d, J = 7.2 Hz, 2H), 6.34 (s, 1H), 5.69 (s, 1H), 5.59 (s, 1H), 5.56 (s, 1H), 
5.28-5.27 (d, J = 3.6 Hz, 1H), 4.26-4.25 (d, J = 4.2 Hz, 1H); 13C NMR (150 MHz, 
CDCl3): $ = 147.5, 145.8, 144.2, 137.9, 136.9, 135.3, 128.9, 128.7, 128.2, 128.1, 127.6, 
127.0, 124.1, 122.1, 115.6, 115.3, 82.2, 56.3; HRMS Calculated for [C25H20N2O4+H]+: 
413.14958, Found: 413.14967. 
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 15e 
4-o-Nitro-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15e) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 86%); 1H NMR 
(600 MHz, CDCl3) $ = 7.68-7.67 (d, J = 8.4 Hz, 1H), 7.62-7.60 (t, J = 7.8 Hz, 1H), 7.47-
7.36 (m, 7H), 7.16-7.13 (t, J = 7.2 Hz, 1H), 7.05-7.02 (t, J = 7.2 Hz, 2H), 6.47-6.46 (d, J 
= 7.8 Hz, 2H), 6.36 (s, 1H), 5.53 (s, 1H), 5.48 (s, 1H), 5.45 (s, 1H), 5.18 (d, J = 3.6 Hz, 
1H), 5.00 (d, J = 3.6 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 147.9, 145.2, 137.8, 
137.5, 135.4, 133.9, 133.7, 129.5, 128.8, 128.6, 128.4, 128.1, 128.0, 127.8, 127.3, 124.8, 
121.8, 118.5, 115.9, 84.0, 50.6; HRMS Calculated [C25H20N2O4+H]+: 413.14958, Found: 
413.14967. 
 
N O
O
pMe-C6H4
Ph
Ph  
 15f 
4- p-Toulyl-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15f) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 93%); 1H NMR 
(600 MHz, CDCl3) $ = 7.36-7.33 (m, 5H), 7.21-7.18 (t, J = 7.2 Hz, 1H), 7.16-7.13 (m, 
2H), 7.01 (d, J = 7.8 Hz, 2H), 6.85-6.83 (m, 2H), 6.76-6.75 (d, J = 8.4 Hz, 2H), 6.11 (s, 
1H), 5.66 (s, 1H), 5.54-5.52 (d, J =11.8 Hz, 2H), 5.29-5.28 (dd, J = 3.6 Hz, J = 3.0 Hz, 
1H), 4.11 (d, J = 3.6 Hz, 1H), 2.29(s, 1H); 13C NMR (150 MHz, CDCl3): $ = 144.88, 
138.0, 137.7, 137.1, 135.9, 135.7, 129.6, 128.7, 128.3, 127.9, 127.7, 127.5, 127.0, 121.7, 
116.2, 114.8, 83.0, 56.4, 21.0; HRMS Calculated for [C26H23NO2 +H]+: 382.18016, 
Found: 382.18161. 
 
 163 
N O
O
Ph
Ph
Me . 
 15g 
4-Propyl-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15g) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 61%); 1H NMR 
(600 MHz, CDCl3) $ = 7.38-7.34 (m, 5H), 7.25-7.22 (m, 3H), 6.99-6.89 (dd, J = 6.0 Hz, J 
= 6.0 Hz, 2H), 6.27 (s, 1H), 5.71 (s, 1H), 5.63 (s, 1H), 5.43 (s, 1H), 5.09 (d, J = 2.4 Hz, 
1H), 3.06-3.04 (m, 1H), 1.47-1.41 (m, 1H), 1.31-1.25 (m, 1H), 1.22-1.16 (m, 1H), 1.09-
1.02 (m, 1H), 0.58-0.55 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 145.81, 
138.29, 137.88, 135.87, 128.68, 128.28, 128.0, 127.4, 127.2, 121.4, 116.4, 115.1, 80.3, 
49.5, 33.85, 18.68, 13.2; HRMS Calculated for [C22H23NO2+H]+: 334.18016, Found: 
334.18031. 
 
N O
O
Ph
Ph
Ph  
15h 
4-Phenyl-ethyl-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15h) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 57%); 1H NMR 
(600 MHz, CDCl3) $ = 7.39-7.33 (m, 5H), 7.25-7.22 (m, 1H), 7.20-7.17 (m, 2H), 7.12-
7.09 (m, 3H), 6.92-6.90 (m, 2H), 6.73-6.71 (dd, J = 8.4 Hz, J = 6.0 Hz, 2H), 6.24 (s, 1H), 
5.68 (d, J = 1.2 Hz, 1H), 5.62 (t, J = 1.2 Hz, 1H), 5.41 (s, 1H), 5.16 (d, J = 2.4 Hz, 1H), 
3.09-3.07 (m, 1H), 2.51-2.46 (m, 1H), 2.35-2.30 (m, 1H), 1.80-1.74 (m, 1H), 1.69-1.63 
(m, 1H); 13C NMR (150 MHz, CDCl3): $ = 145.7, 139.9, 138.1, 137.8, 135.7, 128.7, 
128.36, 128.34, 128.1, 127.9, 127.4, 127.3, 125.9, 121.6, 116.1, 115.6, 80.4, 49.3, 33.1, 
31.6; HRMS Calculated for [C27H25NO2+H]+: 396.19581, Found: 396.19613.  
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 15i 
4-Methyl-imidazole-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15i) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 81%); 1H NMR 
(600 MHz, CDCl3) $ = 7.28-7.25 (m, 3H), 7.22-7.20 (m, 2H), 7.17-7.12 (m, 3H), 6.96 (d, 
J = 1.2 Hz, 1H), 6.81-6.79 (m, 2H), 6.47 (s, 1H), 6.36 (d, J = 1.2 Hz, 1H), 5.67 (s, 1H), 
5.64-5.64 (d, J = 6.6 Hz, 1H), 5.55 (s, 1H), 5.49 (s, 1H), 4.28-4.26 (d, J = 7.2 Hz, 1H), 
2.19 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 144.0, 143.5, 138.8, 137.1, 135.2, 128.7, 
128.6, 128.4, 128.1, 127.7, 127.4, 126.9, 121.9, 120.5, 115.4, 114.8, 81.1, 84.2, 30.9; 
HRMS Calculated for [C23H21N3O2+H]+: 372.17065, Found: 372.17094. 
 
N O
O
Ph
Ph
N
Me
 
 15j 
4-N-methyl-indole-3, 5-bis (1-phenylvinyl) isoxazoline-N-oxide (15j) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 53%); 1H NMR 
(600 MHz, CDCl3) $ = 7.41-7.39 (m, 2H), 7.38-7.35 (m, 4H), 7.22-7.17 (m, 3H), 7.13-
7.10 (t, J = 7.8 Hz, 2H), 7.04-7.02 (t, J = 7.8 Hz, 1H), 6.83-6.81 (m, 2H), 6.49 (s, 1H), 
6.14 (d, J = 1.2 Hz, 1H), 5.70 (s, 1H), 5.56 (s, 1H), 5.50 (d, J = 1.2 Hz, 1H), 5.42 (d, J = 
3.0 Hz, 1H), 5.45 (d, J = 3.6 Hz, 1H), 3.64 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 
145.2, 138.2, 137.4, 137.1, 136.0, 128.9, 128.7, 128.3, 127.9, 127.6, 127.5, 127.19, 
127.12, 125.7, 122.0, 121.6, 119.6, 118.8, 115.7, 114.6, 111.5, 109.3, 82.29, 48.9, 32.6; 
HRMS Calculated for [C28H24N2O2 +H]+:421.19105, Found: 421.19143. 
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N O
O
pMe-C6H4
pCl-C6H4
pCl-C6H4  
 15k 
4-p-Toulyl-3, 5-bis (p-chloribenzylvinyl) isoxazoline-N-oxide (15k) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 95%); 1H NMR 
(600 MHz, CDCl3) $ = 7.35-7.33 (m, 2H), 7.30-7.28 (m, 2H), 7.15-7.13 (dt, J = 8.4 Hz, J 
= 4.8 Hz, 2H), 7.06-7.05 (d, J = 7.8 Hz, 2H), 6.81-6.79 (d, J = 7.8 Hz, 2H), 6.78-6.75 (dt, 
J = 8.4 Hz, J = 4.2 Hz, 2H), 6.04 (s, 1H), 5.64 (s, 1H), 5,53 (s, 1H), 5.49 (s, 1H), 5.25 (d, 
J = 4.2 Hz, 1H), 4.06 (d, J = 4.2 Hz, 1H), 2.31 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 
143.6, 138.1, 136.2, 135.48, 135.42, 134.9, 134.5, 133.9, 129.8, 129.0, 128.8, 128.3, 
128.2, 127.0, 122.3, 115.8, 115.7, 83.0, 56.5, 21.0; HRMS Calculated for 
[C26H21NO2Cl2+H]+: 450.10221, Found: 450.10252. 
 
N O
O
pNO2-C6H4
pCl-C6H4
pCl-C6H4  
 15l 
4-p-Nitro-phenyl-3, 5-bis (p-chloribenzylvinyl) isoxazoline-N-oxide (15l) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 95%); 1H NMR 
(600 MHz, CDCl3) $ = 8.10-8.09 (m, 2H), 7.38-7.36 (m, 2H), 7.29-7.26 (m, 2H), 7.15-
7.13 (m, 2H), 7.04-7.03 (m, 2H), 6.73-6.71 (m, 2H), 6.21 (s, 1H), 5.68 (s, 1H), 5.56 (s, 
2H), 5.25 (d, J = 4.2 Hz, 1H), 4.20 (d, J = 4.2 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 
147.8, 145.4, 143.0, 136.0, 135.1, 134.9, 134.4, 134.3, 129.2, 128.8, 128.5, 128.3, 128.1, 
124.3, 122.7, 116.7, 114.7,82.3, 56.3; HRMS Calculated for [C25H18Cl2N2O4+H]+: 
481.07164, Found: 481.07172. 
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pCl-C6H4  
 15m 
4-Furyl-3, 5-bis (p-chloribenzylvinyl) isoxazoline-N-oxide (15m) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 87%); 1H NMR 
(600 MHz, CDCl3) $ = 7.36-7.32 (m, 5H), 7.19-7.17 (m, 2H), 6.87-6.85 (m, 2H), 6.23 (q, 
J = 3.0 Hz, 1H), 6.07 (s, 1H), 5.89 (d, J = 3.0 Hz, 1H), 5.66 (s, 1H), 5.56 (s, 1H), 5.55 (s, 
1H), 5.44 (d, J = 4.8 Hz, 1H), 4.31 (d, J = 4.8 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 
149.5, 143.0, 142.9, 136.0, 135.2, 134.8, 134.6, 134.0, 129.0, 128.6, 128.4, 128.3, 122.0, 
116.5, 113.2, 110.7, 108.3, 80.2, 50.3; HRMS Calculated for [C24H20NO3Cl2+H]+: 
406.12048, Found: 406.12060. 
 
N O
O
pCl-C6H4
pCl-C6H4
N
N
Me
 
 15n 
4-2'-methyl-imidazole-3, 5-bis (p-chloribenzylvinyl) isoxazoline-N-oxide (15n) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 87%); 1H NMR 
(600 MHz, CDCl3) $ = 7.27-7.25 (m, 3H), 7.17-7.13 (m, 4H), 6.96 (d, J = 1.2 Hz, 1H), 
6.77-6.76 (m, 2H), 6.47 (d, J = 1.2 Hz, 1H), 6.32 (s, 1H), 5.65 (s, 1H), 5.63-5.62 (d, J = 
7.8 Hz, 1H), 5.52 (s, 1H), 4.29 (d, J = 7.2 Hz, 1H), 2.49 (s, 3H); 13C NMR (150 MHz, 
CDCl3): $ = 143.1, 142.7, 136.7, 135.2, 134.6, 134.3, 133.9, 128.9, 128.79, 128.73, 
128.3, 128.2, 122.2, 120.9, 116.5, 114.4, 81.2, 48.3, 31.3; HRMS Calculated for 
[C23H19N3O2Cl2+H]+: 440.09271, Found: 440.09301. 
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4-Toulyl-3, 5-bis (cyclohexenyl) isoxazoline-N-oxide (15o) 
Purified by flash chromatography (hexane-EtOAc) as white solid (yield: 94%); 1H NMR 
(600 MHz, CDCl3) $ = 7.16-7.15 (d, J = 7.8 Hz, 2H), 7.10-7.09 (m, 2H), 6.58 (t, J = 1.8 
Hz, 2H), 4.51 (d, J = 4.2 Hz, 1H), 4.24 (d, J = 4.8 Hz, 1H), 2.34 (s, 3H), 2.25-1.95 (m, 
8H), 1.80-1.41 (m, 8H); 13C NMR (150 MHz, CDCl3): $ = 137.5, 137.2, 134.3, 132.4, 
129.8, 126.9, 126.1, 124.8, 118.3, 86.4, 55.0, 25.8,24.8,22.8, 22.2, 22.19, 22.15, 21.3, 
21.0; HRMS Calculated for [C22H27NO2+H]+: 338.21146, Found: 338.21159.  
N O
O
O
 
 15p 
4-Furyl-3, 5-bis (cyclohexenyl) isoxazoline-N-oxide (15p) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 89%); 1H NMR 
(600 MHz, CDCl3) $ = 7.38 (s, 1H), 6.60-6.58 (m, 1H), 6.34 (m, 1H), 6.19 (d, J = 3.6 Hz, 
1H), 5.81 (s, 1H), 4.72 (d, J = 4.2 Hz, 1H), 4.43 (d, J = 4.2 Hz, 1H), 2.24-2.23 (t, J = 4.2 
Hz, 2H), 2.17-2.12 (m, 3H), 2.06-2.04 (m, 2H), 1.98-1.92 (m, 1H), 1.76-1.48 (m, 8H); 
13C NMR (150 MHz, CDCl3): $ = 151.7, 142.4, 133.8, 132.2, 126.5, 124.8, 115.8, 110.7, 
107.3, 83.2, 48.8, 25.9, 25.5, 24.8, 22.8, 22.3, 22.1, 22.0, 21.3; HRMS Calculated for 
[C19H23NO3+H]+: 314.17507, Found: 314.117533.  
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4-Pyridine-3, 5-bis (cyclohexenyl) isoxazoline-N-oxide (15q) 
Purified by flash chromatography (hexane-EtOAc) as orange solid (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 8.61 (dd, J = 4.8 Hz, J = 3.6 Hz, 2H), 7.17-7.16 (dd, J = 4.8 Hz, J 
= 3.0 Hz, 2H), 6.47 (m, 1H), 5.76 (s, 1H), 4.51 (d, J = 3.6 Hz, 1H), 4.28 (d, J = 4.2 Hz, 
1H), 2.30-1.92 (m, 8H), 1.78-1.40 (m, 8H); 13C NMR (150 MHz, CDCl3): $ = 150.6, 
148.9, 133.7, 132.9, 127.0, 124.5, 122.0, 117.0, 85.4, 54.5, 25.8, 25.7, 24.8, 22.7, 22.1, 
22.05, 22.0, 21.2; HRMS Calculated for [C20H24N2O2+H]+: 325.19105, Found: 
325.19129. 
 
N O
O
NO2  
 15r 
4-p-Nitrophenyl-3, 5-bis (cyclohexenyl) isoxazoline-N-oxide (15r) 
Purified by flash chromatography (hexane-EtOAc) as yellow solid (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 8.25-8.23 (m, 2H), 7.42-7.40 (m, 2H), 6.47-6.45 (p, J = 4.2 Hz, 
1H), 5.76 (s, 1H), 4.51 (d, J = 4.2 Hz, 1H), 4.41 (d, J = 4.2 Hz, 1H), 2.30-1.92 (m, 8H), 
1.78-1.40 (m, 8H); 13C NMR (150 MHz, CDCl3): $ = 147.6, 147.4, 133.7, 133.1, 128.0, 
127.3, 124.56, 124.53, 117.3, 85.7, 55.0, 25.8, 24.8, 22.7, 22.1, 22.09, 22.04, 21.2; 
HRMS Calculated for [C21H24N2O4+H]+: 369.18088, Found: 369.18118. 
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 15s 
4-Propyl-3, 5-bis (cyclohexenyl) isoxazoline-N-oxide (15s) 
Purified by flash chromatography (hexane-EtOAc) as white solid (yield: 64%); 1H NMR 
(600 MHz, CDCl3) $ = 6.45-6.43 (m, 1H), 4.47 (d, J = 2.4 Hz, 1H), 3.13-3.11 (m, 1H), 
2.52-2.48 (m, 1H), 2.29-1.88 (m, 6H), 1.89-1.80 (m, 1H), 1.78-1.30 (m, 13H), 0.95 (t, J = 
7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 135.3, 131.6, 125.1, 124.9, 119.0, 82.9, 
48.5, 34.1, 25.9, 25.5, 24.7, 22.8, 22.3, 22.16, 22.13, 21.4, 19.3, 13.9; HRMS Calculated 
for [C18H27NO2 +H]+: 390.21146, Found: 290.21173. 
 
N O
O
pMeO-C6H4
 
 15t 
4-p-Anisyl-3, 5-bis (cyclohexenyl) isoxazoline-N-oxide (15t) 
Purified by flash chromatography (hexane-EtOAc) as white solid (yield: 90%); 1H NMR 
(600 MHz, CDCl3) $ = 7.26-7.11 (m, 2H), 6.89-6.87 (m, 2H), 6.59-6.58 (m, 1H), 5.73 (s, 
1H), 4.51 (d, J = 4.8 Hz, 1H), 4.23 (d, J = 4.2 Hz, 1H), 3.80 (s, 3H), 2.22-1.94 (m, 8H), 
1.73-1.44 (m, 8H); 13C NMR (150 MHz, CDCl3): $ = 159.1, 134.3, 132.5, 132.2, 128.1, 
126.2, 124.8, 118.4, 114.5, 86.6, 55.2, 54.7, 25.8, 24.8, 22.8, 22.2, 22.1, 21.3; HRMS 
Calculated for [C22H27NO3 +H]+: 354.20637, Found: 354.20658.  
 
N O
O
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4-p-Nitro-phenyl-3, 5-bis (1-furylvinyl)isoxazoline-N-oxide (15u) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 46%); 1H NMR 
(600 MHz, CDCl3) $ = 8.14-8.12 (m, 2H), 7.39 (d, J = 1.8Hz, 1H), 7.11-7.09 (m, 2H), 
6.76 (d, J = 1.8 Hz, 1H), 6.47 (q, J = 2.4 Hz, 1H), 6.39 (q, J = 2.4 Hz, 1H), 6.17-6.16 (d, 
J = 3.0 Hz, 1H), 5.96-5.65 (t, J = 3.6 Hz, 1H), 5.77 (s, 1H), 5.64 (d, J = 1.2 Hz, 1H), 
5.61-5.60 (q, J = 3.6 Hz, 1H), 5.59 (s, 1H), 5.17 (dd, J = 2.4Hz, J = 1.2 Hz, 1H), 4.28 (d, 
J = 3.6 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 150.2, 147.7, 146.2, 142.8, 134.5, 
129.3, 128.2, 126.4, 124.7, 124.0, 120.9, 116.0, 111.4, 110.2, 109.7, 107.6, 107.1, 79.6, 
57.6, 46.2, 33.1, 29.6; HRMS Calculated for [C21H16N2O6+H]+: 393.10811, Found: 
393.08662. 
 
N O
O
pMe-C6H4Me
Me
 
 15v 
4-p-Anisyl-3, 5-bis (methylvinyl) isoxazoline-N-oxide (15v) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 74%); 1H NMR 
(600 MHz, CDCl3) $ = 7.16-7.13 (m, 2H), 6.90-6.88 (m, 2H), 5.67 (s, 1H), 5.23 (t, J = 
1.8 Hz, 1H), 5.07 (s, 1H), 4.97 (s, 1H), 4.64 (d, J = 4.8 Hz, 1H), 4.26 (d, J = 4.8 Hz, 1H), 
3.80 (s, 3H), 1.92 (s, 3H), 1.85 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 159.4, 141.0, 
131.6, 130.6, 128.2, 119.7, 117.8, 114.7, 113.8, 85.3, 55.2, 20.8, 16.9; HRMS Calculated 
for [C16H19NO2+H]+: 258.14886, Found: 258.14896.  
 
N O
O
Me
Me
O
 
            15w 
4-2'-Furyl-3, 5-bis (methylvinyl) isoxazoline-N-oxide (15w) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 71%); 1H NMR 
(600 MHz, CDCl3) $ = 7.40-7.39 (m, 1H), 6.36-6.35 (dd, J = 3.0 Hz, J = 1.8 Hz, 1H), 
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6.23 (d, J = 3.0 Hz, 1H), 5.68 (s, 1H), 5.26 (s, 1H), 5.14 (s, 1H), 5.01 (s, 1H), 4.84 (d, J = 
4.8 Hz, 1H), 4.47 (d, J =4.8 Hz, 1H), 1.97 (s, 3H), 1.85-1.84 (s, 3H); 13C NMR (150 
MHz, CDCl3): $ = 159.4, 141.0, 131.6, 130.6, 128.2, 119.7, 117.8, 114.7, 113.8, 85.3, 
55.2, 20.8, 16.9; HRMS Calculated for [C13H15NO3+H]+: 234.11247, Found: 234.11261. 
 
NO2
O
A'  
2-(2-cyclohexenyl-2-nitrovinyl) furan (A') 
Purified by flash chromatography (hexane-EtOAc) as clear oil (yield: 55%); Z/E isomers 
were not separated. 1H NMR (600 MHz, CDCl3): set 1, $ = 7.81 (s, 1H), 7.57 (d, 1H) 
6.85-6.86 (d, 1H), 6.52-6.53 (dd, J=3.6 Hz, 1H), 5.95-5.96 (m, 1H), 2.17-2.24 (m, 4H), 
1.72-1.83 (m, 3H), 1.62-1.65 (m, 1H); set 2, $ = 7.43 (d, 1H), 6.49-6.50 (d, 1H), 6.41-
6.42 (dd, J=3.6 Hz, J=1.8 Hz, 1H), 6.15 (s, 1H), 5.86-5.88 (t, 1H), 2.17-2.24 (m, 4H), 
1.72-1.83 (m, 3H), 1.62-1.65 (m, 1H); 13C NMR (150 MHz, CDCl3): set 1, $ = 148.0, 
146.1, 144.3, 133.8, 120.8, 117.1, 112.9, 112.0, 26.8, 25.5, 22.5, 21.5; set 2 $ = 149.0, 
148.5, 147.2, 129.1, 128.0, 112.8, 104.9, 29.7, 25.7, 24.5, 22.1; HRMS Calculated for 
[C12H13NO3+H]+: 220.09682, Found: 220.09697.  
 
ON
O
Ph
Ph
O
Ph  
 18a 
4-Phenyl-3 (1-phenylvinyl) 5- (Phenylketone) isoxazoline-N-oxide (18a) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 91%); 1H NMR 
(600 MHz, CDCl3) $ = 7.97-7.95 (m, 2H), 7.62-7.59 (tt, J = 7.2 Hz, 1H), 7.48-7.46 (t, J = 
7.8 Hz, 2H), 7.26-7.21 (m, 6H), 7.06-7.02 (m, 4H), 6.29 (s, 1H), 5.60 (s, 1H), 5.55 (d, J = 
3.6 Hz, 1H), 5.07 (d, J = 3.6 Hz, 1H); 13C NMR (150 MHz, CDCl3) $ = 192.4, 138.1, 
137.9, 135.6, 134.3, 133.7, 129.4, 129.1, 128.9, 128.2, 128.1, 127.9, 127.8, 127.5, 122.3, 
115.6, 81.0, 52.4; HRMS Calculated for [C22H27NO3+H]+: 370.14377, Found: 370.14390. 
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ON
O
pMe-C6H4
Ph
O
Ph  
 18b 
4-p-Toulyl-3 (1-phenylvinyl) 5- (Phenylketone) isoxazoline-N-oxide (18b) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 7.97-7.95 (m, 2H), 7.62-7.60 (tt, J = 6.0 Hz, 1H), 7.49-7.46 (t, J = 
5.4 Hz, 2H), 7.26-7.23 (m, 3H), 7.08-7.05 (m, 4H), 6.93-6.92 (d, J = 7.8 Hz, 2H), 6.24 (s, 
1H), 5.60 (s, 1H), 5.53 (d, J = 3.6 Hz, 1H), 5.01 (d, J = 3.6 Hz, 1H), 2.30 (s, 3H); 13C 
NMR (150 MHz, CDCl3): $ = 192.5, 138.1, 137.9, 135.6, 135.1, 134.3, 133.7, 129.8, 
129.3, 128.9, 128.1, 127.9, 127.7, 127.3, 122.2, 115.6, 81.2, 52.2, 21.0; HRMS 
Calculated for [C25H21NO3+H]+: 384.15942, Found: 384.15955. 
 
ON
O
furyl
Ph
O
Ph   
 18c 
4-Furyl-3 (1-phenylvinyl) 5- (Phenylketone) isoxazoline-N-oxide (18c) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 73%); 1H NMR 
(600 MHz, CDCl3) $ = 8.03-8.01 (m, 2H), 7.65-7.62 (tt, J = 6.0 Hz, J = 2.4 Hz, 1H), 
7.52-7.49 (t, J = 7.8 Hz, 2H), 7.34 (m, 1H), 7.31-7.25 (m, 3H), 7.18-7.16 (m, 2H), 6.28 
(s, 1H), 6.23-6.22 (q, J = 3.6 Hz, 1H), 5.92 (d, J = 3.0 Hz, 1H), 5.70 (d, J = 4.2 Hz, 1H), 
5.67 (s, 1H), 5.35 (d, J = 4.2 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 191.8, 186.8, 
149.2, 143.0, 137.8, 135.5, 134.4, 133.7, 129.5, 128.9, 128.2, 128.1, 127.6, 122.1, 110.7, 
108.6, 78.1, 46.0; HRMS Calculated for [C22H17NO4+Na]+: 382.10498, Found: 
382.10522. 
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ON
O
C3H7
Ph
O
Ph  
 18d 
4-Propyl-3 (1-phenylvinyl) 5- (Phenylketone) isoxazoline-N-oxide (18d) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 62%); 1H NMR 
(600 MHz, CDCl3) $ = 8.03-8.01 (m, 2H), 7.64-7.61 (tt, J = 6.0 Hz, J = 2.4 Hz, 1H), 
7.52-7.50 (t, J = 7.8 Hz, 2H), 7.39-7.29 (m, 5H), 6.37 (s, 1H), 5.78 (s, 1H), 5.32 (d, J = 
3.0 Hz, 1H), 4.06-4.04 (m, 1H), 1.56-1.50 (m, 1H), 1.47-1.41 (m, 1H), 1.31-1.30 (m, 2H), 
0.75 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 193.6, 138.1, 135.6, 134.17, 
134.12, 129.3, 128.8, 128.5, 128.2, 127.6, 122.0, 115.8, 78.6, 45.8, 33.3, 18.9, 13.4; 
HRMS Calculated for [C21H21NO3+H]+: 336.15942, Found: 336.16080. 
 
ON
O
iPr
Ph
O
Ph  
 18e 
4-Iso-Propyl-3 (1-phenylvinyl) 5- (Phenylketone) isoxazoline-N-oxide (18e) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 68%); 1H NMR 
(600 MHz, CDCl3) $ = 8.05-8.04 (m, 2H), 7.65-7.62 (m, 1H), 7.53-7.51 (m, 2H), 7.39-
7.25 (m, 5H), 7.36 (s, 1H), 5.83 (s, 1H), 5.38 (d, J = 2.4 Hz, 1H), 4.02-4.01 (dd, J = 4.2 
Hz, J = 1.2 Hz, 1H), 1.86-1.80 (m, 1H), 0.95-0.89 (m, 3H), 0.82 (d, J = 6.6 Hz, 3H), 0.74 
(t, 3H); 13C NMR (150 MHz, CDCl3): $ = 194.0, 138.2, 135.9, 134.2, 134.1, 129.4, 
128.8, 128.5, 128.3, 127.6, 122.2, 115.0, 75.4, 51.6, 29.3, 19.4, 17.5; HRMS Calculated 
for [C21H21NO3+H]+: 336.15942, Found: 358.15967. 
 
ON
O
pNO2-C6H4
Ph
O
Ph  
 18f 
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4-p-Nitrophenyl-3 (1-phenylvinyl) 5- (Phenylketone) isoxazoline-N-oxide (5f) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 8.08-8.06 (d, J = 7.2 Hz, 2H), 8.00-7.99 (d, J = 8.4 Hz, 2H), 7.66-
7.63 (t, J = 8.4 Hz, 1H), 7.52-7.50 (t, J = 7.8 Hz, 2H), 7.28-7.24 (m, 3H), 7.17-7.15 (m, 
2H), 7.04-7.03 (d, J = 7.8 Hz, 2H), 6.46 (s, 1H), 5.67 (s, 1H), 5.48 (d, J = 4.2 Hz, 1H), 
5.34 (d, J = 4.2 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 191.7, 147.6, 145.2, 138.0, 
135.0, 134.7, 133.6, 129.5, 129.0, 128.6, 128.4, 128.3, 127.9, 124.2, 122.7, 114.9, 80.4, 
51.5; HRMS Calculated for [C24H18N2O5+H]+: 415.12885, Found: 415.21173.  
ON
O
Nap
OEt
O
Ph  
 18g 
4-Napthyl-3 (1-phenylvinyl) 5- (Ethyl ester) isoxazoline-N-oxide (5g) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 88%); 1H NMR 
(600 MHz, CDCl3) $ = 7.85-7.79 (m, 3H), 7.49-7.35 (m, 4H), 7.14-7.12 (m, 3H), 7.03 (d, 
J=3.0, 2H), 6.33 (s, 1H), 5.62 (s, 1H), 4.81 (d, J = 3.0 Hz, 1H), 4.64 (d, J = 3.0 Hz, 1H), 
4.37-4.33 (m, 2H), 1.37-1.35 (t, J = 7.2, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.3, 
137.9, 135.5, 134.0, 133.0, 132.8, 130.3, 129.1, 129.0, 128.1, 127.9, 127.6, 126.9, 126.0, 
125.4, 122.4, 122.1, 78.1, 62.6, 49.1, 14.6; HRMS Calculated for [C20H19NO4+H]+: 
388.15433, Found: 388.15453. 
ON
O
pNO2-C6H4
OEt
O
Ph  
18h 
4-p-nitrophenyl-3 (1-phenylvinyl) 5- (Ethyl ester) isoxazoline-N-oxide (18h) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 8.10-8.07 (m, 2H), 7.30-7.23 (m, 3H), 7.14-7.12 (m, 2H), 6.99-
6.98 (m, 2H), 6.43 (s, 1H), 5.66 (s, 1H), 4.82-4.80 (dd, J = 10.2 Hz, J = 6.6 Hz, 2H), 
4.39-4.35 (m, 2H), 1.39-1.36 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 
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168.2, 147.7, 144.7, 137.8, 134.8, 128.4, 128.3, 128.1, 127.7, 124.2, 122.5, 113.9, 62.7, 
54.1, 14.0; HRMS Calculated for [C20H18N2O6+H]+: 383.12376, Found: 383.12396. 
 
ON
O
pMeC6H4
pBr-C6H4
O
Ph  
18i 
4-p-Toulyl-3 (1-phenylvinyl) 5- (P-bromophenyl Ketone) isoxazoline-N-oxide (18i) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 91%); 1H NMR 
(600 MHz, CDCl3) $ = 7.84-7.82 (m, 2H), 7.64-7.62 (m, 2H), 7.27-7.23 (m, 3H), 7.06-
7.05 (m, 4H), 6.92-6.90 (d, J = 8.4 Hz, 2H), 6.25 (s, 1H), 5.60 (s, 1H), 5.45 (d, J = 4.2 
Hz, 1H), 5.02 (d, J = 3.6 Hz, 1H), 2.30 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 191.7, 
138.2, 137.8, 135.5, 134.9, 132.5, 132.2, 130.8, 129.8, 128.1, 127.9, 127.7, 127.3, 122.4, 
115.5, 81.1, 52.0, 21.0; HRMS Calculated for [C25H20NO3Br+H]+: 462.06993, Found: 
462.07183. 
 
ON
O
pNO2-C6H4
pBr-C6H4
O
Ph  
 18j 
4-p-Nitrophenyl-3 (1-phenylvinyl) 5- (P-bromophenylketone) isoxazoline-N-oxide 
(18j) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 73%); 1H NMR 
(600 MHz, CDCl3) $ = 8.09-8.06 (m, 2H), 8.00-7.99 (d, J = 7.2 Hz, 2H), 7.66-7.63 (tt, J 
= 6.0 Hz, J = 2.4 Hz, 1H), 7.52-7.50 (t, J = 6.6 Hz, 2H), 7.30-7.24 (m, 2H), 7.17-7.15 (m, 
2H), 7.04-7.03 (d, J = 4.8 Hz, 2H), 6.46 (s, 1H), 5.67 (s, 1H), 5.49 (d, J = 4.2 Hz, 1H), 
5.35 (d, J = 4.2 Hz, 1H); 13C NMR (150 MHz, CDCl3): $ = 191.7, 147.6, 145.2, 138.0, 
135.0, 134.7, 133.6, 129.5, 129.0, 128.6, 128.4, 128.3, 127.9, 124.2, 122.7, 114.9, 80.5, 
51.5; HRMS Calculated for [C25H20BrNO4+H]+: 478.06485, Found: 478.06495. 
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ON
O
pMeO-C6H4
pBr-C6H4
O
Ph  
 18k 
4-p-Anisyl-3 (1-phenylvinyl) 5- (P-bromophenyl Ketone) isoxazoline-N-oxide (18k) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 7.84-7.82 (d, J = 8.4 Hz, 2H), 7.64-7.62 (d, J = 9.0 Hz, 2H), 7.27-
7.23 (m, 3H), 7.05-7.04 (m, 2H), 6.93-6.91 (d, J = 8.4 Hz, 2H), 6.77-6.76 (d, J = 6.6 Hz, 
2H), 6.28 (s, 1H), 5.61 (s, 1H), 5.44 (d, J = 3.6 Hz, 1H), 5.01 (d, J = 3.6 Hz, 1H), 3.77 (s, 
3H); 13C NMR (150 MHz, CDCl3): $ = 191.8, 159.5, 138.0, 135.5, 132.5, 132.2, 130.8, 
129.8, 128.6, 128.1, 128.0, 127.7, 122.4, 115.6, 114.5, 81.2, 55.2, 51.7 HRMS Calculated 
for [C25H20BrNO4+H]+: 478.06485, Found: 478.06498. 
 
ON
O
p-Py
pBr-C6H4
O
Ph  
 18l 
4-Pyridine-3 (1-phenylvinyl) 5- (P-bromophenyl Ketone) isoxazoline-N-oxide (18l) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 8.41-8.40 (dd, J = 4.8 Hz, J = 3.0 Hz, 2H), 8.05-8.04 (dd, J = 7.2 
Hz, J = 5.4 Hz, 2H), 7.66-7.63 (t, J = 8.4 Hz, 1H), 7.52-7.50 (t, J = 8.4 Hz, 2H), 7.26-
7.20 (m, 6H), 7.14-7.13 (dd, J = 4.2 Hz, J = 3.0 Hz, 2H), 5.91 (s, 1H), 5.69 (s, 1H); 13C 
NMR (150 MHz, CDCl3): $ = 182.5, 162.8, 162.4, 149.5, 146.9, 137.0, 136.6, 136.3, 
135.7, 135.4, 134.5, 130.2, 128.7, 128.6, 128.4, 126.7, 124.0, 121.8, 121.2; HRMS 
Calculated for [C23H17N2O3Br+H]+: 449.04953, Found: 449.04984. 
N O
O
CO2Me
 
 19a 
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4-Phenyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (18a) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 86%); 1H NMR 
(600 MHz, CDCl3) $ = 7.27-7.22 (m, 6H), 7.01-6.98 (m, 4H), 6.29 (s, 1H), 5.61 (s, 1H), 
4.83 (d, J = 3.0 Hz, 1H), 4.65 (d, J = 3.0 Hz, 1H), 3.89 (s, 3H); 13C NMR (150 MHz, 
CDCl3): $ = 169.4, 137.9, 137.7, 135.4, 129.1, 129.10, 128.7, 128.3, 128.1, 128.0, 127.7, 
127.0, 122.3, 114.7, 78.2, 54.8, 53.1; HRMS Calculated for [C19H17NO4+H]+: 324.12303, 
Found: 324.12316. [!]D26 = 104.5° (c = 1.0 CHCl3). Enantiomeric excess was determined 
by HPLC with a Chiralcel OD-H column; % = 254 nm; eluent: Hexane/Isopropanol = 
90/10; Flow rate: 1.0 mL/min; tminor =10.352 min, tmajor = 12.964 min; ee% = 91%. 
 
N O
O
CO2Me
OMe  
 19b 
4-p-Methoxyphenyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19b) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 82%); 1H NMR 
(600 MHz, CDCl3) $ = 7.29-7.24 (m, 3H), 7.03-7.01 (m, 2H), 6.91-6.89 (m, 2H), 6.78-
6.76 (m, 2H), 6.28 (s, 1H), 5.61 (s, 1H), 4.80 (d, J = 3.0 Hz, 1H), 4.60 (d, J = 2.4 Hz, 
1H), 3.89 (s, 3H), 3.77 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.5, 159.6, 138.0, 
135.4, 129.7, 128.27, 128.21, 128.0, 127.7, 122.3, 114.8, 114.4, 78.4, 55.2, 54.2, 53.1; 
HRMS Calculated for [C20H19NO5+H]+: 354.13360, Found: 354.13373. [!]D26 = 105.6° 
(c = 1.0 CHCl3).  
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =15.288 min, tmajor 
= 19.468 min; ee% = 94%. 
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 19c 
4-P-Toulyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19c) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 89 %); 1H 
NMR (600 MHz, CDCl3) $ = 7.28-7.23 (m, 3H), 7.06-7.02 (m, 4H), 6.89-6.88 (d, J = 8.4 
Hz, 2H), 6.24 (s, 1H), 5.60 (s, 1H), 4.81 (d, J = 2.4 Hz, 1H), 4.62 (d, J = 3.0 Hz, 1H), 
3.89 (s, 3H), 3.30 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.5, 138.2, 137.9, 135.5, 
134.7, 129.7, 128.1, 128.0, 127.7, 126.9, 122.3, 114.8, 78.4, 54.5, 53.1, 21.0; HRMS 
Calculated for [C20H19NO4+H]+: 338.13868, Found: 338.13879. [!]D26 = 102.5° (c = 1.0 
CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 0.5 mL/min; tminor =24.012 min, tmajor 
= 25.484 min; ee% = 91%. 
 
N O
O
CO2Me
N
 
 19d 
4-2'-pyridine-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19d) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 90%); 1H NMR 
(600 MHz, CDCl3) $ = 8.56-8.55 (dt, J = 4.8 Hz, 1H), 7.50-7.47 (td, J = 7.8 Hz, J = 1.8 
Hz, 1H), 7.26-7.22 (m, 3H), 7.17-7.15 (m, 1H), 7.07-7.05 (m, 2H), 6.76-6.75 (d, J = 7.8 
Hz, 1H), 6.31 (s, 1H), 5.62 (s, 1H), 5.19 (d, J = 4.2 Hz, 1H), 4.91 (d, J = 4.2 Hz, 1H), 
3.88(s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.3, 156.3, 150.2, 138.0, 136.7, 135.5, 
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128.21, 128.0, 127.6, 123, 122.4, 122.0, 114.1, 56.3, 53.1; HRMS Calculated for 
[C18H16N2O4+H]+: 325.11828, Found: 325.11836. [!]D26 = 78.6° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel As-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor =14.124 min, tmajor 
= 11.992 min; ee% = 80%. 
 
N O
O
CO2Me
O
 
 19e 
4-2'-Furyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19e) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 71%); 1H NMR 
(600 MHz, CDCl3) $ = 7.32-7.25 (m, 4H), 7.12-7. 10 (m, 2H), 6.28 (s, 1H), 6.24 (dd, J = 
3.0 Hz, J = 1.8 Hz, 1H), 5.95 (d, J = 3.0 Hz, 1H), 5.67 (s, 1H), 4.98 (d, J = 3.0 Hz, 1H), 
4.88 (d, J = 3.6 Hz, 1H), 3.89 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.0, 148.8, 
143.0, 137.8, 135.3, 128.3, 128.1, 127.5, 122.1, 112.0, 110.7, 108.5, 53.2, 48.4; HRMS 
Calculated for [C17H15NO5+H]+: 314.10230, Found: 314.10239. [!]D26 = 94.9° (c = 1.0 
CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; 
% = 254 nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =8.208 
min, tmajor = 7.052 min; ee% = 90%. 
 
N O
O
CO2Me
Ph
 
 19f 
4-2'-Napthyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19f) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 86 %); 1H 
NMR (600 MHz, CDCl3) $ = 7.85-7.79 (m, 3H), 7.48-7.42 (m, 4H), 7.14-7.12 (m, 3H), 
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7.02 (d, J = 3.6 Hz, 2H), 6.34 (s, 1H), 5.62 (s, 1H), 5.51 (s, 1H), 4.83 (s, 1H), 3.96 (s, 
3H); 13C NMR (150 MHz, CDCl3): $ = 187.3, 169.9, 137.8, 135.8, 134.0, 132.8, 130.2, 
129.1, 129.0, 128.1, 127.9, 127.6, 126.9, 126.0, 125.3, 122.5, 122.0, 114.3, 53.3; HRMS 
Calculated for [C23H19NO4+H]+: 374.13868, Found: 374.34876. [!]D26 = 120.1° (c = 1.0 
CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel As-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =18.396 min, tmajor 
= 23.576 min; ee% = 96%. 
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4-Propyl-3-(1-phenylvinyl)-5-(methyl ester) isoxazoline-N-oxide (19g) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 63 %); 1H 
NMR (600 MHz, CDCl3) $ = 7.37-7.34 (m, 3H), 7.24-7.22 (m, 1H), 6.36 (s, 1H), 6.76 (s, 
1H), 4.66 (d, J = 2.4 Hz, 1H), 3.87 (s, 3H), 3.57-3.55 (m, 1H), 1.57-1.19 (m, 4H), 1.01-
0.93 (m, 1H), 0.75 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 170.1, 138.1, 
135.4, 128.5, 128.3, 127.6, 122.1, 114.8, 52.9, 48.9, 33.4, 18.8, 13.3; HRMS Calculated 
for [C16H19NO4+H]+: 290.13868, Found: 290.13895. [!]D26 = 94.5° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel As-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =8.208 min, tmajor 
= 7.052 min; ee% = 88%. 
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4-p-Nitrophenyl-3-(1-phenylvinyl)-5-(methyl ester) isoxazoline-N-oxide (19h) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 8.12-8.07 (m, 2H), 7.31-7.48 (m, 3H), 7.14-7.11 (m, 2H), 7.0-6.8 
(m, 2H), 6.45 (s, 1H), 5.65 (s, 1H), 4.82 (m, 2H), 3.91 (m, 3H); 13C NMR (150 MHz, 
CDCl3): $ = 168.8, 147.8, 144.7, 137.8, 134.8, 128.4, 128.3, 128.1, 127.8, 124.2, 122.6, 
113.9, 54.2, 53.4; HRMS Calculated for [C19H16N2O6+H]+: 369.10811, Found: 
369.10821. [!]D26 = 82.2° (c = 1.0 CHCl3). Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column; % = 254 nm; eluent: Hexane/Isopropanol = 90/10; 
Flow rate: 1.0 mL/min; tminor =5.168 min, tmajor = 5.860 min; ee% = 81%. 
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 19i 
4-o-Nitrophenyl-3-(1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19i) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 82%); 1H NMR 
(600 MHz, CDCl3) $ = 7.81-7.80 (dd, J = 8.4 Hz, J = 7.2 Hz, 1H), 7.65-7.62 (td, J = 7.8 
Hz, J = 1.2 Hz, 1H), 7.45-7.41 (m, 2H), 7.26-7.19 (m, 1H), 7.17-7.14 (m, 2H), 6.95-6.93 
(m, 2H), 6.50 (s, 1H), 5.65 (s, 1H), 5.42 (d, J = 3.0 Hz, 1H), 4.83-4.82 (d, J = 3.0 Hz, 
1H), 3.92 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 168.3, 147.8, 137.9, 135.2, 133.9, 
129.4, 129.3, 128.29, 128.26, 127.5, 125.1, 122.4, 113.8, 53.3, 49.7; HRMS Calculated 
for [C19H16N2O6+H]+: 369.10811, Found: 369.10821. [!]D26 = 72.5° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor = 29.956 min, 
tmajor = 24.792 min; ee% = 70%. 
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 19j 
4-o-Anisyl-3-(1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19j) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 84%); 1H NMR 
(600 MHz, CDCl3) $ = 7.25-7.20 (m, 4H), 7.06-7.04 (m, 2H), 7.01-6.99 (dd, J = 7.8 Hz, J 
= 6.0 Hz, 1H), 6.86-6.83 (td, J = 7.2 Hz, J = 1.2 Hz, 1H), 6.78-6.76 (dd, J = 7.8 Hz, J = 
7.2 Hz, 1H), 6.22 (s, 1H), 5.59 (s, 1H), 5.08-5.07 (d, J = 3.6 Hz, 1H), 4.81 (d, J = 4.2 Hz, 
1H), 3.87 (s, 3H), 3.68 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.5, 156.4, 137.9, 
135.8, 129.6, 128.5, 128.0, 127.7, 127.6, 125.3, 121.9, 120.8, 114.3, 110.7, 55.4, 52.9, 
49.2; HRMS Calculated for [C20H19NO5+H]+: 354.13360, Found: 354.13373. [!]D26 = 
99.5° (c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel 
As-H column; % = 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; 
tminor = 14.828 min, tmajor = 10.184 min; ee% = 88%. 
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4-2', 4' dimethylphenyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19k)  
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 79%); 1H NMR 
(600 MHz, CDCl3) $ = 7.25-7.20 (m, 3H), 6.97-6.95 (m, 4H), 6.90-6.89 (m, 1H), 6.37 (s, 
1H), 5.60 (d, J = 1.2 Hz, 1H), 4.83 (d, J = 3.0 Hz, 1H), 4.69 (d, J = 2.4 Hz, 1H), 3.89 (s, 
3H), 2.29 (s, 3H), 1.83 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.7, 138.2, 136.5, 
135.7, 135.4, 132.3, 130.6, 129.0, 128.1, 127.9, 127.7, 127.4, 122.2, 114.9, 78.0, 53.1, 
50.9, 20.9, 18.2; HRMS Calculated for [C21H21NO4+H]+: 352.15433, Found: 352.15444. 
[!]D26 = 101.1° (c = 1.0 CHCl3). 
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Enantiomeric excess was determined by HPLC with a Chiralcel As-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =16.352 min, tmajor 
= 21.012 min; ee% = 92%. 
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 19l 
4-2' furyl-3 (1-phenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19l)  
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 81%); 1H NMR 
(600 MHz, CDCl3) $ = 7.35-7.34 (m, 1H), 7.28-7.26 (m, 2H), 7.06-7.05 (m, 2H), 6.27 
(dd, J = 3.6 Hz, J = 1.8 Hz, 1H), 6.20 (s, 1H), 6.03 (d, J = 3.6 Hz, 1H), 5.63 (s, 1H), 4.98 
(d, J = 3.6 Hz, 1H), 4.86 (d, J = 3.6 Hz, 1H), 3.89 (s, 3H); 13C NMR (150 MHz, CDCl3): 
$ = 168.8, 148.7, 143.2, 136.0, 134.4; 134.2, 128.8, 128.5, 122.5, 111.7, 110.8, 108.6, 
75.7, 53.3, 48.3;  HRMS Calculated for [C17H14ClNO5+H]+: 348.06333, Found: 
348.06351. [!]D26 = 69.2° (c = 1.0 CHCl3). Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column; % = 254 nm; eluent: Hexane/Isopropanol = 90/10; 
Flow rate: 1.0 mL/min; tminor =18.044 min, tmajor = 23.184 min; ee% = 76%. 
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 19m 
4-o-Anisyl-3 (p-chlorophenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19m) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 88%); 1H NMR 
(600 MHz, CDCl3) $ = 7.26-7.23 (m, 1H), 7.20-7.18 (m, 2H), 7.05-7.03 (dd, J = 7.8 Hz, J 
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= 5.4 Hz, 1H), 7.00-6.97 (m, 2H), 6.89-6.86 (td, J = 7.8 Hz, J = 6.6 Hz, 1H), 6.79 (d, J = 
7.2 Hz, 1H), 6.19 (s, 1H), 5.55 (s, 1H), 5.07 (d, J = 3.6 Hz, 1H), 4.81 (d, J = 4.2 Hz, 1H), 
3.87 (s, 3H), 3.71 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.4, 156.3, 136.2, 134.9, 
133.8129.8, 129.0, 128.5, 128.2, 125.1, 122.2, 120.9, 114.1, 110.7, 77.7, 55.4, 53.0, 48.9; 
HRMS Calculated for [C20H18NClO5+H]+: 388.09463, Found: 388.09473. [!]D26 = 84.5° 
(c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel As-H 
column; % = 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor 
=10.192 min, tmajor = 8.804 min; ee% = 81%. 
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4-p-Anisyl-3 (p-chlorophenylvinyl) 5-(methyl ester) isoxazoline-N-oxide (19n) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 81%); 1H NMR 
(600 MHz, CDCl3) $ = 7.24-7.22 (m, 2H), 6.97-6.94 (m, 4H), 6.81-6.79 (dt, J = 9.0 Hz, J 
= 4.2 Hz, 2H), 6.21 (s, 1H), 5.57 (s, 1H), 4.80 (d, J = 3.0 Hz, 1H), 4.58 (d, J = 3.0 Hz, 
1H), 3.90-3.88 (s, 3H), 3.78 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 169.4, 159.7, 
136.2, 134.5, 134.1, 129.5, 129.0, 128.4, 128.2, 122.6, 114.6, 114.5, 55.3, 54.1, 53.1; 
HRMS Calculated for [C20H18NClO5+H]+: 388.09463, Found: 388.09476. [!]D26 = 110.4° 
(c = 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column; % = 254 nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor 
=6.920 min, tmajor = 11.420 min; ee% = 92%. 
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4-Napthyl-3 (p-chlorophenylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19o) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 91%); 1H NMR 
(600 MHz, CDCl3) $ = 7.87-7.81 (m, 3H), 7.52-7.44 (m, 4H), 7.11-7.09 (m, 2H), 6.95 (d, 
J = 7.8 Hz, 2H), 6.27 (s, 1H), 5.57 (s, 1H), 4.49 (s, 1H), 4.85 (s, 1H), 3.96 (s, 3H); 13C 
NMR (150 MHz, CDCl3): $ = 169.7, 136.1, 134.8, 134.0, 132.7, 130.2, 129.3, 129.1, 
128.9, 128.3, 127.1, 126.1, 125.3, 122.8, 121.9, 114.1, 78.0, 53.3, 50.1; HRMS 
Calculated for [C23H18ClNO4+H]+: 408.09971, Found: 408.09996. [!]D26 = 120.9° (c = 
1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel As-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor =6.148 min, tmajor 
= 9.672 min; ee% = 93%. 
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 19p 
4-o-Anisyl-3 (Methylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19p) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 75%); 1H NMR 
(600 MHz, CDCl3) $ = 7.33-7.30 (td, J = 7.8 Hz, J = 6.6 Hz, 1H), 7.14-7.12 (dd, J = 7.8 
Hz, J = 6.0 Hz, 1H), 6.96-6.92 (m, 2H), 5.71 (s, 1H), 5.25 (s, 1H), 5.13 (d, J = 3.0 Hz, 
1H), 4.69 (d, J = 3.0 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 1.95 (s, 3H); 13C NMR (150 
MHz, CDCl3): $ = 169.6, 156.2, 130.2, 129.7, 127.9, 126.0, 121.1, 119.9, 115.8, 110.9, 
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55.6, 52.9, 48.2, 20.5; HRMS Calculated for [C15H16NO5+H]+: 292.11795, Found: 
292.11810. [!]D26 = 100.1° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel As-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 95/5; Flow rate: 1.0 mL/min; tminor =18.072 min, tmajor 
= 16.452 min; ee% = 81%. 
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 19q 
4-Napthyl-3 (Methylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19q) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 70%); 1H NMR 
(600 MHz, CDCl3) $ = 8.25 (d, J = 7.2Hz, 1H), 7.94-7.93 (dd, J = 7.8 Hz, J = 7.2 Hz, 
1H), 7.87-7.86 (d, J = 9.6 Hz, 1H), 7.66-7.63 (td, J = 8.4 Hz, J = 5.4 Hz, 1H), 7.59-7.56 
(td, J = 8.4 Hz, J = 6.0 Hz, 1H), 7.47-7.44 (t, J = 8.4 Hz, 1H), 7.31 (d, J = 6.6 Hz, 1H), 
5.81 (s, 1H), 5.56 (s, 1H), 5.31 (s, 1H), 4.76 (s, 1H), 3.95 (s, 3H), 1.94 (s, 3H); 13C NMR 
(150 MHz, CDCl3): $ = 170.1, 134.3, 132.8, 130.3, 130.0, 129.36, 129.33, 127.3, 126.2, 
125.5, 124.6, 122.3, 120.3, 115.6, 53.3, 50.2, 20.7; HRMS Calculated for 
[C18H17NO4+H]+: 312.12303, Found: 312.12323. [!]D26 = 114.0° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =8.148 min, tmajor 
= 13.664 min; ee% = 93%. 
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4-Toulyl-3 (Methylvinyl) 5- (methyl ester) isoxazoline-N-oxide (19r) 
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Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 80%); 1H NMR 
(600 MHz, CDCl3) $ = 7.20-7.16 (m, 4H), 5.27 (s, 1H), 4.70 (d, J = 2.4 Hz, 1H), 4.68 (d, 
J = 2.4 Hz, 2H), 3.87 (s, 3H), 2.35 (s, 3H), 1.93 (s, 3H); 13C NMR (150 MHz, CDCl3): $ 
= 169.6; 138.5, 135.4, 130.1, 129.9, 126.8, 120.2, 116.0, 78.3, 54.2, 53.1, 21.1, 20.7; 
HRMS Calculated for [C15H17NO4+H]+: 276.12327, Found: 276.12357. [!]D26 = 94.5° (c 
= 1.0 CHCl3). Enantiomeric excess was determined by HPLC with a Chiralcel As-H 
column; % = 254 nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor 
=7.640 min, tmajor = 8.936 min; ee% = 85%. 
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2-p-Toulyl-3 (cyclohexenyl) 5- (methyl ester) isoxazoline-N-oxide (19s)  
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 80%); 1H NMR 
(600 MHz, CDCl3) $ = 7.19-7.15 (m, 4H), 6.64-6.63 (q, J = 6.0 Hz, 1H), 4.66-4.65 (q, J = 
4.8 Hz, 2H), 3.86 (s, 3H), 2.35 (s, 3H), 2.26-2.23 (m, 1H), 2.15-2.12 (m, 3H), 1.60-1.47 
(m, 4H); 13C NMR (150 MHz, CDCl3): $ = 169.9, 138.2, 135.6, 133.4, 130.0, 126.8, 
124.0, 116.2, 54.1, 53.0, 25.9, 25.7, 22.2, 21.2, 21.1; HRMS Calculated for 
[C18H21NO4+H]+: 316.15433, Found: 316.15441. [!]D26 = 102.8° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 85/15; Flow rate: 1.0 mL/min; tminor =7.356 min, tmajor 
= 12.192 min; ee% = 90%. 
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 19t 
2-Napthyl-3 (cyclohexenyl) 5- (methyl ester) isoxazoline-N-oxide (19t) 
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Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 85%); 1H NMR 
(600 MHz, CDCl3) $ = 8.25 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.86 (d, J = 8.4 
Hz, 1H), 7.66-7.57 (td, J = 7.2 Hz, J = 6.0 Hz, 1H), 7.58-7.56 (td, J = 7.2 Hz, J = 6.0 Hz, 
1H), 7.47 (t, J = 8.4 Hz, 1H), 7.32 (d, J = 6.6 Hz, 1H), 6.72 (s, 1H), 5.53 (s, 1H), 4.71 (s, 
1H), 3.94 (s, 3H), 2.33-2.30 (m, 1H), 2.13-2.04 (m, 3H), 1.59-1.50 (m, 4H); 13C NMR 
(150 MHz, CDCl3): $ = 187.3, 173.3, 170.4, 134.3, 133.6, 133.0, 130.3, 129.3, 129.1, 
127.2, 126.2, 125.9, 124.6, 124.1, 122.4, 115.8, 53.2, 50.1, 25.9, 25.7, 22.2, 21.2; HRMS 
Calculated for [C21H21NO4+H]+: 352.15433, Found: 352.15440. [!]D26 = 101.3° (c = 1.0 
CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 90/10; Flow rate: 1.0 mL/min; tminor =6.896 min, tmajor 
= 11.084 min; ee% = 91%. 
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2-p-Nitrophenyl-3 (cyclohexenyl) 5- (methyl ester) isoxazoline-N-oxide(19u)  
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 93%); 1H NMR 
(600 MHz, CDCl3) $ = 8.28-8.26 (m, 2H), 7.51-7.48 (m, 2H), 6.54-6.52 (p, J = 4.2 Hz, 
1H), 4.84 (d, J = 2.4 Hz, 1H), 4.67 (d, J = 2.4 Hz, 1H), 3.89 (s, 3H), 2.31-2.27 (m, 1H), 
2.16-2.04 (m, 3H), 1.67-1.48 (m, 4H); 13C NMR (150 MHz, CDCl3): $ = 169.3, 145.6, 
134.1, 128.1, 124.7, 123.7, 115.2, 53.9, 53.4, 26.0, 25.8, 22.1, 21.1; HRMS Calculated 
for [C17H18N2O6+H]+: 347.12376, Found: 347.12382. [!]D26 = 62.1° (c = 1.0 CHCl3). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column; % = 254 
nm; eluent: Hexane/Isopropanol = 80/20; Flow rate: 1.0 mL/min; tminor =8.376 min, tmajor 
= 14.728 min; ee% = 65%. 
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 22 
Purified by flash chromatography (hexane-EtOAc) as white floppy solid (yield: 91%); 1H 
NMR (600 MHz, CDCl3) $ = 7.74-7.72 (m, 2H), 7.58-7.55 (m, 1H), 7.45-7.43 (m, 2H), 
7.40-7.38 (m, 4H), 7.36-7.33 (m, 1H), 5.10-5.09 (d, J = 3.6 Hz, 1H), 5.03-5.02 (d, J = 4.2 
Hz, 1H), 4.39-4.35 (q, J = 7.2 Hz, 2H), 1.38-1.36 (t, J = 7.2 Hz, 3H). 13C NMR (150 
MHz, CDCl3): $ = 184.5, 168.1, 137.7, 135.0, 133.6, 129.5, 128.9, 128.8, 128.5, 127.1, 
115.6, 79.4, 62.7, 53.9, 14.1. HRMS Calculated for [C19H17NO5+H]+: 340.11795, Found: 
340.11786.  
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Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 72%); 1H NMR 
(600 MHz, CDCl3) $ = 7.41-7.35 (m, 3H), 7.32-7.30 (m, 2H), 7.28-7.22 (m, 3H), 7.01-
7.00 (m, 2H), 5.19-5.18 (d, J = 4.2 Hz, 1H), 4.24-4.23 (d, J = 4.2 Hz, 1H), 3.65-3.64 (d, J 
= 1.8 Hz, 3H). 13C NMR (150 MHz, CDCl3): $ = 207.0, 137.6, 132.9, 129.4, 129.1, 
128.9, 128.7, 127.7, 79.2, 44.6. HRMS Calculated for [C18H15NO4+H]+: 314.10738, 
Found: 314.10728.  
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Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 86%); 1H NMR 
(600 MHz, CDCl3) $ = 7.32-7.27 (m, 6H), 7.20-7.18 (m, 2H), 7.07-7.06 (m, 2H), 5.26-
5.25 (d, J = 4.8 Hz, 1H) 4.94-4.93 (d, J = 5.4 Hz, 1H), 4.25-4.24 (d, J = 5.4 Hz, 1H), 3.74 
(s, 3H), 3.14-3.13 (d, J = 6.8 Hz, 1H). 13C NMR (150 MHz, CDCl3): $ = 169.8, 162.4, 
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138.4, 136.3, 129.3, 128.8, 128.7, 128.6, 128.4, 127.6, 126.8, 86.4, 70.2, 58.4, 52.7. 
HRMS Calculated for [C18H17NO4+H]+: 312.12303, Found: 312.12296.  
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Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: >98%); 1H 
NMR (600 MHz, CDCl3) $ = 9.28 (br, 1H), 7.75- 7.73 (m, 2H), 7.51-7.48 (m, 1H), 7.37-
7.42 (t, J = 7.2 Hz, 2H), 7.21-7.19 (m, 2H), 7.03-7.01 (d, J = 7.8 Hz, 2H), 4.70 (br, 1H), 
4.4 (br, 1H), 4.06-4.25 (d, J = 6.6 Hz, 1H), 4. 01-4.05 (m, 2H), 1.09-1.06 (m, 3H). 13C 
NMR (150 MHz, CDCl3): $ = 193.6, 173.3, 173.2, 156.3, 137.6, 134.3, 134.2, 134.0, 
131.5, 131.4, 129.4, 129.2, 129.1, 128.5, 73.7, 61.71, 51.7, 20.9, 13.7. HRMS Calculated 
for [C19H19NO5+H]+: 342.13360, Found: 342.13351.  
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 29´ 
Purified by flash chromatography (hexane-EtOAc) as colorless oil. 1H NMR (600 MHz, 
DMSO) $ = 10.9, (s, 1H), 7.45-7.44 (d, J = 5.6, 2H), 7.31-7.19 (m, 8H), 5.86-5.85 (d, J = 
6.0 Hz, 1H), 5.39-5.37 (dd, J = 6.0 Hz, J = 7.8 Hz, 2H), 4.46-4.43 (m, 1H), 4.10-4.09 (d, 
J = 9.0 Hz, 1H), 3.69-3.68 (m, 1H), 3.57-3.51 (m, 1H), 0.79-0.77 (m, 3H). 13C NMR (150 
MHz, DMSO): $ = 172.9, 159.9, 142.0, 139.4, 129.4, 128.1, 128.0, 127.2, 127.1, 126.8, 
74.5, 67.2, 59.8, 49.3, 13.9. HRMS Calculated for [C19H21NO5+H]+: 344.14925, Found: 
344.14913.  
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Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: >81%); 1H 
NMR (600 MHz, CDCl3) $ = 7.57-7.56 (d, J = 7.2 Hz, 2H), 7.43-7.42 (m, 2H), 7.43-7.42 
(t, J = 7.2 Hz, 2H), 7.26-7.16 (m, 4H), 6.42 (s, 1H), 4.60-4.58 (d, J = 10.2 Hz, 1H), 4.20-
4.18 (d, J = 10.2 Hz, 1H), 3.76-3.71 (m, 1H), 3.65-3.60 (m, 1H), 1.05 (s, 9H), 0.86-0.85 
(m, 3H), 0.58-0.57 (d, 18H), 0.3 (s, 3H), 0.28 (s, 3H), -0.17 (s, 3H), -0.31 (s, 3H), -0.38 
(s, 3H), -0.48 (s, 3H). 13C NMR (150 MHz, CDCl3): $ = 172.4, 163.6, 140.5, 137.7, 
129.7, 127.9, 127.8, 127.2, 126.9, 126.8, 126.7, 68.6, 59.9, 50.3, 26.1, 26.0, 25.9, 25.7, 
25.5, 18.3, 17.9, 17.8, 13.7. HRMS Calculated for [C37H63NO5Si3+H]+: 686.40868, 
Found: 686.40860.  
 
N
H
Ph OH
Ph
O
31  
(3R,4R,5R)-3-hydroxy-4-phenyl-5-(1-phenylvinyl) pyrrolidin-2-one (31) 
Purified by flash chromatography (Hexane-EtOAc) as clear liquid (yield: 57%); 1H NMR 
(600 MHz, CDCl3) $ = 7.23-7.28 (m, 3H), 7.18-7.20 (m, 1H), 7.13-7.16 (m, 2H), 7.03 (b, 
1H), 6.97-6.99 (m, 2H), 6.82-6.84 (m, 2H), 5.11 (d, J = 0.6 Hz, 1H), 5.06-5.07 (d, J = 6.0 
Hz, 1H), 5.02 (d, J = 0.6 Hz, 1H), 4.75-4.77 (dd, J = 7.8 Hz, J = 6.0 Hz, 1H), 3.85-3.88 
(dd, J = 7.8 Hz, J = 6.0 Hz, 1H), 3.04-3.05 (d, J = 5.4 Hz, 1H); 13C NMR (150 MHz, 
CDCl3): $ = 177.5, 144.0, 138.9, 133.4, 130.0, 128.3, 128.2, 128.1, 127.8, 127.6, 127.5, 
126.6, 113.8, 72.3, 57.2, 50.8; HRMS Calculated for [C18H17NO2+H]+: 280.13321, 
Found: 280.13330. 
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(3R, 4R)-3-hydroxy-4-phenyl-5-(1-phenylethylidene) pyrrolidin-2-one (31´) 
Purified by flash chromatography (Hexane-EtOAc) as white solid (yield: 79%); 1H NMR 
(600 MHz, CDCl3) set 1: $ = 8.69 (br, 1H), 7.45 (br, 1H), 7.38-7.34 (m, 4H), 7.30-7.21 
(m, 7H), 7.01-7.00 (m, 2H), 6.89-6.87 (m, 2H), 4.79-4.76 (dd, J = 9.0 Hz, J = 6.0 Hz, 
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1H), 4.50-4.48 (d, J = 9.0 Hz, 1H), 2.54-2.54 (d, J = 5.4 Hz, 1H), 1.80 (s, 3H); set 2: $ = 
8.63 (br, 1H), 7.45 (br, 1H), 7.38-7.34 (m, 4H), 7.30-7.21 (m, 7H), 7.14-7.12 (m, 4H), 
4.67-4.65 (dd, J = 8.4 Hz, J = 3.0 Hz, 1H), 4.17-4.16 (d, J = 8.4 Hz, 1H), 2.28-2.27 (d, J 
= 6.6 Hz, 1H), 2.04 (s, 3H); 13C NMR (150 MHz, CDCl3): set 1: $ = 175.2, 140.2, 135.3, 
131.6, 129.1, 128.8, 128.5, 127.9, 127.6, 127.3, 112.8, 71.3, 48.1, 18.2; set 2: $ = 176.2, 
140.7, 136.9, 132.1, 128.6, 128.5, 128.4, 128.0, 127.7, 127.4, 126.6, 114.3, 71.8, 49.1, 
18.7; HRMS Calculated for [C18H17NO2+H]+: 280.13321, Found: 280.13330 
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32  
(3R, 4R, 5R)-3-hydroxy-4-phenyl-5-(bezoketo) pyrrolidin-2-one (32) 
Purified by flash chromatography (Hexane-EtOAc) as white solid (yield: 79%); 1H NMR 
(600 MHz, CDCl3) $ = 7.64-7.65 (d, J = 7.2 Hz, 2H), 7.53-7.55 (t, J = 7.2 Hz, 1H), 7.37-
7.39 (t, J = 7.8 Hz, 2H), 7.10-7.12 (t, J = 7.8 Hz, 1H), 7.04-7.06 (t, J = 7.2 Hz, 2H), 6.86-
6.87 (d, J = 7.8 Hz, 2H), 5.43-5.44 (d, J = 7.2 Hz, 1H), 4.71-4.73 (dd, J = 7.2 Hz, J = 4.2 
Hz, 1H), 4.11-4.14 (t, J = 7.2 Hz, 1H), 3.45-3.46 (d, J = 4.2 Hz, 1H), 2.99 (s, 3H); 13C 
NMR (150 MHz, CDCl3): $ = 194.5, 175.3, 135.8, 133.7, 132.4, 129.8, 128.7, 128.0, 
127.8, 127.8, 71.3, 65.5, 48.0, 30.2; HRMS Calculated for [C18H17NO3+H]+: 296.12812, 
Found: 296.12824. 
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33  
(3R, 4R, 5R)-3-hydroxy-5-((S)-hydroxy(phenyl)methyl)-1-methyl-4-phenylpyrrolidin 
-2-one (33) 
Purified by flash chromatography (EtOAc-MeOH) as white solid (yield: >98%); 1H NMR 
(600 MHz, CDCl3) $ = 7.17-7.28 (m, 10H), 4.81-4.83 (t, J = 6.0 Hz, 1H), 4.51-4.53 (t, J 
= 6.0 Hz, 1H), 4.14-4.16 (dd, J = 6.6 Hz, J = 0.6 Hz, 1H), 3.80-3.82 (dd, J = 6.6 Hz, J = 
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0.6 Hz, 1H), 3.48-3.49 (d, J = 5.4 Hz, 1H), 2.605 (s, 3H), 2.32-2.33 (d, J = 5.4 Hz, 1H); 
13C NMR (150 MHz, CDCl3): $ = 175.8, 140.6, 134.2, 130.0, 128.5, 128.4, 128.1, 127.8, 
126.6, 71.8, 71.7, 47.4, 29.5; HRMS Calculated for [C18H19NO3+H]+: 298.14377, Found: 
298.14391. Enantiomeric excess was determined by HPLC with a Chiralcel AS-H 
column; % = 254 nm; eluent: Hexane/Isopropanol = 70/30; Flow rate: 1.5 mL/min; tminor 
=17.916 min, tmajor = 22.848 min; ee% = 85%. ee% > 99%, after recrystalization. [!]D26 = 
-93.5° (c = 1.0 CHCl3). 
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Part IV 
 
O
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 35a 
2,3,6,7-tetrahydro-2-(1-phenylvinyl)-3-p-tolylbenzofuran-4(5H)-one 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 91%); 1H NMR 
(600 MHz, CDCl3) $ = 7.306-7.295 (t, J = 6.6 Hz, 3H), 7.277-7.253 (m, 2H), 7.052-7.039 
(d, J = 7.8 Hz, 2H), 6.902-6.888 (d, J = 8.4 Hz, 2H), 5.429-5.420 (d, J = 5.4 Hz, 1H), 
5.376 (s, 1H), 5.273 (s, 1H), 4.067-4.060 (d, J = 4.2 Hz, 1H), 2.693-2.645 (dt, J = 18.0 
Hz, J = 10.8 Hz, 1H), 2.594-2.538 (m, 1H), 2.363-2.259 (m, 5H), 2.123-2.075 (m, 2H); 
13C NMR (150 MHz, CDCl3): $ = 194.550, 176.803, 146.599, 139.236, 137.669, 
136.405, 129.304, 128.415, 128.124, 127.231, 126.918, 116.443, 113.018, 93.774, 
50.611, 36.810, 24.076, 21.752, 21.005; HRMS Calculated for [C23H22O2+H]+: 
331.16924, Found: 331.16946. 
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 35b 
2,3,6,7-tetrahydro-3-(4-methoxyphenyl)-2-(1-phenylvinyl)benzofuran-4(5H)-one 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 82%); 1H NMR 
(600 MHz, CDCl3) $ = 7.308-7.297 (t, J = 6.6 Hz, 3H), 7.268-7.250 (m, 2H), 6.923-6.909 
(d, J = 8.4 Hz, 2H), 6.783-6.768 (dd, J = 7.2 Hz, J = 1.8 Hz, 2H), 5.413-5.405 (d, J = 4.8 
Hz, 1H), 5.375 (s, 1H), 5.271 (s, 1H), 4.056-4.049 (d, J = 4.2 Hz, 1H), 3.753 (s, 3H), 
2.694-2.645 (dt, J = 18.0 Hz, J = 11.4 Hz, 1H), 2.597-2.541 (m, 1H), 2.370-2.264 (m, 
2H), 2.126-2.082 (m, 2H); 13C NMR (150 MHz, CDCl3): $ = 194.634, 176.810, 158.491, 
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146.596, 137.666, 134.372, 128.426, 128.142, 128.044, 127.224, 116.421, 114.031, 
112.902, 93.796, 55.173, 50.279, 36.821, 29.658, 24.087, 21.759; HRMS Calculated for 
[C23H22O3+Na]+: 369.14612, Found: 369.14627. 
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 35c 
2-(1-(4-chlorophenyl)vinyl)-2,3,6,7-tetrahydro-3-p-tolylbenzofuran-4(5H)-one 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 7.283-7.265 (m, 2H), 7.208-7.190 (m, 2H), 7.071-7.058 (d, J = 
7.8 Hz, 2H), 6.924-6.910 (d, J = 8.4 Hz, 2H), 5.389-5.381 (d, J = 4.8 Hz, 1H), 5.374 (s, 
1H), 5.295 (s, 1H), 4.035-4.028 (d, J = 4.2 Hz, 1H), 2.693-2.644 (dt, J = 18.0 Hz, J = 
11.4 Hz, 1H), 2.585-2.529 (m, 1H), 2.366-2.261 (m, 5H), 2.127-2.079 (m, 2H); 13C NMR 
(150 MHz, CDCl3): $ = 194.481, 176.614, 145.485, 139.061, 136.598, 136.114, 134.128, 
129.417, 128.627, 128.499, 126.907, 116.498, 113.703, 93.512, 50.724, 36.817, 24.062, 
21.752, 21.027. HRMS Calculated for [C23H21ClO2+H]+: 365.13028, Found: 365.13042. 
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 35d 
2,3,6,7-tetrahydro-2-(1-phenylvinyl)-3-(thiophen-2-yl)benzofuran-4(5H)-one 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 81%); 1H NMR 
(600 MHz, CDCl3) $ = 7.344-7.300 (m, 5H), 7.119-7.108 (dd, J = 5.4 Hz, J = 1.2 Hz, 
1H), 6.869-6.855 (dd, J = 4.8 Hz, J = 3.6 Hz, 1H), 6.653-6.646 (dd, J = 3.6 Hz, J = 0.6 
Hz, 1H), 5.520-5.512 (d, J = 4.8 Hz, 1H), 5.386 (s, 1H), 5.293 (s, 1H), 4.408-4.401 (d, J 
= 4.2 Hz, 1H), 2.687-2.638 (dt, J = 18.0 Hz, J = 11.4 Hz, 1H), 2.584-2.529 (m, 1H), 
2.414-2.367 (dt, J = 16.8 Hz, J = 11.4 Hz, 1H), 2.333-2.282 (m, 1H), 2.132-2.065 (m, 
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2H); 13C NMR (150 MHz, CDCl3): $ = 194.466, 177.156, 146.122, 146.042, 137.498, 
128.525, 128.291, 127.297, 126.991, 124.357, 123.985, 115.973, 113.310, 93.381, 
46.020, 36.828, 29.676, 24.131, 21.643; HRMS Calculated for [C20H18O2S+H]+: 
323.11003, Found: 323.10907. 
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 35e 
1-(4,5-dihydro-2-methyl-5-(1-phenylvinyl)-4-p-tolylfuran-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 86%); 1H NMR 
(600 MHz, CDCl3) $ = 7.334-7.313 (m, 3H), 7.301-7.278 (m, 2H), 7.079-7.066 (d, J = 
7.8 Hz, 2H), 6.897-6.884 (d, J = 7.8 Hz, 2H), 5.397 (s, 1H), 5.284-5.275 (d, J = 5.4 Hz, 
1H), 5.270 (s, 1H), 4.016-4.006 (dd, J = 4.8 Hz, J = 1.2 Hz, 1H), 2.447-2.444 (d, J = 1.8 
Hz, 3H), 2.312 (s, 3H), 1.802 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 195.285, 
168.390, 146.607, 140.278, 137.706, 136.744, 129.512, 128.485, 128.120, 127.242, 
127.187, 115.314, 112.698, 91.089, 54.684, 29.556, 21.020, 14.997; HRMS Calculated 
for [C22H22O2+H]+: 319.16924, Found: 319.16945. 
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1-(4,5-dihydro-2-methyl-4-(4-nitrophenyl)-5-(1-phenylvinyl)furan-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 94%); 1H NMR 
(600 MHz, CDCl3) $ = 8.124-8.101 (m, 2H), 7.351-7.313 (m, 3H), 7.239-7.223 (m, 2H), 
7.153-7.130 (m, 2H), 5.413 (s, 1H), 5.304 (s, 1H), 5.289-5.280 (d, J = 5.4 Hz, 1H), 
4.175-4.166 (d, J = 5.4 Hz, 1H), 2.477 (s, 3H), 1.949 (s, 3H); 13C NMR (150 MHz, 
CDCl3): $ = 193.592, 168.762, 150.837, 147.062, 146.071, 137.331, 128.670, 128.466, 
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128.182, 127.155, 124.040, 115.787, 113.007, 90.040, 54.925, 29.425, 15.230; HRMS 
Calculated for [C21H19NO4+Na]+: 372.12063, Found: 372.12077. 
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1-(4,5-dihydro-2-methyl-5-(1-phenylvinyl)-4-propylfuran-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 65%); 1H NMR 
(600 MHz, CDCl3) $ = 7.325-7.285 (m, 5H), 5.235 (s, 1H), 5.188 (s, 1H), 5.105-5.099 (d, 
J = 3.6 Hz, 1H), 3.000-2.976 (m, 1H), 2.279-2.277 (d, J = 1.2 Hz, 3H), 2.159 (s, 3H), 
1.550-1.418 (m, 2H), 1.257-1.197 (m, 1H), 1.119-1.077 (m, 1H), 0.796-0.772 (t, J = 14.4 
Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 194.328, 166.988, 147.539, 138.602, 
128.390, 127.909, 127.286, 116.505, 112.873, 87.588, 47.846, 36.355, 29.213, 18.983, 
15.289, 13.897. HRMS Calculated for [C18H22O2+H]+: 208.16925, Found: 208.16949. 
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 35h 
1-(4,5-dihydro-2-methyl-5-(1-phenylvinyl)-4-(pyridin-4-yl)furan-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 93%); 1H NMR 
(600 MHz, CDCl3) $ = 8.496-8.486 (dd, J = 4.8 Hz, J = 1.8 Hz, 2H), 7.345-7.325 (m, 
3H), 7.250-7.234 (m, 2H), 6.925-6.914 (dd, J = 4.8 Hz, J = 1.8 Hz, 2H), 5.409 (s, 1H), 
5.297-5.293 (dd, J = 1.8 Hz, J = 0.6 Hz, 1H), 5.272-5.263 (d, J = 5.4 Hz, 1H), 4.041-
4.033 (d, J = 4.8 Hz, 1H), 2.467-2.465 (d, J = 1.2 Hz, 3H), 1.918 (s, 3H); 13C NMR (150 
MHz, CDCl3): $ = 193.825, 168.966, 152.166, 150.246, 146.118, 137.363, 128.659, 
128.430, 127.173, 122.477, 115.044, 113.033, 89.985, 54.448, 29.443, 15.154; HRMS 
Calculated for [C20H19NO2+H]+: 306.1488559, Found: 306.14893. 
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1-(4-(furan-2-yl)-4,5-dihydro-2-methyl-5-(1-phenylvinyl)furan-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 89%); 1H NMR 
(600 MHz, CDCl3) $ = 7.341-7.310 (m, 6H), 6.281-6.273 (dd, J = 3.0 Hz, J = 1.8 Hz, 
1H), 5.979-5.973 (d, J = 3.6 Hz, 1H), 5.458-5.448 (dd, J = 5.4 Hz, J = 0.6 Hz, 1H), 5.436 
(s, 1H), 5.300-5.297 (dd, J = 1.2 Hz, J = 0.6 Hz, 1H), 4.201-4.192 (d, J = 5.4 Hz, 1H), 
2.395-2.393 (d, J = 1.2 Hz, 3H), 1.936 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 
194.612, 168.941, 155.056, 145.951, 141.950, 137.436, 128.492, 128.168, 126.918, 
113.164, 112.698, 110.483, 106.540, 87.606, 48.338, 29.122, 15.128; HRMS Calculated 
for [C19H18O3+Na]+: 317.11428, Found: 317.11386. 
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 35j 
methyl 4,5-dihydro-2-methyl-5-(1-phenylvinyl)-4-p-tolylfuran-3-carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 89%); 1H NMR 
(600 MHz, CDCl3) $ = 7.310-7.264 (m, 5H), 7.057-7.044 (d, J = 7.8 Hz, 2H), 6.922-
6.908 (dd, J = 6.6 Hz, J = 1.8 Hz, 2H), 5.391 (s, 1H), 5.314-5.305 (dd, J = 4.8 Hz, J = 0.6 
Hz, 1H), 5.270-5.268 (d, J = 1.2 Hz, 1H), 3.989-3.979 (dd, J = 4.8 Hz, J = 1.2 Hz, 1H), 
3.493 (s, 3H), 2.410-2.408 (d, J = 1.2 Hz, 3H), 2.300 (s, 3H); 13C NMR (150 MHz, 
CDCl3): $ = 168.212, 166.025, 146.676, 140.664, 137.757, 136.241, 129.169, 128.415, 
128.004, 127.100, 127.013, 112.235, 106.318, 90.068, 53.821, 50.684, 21.030, 14.247; 
HRMS Calculated for [C22H22O3+H]+: 335.16417, Found: 335.16429. 
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 35k 
methyl 4-(4-fluorophenyl)-4,5-dihydro-2-methyl-5-(1-phenylvinyl)furan-3-
carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 90%); 1H NMR 
(600 MHz, CDCl3) $ = 7.313-7.300 (m, 3H), 7.262-7.244 (m, 2H), 6.978-6.907 (m, 4H), 
5.396 (s, 1H), 5.396-5.289 (dd, J = 4.8 Hz, J = 0.6 Hz, 1H), 5.279-5.277 (d, J = 1.2 Hz, 
1H), 4.002-3.994 (d, J = 4.8 Hz, 1H), 3.502-3.500 (d, J = 1.2 Hz, 3H), 2.416-2.412 (t, J = 
2.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 168.492, 165.851, 162.557, 160.932, 
146.523, 139.407, 139.389, 137.659, 128.663, 128.612, 128.488, 128.138, 127.107, 
115.350, 115.208, 112.359, 106.169, 90.575, 53.631, 50.735, 14.272. HRMS Calculated 
for [C21H19FO3+H]+: 339.13909, Found: 339.13913. 
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 35l 
methyl 4,5-dihydro-2-methyl-4-phenethyl-5-(1-phenylvinyl)furan-3-carboxylate) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 71%); 1H NMR 
(600 MHz, CDCl3) $ = 7.346-7.280 (m, 5H), 7.223-7.198 (m, 2H), 7.142-7.113 (m, 1H), 
7.043-7.028 (dd, J = 8.4 Hz, J = 1.8 Hz, 2H), 5.266 (s, 1H), 5.233-5.229 (d, J = 2.4 Hz, 
1H), 5.219-5.211 (d, J = 4.8 Hz, 1H), 3.641 (s, 3H), 3.036-3.008 (m, 1H), 2.547-2.497 
(m, 1H), 2.393-2.341 (m, 1H), 2.285-2.283 (d, J = 1.2 Hz, 3H), 1.975-1.918 (m, 1H), 
1.857-1.794 (m, 1H); 13C NMR (150 MHz, CDCl3): $ = 168.015, 166.248, 147.426, 
141.786, 138.551, 128.426, 128.219, 128.182, 127.916, 127.300, 125.665, 113.051, 
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105.101, 87.741, 50.607, 47.423, 35.353, 32.004, 14.283; HRMS Calculated for 
[C23H24O3+H]+: 349.17982, Found: 349.17985. 
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 35m 
ethyl 4,5-dihydro-2-methyl-5-(1-phenylvinyl)-4-p-tolylfuran-3-carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 86%); 1H NMR 
(600 MHz, CDCl3) $ = 7.325-7.278 (m, 5H), 7.076-7.062 (d, J = 8.4 Hz, 2H), 6.884-
6.881 (d, J = 1.8 Hz, 1H), 6.871 (s, 1H), 5.391 (s, 1H), 5.286-5.285 (d, J = 0.6 Hz, 1H), 
5.272 (s, 1H), 4.009-4.001 (d, J = 4.8 Hz, 1H), 2.949-2.852 (m, 2H), 2.308 (s, 3H), 1.788 
(s, 3H), 1.314-1.289 (t, J = 15.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): $ = 195.125, 
173.130, 146.752, 140.413, 137.720, 136.693, 129.497, 128.444, 128.084, 127.195, 
127.180, 114.155, 112.490, 90.797, 54.695, 29.589, 22.025, 20.998, 11.215. HRMS 
Calculated for [C23H24O3+H]+: 349.17982, Found: 349.17985. 
 
O
OMe
O
O2N
Cl
 
35n 
methyl 5-(1-(4-chlorophenyl)vinyl)-4,5-dihydro-2-methyl-4-(4-nitrophenyl)furan-3-
carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 95%); 1H NMR 
(600 MHz, CDCl3) $ = 8.142-8.120 (m, 2H), 7.313-7.290 (m, 2H), 7.201-7.166 (m, 4H), 
5.415 (s, 1H), 5.327-5.325 (d, J = 1.2 Hz, 1H), 5.278-5.268 (d, J = 6.0 Hz, 1H), 4.092-
4.080 (dd, J = 5.4 Hz, J = 1.2 Hz, 1H), 3.508 (s, 3H), 2.431-2.429 (d, J = 1.2 Hz, 3H); 
13C NMR (150 MHz, CDCl3): $ = 169.203, 165.275, 150.851, 147.073, 144.971, 
135.826, 134.394, 128.842, 128.375, 128.084, 123.949, 113.893, 105.695, 89.293, 
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54.265, 50.939, 14.298. HRMS Calculated forC21H18ClNO5 [C21H18ClNO5+H]+: 
400.09463, Found: 400.09476. 
 
O
MeO
O
O
 
 35o 
2-(1-(furan-2-yl)vinyl)-2,3,6,7-tetrahydro-3-(4-methoxyphenyl)benzofuran-4(5H)-
one 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 83%); 1H NMR 
(600 MHz, CDCl3) $ = 7.384-7.381 (d, J = 1.8 Hz, 1H), 7.119-7.104 (d, J = 9.0 Hz, 2H), 
6.855-6.841 (d, J = 8.4 Hz, 2H), 6.352-6.343 (dd, J = 3.6 Hz, J = 2.4 Hz, 1H), 6.079-
6.073 (d, J = 3.6 Hz, 1H), 5.656 (s, 1H), 5.286-5.276 (d, J = 6.0 Hz, 1H), 5.148 (s, 1H), 
4.200-4.191 (d, J = 5.4 Hz, 1H), 3.785 (s, 3H), 2.690-2.651 (m, 1H), 2.624-2.580 (m, 
1H), 2.387-2.335 (m, 2H), 2.151-2.107 (m, 2H); 13C NMR (150 MHz, CDCl3): $ = 
194.543, 176.559, 158.637, 150.815, 142.504, 136.004, 134.431, 128.273, 116.855, 
114.155, 111.204, 109.488, 107.360, 92.178, 55.231, 50.972, 36.908, 24.025, 21.807. 
HRMS Calculated for [C21H20O4+H]+: 337.14343, Found: 337.14355. 
 
O
Me
O
O
 
 35p 
1-(5-(1-(furan-2-yl)vinyl)-4,5-dihydro-2-methyl-4-p-tolylfuran-3-yl)ethanone Purified 
by flash chromatography (hexane-EtOAc) as colorless oil (yield: 90%); 1H NMR (600 
MHz, CDCl3) $ = 7.405-7.403 (d, J = 1.2 Hz, 1H), 7.154-7.140 (d, J = 8.4 Hz, 2H), 
7.092-7.079 (d, J = 7.8 Hz, 2H), 6.377-6.368 (dd, J = 3.6 Hz, J = 1.8 Hz, 1H), 6.115-
6.109 (d, J = 3.6 Hz, 1H), 5.648 (s, 1H), 5.133 (s, 1H), 5.127 (s, 1H), 4.168-4.161 (d, J = 
4.2 Hz, 1H), 2.451-2.499 (d, J = 1.2 Hz, 3H), 2.345 (s, 3H), 1.862 (s, 3H); 13C NMR (150 
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MHz, CDCl3): $ = 195.260, 168.267, 150.910, 142.468, 140.322, 136.955, 136.241, 
129.621, 127.457, 115.747, 111.211, 109.222, 107.266, 89.675, 55.453, 29.640, 21.060, 
14.877; HRMS Calculated for [C20H20O3+Na]+: 331.13047, Found: 331.12948. 
 
O
OO2N  
 35q 
1-(4,5-dihydro-2-methyl-4-(4-nitrophenyl)-5-(prop-1-en-2-yl)furan-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 85%); 1H NMR 
(600 MHz, CDCl3) $ = 8.202-8.188 (dd, J = 6.6 Hz, J = 1.8 Hz, 2H), 7.391-7.376 (dd, J = 
6.6 Hz, J = 2.4 Hz, 2H), 4.940-4.936 (t, J = 2.4 Hz, 1H), 4.912-4.911 (d, J = 0.6 Hz, 1H), 
4.730-4.720 (d, J = 6.0 Hz, 1H), 4.274-4.263 (dd, J = 6.0 Hz, J = 1.2 Hz, 1H), 2.423-
2.421 (d, J = 1.2 Hz, 3H), 2.031 (s, 3H), 1.792 (s, 3H); 13C NMR (150 MHz, CDCl3): $ = 
193.479, 169.083, 151.157, 147.102, 141.885, 128.171, 124.182, 115.929, 113.157, 
92.845, 54.043, 29.447, 16.731, 15.154; HRMS Calculated for [C16H17NO4+H]+: 
288.123035, Found: 288.12317. 
 
O
OMeON  
 35r 
methyl 4,5-dihydro-2-methyl-5-(prop-1-en-2-yl)-4-(pyridin-4-yl)furan-3-carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 80%); 1H NMR 
(600 MHz, CDCl3) $ = 8.559 (b, 2H), 7.143-7.135 (d, J = 4.8 Hz, 2H), 4.914-4.912 (d, J 
= 1.2 Hz, 2H), 4.743-4.733 (d, J = 6.0 Hz, 1H), 4.069-4.057 (dd, J = 6.0 Hz, J = 1.2 Hz, 
1H), 3.547 (s, 3H), 2.374-2.371 (d, J = 1.8 Hz, 3H), 1.779-1.776 (t, J = 1.8 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): $ = 169.746, 165.519, 152.698, 150.057, 142.180, 122.524, 
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112.869, 104.919, 92.710, 52.928, 50.837, 16.739, 14.159; C15H17NO3 HRMS 
Calculated for [C15H17NO3+H]+: 260.12812, Found: 260.12827. 
 
O
OMeO  
 35s 
methyl 5-cyclohexenyl-4,5-dihydro-2-methyl-4-p-tolylfuran-3-carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 85%); 1H NMR 
(600 MHz, CDCl3) $ = 7.106-7.093 (d, J = 7.8 Hz, 2H), 7.073-7.060 (dd, J = 6.0 Hz, J = 
1.8 Hz, 2H), 5.613 (s, 1H), 4.681-4.672 (d, J = 5.4 Hz, 1H), 4.050-4.039 (dd, J = 5.4 Hz, 
J = 1.2 Hz, 1H), 3.540 (s, 3H), 2.333 (s, 3H), 2.315 (s, 3H), 2.035-1.993 (m, 4H), 1.708-
1.550 (m, 4H); 13C NMR (150 MHz, CDCl3): $ = 168.700, 166.208, 141.393, 136.114, 
135.964, 129.195, 127.038, 124.550, 106.158, 94.696, 52.633, 50.647, 24.878, 22.765, 
22.291, 22.284, 21.030, 14.188; HRMS Calculated for [C20H24O3+H]+: 313.17982, 
Found: 313.17986. 
 
O
O  
 35t 
1-(5-cyclohexenyl-4,5-dihydro-2-methyl-4-p-tolylfuran-3-yl)ethanone 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 83%); 1H NMR 
(600 MHz, CDCl3) $ = 7.129-7.115 (d, J = 8.4 Hz, 2H), 7.075-7.062 (t, J = 7.8 Hz, 2H), 
5.615 (s, 1H), 4.651-4.641 (d, J = 6.0 Hz, 1H), 4.098-4.087 (dd, J = 5.4 Hz, J = 0.6 Hz, 
1H), 2.372-2.370 (d, J = 1.2 Hz, 3H), 2.320 (s, 3H), 2.038-1.984 (m, 4H), 1.880 (s, 3H), 
1.714-1.572 (m, 4H); 13C NMR (150 MHz, CDCl3): $ = 195.166, 168.882, 140.938, 
136.515, 135.633, 129.494, 127.158, 124.834, 115.419, 94.976, 53.424, 29.509, 24.809, 
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22.754, 22.204, 20.943, 14.895. HRMS Calculated for [C20H24O2+H]+: 297.18490, 
Found: 297.18503. 
 
O
OEtOO  
 35u 
ethyl 5-cyclohexenyl-4-(furan-2-yl)-4,5-dihydro-2-phenylfuran-3-carboxylate 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 75%); 1H NMR 
(600 MHz, CDCl3) $ = 7.866-7.846 (m, 2H), 7.445-7.380 (m, 3H), 7.350-7.346 (dd, J = 
1.8 Hz, J = 0.6 Hz, 1H), 6.322-6.314 (dd, J = 3.0 Hz, J = 1.8 Hz, 1H), 6.150-6.145 (d, J = 
3.0 Hz, 1H), 5.779-5.778 (d, J = 0.6 Hz, 1H), 4.991-4.981 (d, J = 6.0 Hz, 1H), 4.451-
4.440 (d, J = 6.6 Hz, 1H), 4.106-4.052 (m, 1H), 4.022-3.969 (m, 1H), 2.115-2.067 (m, 
4H), 1.725-1.573 (m, 4H), 1.082-1.058 (t, J = 14.4 Hz, 3H); 13C NMR (150 MHz, 
CDCl3): $ = 165.971, 164.681, 155.963, 141.473, 135.651, 130.521, 129.836, 129.443, 
127.596, 124.910, 110.362, 105.670, 103.717, 90.058, 59.617, 48.159, 24.878, 22.918, 
22.262, 13.951; HRMS Calculated for [C23H24O4+Na]+: 387.15668, Found: 387.15550. 
 
O
O
 
 35v 
2-cyclohexenyl-2,3,6,7-tetrahydro-3-p-tolylbenzofuran-4(5H)-one 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 92%); 1H NMR 
(600 MHz, CDCl3) $ = 7.103-7.089 (d, J = 8.4 Hz, 2H), 7.060-7.046 (t, J = 8.4 Hz, 2H), 
5.659 (s, 1H), 4.834-4.825 (d, J = 5.4 Hz, 1H), 4.112-4.103 (d, J = 5.4 Hz, 1H), 2.619-
2.493 (m, 2H), 2.386-2.281 (m, 5H), 2.112-2.037 (m, 4H), 1.978-1.976 (d, J = 1.2 Hz, 
2H), 1.732-1.548 (m, 4H); 13C NMR (150 MHz, CDCl3): $ = 194.499, 177.317, 139.743, 
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136.262, 135.363, 129.304, 126.958, 125.461, 116.476, 97.691, 49.197, 36.825, 24.882, 
24.022, 22.710, 22.185, 21.766, 20.990; HRMS Calculated for [C21H24O2+H]+: 
309.18491, Found: 309.18498. 
O
O
Ph
Me  
 35a´ 
2,3,6,7-tetrahydro-2-(1-phenylvinyl)-3-p-tolylbenzofuran-4(5H)-one (cis) 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 12%); 1H NMR 
(600 MHz, CDCl3) $ = 7.26-7.16 (m 3H), 6.93-6.90 (m, 2H), 6.82-6.80 (d, J = 7.8 Hz, 
2H), 6.54-6.52 (d, J = 7.8 Hz, 2H), 5.95-5.93 (dt, J = 9.6 Hz, J = 1.8 Hz, 1H), 5.27 (t, J = 
1.8 Hz, 1H), 5.22 (t, J = 1.2 Hz, 1H), 4.33-4.31 (dd, J = 9.6 Hz, J = 1.8 Hz, 1H), 2.75- 
2.70 (m, 1H), 2.66-2.60 (m, 1H), 2.40-2.31 (m, 2H), 2.21 (s, 3H), 2.18-2.11 (m, 2H). 13C 
NMR (150 MHz, CDCl3): $ = 194.4, 176.7, 143.3, 13836, 134.6, 128.5, 128.1, 127.8, 
126.1, 118.3, 114.1, 89.3, 48.0, 36.9, 24.0, 21.8, 21.03. HRMS Calculated for 
[C23H22O2+H]+: 331.16924, Found: 331.16946. 
O
O
Me
Ph
Me  
 36a 
Purified by flash chromatography (hexane-EtOAc) as colorless oil (yield: 12%); 1H NMR 
(600 MHz, CDCl3) $ = 7.50-7.48 (m, 2H), 7.36-7.35 (m, 2H), 7.34-7.27 (m, 1H), 7.12 
(m, 4H), 5.55 (s, 1H), 2.63-2.59 (m, 1H), 2.50-2.44 (M, 1H), 2.38-2.33 (m, 4H), 2.24-
2.19 (m, 1H), 2.05-1.95 (m, 2H), 1.78 (s, 3H). 13C NMR (150 MHz, CDCl3): $ = 193.5, 
173.3, 144.6, 136.7, 136.6, 134.2, 128.4, 128.3, 127.8, 126.9, 125.0, 122.2, 113.9, 81.4, 
37.5, 29.4, 29.1, 21.2, 20.0. HRMS Calculated for [C23H22O2+H]+: 331.16924, Found: 
331.16946. 
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Part V 
 
N
Me
OH
Ph
O2N Ph
39a-major  
 
(2R, 3R, 4S)-1-benzyl-4-methyl-3-nitro-2-phenylpiperidin-4-ol (39a-major) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as white solid, 
yiled: 85%, m.p: 177.7-179.2?. 1H NMR (600 MHz, CDCl3): $ 7.45-7.52(m, 2H), 7.22-
7.40(m, 8H), 4.71(d, J = 10.2 Hz, 1H), 4.10(d, J = 10.2 Hz, 1H), 3.73(d, J = 13.2 Hz, 
1H), 3.10(d, J = 2.4 Hz, 1H), 2.99(d, J = 13.2 Hz, 1H), 2.77(dq, J = 12.0 Hz, J = 2.4 Hz, 
1H), 2.65(td, J = 12.6 Hz, J = 3.0 Hz, 1H), 1.85(dt, J = 14.4 Hz, J = 3.0 Hz, 1H), 1.74-
1.78(m, 1H), 1.32(s, 3H). 13C NMR (600 MHz, CDCl3): $ 138.7, 137.6, 128.9, 128.8, 
128.5, 128.3, 128.2, 127.0, 97.9, 69.0, 66.2, 58.5, 46.7, 36.7, 27.1. HRMS Calculated for 
C19H23N2O3 [M+H]+: 327.17032, Found: 327.17023. 
 
N
HO
Me
Ph
O2N Ph
39a-minor  
 
(2R, 3R, 4R)-1-benzyl-4-methyl-3-nitro-2-phenylpiperidin-4-ol (39a-minor) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as white solid, 
yiled: 12%, m.p: 169.8-171.4?. 1H NMR (600 MHz, CDCl3): $ 7.40-7.50(m, 2H), 7.18-
7.37(m, 8H), 4.83(d, J = 10.2Hz, 1H), 3.82(d, J = 10.2 Hz, 1H), 3.66(d, J = 13.2 Hz, 1H), 
2.92(d, J = 13.2 Hz, 1H), 2.43(s, 1H), 2.21(t, J = 12.0 Hz, 1H), 1.97(t, J = 12.0 Hz, 1H), 
1.85(dt, J = 13.2 Hz, J = 3.0 Hz, 1H), 1.42(s, 3H). 13C NMR (600 MHz, CDCl3): $ 138.3, 
138.0, 128.9, 128.7, 128.5, 128.3, 127.1, 98.8, 71.6, 67.4, 58.2, 48.7, 38.9, 21.4. HRMS 
Calculated for C19H23N2O3 [M+H]+: 327.17032, Found: 327.17031. 
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N
Me
OH
O2N Ph
39b-major Cl  
 
(2R,3R,4S)-1-benzyl-2-(4-chlorophenyl)-4-methyl-3-nitropiperidin-4-ol (4b-major) 
was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless 
oil, yiled: 86%. 1H NMR (600 MHz, CDCl3): $ 7.16-7.42(m, 9H), 4.61(d, J = 10.2Hz, 
1H), 4.06(d, J = 10.2Hz, 1H), 3.64(d, J = 13.2Hz, 1H), 2.99(d, J = 2.4Hz, 1H), 2.96(d, J 
= 13.2Hz, 1H), 2.73(dq, J = 12.0Hz, J = 2.4Hz, 1H), 2.61(td, J = 12.6Hz, J = 3.0Hz, 1H), 
1.81(dt, J = 13.8Hz, J = 3.0Hz, 1H), 1.64-1.72(m, 1H), 1.28(s, 3H). 13C NMR (600 MHz, 
CDCl3): $ 138.3, 136.2, 134.5, 129.6, 129.2, 128.4, 128.2, 127.1, 97.7, 69.0, 65.5, 58.5, 
46.6, 36.6, 27.1. HRMS Calculated for C19H22ClN2O3 [M+H]+: 361.13135, Found: 
361.13148. 
 
N
HO
Me
O2N Ph
39b-minor Cl  
 
(2R,3R,4R)-1-benzyl-2-(4-chlorophenyl)-4-methyl-3-nitropiperidin-4-ol (39b-minor) 
was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless 
oil, yiled: 10%. 1H NMR (600 MHz, CDCl3): $ 7.14-7.46(m, 9H), 4.74(d, J = 10.2Hz, 
1H), 3.80(d, J = 10.2Hz, 1H), 3.61(d, J = 13.2Hz, 1H), 2.92(dt, J = 12.6Hz, J = 3.0Hz, 
2H), 2.40(s, 1H), 2.20(td, J = 12.6Hz, J = 3.0Hz, 1H), 1.94(td, J = 13.2Hz, J = 4.2Hz, 
1H), 1.84(dt, J = 13.2Hz, J = 3.0Hz, 1H), 1.39(s, 3H). 13C NMR (600 MHz, CDCl3): 
$.138.0, 136.6, 134.5, 130.0, 129.2, 128.4, 128.3, 127.2, 98.7, 71.6, 66.7, 58.2, 48.7, 38.8, 
21.4. HRMS Calculated for C19H22ClN2O3 [M+H]+: 361.13135, Found: 361.13142. 
 
 208 
N
Me
OH
O2N Ph
39c-major OMe  
 
(2R,3R,4S)-1-benzyl-2-(4-methoxyphenyl)-4-methyl-3-nitropiperidin-4-ol (39c-
major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as 
white solid, yiled: 84%, m.p: 142.4-144.9?. 1H NMR (600 MHz, CDCl3): $ 7.24-
7.41(m, 7H), 6.91(d, J = 8.4 Hz, 2H), 4.69(d, J = 10.8 Hz, 1H), 4.06(d, J = 10.8 Hz, 1H), 
3.78(s, 3H), 3.75(d, J = 13.2 Hz, 1H), 3.13(s, 1H), 2.98(d, J = 13.2 Hz, 1H), 2.75-2.78(m, 
1H), 2.62-2.67(m, 1H), 1.81-1.85(m, 1H), 1.70-1.74(m, 1H), 1.32(s, 3H). 13C NMR (600 
MHz, CDCl3): $ 159.7, 138.7, 129.3, 128.4, 128.1, 126.8, 114.3, 97.9, 69.0, 65.4, 58.2, 
55.0, 46.7, 36.7, 27.1. HRMS Calculated for C20H25N2O4 [M+H]+: 357.18088, Found: 
357.18083. 
 
N
HO
Me
O2N Ph
39c-minor OMe  
(2R,3R,4R)-1-benzyl-2-(4-methoxyphenyl)-4-methyl-3-nitropiperidin-4-ol(39c-
minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as 
white solid, yiled: 10%, m.p: 147.3-148.8?. 1H NMR (600 MHz, CDCl3): $ 7.19-
7.41(m, 7H), 6.87(d, J = 8.4 Hz, 2H), 4.79(d, J = 10.2 Hz, 1H), 3.78(s, 3H), 3.76(d, J = 
10.2 Hz, 1H), 3.69(d, J = 13.8 Hz, 1H), 2.88-2.93(m, 2H), 2.44(s, 1H), 2.16-2.24(m, 1H), 
1.90-1.98(m, 1H), 1.80-1.1.87(m, 1H), 1.41(s, 3H). 13C NMR (600 MHz, CDCl3): $ 
159.7, 138.4, 129.8, 128.5, 128.2, 127.0, 114.3, 98.9, 71.6, 66.8, 58.0, 55.2, 48.7, 38.9, 
21.4. HRMS Calculated for C20H25N2O4 [M+H]+: 357.18088, Found: 357.18081. 
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O2N
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39d-major  
 
(2R,3R,4S)-1-benzyl-4-methyl-3-nitro-2-pentylpiperidin-4-ol (39d-major) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 15/1) as colorless oil, 
yiled: 70%. 1H NMR (600 MHz, CDCl3): $ 7.23-7.34(m, 5H), 4.59(d, J = 10.2Hz, 1H), 
3.93(d, J =13.2Hz, 1H), 3.30-3.35(m, 1H), 3.28(d, J = 13.2Hz, 1H), 3.15(d, J = 1.8Hz, 
1H), 2.55-2.65(m, 2H), 1.20-1.75(m, 13H), 0.87(t, J = 7.2Hz, 3H). 13C NMR (600 MHz, 
CDCl3): $ 138.8, 128.5, 128.4, 127.1, 93.4, 69.22, 58.8, 54.2, 45.8, 35.1, 31.9, 28.4, 27.3, 
22.7, 22.4, 13.9. HRMS Calculated for C18H29N2O3 [M+H]+: 321.21727, Found: 
321.21740. 
 
N
Me
OH
O2N
Ph
39e  
 
(2R,3R,4S)-1-cyclohexyl-4-methyl-3-nitro-2-phenylpiperidin-4-ol (39e) was purified 
by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as white solid, yiled: 85%, 
m.p: 143.3-144.5?. 1H NMR (600 MHz, CDCl3): $ 7.24-7.35(m, 5H), 4.60(d, J = 
10.2Hz, 1H), 4.28(d, J = 10.2Hz, 1H), 3.08(d, J = 2.4Hz, 1H), 2.89(td, J = 12.0Hz, J = 
2.4Hz, 1H), 2.77-2.83(m, 1H), 2.18-2.224(m, 1H), 1.89(dt, J = 13.8Hz, J = 3.0Hz, 1H), 
1.60-1.76(m, 4H), 1.38-1.50(m, 3H), 1.27(s, 3H), 1.18(dq, J = 12.0Hz, J = 3.6Hz, 1H), 
0.90-1.01(m, 2H), 0.70-0.78(m, 1H). 13C NMR (600 MHz, CDCl3): $ 137.2, 128.6, 128.4, 
128.1, 98.3, 68.9, 63.5, 57.7, 39.9, 37.2, 31.6, 27.2, 26.3, 26.1, 25.5, 24.1. HRMS 
Calculated for C18H27N2O3 [M+H]+: 319.20162, Found: 319.20155. 
 
 210 
N
Me
OH
O2N
39f Cl  
 
(2R,3R,4S)-2-(4-chlorophenyl)-1-cyclohexyl-4-methyl-3-nitropiperidin-4-ol (39f) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as white solid, 
yiled: 90%, m.p: 161.4-163.5?. 1H NMR (600 MHz, CDCl3): $ 7.22-7.24(m, 4H), 
5.43(d, J = 10.2Hz, 1H), 4.27(d, J = 10.2Hz, 1H), 2.98(d, J = 1.8Hz, 1H), 2.88(td, J 
=12.0Hz, J = 2.4Hz, 1H), 2.79(dq, J = 12.0Hz, J = 2.4Hz, 1H), 2.17(tt, J = 12.0Hz, J = 
3.0Hz, 1H), 1.89(dt, J = 13.8Hz, J = 3.0Hz, 1H), 1.62-1.72(m, 4H), 1.38-1.50(m, 3H), 
1.14-1.23(m 1H), 0.91-1.04(m, 2H), 0.73-0.82(m, 1H). 13C NMR (600 MHz, CDCl3): $ 
136.0, 134.1, 129.5, 129.0, 98.3, 69.0, 62.9, 58.0, 39.8, 37.2, 31.7, 27.2, 26.4, 26.1, 25.5, 
24.1. HRMS Calculated for C18H26ClN2O3 [M+H]+: 353.16265, Found: 353.16285. 
 
N
Me
OH
O2N
39g OMe  
 
(2R,3R,4S)-1-cyclohexyl-2-(4-methoxyphenyl)-4-methyl-3-nitropiperidin-4-ol (39g) 
was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as white solid, 
yiled: 93%, m.p:152.3-154.1?. 1H NMR (600 MHz, CDCl3): $ 7.20(d, J = 8.4Hz, 1H), 
6.82(d, J = 8.4Hz, 1H), 4.57(d, J = 10.2Hz, 1H), 4.21(d, J = 10.2Hz, 1H), 3.77(s, 3H), 
3.05(d, J = 1.8Hz, 1H), 2.86(t, J = 12.0Hz, 1H), 2.78(t, J = 12.0Hz, 1H), 2.22(t, J = 
10.2Hz, 1H), 1.87(dt, J = 13.8Hz, J = 2.4Hz, 1H), 1.58-1.72(m, 4H), 1.35-1.48(m, 3H), 
1.26(s, 3H), 1.14(qd, J = 12.0Hz, J = 3.0Hz, 1H), 0.90-1.02(m, 2H), 0.72-0.80(m, 1H). 
13C NMR (600 MHz, CDCl3): $ 159.4, 129.3, 129.0, 114.1, 98.4, 69.0, 62.9, 57.6, 55.0, 
40.0, 37.2, 31.7, 27.3, 26.4, 26.1, 25.6, 24.1. HRMS Calculated for C19H29N2O4 [M+H]+: 
349.21219, Found: 349.21207. 
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O
N
Me
OH
O2N
39h  
 
(2S,3R,4S)-1-cyclohexyl-2-(furan-2-yl)-4-methyl-3-nitropiperidin-4-ol (39h) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as white solid, 
yiled: 82%, m.p > 130?(decomposed). 1H NMR (600 MHz, CDCl3): $ 7.40(s, 1H), 
6.27(d, J = 1.2Hz, 2H), 4.89(d, J = 10.2Hz, 1H), 4.43(d, J = 10.2Hz, 1H), 2.99(br, 1H), 
2.74-2.85(m, 2H), 2.03(tt, J = 12.0Hz, J = 3.0Hz, 1H), 1.86(dt, J = 13.8Hz, J = 3.0Hz, 
1H), 1.75-1.80(m, 1H), 1.65-1.73(m, 3H), 1.49-1.56(m, 2H), 1.40(qd, J = 12.0Hz, J = 
33.6Hz, 1H).1.03-1.18(m, 1H), 0.98(qt, J = 13.2Hz, J = 3.6Hz, 1H), 0.89(qt, J = 13.2Hz, 
J = 3.6Hz, 1H). 13C NMR (600 MHz, CDCl3): $ 149.6, 143.1, 110.7, 110.1, 95.1, 69.1, 
59.1, 56.9, 40.0, 37.1, 31.6, 27.2, 26.5, 26.1, 25.7, 24.5. HRMS Calculated for 
C16H25N2O4 [M+H]+: 309.18088, Found: 309.18092. 
 
S
N
Me
OH
O2N
39i  
 
(2S,3R,4S)-1-cyclohexyl-4-methyl-3-nitro-2-(thiophen-2-yl)piperidin-4-ol (39i) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 6/1) as white solid, 
yiled: 84%, m.p: 139.5-141.7?. 1H NMR (600 MHz, CDCl3): $ 7.27-7.29(m, 1H), 
6.91(dd, J = 3.6Hz, J = 1.2Hz, 1H), 6.86(dd, J = 5.4Hz, J = 3.6Hz, 1H), 4.62(d, J = 
10.2Hz, 1H), 4.59(d, J = 10.2Hz, 1H), 2.99(d, J = 1.8Hz, 1H), 2.88(td, J = 12.0Hz, J = 
3.0Hz, 1H), 2.76(dq, J = 12.0Hz, J = 3.0Hz, 1H), 2.41(tt, J = 12.0Hz, J = 3.0Hz, 1H), 
1.87(dt, J = 13.8Hz, J = 2.4Hz, 1H), 1.64-1.78(m, 4H), 1.47-1.53(m, 2H), 1.40(qd, J = 
12.0Hz, J = 3.6Hz, 1H), 1.26(s, 3H), 1.19(qd, J = 12.0Hz, J = 3.6Hz, 1H), 0.93-1.08(m, 
2H), 0.86(qt, J = 12.6Hz, J = 3.6Hz, 1H). 13C NMR (600 MHz, CDCl3): $ 141.4, 127.4, 
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126.24, 126.16, 99.2, 69.0, 58.9, 58.0, 39.9, 36.9, 31.6, 27.11, 26.4, 26.1, 25.6, 24.1. 
HRMS Calculated for C16H25N2O3S [M+H]+: 325.15804, Found: 325.15803. 
 
N
Me
OH
O2N
Ph
39j  
 
(2R,3R,4S)-1-butyl-4-methyl-3-nitro-2-phenylpiperidin-4-ol (39j) was purified by 
flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as white solid, yiled: 93%, m.p: 
76.1-78.8 ?. 1H NMR (600 MHz, CDCl3): $ 7.26-7.32(m, 5H), 4.58(d, J = 10.2Hz, 1H), 
3.95(d, J = 10.2H, 1H), 3.09(br, 1H), 2.91(dq, J = 12.0Hz, J = 2.4Hz, 1H), 2.72(td, J = 
12.6Hz, J = 3.0Hz, 1H), 2.32-2.38(m, 1H), 2.01-2.07(m, 1H), 1.91(dt, J = 14.4Hz, J = 
3.0Hz, 1H), 1.77(td, J = 12.6Hz, J = 3.0Hz, 1H), 1.26-1.40(m, 2H), 1.29(s, 3H), 1.15-
1.19(m, 1H), 0.99-1.08(m, 1H), 0.75(t, J = 7.2Hz, 3H). 13C NMR (600 MHz, CDCl3): $ 
137.5, 128.7, 128.5, 128.4, 97.9, 68.9, 65.9, 53.7, 46.5, 36.9, 28.1, 27.2, 20.2, 13.8. 
HRMS Calculated for C16H25N2O3 [M+H]+: 293.18597, Found: 297.18593. 
 
N
Me
OH
O2N
39k  
 
(2R,3R,4S)-1-butyl-4-methyl-3-nitro-2-pentylpiperidin-4-ol (39k) was purified by 
flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as light-yellow oil, yiled: 
68%. 1H NMR (600 MHz, CDCl3): $ 4.47(d, J = 10.2Hz, 1H), 3.21(dt, J = 10.2Hz, J = 
4.2Hz, 1H), 3.16(br, 1H), 2.81(td, J = 12.0Hz, J =3.0Hz, 1H), 2.73(dq, J = 12.6Hz, J = 
2.4Hz, 1H), 2.55-2.61(m, 1H), 2.36-2.42(m, 1H), 1.71(dt, J = 13.8Hz, J = 3.0Hz, 1H), 
1.52-1.64(m, 3H), 1.19-1.50(m, 19H), 0.92(t, J = 7.2Hz, 3H), 0.88(t, J = 7.2Hz, 3H). 13C 
NMR (600 MHz, CDCl3): $ 93.5, 69.1, 58.0, 49.9, 45.9, 35.4, 32.0, 28.2, 27.9, 27.4, 22.8, 
22.4, 20.6, 14.02, 13.96. HRMS Calculated for C15H31N2O3 [M+H]+: 287.23460, Found: 
287.23303. 
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O2N Ph
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39m  
 
(2R,3R,4R,6R)-3-nitro-2,4,6-triphenylpiperidin-4-ol (39m) was purified by flash silica 
gel chromatography (Hexane-EtOAc, v/v 10/1) as white solid, yiled: 83%, m.p: 153.5-
155.2?. 1H NMR (600 MHz, CDCl3): $ 7.41-7.57(m, 6H), 7.22-7.40(m, 9H), 5.22(d, J = 
10.2Hz, 1H), 4.90(d, J = 10.2Hz, 1H), 4.64(dd, J = 10.2Hz, J = 3.0Hz, 1H), 4.31(d, J 
=3.0Hz, 1H), 2.17(dd, J = 13.8Hz, J = 2.4Hz, 1H), 2.01-2.07(m, 2H). 13C NMR (600 
MHz, CDCl3): $ 142.8, 142.3, 138.00, 1129.1, 128.9, 128.7, 128.6, 128.1, 127.7, 127.6, 
126.8, 124.5, 95.6, 74.9, 61.2, 56.4, 48.2. HRMS Calculated for C23H23N2O3 [M+H]+: 
375.17032, Found: 375.17041. 
 
NH
Ph
OH
O2N
Ph
39n Cl  
 
(2R,3R,4R,6R)-2-(4-chlorophenyl)-3-nitro-4,6-diphenylpiperidin-4-ol (39n) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless oil, 
yiled: 81%. 1H NMR (600 MHz, CDCl3): $ 7.46-7.52(m, 6H), 7.32-7.38(m, 6H), 7.24-
7.30(m, 2H), 5.16(d, J = 10.2Hz, 1H), 4.89(d, J = 10.2Hz, 1H), 4.62(dd, J = 10.2Hz, J = 
3.0Hz, 1H), 2.16(dd, J = 14.4Hz, J = 3.0Hz, 1H), 2.00-2.07(m, 2H). 13C NMR (600 MHz, 
CDCl3): $ 142.6, 142.1, 136.6, 134.9, 129.1, 128.9, 128.7, 128.6, 128.2, 127.77, 126.66, 
124.4, 95.5, 74.9, 60.5, 56.3, 48.1. HRMS Calculated for C23H22ClN2O3 [M+H]+: 
409.13135, Found: 409.13141. 
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(2R,3R,4R,6R)-3-nitro-2-pentyl-4,6-diphenylpiperidin-4-ol (39o) was purified by flash 
silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless oil, yiled: 65%. 1H 
NMR (600 MHz, CDCl3): $ 7.27-7.51(m, 10H), 4.76(d, J = 3.0Hz, 1H), 4.27(dd, J = 
12.0Hz, J = 3.0Hz, 1H), 3.64(td, J = 7.2Hz, J = 3.0Hz, 1H), 3.02(dd, J = 13.8Hz, J = 
12.0Hz, 1H), 1.96(dd, J = 13.8Hz, J = 3.0Hz, 1H), 1.25-1.56(m, 9H), 0.90(t, J = 7.2Hz, 
3H). 13C NMR (600 MHz, CDCl3): $ 143.2, 142.4, 128.9, 128.8, 128.7, 127.5, 126.6, 
125.4, 91.0, 73.1, 55.13, 55.12, 38.6, 32.5, 31.6, 25.9, 22.4, 14.0. HRMS Calculated for 
C22H29N2O3 [M+H]+: 349.21727, Found: 349.21722. 
N
Me
OH
O2N Ph
O
39r-major  
 
(2R,3R,4S)-1-(4-methoxybenzyl)-4-methyl-3-nitro-2-phenylpiperidin-4-ol(39r-
major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as 
white solid, yiled: 79%, m.p: 130.1-131.9?. 1H NMR (600 MHz, CDCl3): $ 7.29-
7.46(m, 5H), 7.12(d, J = 8.4 Hz, 2H), 6.83(d, J = 8.4 Hz, 2H), 4.67(d, J = 10.2 Hz, 1H), 
4.05(d, J = 10.2 Hz, 1H), 3.78(s, 3H), 3.64(d, J = 13.2 Hz, 1H), 3.08(d, J = 2.4 Hz, 1H), 
2.92(d, J = 13.2 Hz, 2H), 2.73-2.78(m, 1H), 2.61(td, J = 12.0Hz, J = 2.4Hz, 1H), 1.84(dt, 
J = 13.8Hz, J = 2.4Hz, 1H), 1.68-1.74(m, 1H), 1.30(s, 3H). 13C NMR (600 MHz, CDCl3): 
$ 158.7, 137.7, 130.5, 129.7, 128.9, 128.7, 128.3, 113.6, 97.9, 69.0, 66.1, 57.8, 55.2, 46.5, 
36.7, 27.1. HRMS Calculated for C20H25N2O4 [M+H]+: 357.18088, Found: 357.18078. 
 
N
HO
Me
O2N Ph
O
39r-minor  
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(2R,3R,4R)-1-(4-methoxybenzyl)-4-methyl-3-nitro-2-phenylpiperidin-4-ol (4o-
minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as 
white solid, yiled: 11%, m.p: 152.1-153.8?. 1H NMR (600 MHz, CDCl3): $ 7.26-
7.49(m, 5H), 7.09(d, J = 8.4 Hz, 2H), 6.81(d, J = 8.4 Hz, 2H), 4.81(d, J = 5.4 Hz, 1H), 
3.77-3.82(m, 1H), 3.78(s, 1H), 3.59(d, J = 13.2 Hz, 1H), 2.93(d, J = 12.6 Hz, 1H), 2.88(d, 
J = 12.6 Hz, 1H), 2.50(br, 1H), 2.20(t, J = 12.0 Hz, 1H), 1.90-2.02(m, 1H), 1.85(dt, J = 
13.2 Hz, J = 2.4Hz, 1H), 1.40(s, 3H). 13C NMR (600 MHz, CDCl3): $ 158.8, 129.7, 
129.2, 128.8, 128.7, 127.6, 113.7, 98.8, 71.6, 67.3, 57.5, 55.2, 48.5, 38.8, 21.4. HRMS 
Calculated for C20H25N2O4 [M+H]+: 357.18088, Found: 357.18090. 
 
NH
Ph
OH
O2N
Ph
39q
O
 
 
(2S,3R,4R,6R)-2-(furan-2-yl)-3-nitro-4,6-diphenylpiperidin-4-ol (39q) was purified by 
flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless oil, yield: 75%. 
1H NMR (600 MHz, CDCl3): $ 7.51-7.54(m, 2H), 7.41-7.46(m, 3H), 7.24-7.39(m, 6H), 
6.40(d, J = 3.00Hz, 1H), 6.33(dd, J = 3.0Hz, J = 1.8Hz, 1H), 5.43(d, J = 10.2Hz, 1H), 
5.07(d, J = 10.2Hz, 1H), 4.61(dd, J = 11.4Hz, J = 3.0Hz, 1H), 4.24(d, J = 3.0Hz, 1H), 
2.17(dd, J = 13.8Hz, J = 3.0Hz, 1H), 2.00-2.09(m, 2H). 13C NMR (600 MHz, CDCl3): $ 
150.7, 143.2, 142.12, 142.06, 128.8, 128.6, 128.2, 127.7, 126.7, 124.4, 110.3, 108.7, 92.8, 
74.9, 56.0, 54.8, 47.7. HRMS Calculated for C21H21N2O4 [M+H]+: 365.14958, Found: 
365.14957. 
 
N
Me
HO
O2N
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39t-major
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Me
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(2R,3R,4S,5S)-1-benzyl-4,5-dimethyl-3-nitro-2-phenylpiperidin-4-ol (39t-major) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as colorless oil, 
yield: 53%. 1H NMR (600 MHz, CDCl3): $ 7.25-7.62(m, 10H), 5.21(d, J = 10.2Hz, 1H), 
4.09(d, J = 10.2Hz, 1H), 4.04(d, J = 11.4Hz, 1H), 3.73(dd, J = 13.8Hz, J = 10.2Hz, 1H), 
2.99(d, J = 13.8Hz, 1H), 2.88(dd, J = 12.0Hz, J = 3.6Hz, 1H), 2.31-2.40(m, 1H), 2.22(t, J 
= 12.0Hz, 1H), 1.21(s, 3H), 1.00(d, J = 6.6Hz, 3H). 13C NMR (600 MHz, CDCl3): $ 
139.8, 138.6, 138.5, 128.8, 128.6, 128.54, 128.48, 128.36, 128.2, 127.1, 127.0, 94.2, 67.2, 
59.0, 58.3, 55.0, 44.6, 34.4, 15.9, 11.6. HRMS Calculated for C20H25N2O3 [M+H]+: 
341.18597, Found: 341.18594. 
 
N
HO
Me
O2N
Ph
39t-minor
Ph
Me
 
 
(2R,3R,4R,5S)-1-benzyl-4,5-dimethyl-3-nitro-2-phenylpiperidin-4-ol (4q-minor) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as white solid, 
yield: 22%. m.p: 195.3-197.4?. 1H NMR (600 MHz, CDCl3): $ 7.20-7.50(m, 10H), 
4.70(d, J =10.2Hz, 1H), 4.11(d, J =10.2Hz, 1H), 3.70(d, J = 13.8Hz, 1H), 2.96(d, J = 
13.8Hz, 1H), 2.91(d, J = 1.8Hz, 1H), 2.63(dd, J = 12.0Hz, J = 4.2Hz, 1H), 2.41(t, J = 
12.0Hz, 1H), 1.75-1.781(m, 1H), 1.27(s, 3H), 0.96(d, J = 6.6Hz, 3H). 13C NMR (600 
MHz, CDCl3): $ 138.7, 137.7, 129.0, 128.8, 128.5, 128.2, 127.0, 98.9, 70.7, 66.2, 58.4, 
54.1, 38.6, 23.8, 11.5. HRMS Calculated for C20H25N2O3 [M+H]+: 341.18597, Found: 
341.18589. 
 
S
N
Me
OH
O2N
39l-major  
 
(2S,3R,4S)-1-butyl-4-methyl-3-nitro-2-(thiophen-2-yl)piperidin-4-ol (39l-major) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless oil, 
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yield: 85%. 1H NMR (600 MHz, CDCl3): $ 7.27(d, J = 4.8Hz, 1H), 6.91(d, J = 4.8Hz, 
1H), 6.85-6.88(m, 1H), 4.57(d, J = 10.2Hz, 1H), 4.31(d, J = 10.2Hz, 1H), 3.04(br, 1H), 
2.90(dq, J = 12.0Hz, J = 2.4Hz, 1H), 2.70(td, J = 15.6Hz, J = 3.0Hz, 1H), 2.54(, dt, J = 
13.2Hz, J = 8.4Hz, 1H), 2.08-2.14(m, 1H), 1.88(dt, J = 13.8Hz, J = 2.4Hz, 1H), 1.75(td, J 
= 13.2Hz, J = 4.8Hz, 1H), 1.36-1.42(m, 1H), 1.28(s, 3H), 1.06-1.22(m 2H), 0.79(t, J = 
7.2Hz, 3H). 13C NMR (600 MHz, CDCl3): $ 141.6, 127.5, 126.2, 98.7, 68.9, 61.4, 53.9, 
46.6, 36.6, 28.2, 27.1, 20.2, 13.9. HRMS Calculated for C14H23N2O3 [M+H]+: 299.14239, 
Found: 299.14237. 
 
S
N
HO
Me
O2N
39l-minor  
 
(2S,3R,4R)-1-butyl-4-methyl-3-nitro-2-(thiophen-2-yl)piperidin-4-ol (39l-minor) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as colorless oil, 
yield: 5%. 1H NMR (600 MHz, CDCl3): $ 7.26(d, J = 5.4Hz, 1H), 6.97(d, J = 3.0Hz, 1H), 
6.87-6.89(m, 1H), 4.70(d, J = 10.2Hz, 1H), 4.06(d, J = 10.2Hz, 1H), 3.08(dt, J = 12.6Hz, 
J = 3.6Hz, 1H), 2.52(dt, J = 13.2Hz, J = 6.4Hz, 1H), 2.37(br, 1H), 2.30(td, J = 12.6Hz, J 
= 3.0Hz, 1H), 2.04-2.09(m, 1H), 2.00(td, J = 12.6Hz, J = 3.0Hz, 1H), 1.91(dt, J = 
13.2Hz, J = 3.0Hz, 1H), 1.34-1.40(m, 4H), 1.07-1.23(m, 2H), 0.79(t, J = 7.8Hz, 3H). 13C 
NMR (600 MHz, CDCl3): $ 141.9, 127.9, 126.3, 126.1, 99.7, 71.4, 62.6, 53.6, 48.5, 38.8, 
28.1, 21.4, 20.2, 13.9. HRMS Calculated for C14H23N2O3 [M+H]+: 299.14239, Found: 
299.14234. 
 
NH
Ph
OH
O2N
Ph
39p OMe  
 
(2R,3R,4R,6R)-2-(4-methoxyphenyl)-3-nitro-4,6-diphenylpiperidin-4-ol (39p) was 
purified by flash silica gel chromatography (Hexane-EtOAc, v/v 8/1) as colorless oil, 
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yield: 80%. 1H NMR (600 MHz, CDCl3): $ 7.52(d, J = 8.4Hz, 2H), 7.44-7.49(m, 4H), 
7.24-7.37(m, 6H), 6.89(d, J = 8.4Hz, 1H), 5.18(d, J = 10.2Hz, 1H), 4.85(d, J = 10.2Hz, 
1H), 4.62(dd, J = 11.4Hz, J = 3.0Hz, 1H), 4.30(d, J = 3.0Hz, 1H), 3.79(s, 3H), 2.15(dd, J 
= 13.8Hz, J = 3.0Hz, 1H), 2.00-2.06(m, 2H). 13C NMR (600 MHz, CDCl3): $ 160.1, 
1142.9, 142.4, 130.0, 128.7, 128.5, 128.1, 127.6, 126.7, 124.4, 114.2, 95.7, 74.9, 60.6, 
56.4, 55.2, 48.2. HRMS Calculated for C24H25N2O4 [M+H]+: 405.18088, Found: 
405.18082. 
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(2S,3S,4R)-4-methyl-3-nitro-2-phenyl-1-((S)-1-phenylethyl)piperidin-4-ol (41a-
major) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as 
colorless oil, yield: 55%. 1H NMR (600 MHz, CDCl3): $ 7.20-7.55(m, 10H), 4.75(d, J = 
10.2Hz, 1H), 4.39(d, J = 10.2Hz, 1H), 3.81(q, J = 7.2Hz, 1H), 3.06(d, J = 3.0Hz, 1H), 
2.89(td, J = 12.0Hz, J = 2.4Hz, 1H), 2.38(dq, J = 12.0Hz, J = 2.4Hz, 1H), 1.79(dt, J = 
13.8Hz, J = 2.4Hz, 1H), 1.57-1.65(m, 1H), 1.31(s, 3H), 1.28(d, J = 7.2Hz, 3H). 13C NMR 
(600 MHz, CDCl3): $ 143.3, 136.9, 129.0, 128.8, 128.0, 127.4, 126.5, 98.2, 69.3, 63.8, 
54.9, 38.7, 36.9, 27.3, 8.6. HRMS Calculated for C20H25N2O3 [M+H]+: 341.18597, 
Found: 341.18592. [!]D 26 = -95.4° (c = 1.0 in MeOH). 
 
41a-minor
N
Ph
OH
Me
H
MeO2N Ph
 
 
(2R,3R,4S)-4-methyl-3-nitro-2-phenyl-1-((S)-1-phenylethyl)piperidin-4-ol (41a-
minor) was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 10/1) as 
white solid, yield: 10%. m.p = 135.5-137.8?. 1H NMR (600 MHz, CDCl3): $ 7.22-
7.45(m, 8H), 7.01(d, J = 7.2Hz, 2H), 4.53(d, J = 10.2Hz, 1H), 3.97(d, J = 10.2Hz, 1H), 
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3.90(q, J = 7.2Hz, 1H), 2.93(dq, J = 12.0Hz, J = 3.0Hz, 1H), 2.85(d, J = 3.0Hz, 1H), 
2.45(td, J = 12.0Hz, J = 3.0Hz, 1H), 1.88(dt, J = 13.8Hz, J = 3.0Hz, 1H), 1.72(tq, J = 
12.0Hz, J = 2.4Hz, 1H), 1.37(d, J = 7.2Hz, 3H), 1.23(s, 3H). 13C NMR (600 MHz, 
CDCl3): $ 137.9, 137.8, 129.0, 128.7, 128.6, 127.9, 127.2, 99.2, 68.8, 64.2, 56.4, 39.7, 
37.0, 27.3, 18.8. HRMS Calculated for C20H25N2O3 [M+H]+: 341.18597, Found: 
341.18606. [!]D 26 = -33.7° (c = 1.0 in MeOH). 
 
N
OH
Me
HPh
O2N
OO
41d-major  
 
(S)-methyl-2-((2R,3R,4S)-4-hydroxy-4-methyl-3-nitro-2-phenylpiperidin-1-yl)-3-
methylbutanoate (41d-major) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v 5/1) as white solid, yield: 48%. m.p = 295.4-297.9 ?. 1H NMR (600 MHz, 
CDCl3): $ 7.26-7.35(m, 5H), 4.63(d, J = 10.2Hz, 1H), 4.24(d, J = 10.2Hz, 1H), 3.72(s, 
1H), 2.98(br, 1H), 2.75-2.82(m, 2H), 2.63(d, J = 11.4Hz, 1H), 2.05-2.13(m, 1H), 1.91(dt, 
J = 13.8Hz, J = 3.0Hz, 1H), 1.66-1.72(m, 1H), 1.29(s, 3H), 0.90(d, J = 6.6Hz, 3H), 
0.67(d, J = 6.6Hz, 1H). 13C NMR (600 MHz, CDCl3): $ 171.1, 136.2, 128.9, 128.7, 98.1, 
68.8, 67.3, 64.5, 50.8, 41.0, 37.0, 27.3, 26.5, 20.1, 19.1. HRMS Calculated for 
C18H27N2O5 [M+H]+: 351.19234, Found: 351.19133. [!]D 26 = -43.2° (c = 1.0 in MeOH). 
 
41d-minor
N
Me
HO
HPh
O2N
OO
 
 
(S)-methyl-2-((2R,3R,4R)-4-hydroxy-4-methyl-3-nitro-2-phenylpiperidin-1-yl)-3-
methylbutanoate (41d-minor) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v 5/1) as white solid, yield: 14%. m.p = 131.1-132.9 ?.1H NMR (600 MHz, 
CDCl3): $ 7.26-7.34(m, 5H), 4.76(d, J = 10.2Hz, 1H), 3.99(d, J = 10.2Hz, 1H), 3.72(s, 
3H), 3.00(dt, J = 12.6Hz, J = 3.6Hz, 1H), 2.56(d, J = 11.4Hz, 1H), 2.42-2.48(m, 1H), 
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2.35(s, 1H), 2.02-2.19(m, 1H), 1.92-1.96(m, 1H), 1.36(s, 3H), 0.86(d, J = 6.6Hz, 3H), 
0.66(d, J = 6.6Hz, 3H). 13C NMR (600 MHz, CDCl3): $ 171.3, 136.6, 128.8, 128.6, 98.9, 
71.4, 67.1, 65.3, 50.7, 42.9, 39.0, 26.7, 21.3, 20.0, 19.1. HRMS Calculated for 
C18H27N2O5 [M+H]+: 351.19234, Found: 351.19141. [!]D 26 = -80.8° (c = 1.0 in MeOH). 
 
41e-minor41e-major
N
OH
Me
Ph
O2N
O O
Ph
H
N
Me
HO
Ph
O2N
O O
Ph
H
 
 
(S)-methyl-2-((2R,3R,4S(R))-4-hydroxy-4-methyl-3-nitro-2-phenylpiperidin-1-yl)-3-
phenylpropanoate (41e) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v 5/1) as colorless oil with overall isolated yield 65% (two diasterisomers 
cannot be separated). 1H NMR (600 MHz, CDCl3): $ 6.80-37(m, 10H+1.7H), 4.63(d, J = 
10.2Hz, 0.17H), 4.98(d, J = 10.2H, 1H), 4.39(d, J = 10.2Hz, 1H), 4.31(d, J = 10.2Hz, 
0.17H), 3.72(s, 3H), 3.55(s, 0. 42H), 3.50(dd, J = 9.6Hz, J = 3.0Hz, 0.17H), 3.28(dd, J = 
9.6Hz, J = 6.0Hz, 1H), 3.23(td, J = 12.0Hz, J = 3.0Hz, 0.17H), 2.78-3.06(m, 5H+0.85H), 
2.01-2.004(m, 0.17H), 1.90-1.96(m, 1H), 1.73-1.80(m, 0.17H), 1.65-1.72(m, 1H), 1.29(s, 
0.42H), 1.26(s, 3H). 13C NMR (600 MHz, CDCl3): $ 171.8(172.2), 138.3(138.2), 
135.6(135.9), 129.7, 129.2, 129.1, 129.0, 128.7, 128.6, 128.2, 127.9, 126.3, 126.2, 
97.5(97.9), 68.9(69.0), 64.6(63.8, 63.7), 62.1, 51.3(51.8), 40.7(41.7), 36.9(36.8), 35.3, 
(30.1), 27.15(27.12). HRMS Calculated for C22H27N2O5 [M+H]+: 399.19145, Found: 
399.19194. 
 
N
H
N
O
OPh
PhO
42a  
 
 221 
(S)-methyl-2-((5S,6R)-5-acetamido-5,6-dihydro-4-methyl-6-phenylpyridin-1(2H)-yl)-
3-phenylpropanoate (42a) was purified by flash silica gel chromatography (Hexane-
EtOAc, v/v 3/1) as white solid with overall isolated yield 80%. m.p >160?
(decomposed). 1H NMR (600 MHz, CDCl3): $ 7.17-7.27(m, 6H), 7.04-7.10(m, 4H), 
5.65(br, 1H), 5.98(d, J = 9.6Hz, 1H), 5.44(dd, J = 9.0Hz, J = 4.8Hz, 1H), 3.76(d, J = 
4.8Hz, 1H), 3.58(t, J = 7.2Hz, 1H), 3.42-3.52(m, 1H), 3.47(s, 1H), 3.30-3.35(m, 1H), 
2.98(dd, J = 13.8Hz, J = 7.2Hz, 1H), 2.88(dd, J = 13.8Hz, J = 7.2Hz, 1H), 1.82(s, 3H), 
1.73(s, 3H). 13C NMR (600 MHz, CDCl3): $ 173.0, 169.2, 138.2, 138.0, 133.0, 129.2, 
128.9, 128.25, 128.21, 127.7, 126.4, 122.6, 66.8, 64.7, 53.5, 51.11, 44.9, 35.4, 23.2, 20.2. 
HRMS Calculated for [M+H]+:, Found:. [!]D 26 = -18.4° (c = 1.0 in MeOH). 
 
N
O2N
Ph
O
O
Ph
42b  
 
(S)-methyl-2-((R)-5,6-dihydro-4-methyl-3-nitro-2-phenylpyridin-1(2H)-yl)-3-phenyl 
propanoate (7b). 7b was purified by flash silica gel chromatography (Hexane-EtOAc, 
v/v 10/1) as colorless oil, yield: 65%. 1H NMR (600 MHz, CDCl3): $ 7.10-7.22(m, 6H), 
6.98-7.01(m, 2H), 6.81-6.86(m, 2H), 4.97(s, 1H), 3.74(s, 3H), 3.42(dd, J = 9.0Hz, J = 
6.6Hz, 1H), 3.22(qd, J = 5.4Hz, J = 3.0Hz, 1H), 2.93(dd, J = 13.8Hz, J = 6.0Hz, 1H), 
2.78(dd, J = 13.8Hz, J = 6.0Hz, 1H), 2.68(td, J = 12.0Hz, J = 3.0 Hz, 1H), 2.52-2.60(m, 
1H), 2.14-2.19(m, 1H), 1.97(s, 3H). 13C NMR (600 MHz, CDCl3): $ 172.00, 147.7, 
137.7, 136.9, 135.1, 129.4, 129.2, 128.3, 128.2, 128.1, 126.2, 63.8, 62.2, 51.3, 41.2, 35.6, 
32.2, 19.8. HRMS Calculated for C22H25N2O4 [M+H]+: 381.18088, Found: 381.18092. 
[!]D 26 = -21.3° (c = 1.0 in MeOH). 
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41´ was purified by flash silica gel chromatography (Hexane-EtOAc, v/v 2/1) as colorless 
oil with overall isolated yield 81%. 1H NMR (600 MHz, CDCl3): $ 7.10-7.41(m, 11H), 
6.56 (d, J = 7.8 Hz, 2H), 4.20(t, J = 10.2 Hz, 1H), 3.70(s, 3H), 3.64(d, J = 10.2Hz, 1H), 
3.05 (s, 3H), 2.82 (dt, J = 12.6 Hz, J = 3.0Hz, 1H), 2.58(td, J = 12.6Hz, J = 3.0Hz, 1H), 
2.49(d, J = 12.6Hz, 1H), 2.00-2.08(m, 1H), 1.91(td, J = 13.2Hz, J = 4.8 Hz, 1H), 1.75(dt, 
J = 13.8Hz, J = 1.2Hz, 1H), 1.26(s, 3H), 0.86(d, J = 6.6Hz, 1H), 0.63(d, J = 6.6 Hz, 1H). 
13C NMR (600 MHz, CDCl3): $ 171.7, 165.5, 139.3, 131.2, 129.0, 128.4, 128.3, 127.9, 
125.1, 123.2, 84.2(q, J = 103.2 Hz, 1C), 71.0, 70.9, 67.8, 66.4, 58.8, 54.5, 50.5, 41.5, 
38.5, 27.7, 26.7, 20.1, 19.2. HRMS Calculated for C28H35F3N2O5 [M+H]+: 537.25708, 
Found: 537.25337. [!]D 26 = -112.6° (c = 1.0 in MeOH). 
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Part VI 
 
NH
NN
N
O
NH2OTBSO
O O G-1 (46)
 
G-1 (46). 1H NMR (600 MHz, d6-DMSO): ! 10.45 (br, s, 1 H, NH1), 7.89 (s, 1 H, H8), 
6.51 s, 2 H, NH2), 5.91 (d, 1H, H1’, J = 2.4Hz), 5.24 (dd, 1H, H2’, J = 6.0, 2.4 Hz), 4.88 
(dd, 1 H, H3’, J = 6.0, 2.8Hz), 4.13 (m, 1 H, H4’, J = 10.0, 2.4Hz), 3.69 (m, 2 H, H5’, J = 
11.2, 6.0 Hz), 1.50 (s, 3 H, CH3), 1.31 (s, 3 H, CH3), 0.81 (s, 9 H, t-Bu), -0.03 (s, 6H, 
Si(CH3)2). 13C NMR (600 MHz d6-DMSO) ! -5.63, 17.85, 25.18, 25.63, 26.88, 63.39, 
80.89, 83.62, 86.84, 88.36, 112.90, 116.75, 135.68, 150.49, 153.68, 156.71 
 
O2N
-O
O2N
NO2
O-
NO2
Na+Na+
Na2TNBP (47)  
Na2TNBP (47) 1H NMR (600 MHz, d6-DMSO): ! 8.00 (s, 4 H, 3, 5, 3’, 5’ H). 13C NMR 
(600 MHz d6-DMSO) ! 115.19, 127.54, 143.92, 158.96. 
 
O2N
-O
O2N
NO2
O-
NO2
Bu4N+
Na2TNBP (48)
Bu4N+
 
(Bu4N)2•TNBP (48) Dissolve Bu4NF (250mg, 0.958mmol) in 20ml distilled water 
followed by adding Na2TNBP (500mg, 1.222mmol), stir to dark red clear solution. 
CH2Cl2 (20ml) was applied to extract the (Bu4N)2•TNBP. Then the dark red organic 
solution was washed by distilled water (20ml?3) to remove NaF and dried under 
vacuum to black solid (763mg, 90%).  1H NMR (600 MHz, d6-DMSO): ! 7.93 (s, 4 H, 
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TNBP), 3.18-3.12 (m, 16 H, CH2'"), 1.61-1.49 (m, 16 H, CH2-#), 1.33-1.25 (m, 16 H, 
CH2-%), 0.92 (t, 24 H, CH3, J = 7.5). 13C NMR (600 MHz d6-DMSO) ! 13.42, 19.14, 
22.99, 57.43, 113.95, 126.62, 143.26, 157.87.  
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ORTEP Drawings of the X-ray Crystal Structures 
 
 
Figure 1.   Perspective view of the molecular structure of 4e-cis with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability.  
                  CCDC :704977 
 
 
Figure 2.   Perspective view of the molecular structure of 4e-trans with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability.  
                 CCDC: 704978 
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Figure 3.   Perspective view of the molecular structure 6a-cis showing the syn 
relationship of the hydrogen atoms bound to C(3) and C(4) within molecule 
6a of C22H25NO3 with the atom labeling scheme.  The thermal ellipsoids are 
scaled to enclose 30% probability.  
                  CCDC: 704979 
 
 
 
Figure 4.   Perspective view of the molecular structure 6a-trans showing the anti 
relationship of the hydrogen atoms bound to C(25) and C(26) within molecule 
6a of C22H25NO3 with the atom labeling scheme.  The thermal ellipsoids are 
scaled to enclose 30% probability.  
                  CCDC 704979 
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Figure 5.   Perspective view of the molecular structure of 6a-trans with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability.  
                  CCDC 704980 
 
 
Figure 6.  Perspective view of the molecular structure of 12g-major with the atom 
labeling scheme. The CMe=CH2 substituent containing carbons C(7)-C(9) 
exhibits a two-site rotational disorder. The thermal ellipsoids are scaled to 
enclose 30% probability. 
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Figure 7.  Perspective view of the molecular structure of 12a-minor with the atom 
labeling scheme. The thermal ellipsoids are scaled to enclose 30% 
probability. 
 
Figure 8.  Perspective view of the molecular structure of 11a-major with the atom 
labeling scheme. The thermal ellipsoids are scaled to enclose 30% 
probability. 
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Figure 9.  Perspective view of the molecular structure of 12f-major with the atom 
labeling scheme. The thermal ellipsoids are scaled to enclose 30% 
probability. 
 
 
Figure 10.  Perspective view of the molecular structure of 13b with the atom labeling  
scheme. The thermal ellipsoids are scaled to enclose 30% probability. 
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Figure 11. Perspective view of the molecular structure of 15c with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability. CCDC: 
755528. 
 
 
 
Figure 12. Perspective view of the molecular structure of 18g with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability. CCDC: 
755527. 
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Figure 13. Perspective view of the molecular structure of aux-g with the atom labeling 
scheme. The thermal ellipsoids are scaled to enclose 30% probability. CCDC: 
755526. 
 
 
Figure 14. Perspective view of the molecular structure of 33 with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability. CCDC: 
755529. 
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Figure 15. Perspective view of the molecular structure of 39a-major with the atom 
labeling scheme.  The thermal ellipsoids are scaled to enclose 30% 
probability. CCDC Number: 712066 
 
 
Figure 16. Perspective view of the molecular structure of 39a-minor with the atom 
labeling scheme.  The thermal ellipsoids are scaled to enclose 30% 
probability. CCDC Number: 712068 
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Figure 17. Perspective view of the molecular structure of 39e with the atom labeling 
scheme.  The thermal ellipsoids are scaled to enclose 30% probability CCDC 
Number: 712067 
 
 
Figure 18. Perspective view of the molecular structure of 41d-major with the atom 
labeling scheme.  The thermal ellipsoids are scaled to enclose 30% 
probability. CCDC Number: 712069 
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Figure 19. Perspective view of the molecular structure of 41d-minor with the atom 
labeling scheme.  The thermal ellipsoids are scaled to enclose 30% 
probability. CCDC Number: 712070 
 
 
Figure 20. Perspective view of the molecular structure of 41a-minor with the atom 
labeling scheme.  The thermal ellipsoids are scaled to enclose 30% 
probability. CCDC Number: 712071 
 
